# (19), World Intellectual Property Organization International Bureau





### (43) International Publication Date 1 August 2002 (01.08.2002)

**PCT** 

# (10) International Publication Number WO 02/059271 A2

(51) International Patent Classification7:

C12N

(21) International Application Number: PCT/US02/02176

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/263,757 25 January 2001 (25.01.2001) US 60/286,090 25 April 2001 (25.04.2001) US 60/292,517 23 May 2001 (23.05.2001) US

(71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Guithershurg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ORR, Michael, S. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). NATION, Michele


[US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). DIGGANS, James, C. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ZENG, Wen [CN/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

- (74) Agent: MORGAN, LEWIS & BOCKIUS LLP; TUS-CAN, Michael S., WEIMAR, Elizabeth C. et al., 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,

[Continued on next page]

(54) Title: GENE EXPRESSION PROFILES IN BREAST TISSUE

- 33 Tissue Samples



(57) Abstract: The present invention results from the examination of tissue from breast carcinomas to identify genes differentially expressed between tumor biopsies and normal tissue. The invention includes diagnostic and screening methods using these genes as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.

.

# WO 02/059271 A2



GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

 with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

#### Published:

 without international search report and to be republished upon receipt of that report For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# GENE EXPRESSION PROFILES IN BREAST TISSUE

INVENTORS: Michael S. Orr, Michele Nation, J.C. Diggans and Wen Zeng

# 5 RELATED APPLICATIONS

This application claims the priority of U.S. Provisional Application Nos. 60/263,757, filed January 25, 2001, 60/286,090, filed April 25, 2001, and 60/292,517, filed May 23, 2001, all of which are herein incorporated by reference in their entirety.

# 10 BACKGROUND OF THE INVENTION

One of the most pressing health issues today is breast cancer. In the industrial world, about one woman in every nine can expect to develop breast cancer in her lifetime. In the United States, it is the most common cancer amongst women, with an annual incidence of about 175,000 new cases and nearly 50,000 deaths. Despite an ongoing improvement in our understanding of the disease, breast cancer has remained resistant to medical intervention. Most clinical initiatives are focused on early diagnosis, followed by conventional forms of intervention, particularly surgery and chemotherapy. Such . interventions are of limited success, particularly in patients where the tumor has undergone metastasis. There is a pressing need to improve the arsenal of therapies available to provide more precise and more effective treatment in a less invasive way. A promising area for the development of new modalities has emerged from recent understanding of the genetics of cancer.

One model used to characterize breast carcinogenesis asserts that normal cells undergo a multi-step process that broadly includes the steps of hyperplasia, pre-malignant change and in situ carcinoma. Multiple factors lead to atypical cell proliferation followed by carcinoma in situ. Carcinoma in situ is characterized as either ductal or lobular in form with the majority of invasive carcinomas being classified as ductal (85-95%). Among the ductal carcinomas, 15-20% encompass tubular, medullary, mucinous, papillary, adenoid, cystic, metaplastic, apocrine, squamous, secretory, lipid-rich, and cystic hypersecretory while the remaining ductal carcinomas are not specified.

To date, researchers have been able to identify a few genetic alterations believed to underlie tumor development. These genetic alterations include amplification of oncogenes and mutations that result in the loss of tumor suppressor genes. Tumor suppressor genes are genes that, in their wild-type alleles, express proteins that suppress abnormal cellular

15

20

)

25

30

20

25

30

proliferation. When the gene coding for a tumor suppressor protein is mutated or deleted, the resulting mutant protein or the complete lack of tumor suppressor protein expression may fail to correctly regulate cellular proliferation, and abnormal proliferation may take place, particularly if there is already existing damage to the cellular regulatory mechanism.

A number of well-studied human tumors and tumor cell lines have missing or non-functional tumor suppressor genes. Examples of tumor suppressor genes include, but are not limited to, the retinoblastoma susceptibility gene or RB gene, the p53 gene, the deletion in colon carcinoma (DCC) gene and the neurofibromatosis type 1 (NF-1) tumor suppressor gene (Weinberg, Science 254,1138-1146 (1991)). Loss of function or inactivation of tumor suppressor genes may play a central role in the initiation and/or progression of a significant number of human cancers.

Classification of heterogeneous populations of tumor types is a daunting task; yet, studies utilizing gene expression patterns to identify subtypes of cancer have produced initial results (see Perou, C. M. et al., Proc Natl Acad Sci USA 96, 9212-9217 (1999), Golub, T. R. et al., Science 286, 531-7 (1999), Alizadeh, A. A. et al., Nature 403, 503-11 (2000), Alon, U. et al. Proc Natl Acad Sci USA 96, 6745-50 (1999) and Bittner, M. et al., Nature 406, 536-40 (2000)). For example, molecular classification of B-cell lymphoma by gene expression profiling elucidated clinically distinct diffuse large-B-cell lymphoma subgroups (see Alizadeh supra). Stratification of patients based on their distinctive gene expression profiles may allow researchers to precisely group similar patient populations for evaluating chemotherapeutic agents. The more homogenous population of patients decreases the variability of patient-to-patient responses leading to the development of agerocapable of eradicating specific subtypes of cancers previously unknown using standard classification techniques.

A study by Martin et al. (Cancer Res 60, 2232-8 (2000)) used a custom microarray composed of 124 genes discovered by differential display associated with either normal breast epithelial cells or from the MDA-MB-435 malignant breast tumor cell line. Using the custom microarray, researchers examined the relationship between expression patterns discovered by clustering a number of genes with clinical stages of breast cancer, indicating that gene expression patterns were capable of grouping breast tumors into distinct categories (Martin et al., supra).

The utilization of gene expression profiles to classify tumors, to identify drug targets, to identify diagnostic markers and/or to gain further insights into the consequences of chemotherapeutic treatments could facilitate the design of more efficacious patient—

10

15

20

25

30

specific stratagems for treating a variety of cancers. In breast cancer, studies utilizing limited numbers of genes have classified tumors into subtypes based on gene expression profiles, and this study indicated a diversity of molecular phenotypes associated with breast tumors (Perou, C. M. et al., Nature 406, 747-52 (2000).

Although these studies have demonstrated that expression profiling may be used to produce improvements in diagnosis of breast cancer as well as the development of improved therapeutic strategies, further studies are needed as only a small portion of the genome was studied and analyses containing greater numbers of genes will advance our understanding of breast tumors even further. Accordingly, there remains a need in the art for materials and methods that permit a more accurate diagnosis of breast cancer and, in particular, ductal carcinoma. In addition, there remains a need in the art for methods to treat and methods to identify agents that can effectively treat breast cancer. The present invention meets these and other needs.

### SUMMARY OF THE INVENTION

The present invention is based on the discovery of the genes and their expression profiles associated with various types and stages of breast cancer.

The invention includes methods of diagnosing breast cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer.

The invention also includes methods of detecting the progression of breast cancer. For instance, methods of the invention include detecting the progression of breast cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer progression. In some preferred embodiments, PCA (Principal Component Analysis) based on all or a portion of the group of 50 genes identified in Table 1 may be used to differentiate between the different stages of breast cancer such as normal versus DCIS (ductal carcinoma *in-situ*) or DCIS versus microinvasive tissue samples. In some preferred embodiments, one or more genes may be selected from Tables 1, 3, 4 and/or 5.

In some aspects, the present invention provides a method of monitoring the treatment of a patient with breast cancer, comprising administering a pharmaceutical composition to the patient and preparing a gene expression profile from a cell or tissue

4

sample from the patient and comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising breast cancer cells or to both. In some preferred embodiments, the gene profile will include the expression level of one or more genes in Tables 1-5.

5

10

15

20

25

30

Another aspect of the present invention includes a method of treating a patient with breast cancer, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5, preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells and comparing the patient expression profile to a gene expression profile from an untreated cell population comprising breast cancer cells.

In another aspect, the present invention provides a method of identifying ductal carcinoma in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 1-5, wherein differential expression of the genes in Tables 1-5 is indicative of ductal carcinoma. In addition, by determining the expression level of two or more genes in the group of genes listed in Tables 1-5, one skilled in the art can differentiate between DCIS and a cribiform type of DCIS that is more prone to microinvasion.

In another aspect, the present invention provides a method of detecting the progression of carcinogenesis in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast carcinogenesis. Figures 6 and 7 are a graphical representation of how the genes listed in Table 5 cluster with disease stages in breast cancer.

The invention further includes methods of screening for an agent capable of modulating the onset or progression of breast cancer, comprising the steps of exposing a cell to the agent; and detecting the expression level of two or more genes from Tables 1-5. In some embodiments, the breast cancer may be a ductal carcinoma. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5. In some preferred methods, it may be desirable to detect all or nearly all of the genes in the tables.

The invention further includes compositions comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5 as well as solid supports comprising at least two probes, wherein each of the probes comprises a sequence that specifically hybridizes to

10

15

20

a gene in Tables 1-5. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5.

The invention further includes computer systems comprising a database containing information identifying the expression level in breast tissue of a set of genes comprising at least two genes in Tables 1-5 and a user interface to view the information. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5. The database may further include sequence information for the genes, information identifying the expression level for the set of genes in normal breast tissue and cancerous tissue and may contain links to external databases such as GenBank.

Lastly, the invention includes methods of using the databases, such as methods of using the disclosed computer systems to present information identifying the expression level in a tissue or cell of at least one gene in Tables 1-5, comprising the step of comparing the expression level of at least one gene in Tables 1-5 in the tissue or cell to the level of expression of the gene in the database. In some preferred embodiments, two or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an E- northern showing the expression of topoisomerase II alpha in various tissue types.

Figure 2 is an E-northern showing the expression of ICBP90 in various tissue types.

Figure 3 is an E-northern showing the expression of MCT4 gene.

Figure 4 is an E-northern showing the expression of the frizzled related protein.

Figure 5 is an E-northern showing the expression of an EST Affy ID AI668620.

Figure 6 is a PCA of the set of 28 samples using the top 50 genes identified by p-

values.

Figure 7 is a PCA of the set of 33 samples using the top 50 genes and ESTs identified by p-values.

Figure 8 is a PCA of the set of 91 samples using the top 31 myo-lamina genes and ESTs.

30

25

# DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Many biological functions are accomplished by altering the expression of various genes through transcriptional (e.g., through control of initiation, provision of RNA precursors, RNA processing, etc.) and/or translational control. For example, fundamental

6

biological processes such as cell cycle, cell differentiation and cell death, are often characterized by the variations in the expression levels of groups of genes.

5

10

15

20

25

30

Changes in gene expression also are associated with pathogenesis. For example, the lack of sufficient expression of functional tumor suppressor genes and/or the over expression of oncogene/protooncogenes could lead to tumorgenesis or hyperplastic growth of cells (Marshall, *Cell* 64, 313-326 (1991); Weinberg, *Science*, 254, 1138-1146 (1991)). Thus, changes in the expression levels of particular genes (e.g., oncogenes or tumor suppressors) serve as signposts for the presence and progression of various diseases.

Monitoring changes in gene expression may also provide certain advantages during drug screening and development. Often drugs are pre-screened for the ability to interact with a major target without regard to other effects the drugs have on cells. Often such other effects cause toxicity in the whole animal, which prevent the development and use of the potential drug.

Applicants have examined samples from normal breast tissue and from cancerous breast tissue to identify global changes in gene expression between tumor biopsies and normal tissue. These global changes in gene expression, also referred to as expression profiles, provide useful markers for diagnostic uses as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

The gene expression profiles described herein were derived from normal and tumor samples from female patients between the ages of 39 and 52 years old, and were from three different ethnic origins (Caucasian, African-American and Asian). Infiltrating Ductal Carcinoma (IDC) patient samples were studied for cancer-related expression, as 85% of the breast cancer patients were afflicted with this form of the disease.

Histological analysis of each tissue sample was performed and samples were segregated into either normal or malignant categories. The normal tissue samples were acquired from neighboring tissue of patients suffering from one of the following disorders: macromastia, mild fibrosis, infiltrating lobular carcinoma, or infiltrating ducal carcinoma, however; each tissue was diagnosed as normal by histological analysis. Samples were also characterized by the type and grade of IDC for each patient sample utilized in the study.

The present invention provides compositions and methods to detect the level of expression of genes that may be differentially expressed dependent upon the state of the cell, *i.e.*, normal versus cancerous. These expression profiles of genes provide molecular tools for evaluating toxicity, drug efficacy, drug metabolism, development, and disease

monitoring. Changes in the expression profile from a baseline profile can be used as an indication of such effects. Those skilled in the art can use any of a variety of known techniques to evaluate the expression of one or more of the genes and/or gene fragments identified in the instant application in order to observe changes in the expression profile in a tissue or sample of interest.

### **Definitions**

5

10

15

20

25

30

In the description that follows, numerous terms and phrases known to those skilled in the art are used. In the interest of clarity and consistency of interpretation, the definitions of certain terms and phrases are provided.

As used herein, the phrase "detecting the level of expression" includes methods that quantify expression levels as well as methods that determine whether a gene of interest is expressed at all. Thus, an assay which provides a yes or no result without necessarily providing quantification of an amount of expression is an assay that requires "detecting the level of expression" as that phrase is used herein.

As used herein, oligonucleotide sequences that are complementary to one or more of the genes described herein, refers to oligonucleotides that are capable of hybridizing under stringent conditions to at least part of the nucleotide sequence of said genes. Such hybridizable oligonucleotides will typically exhibit at least about 75% sequence identity at the nucleotide level to said genes, preferably about 80% or 85% sequence identity or more preferably about 90% or 95% or more nucleotide sequence identity to said genes.

"Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

The terms "background" or "background signal intensity" refer to hybridization signals resulting from non-specific binding, or other interactions, between the labeled target nucleic acids and components of the oligonucleotide array (e.g., the oligonucleotide probes, control probes, the array substrate, etc.). Background signals may also be produced by intrinsic fluorescence of the array components themselves. A single background signal can be calculated for the entire array, or a different background signal may be calculated for each target nucleic acid. In a preferred embodiment, background is calculated as the average hybridization signal intensity for the lowest 5% to 10% of the probes in the array, or, where a different background signal is calculated for each target gene, for the lowest 5%

to 10% of the probes for each gene. Of course, one of skill in the art will appreciate that where the probes to a particular gene hybridize well and thus appear to be specifically binding to a target sequence, they should not be used in a background signal calculation. Alternatively, background may be calculated as the average hybridization signal intensity produced by hybridization to probes that are not complementary to any sequence found in the sample (e.g., probes directed to nucleic acids of the opposite sense or to genes not found in the sample such as bacterial genes where the sample is mammalian nucleic acids). Background can also be calculated as the average signal intensity produced by regions of the array that lack any probes at all.

5

10

15

20

25

30

The phrase "hybridizing specifically to" refers to the binding, duplexing or hybridizing of a molecule substantially to or only to a particular nucleotide sequence or sequences under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.

Assays and methods of the invention may utilize available formats to simultaneously screen at least about 100, preferably about 1000, more preferably about 10,000 and most preferably about 1,000,000 or more different nucleic acid hybridizations.

The terms "mismatch control" or "mismatch probe" refer to a probe whose sequence is deliberately selected not to be perfectly complementary to a particular target sequence. For each mismatch (MM) control in a high-density array there typically exists a corresponding perfect match (PM) probe that is perfectly complementary to the same particular target sequence. The mismatch may comprise one or more bases that are not complementary to the corresponding bases of the target sequence.

While the mismatch(s) may be located anywhere in the mismatch probe, terminal mismatches are less desirable as a terminal mismatch is less likely to prevent hybridization of the target sequence. In a particularly preferred embodiment, the mismatch is located at or near the center of the probe such that the mismatch is most likely to destabilize the duplex with the target sequence under the test hybridization conditions.

The term "perfect match probe" refers to a probe that has a sequence that is perfectly complementary to a particular target sequence. The test probe is typically perfectly complementary to a portion (subsequence) of the target sequence. The perfect match (PM) probe can be a "test probe", a "normalization control" probe, an expression level control probe and the like. A perfect match control or perfect match probe is, however, distinguished from a "mismatch control" or "mismatch probe."

10

15

20

25

30

As used herein a "probe" is defined as a nucleic acid, preferably an oligonucleotide, capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, U, C or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in probes may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages.

The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but with only insubstantial hybridization to other sequences or to other sequences such that the difference may be identified. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.

Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The "percentage of sequence identity" or "sequence identity" is determined by comparing two optimally aligned sequences or subsequences over a comparison window or span, wherein the portion of the polynucleotide sequence in the comparison window may optionally comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical subunit (e.g., nucleic acid base or amino acid residue) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Percentage sequence identity when calculated using the programs GAP or BESTFIT (see below) is calculated using default gap weights.

Homology or identity may be determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx,

10

15

20

25

30

tblastn and tblastx (Karlin et al., Proc Natl Acad Sci USA 87, 2264-2268 (1990) and Altschul, J Mol Evol 36, 290-300 (1993), fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al., (Nature Genet 6, 119-129 (1994)) which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., Proc Natl Acad Sci USA 89, 10915-10919, (1992) fully incorporated by reference). Four blastn parameters were adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink<sup>th</sup> position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

#### Uses of Differentially Expressed Genes

The present invention identifies those genes differentially expressed between normal breast tissue and cancerous breast tissue. One of skill in the art can select one or more of the genes identified as being differentially expressed in Tables 1-5 and use the information and methods provided herein to interrogate or test a particular sample. For a particular interrogation of two conditions or sources, it may be desirable to select those genes which display a great deal of difference in the expression pattern between the two conditions or sources. At least a two-fold difference may be desirable, but a three-fold, five-fold or ten-fold difference may be preferred in some instances. Interrogations of the genes or proteins can be performed to yield different information.

Diagnostic Uses for the Breast Cancer Markers

10

15

20

25

30

As described herein, the genes and gene expression information provided in Tables 1-5 may be used as diagnostic markers for the prediction or identification of the malignant state of breast tissue. For instance, a breast tissue sample or other sample from a patient may be assayed by any of the methods known to those skilled in the art, and the expression levels from one or more genes from Tables 1-5, may be compared to the expression levels found in normal breast tissue, tissue from breast carcinoma or both. Expression profiles generated from the tissue or other samples that substantially resemble an expression profile from normal or diseased breast tissue may be used, for instance, to aid in disease diagnosis. Comparison of the expression data, as well as available sequence or other information may be done by researcher or diagnostician or may be done with the aid of a computer and databases as described herein.

For example, genes over-expressed by 3-fold or greater, as well as having the smallest p-values from a t-test, were discovered by comparing 13 normal tissue samples and 15 infiltrating ductal carcinoma tissue samples composed of mostly stage II and III tissue samples. This analysis provided a set of genes (listed in Table 1) capable of distinguishing between the 13 normal and 15 tumor samples by PCA (Principal Component Analysis). In order to evaluate the ability of the genes to distinguish between normal and tumor tissue samples, a group of 33 tissues was selected from an existing gene expression database composed of normal, benign, DCIS (ductal carcinoma *in-situ*), microinvasive, stage I, stage II, and stage III breast cancer samples. PCA of the 33 tissue samples indicated that the genes selected based on the smallest p-values classified 32 out of 33 tissue samples correctly, while one stage I tissue sample was misclassified as a normal sample. Accordingly, these genes can be used diagnostically to differentiate normal/benign samples from tissue samples containing intraductal or infiltrating ductal carcinoma of the breast.

In another study, the PCA based on this group of genes indicates that these genes may be used to differentiate between the different stages of breast cancer such as normal versus DCIS or DCIS versus microinvasive tissue samples as graphically shown in Figures 6 and 7. The DCIS sample that contained focal microinvasions was grouped with the Stage I and II tumor samples. This group of genes may be used to determine if a DCIS sample contains microinvasions.

Use of the Breast Cancer Markers for Monitoring Disease Progression

Molecular expression markers for breast cancer can be used to confirm the type and progression of cancer made on the basis of morphological criteria. For example, normal

12

breast tissue could be distinguished from invasive carcinoma based on the level and type of genes expressed in a tissue sample. In some situations, identifications of cell type or source is ambiguous based on classical criteria. In these situations, the molecular expression markers of the present invention are useful.

In addition, progression of ductal carcinoma in situ to microinvasive carcinoma can be monitored by following the expression patterns of the involved genes using the molecular expression markers of the present invention. Monitoring of the efficacy of certain drug regimens can also be accomplished by following the expression patterns of the molecular expression markers.

5

10

15

20

25

30

CONTRACTOR AND CONTRACTOR

In addition to the different disease progression stages which have been shown in Figures 6-7, as shown in the examples below, other developmental stages can be identified using these same molecular expression markers. While the importance of these markers in development has been shown here, variations in their expression may occur at other times. For example, variation in the expression level of one or more of the marker genes identified herein may be use to distinguish benign stages of breast cancer from malignant states.

As described above, the genes and gene expression information provided in Tables 1-5 may also be used as markers for the direct monitoring of disease progression, for instance, the development of breast cancer. For instance, a breast tissue sample or other sample from a patient may be assayed by any of the methods known to those of skill in the art, and the expression levels in the sample from a gene or genes from Tables 1-5 may be compared to the expression levels found in normal breast tissue, tissue from breast cancer or both. Comparison of the expression data, as well as available sequence or other informationary be done by researcher or diagnostician or may be done with the aid of a computer and databases as described herein.

For instance, methods of this invention may use the 35 gene group (profile) composed of genes expressed in myoepithelial cells and basal lamina components in Table 3. The absence of both myoepithelial cells or basement membrane components usually indicates that the intraductal carcinoma is invasive. This group of 35 genes listed in Table 3 may be used to determine if myoepithelial and/or basal lamina components are present in a tissue sample. It includes 23 genes exhibiting a fold change of 3 fold or higher and 12 genes displaying a change of less than 3 fold. This group of 23 genes was used to distinguish between normal and tumor samples for a group of 33 tissue samples. In this study, the 23 genes were able to classify 32 out of 33 samples correctly and 26 out of 28 samples used to isolate this subgroup of genes. This group of genes can be used to identify

WO 02/059271

the various stages of ductal carcinoma tissues more discretely than the 50-gene set. The study also demonstrates that this group of genes can differentiate between DCIS and a cribiform type of DCIS that is more prone to microinvasion. Clinically, the ability to discern DCIS with microinvasions or phenotypes prone to microinvasions such as the cribiform type would allow subgrouping of the samples containing microinvasions as a type of patient that should be treated more aggressively than DCIS patients lacking this gene expression fingerprint. A subclass of DCIS (cribiform type) based on the gene expression fingerprint may be subgrouped as a micro invasive sample based on the gene expression pattern associated with this sample.

10

15

5

## Use of the Breast Cancer Markers for Drug Screening

According to the present invention, potential drugs can be screened to determine if application of the drug alters the expression of one or more of the genes identified herein. This may be useful, for example, in determining whether a particular drug is effective in treating a particular patient with breast cancer. In the case where a gene's expression is affected by the potential drug such that its level of expression returns to normal, the drug is indicated in the treatment of breast cancer. Similarly, a drug which causes expression of a gene which is not normally expressed by epithelial cells in the breast, may be contraindicated in the treatment of breast cancer.

20

25

According to the present invention, the genes identified in Tables 1-5 may also be used as markers to evaluate the effects of a candidate drug or agent on a cell, particularly a cell undergoing malignant transformation, for instance, a breast cancer cell or tissue sample. A candidate drug or agent can be screened for the ability to stimulate the transcription or expression of a given marker or markers (drug targets) or to down-regulate or inhibit the transcription or expression of a marker or markers. According to the present invention, one can also compare the specificity of a drug's effects by looking at the number of markers affected by the drug and comparing them to the number of markers affected by a different drug. A more specific drug will affect fewer transcriptional targets. Similar sets of markers identified for two drugs indicates a similarity of effects.

30

Assays to monitor the expression of a marker or markers as defined in Tables 1-5 may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

Agents that are assayed in the above methods can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agents action. Agents can be selected or designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

The agents of the present invention can be, as examples, peptides, small chemical molecules, vitamin derivatives, as well as carbohydrates, lipids, oligonucleotides and covalent and non-covalent combinations thereof. Dominant negative proteins, DNA encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" as used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the parent peptide but topographically and functionally similar to the parent peptide (see Grant in Molecular Biology and Biotechnology, Meyers, ed., VCH Publishers (1995)). A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

#### 25 Assay Formats

5

10

15

20

30

The genes identified as being differentially expressed in breast cancer may be used in a variety of nucleic acid detection assays to detect or quantify the expression level of a gene or multiple genes in a given sample. For example, traditional Northern blotting, nuclease protection, RT-PCR and differential display methods may be used for detecting gene expression levels.

The protein products of the genes identified herein can also be assayed to determine the amount of expression. Methods for assaying for a protein include Western blot, immunoprecipitation, radioimmunoassay. It is preferred, however, that the mRNA be assayed as an indication of expression. Methods for assaying for mRNA include Northern

10

15

20

25

30

blots, slot blots, dot blots, and hybridization to an ordered array of oligonucleotides. Any method for specifically and quantitatively measuring a specific protein or mRNA or DNA product can be used. However, methods and assays of the invention are most efficiently designed with PCR or array or chip hybridization-based methods for detecting the expression of a large number of genes.

Any hybridization assay format may be used, including solution-based and solid support-based assay formats. A preferred solid support is a high density array also known as a DNA chip or a gene chip. One variation of the DNA chip contains hundreds of thousands of discrete microscopic channels that pass completely through it. Probe molecules are attached to the inner surface of these channels, and molecules from the samples to be tested flow through the channels, coming into close proximity with the probes for hybridization. In one assay format, gene chips containing probes to at least two genes from Tables 1-5 may be used to directly monitor or detect changes in gene expression in the treated or exposed cell as described herein. Assays of the invention may measure the expression levels of about one, two, three, five, seven, ten, 15, 20, 25, 50, 100 or more genes in the Tables.

The genes and ESTs of the present invention may be assayed in any convenient sample form. For example, samples may be assayed in the form mRNA or reverse transcribed mRNA. Samples may be cloned or not and the samples or individual genes may be amplified or not. The cloning itself does not appear to bias the representation of genes within a population. However, it may be preferable to use polyA+RNA as a source, as it can be used with less processing steps. In some embodiments, it may be preferable to assay the protein or peptide expressed by the gene.

The sequences of the expression marker genes of Tables 1-5 are available in the public databases. Tables 1-5 provide the Accession numbers and name for each of the sequences. The sequences of the genes in GenBank are herein expressly incorporated by reference in their entirety as of the filing date of this application. (see <a href="https://www.ncbi.nim.nih.gov">www.ncbi.nim.nih.gov</a>).

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a gene identified in Tables 1-5. For instance, as described above, mRNA expression may be monitored directly by hybridization of probes to the nucleic acids of the invention. Cell lines are exposed to an agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook et al., Molecular Cloning - A Laboratory Manual, Cold Spring Harbor

10

15

20

25

30

I CATECOROR OIN MINISTER

16

PCT/US02/02176

Laboratory Press, Cold Spring Harbor, NY (1989)). In some embodiments, it may be desirable to amplify one or more of the RNA molecules isolated prior to application of the RNA to the gene chip. Using techniques well known in the art, the RNA may be reverse transcribed and amplified in the form of DNA or may be reverse transcribed into DNA and the DNA used as a template for transcription to generate recombinant RNA. Any method that results in the production of a sufficient quantity of nucleic acid to be hybridized effectively to the gene chip may be used.

In another format, cell lines that contain reporter gene fusions between the open reading frame and or the 3' or 5' regulatory regions of a gene in Tables 1-5 and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenical acetyltransferase (Alam et al., Anal Biochem 188, 245-254 (1990)). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of the nucleic acid.

In another assay format, cells or cell lines are first identified which express one or more of the gene products of the invention physiologically. Cells and/or cell lines so identified would preferably comprise the necessary cellular machinery to ensure that the transcriptional and/or translational apparatus of the cells would faithfully mimic the response of normal or cancerous breast tissue to an exogenous agent. Such machinery would likely include appropriate surface transduction mechanisms and/or cytosolic factors. Such cell lines may be, but are not required to be, derived from breast tissue. The cells and/or cell lines may then be contacted with an agent and the expression of one or more of the genes of interest may then be assayed. The genes may be assayed at the mRNA level and/or at the protein level.

In some embodiments, such cells or cell lines may be transduced or transfected with an expression vehicle (e.g., a plasmid or viral vector) containing an expression construct comprising an operable 5'-promoter containing end of a gene of interest identified in Tables 1-5 fused to one or more nucleic acid sequences encoding one or more antigenic fragments. The construct may comprise all or a portion of the coding sequence of the gene of interest which may be positioned 5'- or 3'- to a sequence encoding an antigenic fragment. The coding sequence of the gene of interest may be translated or un-translated after transcription of the gene fusion. At least one antigenic fragment may be translated. The antigenic

17

fragments are selected so that the fragments are under the transcriptional control of the promoter of the gene of interest and are expressed in a fashion substantially similar to the expression pattern of the gene of interest. The antigenic fragments may be expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides. In some embodiments, gene products of the invention may further comprise an immunologically distinct tag. Such a process is well known in the art (see Sambrook et al., supra).

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions; for example, the agent comprises a pharmaceutically acceptable excipient and is contacted with cells comprised in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and serum incubated at 37°C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (e.g., ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the "agent-contacted" sample compared to the control will be used to distinguish the effectiveness of the agent.

Another embodiment of the present invention provides methods for identifying agents that modulate the levels, concentration or at least one activity of a protein(s) encoded by the genes in Tables 1-5. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention produced in a cell population that has been exposed to the agent to be tested may be compared to the amount produced in an un-exposed control cell population. In this format, probes such as specific antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe, such as a specific antibody.

5

10

15

20

25

30

Probe Design

5

10

15

20

25

30

DESCRIPTION OF THE PROPERTY AND LA

Probes based on the sequences of the genes described herein may be prepared by any commonly available method. Oligonucleotide probes for assaying the tissue or cell sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary genes or transcripts. Typically the oligonucleotide probes will be at least 10, 12, 14, 16, 18, 20 or 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 nucleotides will be desirable.

One of skill in the art will appreciate that an enormous number of array designs are suitable for the practice of this invention. The high density array will typically include a number of probes that specifically hybridize to the sequences of interest. See WO 99/32660 for methods of producing probes for a given gene or genes. In addition, in a preferred embodiment, the array will include one or more control probes.

High density array chips of the invention include "test probes." Test probes may be oligonucleotides that range from about 5 to about 500 or about 5 to about 50 nucleotides, more preferably from about 10 to about 40 nucleotides and most preferably from about 15 to about 40 nucleotides in length. In other particularly preferred embodiments, the probes are about 20 or 25 nucleotides in length. In another preferred embodiment, test probes are double or single strand DNA sequences. DNA sequences may be isolated or cloned from natural sources or amplified from natural sources using natural nucleic acid as templates. These probes have sequences complementary to particular subsequences of the genes whose expression they are designed to detect. Thus, the test probes are capable of specifically hybridizing to the target nucleic acid they are to detect.

In addition to test probes that bind the target nucleic acid(s) of interest, the high density array can contain a number of control probes. The control probes fall into three categories referred to herein as (1) normalization controls; (2) expression level controls; and (3) mismatch controls.

Normalization controls are oligonucleotide or other nucleic acid probes that are complementary to labeled reference oligonucleotides or other nucleic acid sequences that are added to the nucleic acid sample. The signals obtained from the normalization controls after hybridization provide a control for variations in hybridization conditions, label intensity, "reading" efficiency and other factors that may cause the signal of a perfect hybridization to vary between arrays. In a preferred embodiment, signals (e.g., fluorescence

19

intensity) read from all other probes in the array are divided by the signal (e.g., fluorescence intensity) from the control probes thereby normalizing the measurements.

Virtually any probe may serve as a normalization control. However, it is recognized that hybridization efficiency varies with base composition and probe length. Preferred normalization probes are selected to reflect the average length of the other probes present in the array, however, they can be selected to cover a range of lengths. The normalization control(s) can also be selected to reflect the (average) base composition of the other probes in the array, however in a preferred embodiment, only one or a few probes are used and they are selected such that they hybridize well (i.e., no secondary structure) and do not match any target-specific probes.

Expression level controls are probes that hybridize specifically with constitutively expressed genes in the biological sample. Virtually any constitutively expressed gene provides a suitable target for expression level controls. Typical expression level control probes have sequences complementary to subsequences of constitutively expressed "housekeeping genes" including, but not limited to the  $\beta$ -actin gene, the transferrin receptor gene, the GAPDH gene, and the like.

Mismatch controls may also be provided for the probes to the target genes, for expression level controls or for normalization controls. Mismatch controls are oligonucleotide probes or other nucleic acid probes identical to their corresponding test or control probes except for the presence of one or more mismatched bases. A mismatched base is a base selected so that it is not complementary to the corresponding base in the target sequence to which the probe would otherwise specifically hybridize. One or more mismatches are selected such that under appropriate hybridization conditions (e.g., stringent conditions) the test or control probe would be expected to hybridize with its target sequence, but the mismatch probe would not hybridize (or would hybridize to a significantly lesser extent). Preferred mismatch probes contain a central mismatch. Thus, for example, where a probe is a twenty-mer, a corresponding mismatch probe may have the identical sequence except for a single base mismatch (e.g., substituting a G, a C or a T for an A) at any of positions 6 through 14 (the central mismatch).

Mismatch probes thus provide a control for non-specific binding or cross hybridization to a nucleic acid in the sample other than the target to which the probe is directed. Mismatch probes also indicate whether a hybridization is specific or not. For example, if the target is present the perfect match probes should be consistently brighter

5

10

15

20

25

30

than the mismatch probes. In addition, if all central mismatches are present, the mismatch probes can be used to detect a mutation. The difference in intensity between the perfect match and the mismatch probe (I(PM) - I(MM)) provides a good measure of the concentration of the hybridized material.

5

10

15

20

25

30

#### Nucleic Acid Samples

As is apparent to one of ordinary skill in the art, nucleic acid samples used in the methods and assays of the invention may be prepared by any available method or process. Methods of isolating total mRNA are also well known to those of skill in the art. For example, methods of isolation and purification of nucleic acids are described in detail in Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 24, Hybridization With Nucleic Acid Probes: Theory and Nucleic Acid Probes, P. Tijssen, ed., Elsevier Press, New York (1993). Such samples include RNA samples, but also include cDNA synthesized from a mRNA sample isolated from a cell or tissue of interest. Such samples also include DNA amplified from the cDNA, and an RNA transcribed from the amplified DNA. One of skill in the art would appreciate that it may be desirable to inhibit or destroy RNase present in homogenates before homogenates can be used.

Biological samples may be of any biological tissue or fluid or cells from any organism as well as cells raised *in vitro*, such as cell lines and tissue culture cells. Frequently the sample will be a "clinical sample" which is a sample derived from a patient. Typical clinical samples include, but are not limited to, breast tissue biopsy, sputum, blood, blood-cells (*e.g.*, white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom.

Biological samples may also include sections of tissues, such as frozen sections or formalin fixed sections taken for histological purposes.

#### Solid Supports

Solid supports containing oligonucleotide probes for differentially expressed genes can be any solid or semisolid support material known to those skilled in the art. Suitable examples include, but are not limited to, membranes, filters, tissue culture dishes, polyvinyl chloride dishes, beads, test strips, silicon or glass based chips and the like. Suitable glass wafers and hybridization methods are widely available, for example, those disclosed by Beattie (WO 95/11755). Any solid surface to which oligonucleotides can be bound, either directly or indirectly, either covalently or non-covalently, can be used. In some

21

embodiments, it may be desirable to attach some oligonucleotides covalently and others non-covalently to the same solid support.

A preferred solid support is a high density array or DNA chip. These contain a particular oligonucleotide probe in a predetermined location on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence. Such predetermined locations are termed features. There may be, for example, from 2, 10, 100, 1000 to 10,000, 100,000 or 400,000 of such features on a single solid support. The solid support, or the area within which the probes are attached may be on the order of a square centimeter.

Oligonucleotide probe arrays for expression monitoring can be made and used according to any techniques known in the art (see for example, Lockhart et al., Nat Biotechnol 14, 1675-1680 (1996); McGall et al., Proc Nat Acad Sci USA 93, 13555-13460 (1996)). Such probe arrays may contain at least two or more oligonucleotides that are complementary to or hybridize to two or more of the genes described herein. Such arrays my also contain oligonucleotides that are complementary or hybridize to at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 70 or more the genes described herein.

Methods of forming high density arrays of oligonucleotides with a minimal number of synthetic steps are known. The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling (see Pirrung et al., (1992) U.S. Patent No. 5,143, 854; Fodor et al., (1998) U.S. Patent No. 5,800,992; Chee et al., (1998) U.S. Patent No. 5,837,832).

In brief, the light-directed combinatorial synthesis of oligonucleotide arrays on a glass surface proceeds using automated phosphoramidite chemistry and chip masking techniques. In one specific implementation, a glass surface is derivatized with a silane reagent containing a functional group, e.g., a hydroxyl or amine group blocked by a photolabile protecting group. Photolysis through a photolithogaphic mask is used selectively to expose functional groups which are then ready to react with incoming 5' photoprotected nucleoside phosphoramidites. The phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group). Thus, the phosphoramidites only add to those areas selectively exposed from the preceding step. These steps are repeated until the desired array of sequences have been synthesized on the solid surface. Combinatorial synthesis of different oligonucleotide

5

10

15

20

25

30

٠.٠

22

analogues at different locations on the array is determined by the pattern of illumination during synthesis and the order of addition of coupling reagents.

In addition to the foregoing, additional methods which can be used to generate an array of oligonucleotides on a single substrate are described in Fodor *et al.*, WO 93/09668. High density nucleic acid arrays can also be fabricated by depositing pre-made or natural nucleic acids in predetermined positions. Synthesized or natural nucleic acids are deposited on specific locations of a substrate by light directed targeting and oligonucleotide directed targeting. Another embodiment uses a dispenser that moves from region to region to deposit nucleic acids in specific spots.

10

15

20

25

30

5

#### Hybridization

Nucleic acid hybridization simply involves contacting a probe and target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing (see Lockhart et al., WO 99/32660). The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids to be detected, typically through detection of an attached detectable label. It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids. Under low stringency conditions (e.g., low temperature and/or high salt) hybrid duplexes (e.g., DNA-DNA, RNA-RNA or RNA-DNA) will form even where the annealed sequences are not perfectly complementary. Thus, specificity of hybridization is reduced at lower stringency. Conversely, at higher stringency (e.g., higher temperature or lower salt) successful hybridization requires fewer mismatches. One of skill in the art will appreciate that hybridization conditions may be selected to provide any degree of stringency. In a preferred embodiment, hybridization is performed at low stringency, in this case in 6x SSPE-T at 37°C (0.005% Triton x-100) to ensure hybridization and then subsequent washes are performed at higher stringency (e.g., 1× SSPE-T at 37°C) to eliminate mismatched hybrid duplexes. Successive washes may be performed at increasingly higher stringency (e.g., down to as low as 0.25× SSPET at 37°C to 50°C) until a desired level of hybridization specificity is obtained. Stringency can also be increased by addition of agents such as formamide. Hybridization specificity may be evaluated by comparison of hybridization to the test probes with hybridization to the various controls that can be present (e.g., expression level control, normalization control, mismatch controls, etc.).

In general, there is a tradeoff between hybridization specificity (stringency) and signal intensity. Thus, in a preferred embodiment, the wash is performed at the highest stringency that produces consistent results and that provides a signal intensity greater than approximately 10% of the background intensity. Thus, in a preferred embodiment, the hybridized array may be washed at successively higher stringency solutions and read between each wash. Analysis of the data sets thus produced will reveal a wash stringency above which the hybridization pattern is not appreciably altered and which provides adequate signal for the particular oligonucleotide probes of interest.

#### Signal Detection

The hybridized nucleic acids are typically detected by detecting one or more labels attached to the sample nucleic acids. The labels may be incorporated by any of a number of means well known to those of skill in the art (see Lockhart *et al.*, WO 99/32660).

#### 15 Databases

10

20

25

30

The present invention includes relational databases containing sequence information, for instance for one or more of the genes of Tables 1-5, as well as gene expression information in various breast tissue samples. Databases may also contain information associated with a given sequence or tissue sample such as descriptive information about the gene associated with the sequence information, descriptive information concerning the clinical status of the tissue sample, or information concerning the patient from which the sample was derived. The database may be designed to include different parts, for instance a sequence database and a gene expression database. Methods for the configuration and construction of such databases are widely available, for instance, see Akerblom *et al.*, (1999) U.S. Patent No. 5,953,727, which is specifically incorporated herein by reference in its entirety.

The databases of the invention may be linked to an outside or external database. In a preferred embodiment, as described in Tables 1-5, the external database is GenBank and the associated databases maintained by the National Center for Biotechnology Information (NCBI).

Any appropriate computer platform may be used to perform the necessary comparisons between sequence information, gene expression information and any other information in the database or provided as an input. For example, a large number of computer workstations are available from a variety of manufacturers, such has those

available from Silicon Graphics. Client-server environments, database servers and networks are also widely available and appropriate platforms for the databases of the invention.

The databases of the invention may be used to produce, among other things, electronic Northern blots (E-Northerns) to allow the user to determine the cell type or tissue in which a given gene is expressed and to allow determination of the abundance or expression level of a given gene in a particular tissue or cell. The E-northern analysis can be used as a tool to discover tissue specific candidate therapeutic targets that are not over-expressed in tissues such as the liver, kidney, or heart. These tissue types often lead to detrimental side effects once drugs are developed and a first-pass screen to eliminate these targets early in the target discovery and validation process would be beneficial.

The databases of the invention may also be used to present information identifying the expression level in a tissue or cell of a set of genes comprising at least one gene in Tables 1-5 comprising the step of comparing the expression level of at least one gene in Tables 1-5 in the tissue to the level of expression of the gene in the database. Such methods may be used to predict the physiological state of a given tissue by comparing the level of expression of a gene or genes in Tables 1-5 from a sample to the expression levels found in tissue from normal breast tissue, tissue from breast carcinoma or both. Such methods may also be used in the drug or agent screening assays as described herein.

20

25

30

000000 MO 000007440 L

5

10

15

Kits

The invention further includes kits combining, in different combinations, high-density oligonucleotide arrays, reagents for use with the arrays, signal detection and array-processing instruments, gene expression databases and analysis and database management software described above. The kits may be used, for example, to monitor the progression of breast cancer, to identify genes that show promise as new drug targets and to screen known and newly designed drugs as discussed above.

The databases packaged with the kits are a typically a compilation of expression patterns from human breast cancer tissue or cell lines and for gene and gene fragments as described herein (corresponding to the genes of Tables 1-5). In particular, the database software and packaged information include the expression results of Tables 1-5 that can be used to predict the cancerous state of a tissue sample by comparing the expression levels of the genes in the tissue or cell sample to the expression levels presented in Tables 1-5.

The kits may used in the pharmaceutical industry, where the need for early drug testing is strong due to the high costs associated with drug development, but where bioinformatics, in particular gene expression informatics, is still lacking. These kits will reduce the costs, time and risks associated with traditional new drug screening using cell cultures and laboratory animals. The results of large-scale drug screening of pre-grouped patient populations, pharmacogenomics testing, can also be applied to select drugs with greater efficacy and fewer side-effects. The kits may also be used by smaller biotechnology companies and research institutes who do not have the facilities for performing such large-scale testing themselves.

Databases and software designed for use with use with microarrays is discussed in Balaban et al., (2001) U.S. Patent Nos. 6,229,911, a computer-implemented method for managing information, stored as indexed tables, collected from small or large numbers of microarrays, and 6,185,561, a computer-based method with data mining capability for collecting gene expression level data, adding additional attributes and reformatting the data to produce answers to various queries. Chee et al., (1999) U.S. Patent No. 5,974,164, disclose a software-based method for identifying mutations in a nucleic acid sequence based on differences in probe fluorescence intensities between wild type and mutant sequences that hybridize to reference sequences. The object of the method is to predict regions or positions of mutation.

20

5

10

15

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The preceding working examples therefore, are illustrative only and should not be construed as limiting in any way the scope of the invention.

#### **Examples**

### Example 1: Preparation of Breast Cancer Profiles

Tissue Sample Acquisition and Preparation

30

25

The patient tissue samples were derived from female patients; the average age for the normal and tumor samples was 39 and 52 years respectively. They stem from three different ethnic origins (Caucasian, African-American, and Asian). Furthermore, all tissue samples from Infiltrating Ductal Carcinoa (IDC) patient samples were studied for cancer-related expression, as 85% of the breast cancer patients were afflicted with this form of the

15

20

25

30

NEDWIN - NO 0305037143 1 -

disease. The samples are composed of normal, benign, DCIS (ductal carcinoma *in-situ*), microinvasive, stage II, and stage III breast cancer samples.

Histological analysis of each of the tissue samples was performed and samples were segregated into either normal or malignant categories. The normal tissue samples were acquired from neighboring tissue of patients suffering from one of the following disorders: macromastia, mild fibrosis, infiltrating lobular carcinoma, or infiltrating ducal carcinoma, however; each tissue was diagnosed as normal by histological analysis.

With minor modifications, the sample preparation protocol followed the Affymetrix GeneChip Expression Analysis Manual. Frozen tissue was first ground to powder using the Spex Certiprep 6800 Freezer Mill. Total RNA was then extracted using Trizol (Life Technologies). The total RNA yield for each sample (average tissue weight of 300 mg) was 200-500  $\mu$ g. Next, mRNA was isolated using the Oligotex mRNA Midi kit (Qiagen). Since the mRNA was eluted in a final volume of 400  $\mu$ l, an ethanol precipitation step was required to bring the concentration to 1  $\mu$ g/ $\mu$ l. Using 1-5  $\mu$ g of mRNA, double stranded cDNA was created using the SuperScript Choice system (Gibco-BRL). First strand cDNA synthesis was primed with a T7-(dT<sub>24</sub>) oligonucleotide. The cDNA was then phenol-chloroform extracted and ethanol precipitated to a final concentration of 1  $\mu$ g/ $\mu$ l.

From 2 µg of cDNA, cRNA was synthesized according to standard procedures. To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added to the reaction. After a 37°C incubation for six hours, the labeled cRNA was cleaned up according to the Rneasy Mini kit protocol (Qiagen). The cRNA was then fragmented (5× fragmentation buffer: 200 mM Tris-Acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94°C.

55 μg of fragmented cRNA was hybridized on the human and the Human Genome U95 set of arrays for twenty-four hours at 60 rpm in a 45°C hybridization oven. The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations. To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between. Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Following hybridization and scanning, the microarray images were analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. After all chips passed QC, the data was analyzed using Affymetrix GeneChip software (v3.0), and Experimental Data Mining Tool (EDMT) software (v1.0).

10

15

20

25

30

Gene Expression Analysis

All samples were prepared as described and hybridized onto the Affymetrix Human Genome U95 array. Each chip contains 16-20 oligonucleotide probe pairs per gene or cDNA clone. These probe pairs include perfectly matched sets and mismatched sets, both of which are necessary for the calculation of the average difference. The average difference is a measure of the intensity difference for each probe pair, calculated by subtracting the intensity of the mismatch from the intensity of the perfect match. This takes into consideration variability in hybridization among probe pairs and other hybridization artifacts that could affect the fluorescence intensities. Using the average difference value that has been calculated, an absolute call for each gene or EST is made.

The absolute call of present, absent or marginal is used to generate a Gene Signature, a tool used to identify those genes that are commonly present or commonly absent in a given sample set, according to the absolute call. For each set of samples, a median average difference was calculated using the average differences of each individual sample within the set. The median average difference typically must be greater than 20 to assure that the expression level is at least two standard deviations above the background noise of the hybridization. For the purposes of this study, only the genes and gene fragments with a median average difference greater than 20 were further studied in detail.

The Gene Signature for one set of samples is compared to the Gene Signature of another set of samples to determine the Gene Signature Differential. This comparison identifies the genes that are consistently present in one set of samples and consistently absent in the second set of samples.

The Gene Signature Curve is a graphic view of the number of genes consistently present in a given set of samples as the sample size increases, taking into account the genes commonly expressed among a particular set of samples, and discounting those genes whose expression is variable among those samples. The curve is also indicative of the number of samples necessary to generate an accurate Gene Signature. As the sample number increases, the number of genes common to the sample set decreases. The curve is generated using the positive Gene Signatures of the samples in question, determined by adding one sample at a time to the Gene Signature, beginning with the sample with the smallest number of present genes and adding samples in ascending order. The curve displays the sample size required for the most consistency and the least amount of expression variability from sample to sample. The point where this curve begins to level off represents the minimum

number of samples required for the Gene Signature. Graphed on the x-axis is the number of samples in the set, and on the y-axis is the number of genes in the positive Gene Signature. As a general rule, the acceptable percent of variability in the number of positive genes between two sample sets should be less than 5%.

5

10

20

25

30

A LEVEL COSON CHIEF THE THE PROPERTY IS

#### Fold Change analysis

The data was first filtered to exclude all genes that showed no expression in any of the samples. The ratio (tumor/normal) was calculated by comparing the mean expression value for each gene in the breast cancer sample set against the mean expression value of that gene in the normal breast sample set. For Table 2, genes were included in the analysis if they had a fold change  $\geq 3$  in either direction, and a p-value < 0.05 as determined by a two-tail unequal variance t-test. Out of the  $\sim 60,000$  genes surveyed by the Human Genome U95 set, 802 genes were present in the overall fold change analysis

#### 15 Expression Profiles of Genes Differentially Expressed in Breast Cancer

Using the above described methods, genes that were predominantly over-expressed in breast cancer, or predominantly under-expressed in breast cancer were identified. Genes with consistent differential expression patterns provide potential targets for broad range diagnostics and therapeutics. For simplicity, applicants examined known genes by hierarchical cluster analysis developed by Eisen and colleagues to determine if functionally related genes would cluster together (see Eisen, et al. Proc Natl Acad Sci USA 95, 14863-14868 (1998)).

Table 2 lists the genes determined to be differentially expressed in cancerous breast tissues compared to normal breast tissue, with the fold change value for each gene. These genes or subsets of these genes comprise an overall breast cancer gene expression profile.

The well-characterized proliferation marker for breast cancer KI-67 had an average-fold change value of 2.8, which was calculated from 15 IDC tissue samples analyzed (see Gerdes, Semin Cancer Biol 1, 199-206 (1990)). As the fold change was below the present 3 fold criteria, the fold change value was not presented in Table 2. Some genes previously shown to be over or under expressed in breast cancer as indicated from the literature such as cytokeratins 5, 14, 15, 17, maspin, MMP 9 and 11, fibronectin, and pituitary tumor transforming 1, etc. are displayed in Table 2 as well as some genes such as p57(kip2), p63/p51/KET, mitosin, and pCDC55 whose expression levels were not previously known to vary in breast cancer.

29

The pituitary-tumor transforming 1 gene has been shown to produce *in vitro* and *in vivo* tumor-inducing activity (see Zhang *et al. Mol Endocrinol* 13, 156-66 (1999). In a recent publication, pituitary-tumor transforming 1 has been shown to be over-expressed in mammary adenocarcinomas (see Saez *et al. Oncogene* 18, 5473-6 (1999)). Also, another study discovered that all 48 colon carcinomas examined over-expressed PTTG1 as compared to normal colorectal tissue, and invasion of the surrounding tissue was associated with higher PTTG1 expression levels (see Heaney *et al.* Expression of pituitary-tumour transforming gene in colorectal tumours [see comments] *Lancet* 355, 716-9 (2000)).

Genes listed in Table 2, not reported in the literature to be over-expressed in human breast cancer tissues, include RAD2, FLS353, CKS2, cyclin-selective ubiquitin carrier protein E2-C, ZWINT, Lamin B1 and H2A.X. Although FLS353 has been recently found to be over-expressed in colorectal cancer (see Hufton *et al. FEBS Lett* 463, 77-82 (1999)), differential expression of FLS353 in breast tumor cells had not been previously demonstrated.

Cyclin-ubiquitin carrier protein E2-C is another gene over-expressed in breast cancer, which was discovered in this study. Previous studies have shown that when a dominant-negative form of the protein is over-expressed, the mammalian cells arrested in M phase and evidence was provided indicating that this mutant form of cyclin-ubiquitin carrier protein E2-C blocked the destruction of both cyclin A and B (see Townsley et al., Proc Natl Acad Sci USA 94, 2362-7 (1997)).

The expression levels of the genes in Tables 4 and 5 are associated with various stages of infiltrating ductal carcinoma (Table 4) or infiltrating lobular carcinoma (Table 5). The Tables present the fold change value of expression in the particular disease state compared to normal breast tissue. The genes in these tables may be used alone, or in combination with those listed in Tables 1-3 in the methods, compositions, databases and computer systems of the invention.

#### Example 2: Diagnostic Subset of Breast Cancer Associated Genes

Table 1 lists the members of a diagnostic subset of genes selected by p-value. This group of genes can be used to differentiate between normal/benign and breast tumor tissue samples including two DCIS samples. Assays using these genes are capable of distinguishing between normal and tumor samples with near 100% efficiency (see Figure 6). Only 1 of the 33 samples shown was misclassified as a normal sample based on the gene

5

10

15

20

25

30

expression profile when this set of genes was used to analyze the 33 sample set (see Figure 7).

Figures 6 and 7 are three-dimensional plots displaying the relationship of variance derived from gene expression data obtained from patient samples. In Figure 6, normal tissue samples are displayed as darker spheres and the infiltrating ductal carcinoma tissue samples are the lighter spheres. The x-axis represents the first principal component that contains the greatest variance in data of 80%. The y-axis represents the second principal component of 4%. The z-axis represents the third principal component of 3%. Figure 7 displays the results obtained from a separate 33 sample set which is composed of new samples that have no relation to the 28 sample set utilized to discover the gene set of Table 1. Again, the x, y, and z-axes represent the first (63%), second (10%), and third principal components (6%), respectively.

The gene set of Table 1 can thus be used to distinguish normal from cancerous breast tissue.

Example 3: Myoepithelial and Luminal Cell Marker Genes Examined on a Global Scale

Previous studies have indicated that myoepithelial cells express both epithelial and smooth muscle gene expression markers while luminal epithelial cells fail to express these genes (see Lazard et al., Proc Natl Acad Sci USA 90, 999-1003 (1993)). Cluster analysis identified a group 35 fragments representing 31 genes into one highly correlative cluster and the combination of genes and ESTs are listed in Table 3.

Previous studies have indicated that calponin and myosin heavy chain are expressed in smooth muscle cells and myoepithelial cells while luminal epithelium lack the expression of these genes. Furthermore, the proteins are usually not expressed in invasive ductal carcinoma of the breast (Lazard, et al., supra). Both calponin (fold change -11) and myosin heavy chain (fold change -10.8) were under-expressed in IDC. As indicated in Table 3, other genes associated with smooth muscle that were under-expressed such as smooth muscle gamma-actin, myosin light chain kinase, myosin, heavy polypeptide 11, and Leiomodin 1 and both mysoin polypeptide 11 and leiomodin 1 have not been previously reported to be under-expressed in breast cancer as compared to normal tissue samples.

The expression pattern represented in this particular cluster indicates that a preponderance of tissue samples diagnosed as infiltrating ductal carcinoma exhibit a luminal phenotype while myoepithelial cells were absent. More evidence to support this finding includes the under-expression of cytokeratins 5, 14, 15, and 17 in the tumor samples as

5

10

15

20

25

30

10

15

20

25

30

47

٠٠. ٨٠

shown in Table 3. Normal myoepithelial cells express cytokeratins 5, 14, 15, and 17 and breast carcinoma cells do not (Trask et al. Proc Natl Acad Sci USA 87, 2319-2323 (1990)). A previous study has indicated that myoepithelial cells are present in normal, benign lesions, grade I infiltrating ductal carcinoma but are absent in carcinomas of grades II and III (Gusterson et al. Cancer Res 42, 4763-4770 (1982)).

In addition, components of the basal lamina such as laminin were under-expressed in the infiltrating ductal carcinoma relative to normal tissue samples (Table 3). Both laminin S B3 and laminin-related protein were under-expressed as indicated in Table 3. It has been reported that myoepithelial and basal lamina markers are useful in differentiating microinvasive from ductal carcinomas of the breast (Damiani *et al. Virchows Arch* 434, 227-234 (1999)).

The set of 35 fragments representing 31 genes as shown in Table 3 could distinguish between intraductal carcinoma and microinvasive DCIS tissue samples based on the disappearance of genes expressed in either basal lamina or myoepithelial cells. There is evidence in the literature that the collapse of the basement membrane as well as the disappearance of an intact myoepithelial cell layer occurs during the invasion process. A multi-gene screen utilizing either of these sets of genes can be used to differentiate between benign and invasive breast neoplasm based on the gene expression fingerprint elucidated in this study.

Figure 8 shows the results of PCA of the 91 sample set with all 35 fragments (representing 31 genes and ESTs) in Table 3. These results demonstrate that PCA using the genes in Table 3 is able to distinguish between non-invasive and invasive breast tissue samples. Figure 8 provides evidence that this group of genes is diagnostically useful for differentiating DCIS samples that are intraductal (non-invasive) from those containing microinvasion. As shown in Figure 8, this group of genes and ESTs is capable of differentiating between two subtypes of DCIS and may constitute a set that is a more sensitive predictor of a microinvasion phenotype.

#### Example 4: Discovery of Breast Tissue Specific Genes in IDC

Electronic northern (E-northern) analysis determines if a gene of interest is present in a tissue from a database of gene expression information, and if it is present, then at what levels. Expression levels were determined using a GeneChip set that evaluated the expression levels of 60,000 genes in each type of tissue from 28 different normal human tissues. Similar to multi-tissue northern blot analysis, E-northern analysis quickly

10

15

20

25

30

determines if a gene of interest is expressed in a particular tissue type and also at what level. E-northern analysis of multiple tissue samples can be evaluated and the determination of exactly how many samples of a particular group that express the gene of interest is tabulated and statistical analysis can be implemented. Multiple samples from the same tissue are not available at this time using conventional multi-tissue northern blot analysis.

The E-northern analysis can be used as a tool to discover tissue specific candidate therapeutic targets that are not over-expressed in tissues such as the liver, kidney, or heart. These tissue types often lead to detrimental side effects once drugs are developed and a first-pass screen to eliminate these targets early in the target discovery and validation process would be beneficial. Furthermore, different tissues have very unique gene expression profiles related to parameters such as proliferation, differentiation, or cell types contained in the tissue that can provide interesting clues into the biological roles of the ESTs.

E-northern analysis was performed for many of the genes clustered in Table 2. Analysis of the E-northerns revealed that most of the genes were expressed at elevated levels in the thymus. There is high rate of mitosis present in the thymus during T-lymphocyte maturation and many proliferation-associated genes are expressed at elevated levels such as CDC2, cyclin B1, and topoisomerase II alpha. Figure 1 displays the E-northern analysis for topoisomerase II alpha indicating elevated levels of expression in the thymus as compare to the other tissue types detected. Figure 2 shows the results of an E-Northern analysis of transcription factor ICBP90, implicated to be involved with topoisomearse II alpha expression. ICBP90 was also expressed at high levels relative to the other tissue types in the thymus (Figure 2). A study by Hopfner et al. indicated that adult thymus and fetal thymus contained the highest levels of ICBP90 using a 50-tissue RNA dot blot protocol (Hopfner et al. Cancer Res 60, 121-128 (2000)). Most of the genes contained in this cluster contained the highest levels of expression in the thymus.

Figure 3 shows the results of an E-Northern analysis of the monocarboxylate transporter 4 (MCT4; formerly known as MCT3) which was grouped with genes associated with proliferation. MCT4 is most evident in cells with a high glycolytic rate such as muscle, white blood cells, and tumor cells (Halestrap et al., Biochem J 343 (Pt 2), 281-299 (1999)). A group of multi-tissue northern blots from a recent publication indicate that MCT4 is expressed at high levels in leukocytes but also other tissue types as well (Price et al., Biochem J 329, 321-328 (1998)). Furthermore, electronic-northern analysis indicated high levels of MCT4 were expressed in blood and white blood cells (Figure 3).

WO 02/059271

:

A previously uncharacterized gene only expressed in breast tissue was identified from this study and an E-Northern analysis of the expression pattern of this gene is shown in Figure 4. The distribution pattern of the expression of the gene shows it be used as a marker for breast cancer. The E-northern analysis only displays tissues where the gene of interest is present at detectable levels and breast tissue was the only tissue that this particular gene was under-expressed by -4.2 fold in IDC making it particularly useful as a diagnostic marker.

Another gene that may be used as a diagnostic marker that was not present in a particular cluster is the secreted frizzled-related protein 1. This gene was under-expressed in IDC by -17.7 fold, and the E-northern analysis shown in Figure 5 indicates that it was expressed at greatest levels in breast tissue as well as in the cervix. Using the combination of clustering, fold-change analysis, and E-northern analysis on microarray data one skilled in the art can readily select additional therapeutic and diagnostic markers.

15

20

10

5

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents and publications referred to in this application are herein incorporated by reference in their entirety.

Table	1: Top 50	Table 1: Top 50 by p-value		i			
##	SedID	Affy	Genbank	Description	Fold Change	p-values	
~	1006	37892_at	J04177	Cluster Incl J04177:Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds=(161,5581) /gb=J04177 /gi=179729 /ug=Hs.82772 /len=6158	10.18941323	1.24E-12	
0	278	35832 <u>a</u> t	AB029000	Cluster Incl AB029000:Homo sapiens mRNA for KIAA1077 protein, partial cds /cds=(0,2456) /gb=AB029000 /gi=5689490 /ug=Hs.70823 /len=4834	4.243716901	2.469E-12	
ო	1227	38566_at	X60382	Cluster Incl X60382:H.sapiens COL.10A1 gene for collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198	9.164231149	4.719E-12	
4	1226	38181_at	X57766	Cluster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=456256 /ug=Hs.155324 /len=2247	13.96572736	5.309E-12	
ιo	1159	1651_at	U73379	U73379 /FEATURE= /DEFINITION=HSU73379 Human cyclin-selective ubiquitin carrier protein mRNA, complete cds	4.802394237	5.8315E-11	
ဖ	1161	33143_s_at	at U81800	Cluster Incl U81800:Homo sapiens monocarboxylate transporter (MCT3) mRNA, complete cds /cds=(62,1459) /gb=U81800 /gi=2463633 /lon=1982	0.07793742	6.2406E-11	
~	296	34342_s_at	AF052124	Cluster Incl AF052124:Homo sapiens clone 23810 osteopontin mRNA, complete cds /cds=(87,989) /db=AF052124 /gi=3360431 /ug=Hs.313 /len=1504	8.862541971	1.1789E-10	
<b>∞</b>	1008	31859_at	J05070	Cluster Incl J05070:Human type IV collagenase mRNA, complete cds /cds=(19,2142) /gb=J05070 /gi=177204 /ug=Hs, 151738 /len=2334	4.66285568	1.68E-10	
တ	961	38116_at	D14657	Cluster Incl D14657:Human mRNA for KIAA0101 gene, complete cds /cds=(61,396) /gb=D14657 /gi=285938 /ug=Hs.81892 /len=836	0.17	2.1736E-10	
10	1007	2092_s_at	J04765	J04765 /FEATURE= /DEFINITION=HUMOSTRO Human osteopontin mRNA, complete cds	4.119810176	3.9853E-10	
<b>=</b>	277	39109_at	AB024704	Cluster Incl AB024704:Homo sapiens mRNA for fls353, completeds /cds=(471,2714) /gb=AB024704 /gi=4589928 / Jen=3403	0.228960682	6.59E-10	

BAIGNOCID: -WO MONEGOTTAD 1 5

p-values	7.4333E-10	7.7763E-10	9.3518E-10	1.10E-09	1.5685E-09	1.5906E-09	1.7499E-09	2.013E-09	2.0933E-09	2.11E-09
Fold Change	9.431588747	10.43	5.975488989	6.152409861	0.068952382	0.139391318	0.047728145	7.363245733	8.54	0.233878866
Description	Cluster Incl M10905:Human cellular fibronectin mRNA /cds=(0,2383) /gb=M10905 /gi=182696 /ug=Hs.118162 /len=2384	Cluster Incl Y15915:Homo sapiens mRNA for chimaeric transcript of collagen type 1 alpha 1 and platelet derived growth factor beta, 1068 bp /cds=(0,1067) /gb=Y15915 /gi=3288486 /ug=Hs.172928 /len=1068	Cluster Incl AA203213:zx57e04.r1 Homo sapiens cDNA, 5 end /clone≂IMAGE-446622 /clone_end=5" /gb=AA203213 /gi=1798923 /ug=Hs.833 /len=879"	Cluster Incl M97936:Human transcription factor ISGF- · 6.152409861 3 mRNA sequence /cds=UNKNOWN /gb=M97936 /gi=475254 /ug=Hs.21486 /len=2607	Cluster Incl L32137:Human germline oligomeric matrix protein (COMP) mRNA, complete cds /cds=(25,2298) /gb=L32137 /gi=602449 /ug=Hs.1584 /len=2439	Cluster Incl AL050118:Homo sapiens mRNA; cDNA DKFZp586C201 (from clone DKFZp586C201) /cds=(0,936) /gb=AL050118 /gi=4884143 /ug=Hs.184641 /len=2621	Cluster Incl AA418080:zv97h07.s1 Homo sapiens CDNA, 3 end /clone=IMAGE-767773 /clone_end=3" /gb=AA418080 /gi=2079881 /ug=Hs.3972 /len=543"	Cluster Incl M91670:Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds /cds=(59,736) /gb=M91670 /gi=181915 /ug=Hs.174070 /len=890	Cluster Incl AA203476:zx55e01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446424 /clone_end≐5" /gb=AA203476 /gi=1799203 /ug=Hs.159626 /len=828"	Cluster Incl L37747:Homo sapiens lamin B1 gene /cds=(340,2100) /gb=L37747 /gi=576839 /ug=Hs.89497 /len=2849
Genbank	M10905	Y15915	AA203213	M97936	L32137	AL050118	AA418080	M91670	AA203476	L37747
Affy	31720_s_at	35474_s_at	38432_at	33338_at	40161_at	32190_at	34778_at	40619_at	40412_at	37985_at
SealD	1030	1240	85	1059	1021	892	105	1057	83	1025
##	12	5	4	5	9	17	8	19	20	21

<b>p-values</b> 2.35E-09	2.42E-09	2.6578E-09	2.8399E-09	3.1699E-09	3.56E-09	4.0319E-09	4.2586E-09	5.41E-09
Fold Change 7.935291557	4.329038319	0.233804467	0.16	0.284181885	6.816530863	10.36	0.103783146	4.690939862
<u>Description</u> M13755 /FEATURE=mRNA /DEFINITION=HUMIFN15K Human interferon- induced 17-kDa/15-kDa protein mRNA, complete cds	Cluster Incl X14850:Human H2A.X mRNA encoding histone H2A.X /cds=(73,504) /gb=X14850 /gi=31972 /ug=Hs.147097 /len=1585	Cluster Incl X54942:H.sapiens ckshs2 mRNA for Cks1 protein homologue /cds=(95,334) /gb=X54942 /gi=29978 /uq=Hs.83758 /len=612	M91670 /FEATURE= /DEFINITION=HUME2EP! Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds	Cluster Incl K02581:Human thymidine kinase mRNA, complete cds /cds=(57,761) /gb=K02581 /gi=339708 /ua=Hs.105097 /len=1421	Cluster Incl Al375913:tc14c08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2063822 /clone_end=3" /gb=Al375913 /gi=4175903 /ug=Hs.156346 /len=916"	Cluster Incl AF067656:Homo sapiens ZW10 interactor Zwint mRNA, complete cds /cds=(24,857) /gb=AF067656 /gi=3901271 /ug=Hs.42650 /len=1639	Cluster Incl AA704137:ag47g01.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1119984 /clone_end=3" /gb=AA704137 /gi=2714055 /ug=Hs.125359 /len=923"	L47276 /FEATURE=UTR#1 /DEFINITION=HUMTOPATR Homo sapiens (cell line HL-60) alpha topoisomerase truncated-form mRNA, 3"UTR
<u>Genbank</u> M13755	X14850	X54942	M91670	K02581	Al375913	AF067656	AA704137	L47276
<b>Affy</b> 1107_s_at	40195_at	40690_at	893_at	41400_at	40145_at	35995_at	39395_at	904_s_at
SeqID 1034	1221	1224	1057	1010	44	303	205	1027
75 ## 75 ##	23	24	25	56	27	78	59	30

DAIDDOOM - MICH MONEONTIAN I .

<b>Affy</b> 39969_at A	<b>Affy</b> 39969_at A	`∢	Genbank AA255502	Description Cluster Incl AA255502:zr85b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-682451 /clone_end=5" /gb=AA255502 /gi=1892406 /ug=Hs.46423 /len=348"	Fold Change 0.222082398	<b>p-values</b> 5.4948E-09
U05340	38414_at U05340		ਹੁ <u>ខ</u> ុ	Cluster Incl U05340:Human p55CDC mRNA, complete cds /cds=(110,1609) /gb=U05340 /gi=468031 /ug=Hs.82906 /len=1686	0.0564074	5.77E-09
1216 31719_at X02761 Clu pre /ug	X02761		Clu Pre /ug	Cluster Incl X02761:Human mRNA for fibronectin (FN precursor) /cds=(0,6987) /gb=X02761 /gl=31396 /ug=Hs.118162 /len=7680	0.145966282	5.79E-09
U74612	U74612		Clus 3/fo cds	Cluster Incl U74612:Human hepatocyte nuclear factor 3/fork head homolog 11A (HFH-11A) mRNA complete cds /cds=(114,2519) /gb=U74612 /gi=1842252 /ug=Hs.239 /len=3474	0.075355998	5.93E-09
M25753	M25753		Clusi /cds= /ug=l	Cluster Incl M25753:Human cyclin B mRNA, 3 end /cds=UNKNOWN /gb=M25753 /qi=181243 /ug=Hs.23960 /len=1452"	7.624017858	5.98E-09
1002 32305_at J03464 Clust mRN /cds=//dg=h	J03464		Clust mRN /cds=	Cluster Incl J03464:Human collagen alpha-2 type I mRNA, complete cds, clone pHCOL2A1 /cds=(469,4569) /gb=J03464 /gi=179595 /ug=Hs.179573 /len=5416	7.973012437	6.70E-09
1222 38112_g_at X15998 Clust chonc variar /gb=X	_at X15998		Clust chone variar /gb=X	Cluster Incl X15998:H.sapiens mRNA for the chondroitin sulphate proteoglycan versican, V1 splice variant; precursor peptide /cds=(266,7495) /gb=X15998 /gi=37662 /ug=Hs.81800 /len=8224	0.273622601	6.7E-09
279	_at AC003107		Cluste chrorr the C(	Cluster Incl AC003107:Human DNA from chromosome 19-specific cosmid R30064 containing the COMP gene, genomic sequence /cds=(0,2453) /gb=AC003107 /gi=2623749 /ug=Hs.1584 /len=2454	0.139924253	7.063E-09
1041 1577_at M23263 M2326 Huma	M23263		M2326 Huma	M23263 /FEATURE= /DEFINITION=HUMARB Human androgen receptor mRNA, complete cds	12.37	7.3252E-09
276 41812_s_at AB020713 Cluste KIAA( /gb=A	at AB020713		Cluste KIAA( /gb=A	Cluster Incl AB020713:Homo saplens mRNA for KIAA0906 protein, partial cds /cds=(0,2772) /gb=AB020713 /gi=4240300 /ug=Hs.56966 /len=4217	0.184984291	8.5667E-09

8.99E-09	9.64E-09	1.0442E-08	1.1081E-08	1.1279E-08	1.2153E-08	1.4629E-08
<b>Fold Change</b> 4.165483399	0.216723881	0.292506358	3.425226104	8.270850261	0.054106026	0.17504844
Description Cluster Incl U59877:Human low-Mr GTP-binding protein (RAB31) mRNA, complete cds /cds=(60,644) /gb=U59877 /gi=1388194 /ug=Hs.223025 /len=907	Cluster Incl AF095448:Homo sapiens putative G protein-coupled receptor (RAIG1) mRNA, complete cds /cds=(99,1172) /gb=AF095448 /gi=4063889 /ug=Hs. 194691 /len=2288	Cluster Incl Al885852:wl62d08.x1 Homo saplens cDNA, 3 end /clone=IMAGE-2429487 /clone_end=3" /gb=Al885852 /gi=5591016 /ug=Hs.795 /len=580"	M29874 /FEATURE= /DEFINITION=HUMCYP2BB Human cytochrome P450-IIB (hIIB1) mRNA, complete cds	M15205 /FEATURE=cds /DEFINITION=HUMTKRA Human thymidine kinase gene, complete cds, with clustered Alu repeats in the introns	Cluster Incl AC004770:Homo sapiens chromosome 11, BAC CIT-HSP-311e8 (BC269730) containing the hFEN1 gene /cds=(2644,3786) /gb=AC004770 /qi=3212836 /uq=Hs.4756 /len=4522	Cluster Incl X70940:H.sapiens mRNA for elongation factor 1 alpha-2 /cds=(83,1474) /gb=X70940 /gi=38455 /ug=Hs.2642 /len=1755
Genbank	AF095448	AI885852	M29874	M15205	AC004770	X70940
Affy 33371_s	33730_at	32609_at	1371_s_at	910_at	41583_at	35174 <u>i_at X70940</u>
<b>SeqID</b> 1155	307	756	1044	1036	281	1233
## 4	45	43	<u></u>	÷ 45	46	47

	senjex-d	9.03E-07	6.70E-09	2.35E-08	2.35E-09	5.98E-09	1.32E-04	1.33E-06
	<b>Fold Change</b>	12.80130327	7.973012437	7.957396249	7.935291557	7.624017858	7.205250917	6.987016934
	Cluster Description	Cluster Incl J04177:Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds=(161,5581) /gb=J04177 /gi=179729 /ug=Hs.82772 /len=6158	Cluster Incl X60382:H.sapiens COL10A1 gene for collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198	Cluster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=456256 /ug=Hs.155324 /len=2247	U73379 /FEATURE= /DEFINITION=HSU73379 Human cyclin-selective ubiquitin carrier protein mRNA, complete cds	Cluster Incl U81800:Homo sapiens monocarboxylate transporter (MCT3) mRNA, complete cds /cds=(62,1459) /gb=U81800 /gi=2463633 /ug=Hs.85838 /len=1982	Cluster Incl AF052124:Homo sapiens clone 23810 osteopontin mRNA, complete cds /cds=(87,989) /gb=AF052124 /gi=3360431 /ug=Hs.313 /len=1504	Cluster Incl J05070:Human type IV collagenase mRNA, complete cds /cds=(19,2142) /gb=J05070 /gl=177204 /ug=Hs.151738 /len=2334
	Cluster#	Hs.82772	Hs.179729	Hs.155324	Hs.93002	Hs.85838	Hs.313	Hs.151738
	Gene Name	collagen, fype XI, alpha 1	collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	matrix metalloproteinase 11 (stromelysin 3)	ubiquitin carrier protein E2-C	solute carrier family 16 (monocarboxylic acid transporters), member 3	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T- lymphocyte activation 1)	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)
3-C-D-E	Genbank	J04177	X60382	X57766	U73379	U81800	AF052124	
Table 2: Final Chip A-B-C-D-E	Affy	37892_at	38566_at	38181_at	1651_at	33143_s_at	34342_s_at	31859_at
Table 2:	SeqID	1006	1227	1226	1159	1161	296	1008
·	<b>#</b> #	<del>-</del>	8	ო	4	<b>ω</b>	φ	_

					40		•	C110002/021/
p-values	1.20E-04		1.10E-09	1.72E-04	1.76E-02	1.69E-07	6.09E-06	2.18E-06
Fold Change	6.188665921		6.152409861	6.01925663	5.903615342	5.34214829	5.267240726	4.694613277
Cluster Description	J04765 /FEATURE=	/DEFINITION≂HUMOSTRO Human osteopontin mRNA, complete cds	Cluster Incl AB024704:Homo sapiens mRNA for fls353, complete cds /cds=(471,2714) /gb=AB024704 /gi=4589928 /ug=Hs.9329 /len=3403	Cluster Incl M10905:Human cellular fibronectin mRNA /cds=(0,2383) /gb=M10905 /gi=182696 /ug=Hs.118162 /len=2384	Cluster Incl Y15915:Homo sapiens mRNA for chimaeric transcript of collagen type 1 alpha 1 and platelet derived growth factor beta, 1068 bp /cds=(0,1067) /gb=Y15915 /gi=3288486 /ug=Hs.172928 /len=1068	Cluster Incl M97936:Human transcription factor ISGF-3 mRNA sequence /cds=UNKNOWN /gb=M97936 /gi=475254 /ug=Hs.21486 /len=2607	Cluster Incl L32137:Human germline oligomeric matrix protein (COMP) mRNA, complete cds /cds=(25,2298) /gb=L32137 /gi=602449 /ug=Hs.1584 /len=2439	Hs.174070 Cluster Incl M91670:Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds /cds=(59,736) /gb=M91670 /gi=181915 /ug=Hs.174070 /len=890
Cluster#	Hs.313		Hs.9329	Hs.118162	Hs.172928	Hs.21486	Hs.1584	Hs.174070
Gene Name	secreted	phosphoprotein 1 (osteopontin, bone sialoprotein I, early T- lymphocyte activation 1)	chromosome 20 open reading frame 1	fibronectin 1	collagen, type I, alpha 1	signal transducer and activator of transcription 1, 91kD	cartilage oligomeric matrix protein (pseudoachondroplasi a, epiphyseal dysplasia 1, multiple)	ubiquitin carrier protein
Genbank	J04765		AB024704	M10905	Y15915	M97936	L32137	M91670
Affy	2092_s_at		39109_at	31720_s_at M10905	35474_s_at	33338_at	40161_at	40619_at
SedID	1007		277	1030	1240	1059	1021	1057
##	œ		တ	9	<del>-</del>	12	<del>6</del>	4

<b>p-values</b> 5.41 <b>E-</b> 09	1.68E-10	1.97E-06	3.67E-07	1.59E-08	9.67E-08	8.99E-09	0.00077416	1.88E-07
<b>Fold Change</b> 4.690939862	4.66285568	4.621425831	4.485125913	4.465375169	4.357390421	4.165483399	4.09	4.002408289
Cluster Incl AA203476:zx55e01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446424 /clone_end=5" /gb=AA203476 /gi=1799203 /ug=Hs.159626 /len=828"	Cluster Incl L37747:Homo sapiens lamin B1 gene /cds=(340,2100) /gb=L37747 /gi=576839 /ug=Hs,89497 /len=2849	M13755 /FEATURE=mRNA /DEFINITION=HUMIFN15K Human interferon- induced 17-kDa/15-kDa protein mRNA,	Cluster Incl X14850:Human H2A.X mRNA encoding histone H2A.X /cds=(73,504) /gb=X14850 /gi=31972 /ug=Hs.147097 /len=1585	Cluster Incl X54942:H.saplens ckshs2 mRNA for Cks1 protein homologue /cds=(95,334) /gb=X54942 /gi=29978 /ug=Hs,83758 /len=612	Hs.105097 Cluster Incl K02581:Human thymidine kinase mRNA, complete cds /cds=(57,761) /gb=K02581 /gl=339708 /ug=Hs.105097 /len=1421	Cluster Incl AF067656:Homo sapiens ZW10 interactor Zwint mRNA, complete cds /cds=(24,857) /gb=AF067656 /gl=3901271 /ug=Hs,42650 /len=1639	M97935 Homo sapiens transcription factor ISGF-3 mRNA, complete cds (_5, _MA, MB, _3 represent transcript regions 5 prime, MiddleA, MiddleB, and 3 prime respectively)	L47276 /FEATURE=UTR#1 /DEFINITION=HUMTOPATR Homo sapiens (cell line HL-60) alpha topoisomerase truncated form mRNA, 3"UTR
Cluster# Hs.252587	Hs.89497	Hs.833	Hs.147097	Hs.83758	Hs.105097	Hs.42650	Hs.21486	
Gene Name pituitary tumor- transforming 1	lamin B1	interferon-stimulated protein, 15 kDa	H2A histone family, member X	CDC28 protein kinase 2	thymidine kinase 1, soluble	ZW10 interactor	signal transducer and activator of transcription 1, 91kD	
<u>Genbank</u> AA203476	L37747	M13755	X14850	X54942	K02581	AF067656	M97935	L47276
Affy 40412_at	37985_at	1107_s_at	40195_at	40690_at	41400_at	35995_at	AFFX- HUMISGF3A/ M97935_MA_ at	904.s.at
SeqID 83	1025	1034	1221	1224	1010	303	1058	1027
## 15	16	17	18		20	24	8	23

÷.

					42		
p-values	1.06E-06	2.48E-06	2.95E-07	2.60E-08	4.11E-03	1.28E-05	3.71E-04
Fold Change	3.870563686	3.855167487	3.813256493	3.80895841	3.800908625	3.796503387	3.781923678
Cluster Description	Cluster Incl U05340:Human p55CDC mRNA, complete cds /cds=(110,1609) /gb=U05340 /gi=468031 /ug=Hs.82906 /len=1686	Cluster Incl X02761:Human mRNA for fibronectin (FN precursor) /cds=(0,6987) /gb=X02761 /gi=31396 /ug=Hs.118162 /len=7680	Cluster Incl U74612:Human hepatocyte nuclear 3.813256493 factor-3/fork head homolog 11A (HFH-11A) mRNA complete cds /cds=(114,2519) /gb=U74612 /gi=1842252 /ug=Hs.239 /len=3474	Cluster Incl M25753:Human cyclin B mRNA, 3 end /cds=UNKNOWN /gb=M25753 /gi=181243 /ug=Hs.23960 /len=1452"	Cluster Incl J03464:Human collagen alpha-2 type I mRNA, complete cds, clone pHCOL2A1 /cds=(469,4569) /gb=J03464 /gi=179595 /ug=Hs.179573 /len=5416	Cluster Incl X15998:H.sapiens mRNA for the chondroitin sulphate proteoglycan versican, V1 splice-variant; precursor peptide /cds=(266,7495) /gb=X15998 /gi=37662 /ug=Hs.81800 /len=8224	Cluster Incl AC003107:Human DNA from chromosome 19-specific cosmid R30064 containing the COMP gene, genomic sequence /cds=(0,2453) /gb=AC003107 /gi=2623749 /ug=Hs.1584 /len=2454
Cluster#	Hs.82906	Hs.118162	Hs.239	Hs.23960	Hs.179573	Hs.81800	Hs.1584
Gene Name	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	fibronectin 1	forkhead box M1	cyclin B1	collagen, type I, alpha 2	chondroitin sulfate proteoglycan 2 (versican)	cartilage oligomeric matrix protein (pseudoachondroplasi a, epiphyseal dysplasia 1, multiple)
Genbank	U05340	X02761	U74612	M25753		X15998	AC003107
		31719_at	34715_at		32305_at	38112 <u>g</u> at	40162_s_at
SeqID	1136	1216	1160	1043	1002	1222	279
##	24	25	56	27	<b>8</b>	. 50	30

DEIEDOCID- 2000 0005007180 1

##	SealD	Affx	Genbank	Gene Name	Cluster#	Cluster Description	Fold Change	p-values
93	1041	1577_at	M23263	androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)	Hs.99915	M23263 /FEATURE= /DEFINITION=HUMARB Human androgen receptor mRNA, complete cds	3.74871763	9.37E-05
32	1155	33371_s_at	U59877	RAB31, member RAS Hs.223025 oncogene family	Hs.223025	Cluster Incl U59877:Human low-Mr GTP- binding protein (RAB31) mRNA, complete cds /cds=(60,644) /gb=U59877 /gi=1388194 /ug=Hs.223025 /len=907	3.620640004	1.57E-07
33	307	33730_at	AF095448	retinoic acid induced 3	Hs.194691	Cluster Incl AF095448:Homo sapiens putative G protein-coupled receptor (RAIG1) mRNA, complete cds /cds=(99,1172) /gb=AF095448 /gi=4063889 /ug=Hs.194691 /len=2288	3.607432569	1.35E-04
8	1044	1371_s_at	M29874	cytochrome P450, subfamily IIB (phenobarbital- inducible)	Hs.1360	M29874 /FEATURE= /DEFINITION=HUMCYP2BB Human cytochrome P450-IIB (hIIB1) mRNA, complete cds	3.556183255	5.17E-03
35	1036	910_at	M15205	thymidine kinase 1, soluble	Hs.105097	M15205 /FEATURE=cds /DEFINITION=HUMTKRA Human thymidine kinase gene, complete cds, with clustered Alu repeats in the introns	3.539960818	1.67E-05
36	281	41583_at	AC004770	·	·	Cluster Incl AC004770:Homo saplens chromosome 11, BAC CIT-HSP-311e8 (BC269730) containing the hFEN1 gene /cds=(2644,3786)/gb=AC004770 /gi=3212836 /ug=Hs.4756 /len=4522	3.437302377	9.47E-08
37	1233	35174_i_at	X70940	eukaryotic translation elongation factor 1 alpha 2	Hs.2642	Cluster Incl X70940:H.sapiens mRNA for elongation factor 1 alpha-2 /cds=(83,1474) /gb=X70940 /gi=38455 /ug=Hs.2642 /len=1755	3.435786237	3.03E-03
38	1231	425_at	X67325	interferon, alpha- inducible protein 27	Hs.278613	X67325 /FEATURE=cds /DEFINITION=HSP27 H.sapiens p27 mRNA	3.427509519	1.22E-03

p-values	2.25E-05	4.06E-07	6.11E-04	5.33E-04	1.78E-04	7.75E-07	0.000054	0.00000608
Fold Change	3.247818871	3.190855222	3.147501909	3.044487778	3.044067136	3.036676875	0.327422466	0.326731583
Cluster Description	Cluster Incl M77836:Human pyrroline 5- carboxylate reductase mRNA, complete cds /cds=(11,970) /gb=M77836 /gi=189497 /ug=Hs.79217 /len=1792	Cluster Incl M63193:Human platelet-derived endothelial cell growth factor mRNA, complete cds /cds=(123,1571) /gb=M63193 /gi=189700 /ua=Hs.73946 /len=1587	Cluster Incl U70370:Human hindlimb expressed homeobox protein backfoot (Bft) mRNA, complete cds /cds=(111,1055) /gb=U70370 /gi=1870670 /ug=Hs.84136		Cluster Incl L29254:Human (clone P1-5) L- Iditol-2 dehydrogenase gene /cds=(137,1210) /gb=L29254 /gi=808013 /ug=Hs.878 /len=2519	X05360 /FEATURE=cds /DEFINITION=HSCDC2 Human CDC2 gene involved in cell cycle control	Cluster Incl AF002282:Homo sapiens alpha- actinin-2 associated LIM protein mRNA, alternatively spliced product, complete cds /cds=(46,996) /gb=AF002282 /gi=3138923 /ug=Hs.135281 /len=1347	U50527 /FEATURE= /DEFINITION=HSU50527
Cluster#	Hs.79217	Hs.73946	Hs.84136	Hs.105440	Hs.878	Hs.184572	Hs.135281	Hs.22174
Gene Name	pyrroline-5- carboxylate reductase 1	endothelial cell growth factor 1 (platelet-derived)	paired-like homeodomain transcription factor 1	hepatocyte nuclear factor 3, alpha	sorbitol dehydrogenase	cell division cycle 2, G1 to S and G2 to M	alpha-actinin-2- associated LIM protein	
Genbank	M77836	M63193	U70370	U39840	L29254	X05360	AF002282	U50527
Affy	37741_at	36879_at	37920_at	37141_at	38763_at	1803_at	39690_at	1527_s_at
SealD	1053	1049	1158	1149	1020	1219	285	1153
##	48	49	90	5	52	53	22	22

p-values	0.0000229	0.000191	0.0001	2.84 <b>E-</b> 08	0.000642	0.00000552	0.0000133	0.000834
Fold Change	0.326719388	0.326431324	0.323566748	0.323306977	0.323187581	0.323178779	0.321819387	0.3197207
Cluster Description	Cluster Incl AF001691:Homo sapiens 195 kDa cornified envelope precursor mRNA, complete cds /cds=(90,5360) /gb=AF001691 /gj=3168845 /ug=Hs.74304 /len=6227	U84487 /FEATURE= /DEFINITION=HSU84487 Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds	Cluster Incl D84110:Homo sapiens mRNA for RBP-MS/type 4, complete cds /cds=(566,1156) /gb=D84110 /gi=1669552 /ug=Hs.80248 /len=1594	Cluster Incl D14686:Human gene for glycine cleavage system T-protein /cds=(145,1356) /gb=D14686 /gi=994760 /ug=Hs.102 /len=2119	Cluster Incl J02876:Human placental folate binding protein mRNA, complete cds /cds=(262,1029) /gb=J02876 /gi=182413 /ug=Hs.24194 /len=1211	S62539 /FEATURE= /DEFINITION=S62539 insulin receptor substrate-1 [human, skeletal muscle, mRNA, 5828 nt]		Cluster Incl U58516:Human breast epithelial antigen BA46 mRNA, complete cds /cds=(60,1223)/gb=U58516/gi=1381161 /ug=Hs.3745/len=1934
Cluster #	Hs.74304	Hs.80420	Hs.80248	Hs.102	Hs.24194	Hs.96063	Hs.180433	Hs.3745
Gene Name	periplakin	small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin)	RNA-binding protein gene with multiple splicing	aminomethyltransfera se (glycine cleavage system protein T)	folate receptor 2 (fetal)	insulin receptor substrate 1	rTS beta protein	milk fat globule-EGF factor 8 protein
Genbank	AF001691	U84487	D84110	D14686	J02876	S62539	X67098	<b>U58516</b>
Affy	36890_at		38049_g_at	41120_at	33871_s_at	851_s_at	33263_at	34403_at
SeqID	284	1164	973	. 963	1001	1120	1230	1154
#1	26	29	28	20	09	61	62	83

BLIEDOCID- JAIO MORO27182 I 5

p-values	0.000387	0.00529	0.00523	0.000012	0.0224	0.0000881	0.000764
Fold Change	0.319370936	0.317801655	0.314829644	0.313476219	0.313295747	0.312357015	0.31152273
Cluster Description	Cluster Incl V00568:Human mRNA encoding the c-myc oncogene /cds=(558,1877) /gb=V00568 /gi=34815 /ug=Hs.79070 /len=2121	Cluster Incl M22324:Human aminopeptidase N/CD13 mRNA encoding aminopeptidase N, complete cds /cds=(120,3023) /gb=M22324 /gi=178535 /ug=Hs.1239 /len=3477	Cluster Incl AF027208:Homo sapiens AC133 antigen mRNA, complete cds /cds=(37,2634) /gb=AF027208 /gi=2688948 /ug=Hs.112360 /len=3794	D00632 /FEATURE= /DEFINITION=HUMGSHPXA Homo sapiens mRNA for glutathione peroxidase, complete cds	L22524 /FEATURE=expanded_cds /DEFINITION=HUMMATRY06 Human matrilysin gene, exon 6 and complete cds	Cluster Incl Z26653:H.saplens mRNA for laminin M chain (merosin) /cds=(49,9381) /gb=Z26653 /gi=438055 /ug=Hs.75279 /len=9534	L13740 /FEATURE= /DEFINITION=HUMTR3A Human TR3 orphan receptor mRNA, complete cds
Cluster#	Hs.79070	Hs.1239	Hs.112360	Hs.172153	Hs.2256	Hs.75279	Hs.1119
Gene Name	v-myc avian myelocytomatosis viral oncogene homolog	alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)	prominin (mouse)-like 1	glutathione peroxidase 3 (plasma)	matrix metalloproteinase 7 (matrilysin, uterine)	aminin, alpha 2 (merosin, congenital muscular dystrophy)	nuclear receptor subfamily 4, group A, member 1
	? E 2 E	an am	pror 1	glutathior peroxidas (plasma)	matrix metallo (matrily	laminin, (merosir muscula	subj mer
Genbank			8	D00632 gluta perox (plas	L22524 matri metal	Z26653 lamii (mer mus	L13740 nucl subj
Affy	37724_at V00568	39385_at M22324	8	D00632	668_s_at L22524	36917_at Z26653	279_at L13740
	V00568	M22324	AF027208	D00632	L22524	Z26653	L13740

Seq10         Afft, AF08288         Genta Name (amonated and action)         Cluster incl. AF08288; Homo sapiens gamma.         Columnal. 2- and actions (amonated and action)         Columnal (amonated				48					
Affy (and both)         Gene Name (and both)         Cluster fined AF082868 (homo septens gamma (gamma)         Cluster Incl AF082868 (homo septens gamma (gamma)           38339_at AF082868         AF082868         butyrobetaine butyrobetaine hydroxylase (BBH) mRNA, complete cds (ods=(68,1229) (др=AF082888 dioxygensee)           37251_s_at AF016004         glycoprotein M6B         Hs.5422         Cluster Incl AF016004 (дg=3387766 /ug=Hs.78361 mRNA, complete cds /cds=(28,1051) (др=Hs.78361 mRNA, complete cds /cds=(28,1051) (др=Hs.78361 mRNA, complete cds /cds=(28,1051) (дg=Hs.78361 mRNA, complete cds /cds=(28,1051) (дg=Hs.78361 mRNA, complete cds /cds=(28,1051) (дg=Hs.78361 mRNA, complete cds /cds=(28,1051) (dg=Hs.78361 mrNA, complete cds /cds=(28,1051) (dg=Hs.18485 mrNA, complete cds /cds=(28,1051) (dg=Hs.1	p-values 0.0000193	0.00000415	0.000274	0.000239	0.0000802	1.85E-07	7.42E-08	0.00149	
Affy Genbank (gamma), 2- oxoglutariae dioxygenase (gamma-), 2- oxoglutariae dioxygenase (gamma-butyrobetaine hydroxylase)         Hs.9667           37251_s_at         AF016004 AF016004 glycoprotein M6B Hs.5422         Hs.5422           32025_at         Y11306 transcription factor 7- Hs.285857 like 2 (T-cell specific, HMG-box) protease inhibitor 5 (maspin)         Hs.55279 (maspin)           34301_r_at         Z19574 keratin 17 Hs.2785         Hs.2785           35752_s_at         M15036 protein S (alpha)         Hs.64016           32052_at         L48215 hemoglobin, beta         Hs.155376	Fold Change 0.310894189	0.308897008	0.306961223	0.303827048	0.303503697	0.300299695	0.297519832	0.296769339	
Affy Genbank Gene Name  38339_at AF082868 butyrobetaine (gamma), 2- oxoglutarate dioxygenase (gamma- butyrobetaine hydroxylase)  37251_s_at AF016004 glycoprotein M6B  32025_at Y11306 transcription factor 7- like 2 (T-cell specific, HMG-box)  863_g_at U04313 protease inhibitor 5 (maspin)  34301_r_at Z19574 keratin 17  Kinase inhibitor 1C (p57, Kip2)  35752_s_at M15036 protein S (alpha)  32052_at L48215 hemoglobin, beta H		Cluster Incl AF016004:Homo sapiens m6b1 mRNA, complete cds /cds=(254,1051) /gb=AF016004 /gi=3387766 /ug=Hs.78361 /len=1616	Cluster Incl Y11306:Homo sapiens mRNA for hTCF-4 /cds=(307,2097) /gb=Y11306 /gi=4469251 /ug=Hs.154485 /len=2444	U04313 /FEATURE= /DEFINITION=HSU04313 Human maspin mRNA, complete cds	Cluster Incl Z19574:H.sapiens gene for ୍ରଧ୍ୟକ:atin 17 /cds=(64,1362) /gb=Z19574 /gi≈30378 /ug=Hs.2785 /len=1518	Cluster Incl U22398:Human Cdk-inhibitor p57KIP2 (KIP2) mRNA, complete cds /cds=(260,1210) /gb=U22398 /gi=790247 /ug=Hs.106070 /len=1511	Cluster Incl M15036:Human vitamin K-dependent plasma protein S mRNA, complete cds /cds=(146,2176) /gb=M15036 /gi=190288 /ug=Hs.64016 /len=3309	Cluster Incl L48215:Horno sapiens beta-globin (HBB) gene, with a to c allele 28 bp 5 to exon 1, (J00179 bases 61971-63802) /cds=(50,493) /gb=L48215 /gi=1066772 /ug=Hs.155376 /len=626"	
Affy Genbank Gene Name (gamma), 2- oxoglutarate dioxygenase (gamma- butyrobetaine hydroxylase) 37251_s_at AF016004 glycoprotein M6B HMG-box) 863_g_at U04313 protease inhibitor 5 (maspin) 34301_r_at Z19574 keratin 17 39545_at U22398 cyclin-dependent kinase inhibitor 1C (p57, Kip2) 35752_s_at M15036 protein S (alpha) 32052_at L48215 hemoglobin, beta	Cluster#	Hs.5422	Hs.285857	Hs.55279	Hs.2785	Hs.106070	Hs.64016	Hs.155376	
38339_at AF 38339_at AF 37251_s_at AF 32025_at Y1 34301_r_at Z1 39545_at U2 35752_s_at M1 32052_at L4#	Gene Name butyrobetaine (gamma), 2- oxoglutarate dioxygenase (gamma- butyrobetaine hydroxylase)	glycoprotein M6B	transcription factor 7- like 2 (T-cell specific, HMG-box)		keratin 17	cyclin-dependent kinase inhibitor 1C (p57, Kip2)			
	<u>Senbank</u> AF082868	AF016004	Y11306	U04313	Z19574	U22398	M15036	L48215	
305 305 305 1239 1135 1143 1035	<b>Any</b> 38339_at	37251_s_at	32025_at	863 <u>g</u> at	34301_r_at	39545_at	35752_s_at	32052_at	
	305 305	290	1239	1135	1242	1143	1035	1028	
# 7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	# 2	72	73	74	75	92	12	78	
7		Seque Arry Genbank Gene Name Cluster # Cluster Description Fold Change 305 38339_at AF082868 butyrobetaine Hs.9667 Cluster Incl AF082868:Homo sapiens gamma 0.310894189 (gamma), 2- butyrobetaine hydroxylase)  dioxygenase (gamma- /gi=3746804 /ug=Hs.9667 /len=1584	Sequence         Arty         Gene Name         Cluster #*         Cluster Description         Fold Change           305         38339_at         AF082868         butyrobetaine         Hs.9667         Cluster Incl AF082868:Homo saplens gamma         0.310894189           305         38339_at         AF082868         butyrobetaine         Hs.9667         Cluster Incl AF082868:Homo saplens gamma         0.310894189           4         complete cds /cds=(66,1229) /gb=AF082868         complete cds /cds=(66,1229) /gb=AF082868         complete cds /cds=(66,1229) /gb=AF082868           4         butyrobetaine         hydroxylase)         hydroxylase)         Hs.5422         Cluster Incl AF016004 /gi=3387766 /ug=Hs.78361         cluster Incl AF016004 /gi=3387766 /ug=Hs.78361           290         37251_s_at         AF016004         glycoprotein M6B         Hs.5422         Cluster Incl AF016004 /gi=3387766 /ug=Hs.78361           7/8b=AF016004 /gi=3387766 /ug=Hs.78361         AF016004 /gi=3387766 /ug=Hs.78361         AF016004	Sequence         Atry         Gene Name         Cluster Incl AF082868:Homo sapiens gamma         Fold Change           305         38339_at         AF082868         butyrobetaine         Hs.9667         Cluster Incl AF082868:Homo sapiens gamma         0.310894189           305         38339_at         AF082868         butyrobetaine         Hs.9667         Cluster Incl AF082868         Complete cds /cds=(66,1229) /gb=AF082868           dioxygenase (gamma-butyrobetaine hydroxylase)         /gi=3746804 /ug=Hs.9667 /len=1584         0.308897008           290         37251_s_at         AF016004         glycoprotein M6B         Hs.5422         Cluster Incl AF016004 /gi=3387766 /ug=Hs.78361         0.308897008           1239         32025_at         Y11306         transcription factor 7- Hs.285857         Cluster Incl Y11306:Homo sapiens mRNA for like 2 (T-cell specific, like 2 (T-cell	366/12         Atry Gene Name (Cluster #*)         Cluster Third AF082868: Homo sapients gamma (Cluster Incl AF082868: Homo sapients gamma)         Cluster Incl AF082868: Homo sapients gamma (Cluster Incl AF082868: Homo sapients gamma)         Fold Change p-values p-values           305         38339_at AF082868 butyrobetaine (Cogulutanta)         Hs.9667 (Cluster Incl AF016004 /ug=Hs.9667 /len=1584)         0.310894189 (Cluster Incl AF016004 /ug=Hs.9667 /len=1584)         0.310897008         0.0000193 (Cluster Incl AF016004 /ug=Hs.9667 /len=1584)           290         37251_s_at AF016004 glycoprotein M6B         Hs.5422 Hs.9667 /len=1646 /len=1646         Cluster Incl AF016004 /ug=Hs.78361         0.308897008         0.0000415 /len=1646           1239         32025_at Y11306 transcription factor 7- Hs.285867 Cluster Incl Y11306-Homo saplens mRNA for Ille 2 (T-cell specific, HMG-box)         HmG-box)         HTCF-4 /cds=(307,2097) /gb=Y11306 /len=2444         0.308897048         0.000274           1135         863_g_at U04313 protease inhibitor 5 Hs.55279 U04313 /FEATURE=/DEFINITION=HSU04313         Hs.55279 U04313 /FEATURE=/DEFINITION=HSU04313         0.000239 /len=2444         0.000239 /len=2444	369III.2         Atty         Gene Name         Cluster Incl AF082668. Homo saplens gamma         Fold Change         p-values           305         38339_at         AF082868         butyrobetaine         Hs.3667         Cluster Incl AF082868. Homo saplens gamma         0.310894189         0.0000193           305         38339_at         AF082868         butyrobetaine         Hs.3667         Cluster Incl AF082688. Homo saplens gamma         0.310894189         0.0000193           290         37251_s_at         AF016004         glycoprotein M6B         Hs.5422         Cluster Incl AF016004:Homo saplens m6b1         0.308897008         0.00000415           1239         37251_s_at         AF016004         glycoprotein M6B         Hs.5422         Cluster Incl AF016004:Homo saplens m8b1         0.308897008         0.0000744           1239         32025_at         Y11306         transcription factor 7- Hs.285857         Hs.28587 Cluster Incl X1306:Homo saplens mRNA for Hack T1306         0.308897008         0.0000274           1135         863_g_at         U04313         protease inhibitor 5         Hs.55279         U04313 FEATURE=/DEFINITION=HSU04313         0.303803897         0.0000239           1242         34301_r_at         Z19574         keratin 17         Hs.2785         Cluster Incl Z19574:Hsaplens gane for G44,1362) /gb=Z19574         0.303360389	Seque	3839_at   AF09288   Butynobelane   Hs.3667 Cluster Incl AF092888:Home septeng gamma)	3839_at   AF002089   Dutyrobelaine   Hs.9697 Cluster Inch ATV   Cluster Inch ATV   Cluster Inch ATV   Cluster Inch ATV   Cluster Inch AF002088   Cluster Inch AF002088   Dutyrobelaine   Hs.9697 Cluster Inch AF002088   Dutyrobelaine   Hs.542 Cluster Inch AF002088   Dutyrobelaine   Hs.76004   Julyrobelaine   Hs.76004   Julyrobelaine   Hs.542 Cluster Inch AF002084   Dutyrobelaine   Hs.76004   Julyrobelaine   Julyrobelaine   Hs.76004   Julyrobelaine   Julyrobelaine   Hs.76004   Julyrobelaine   Julyrobelaine   Julyrobelaine   Hs.76004   Julyrobelaine   Julyrobelaine   Julyrobelaine   Julyrobelaine   Hs.76007   Julyrobelaine   Julyrobelaine   Julyrobelaine   Julyrobelaine   Julyrobelaine   Julyrobelaine   Hs.76007   Julyrobelaine   Julyrobe

DAISTOCIO - JUN - 0000007140 |

p-values	0.0000556	0.00000184	0.00999	0.00000996	0.00688	8.07E-07	0.000483
Fold Change	0.295641772	0.29509428	0.29444252	0.292877726	0.29048531	0.2896161	0.288749983
Cluster Description	Cluster Incl AF052389:Homo sapiens LtM domain binding protein (LDB1) mRNA, complete cds /cds=(254,1297) /gb=AF052389 /gi=3044065 /ug=Hs.4980 /len=2398	Cluster Incl AJ000388:Homo sapiens mRNA for calpain-like protease CANPX /cds=(182,2107) /gb=AJ000388 /gi=2274961 /ua=Hs.169172 /len=3615	Cluster Incl M12272:Homo sapiens alcohol dehydrogenase class I gamma subunit (ADH3) mRNA, complete cds /cds=(80,1207) /gb=M12272 /gi=178147 /ug=Hs.2523 /len=1466	Hs.184222 Cluster Incl U85267:Homo sapiens down syndrome candidate region 1 (DSCR1) gene, alternative exon 1, complete cds /cds=(84,677) /gb=U85267 /gi=2612867 /ug=Hs.184222 /len=2272		Cluster Incl AL021977:bK447C4.1 (novel MAFF (v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein F) LIKE protein) /cds=(0,494) /gb=AL021977/gi=4914526 /ug=Hs.51305 /len=2128	Cluster Incl Z22865:H.saplens dermatopontin mRNA, complete CDS /cds=(12,617) /gb=Z22865 /gi=311613 /ug=Hs.80552 /len=729
Cluster#	Hs.4980	Hs.169172	Hs.2523	Hs.184222	Hs.155223	Hs.51305	Hs.80552
Gene Name	LIM domain binding 2,polymyositis/sclerod erma autoantigen 2 (100kD)	calpain-like protease	alcohol dehydrogenase 1 (class I), alpha polypeptide,alcohol dehydrogenase 3 (class I), gamma	Down syndrome critical region gene 1	stanniocalcin 2	v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein F	dermatopontin
Genbank	AF052389	AJ000388	M12272	U85267	AF098462	AL021977	<b>Z</b> 22865
Affy	36065_at	40475_at	36247_f_at	32168_s_at	32043_at	36711_at	38059 <u>g</u> at
SegID	298	848	1031	1165	308	851	1243
##	62	80	28	82	83	84	82

					50				
p-values	0.00000058	0.000216	0.0000355	0.00679	0.000174	0.0000231	0.000495	0.00000039	0.000161
Fold Change	0.288106064	0.287855932	0.287831724	0.287696584	0.285399252	0.283121329	0.282677481	0.281207961	0.279338963
Cluster Description	Cluster Incl J04111:Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1 /cds=(974,1969) /gb=J04111 /gi=186624 /ug=Hs.78465 /len=3336	L24203 /FEATURE= /DEFINITION=HUMDK Homo sapiens ataxia-telanglectasla group D- associated protein mRNA, complete cds			L19871 /FEATURE= /DEFINITION=HUMATF3X Human activating transcription factor 3 (ATF3) mRNA, complete cds	Cluster Incl U31384:Human G protein gamma- 11 subunit mRNA, complete cds /cds=(107,328) /gb=U31384 /gi=995920 /ug=Hs.83381 /len=622	Cluster Incl AB002409:Homo sapiens mRNA for SLC, complete cds /cds=(58,462) /gb=AB002409 /gi=2335034 /ug=Hs.57907 /len=852	L08488 /FEATURE= /DEFINITION=HUMINOS Human inositol polyphosphate 1-phosphatase mRNA, complete cds	Cluster Incl U48959:Homo sapiens myosin light chain kinase (MLCK) mRNA, complete cds //cds=(119,5863) /gb=U48959 /gi=1377819 /ug=Hs.211582 /len=5926
Cluster#	Hs.78465	Hs.82237	Hs.173859	Hs.171695	Hs.460	Hs.83381	Hs.57907	Hs.32309	Hs.211582
Gene Name	v-jun avian sarcoma virus 17 oncogene homolog	ataxia-telangiectasia group D-associated protein	frizzled (Drosophila) homolog 7	dual specificity phosphatase 1	activating transcription factor 3	guanine nucleotide binding protein 11	small inducible cytokine subfamily A (Cys-Cys), member 21	inositol polyphosphate-1- phosphatase	myosin, light polypeptide kinase
Genbank	J04111	L24203	AB017365	X68277	L19871	U31384	AB002409	108488	U48959
Affy	32583_at	1898_at	3322_at	1005_at	287_at	37908_at	36503_at	656_at	32847_at
SealD	1004	1019	274	1232	1017	1145	270	1013	1151
##	88	87	88	88	06		95	63	96

					31	L			
	sanna-d	0.00000917	0.00000688	0.000014	6.7E-09	0.0000349	4.33E-07	0.00000159	0.000228
	Fold Change	0.278228021	0.276610822	0.273963608	0.273622601	0.26818697	0.267616256	0.263585259	0.260058306
	Cluster Description	Cluster Incl S62539:insulin receptor substrate-1 [human, skeletal muscle, mRNA, 5828 nt] /cds=(1020,4748) /gb=S62539 /gi=386256 /ug=Hs.96063 /len=5799	U22398 /FEATURE= /DEFINITION=HSU22398 Human Cdk-inhibitor p57KIP2 (KIP2) mRNA, complete cds	Cluster Incl U07919:Human aldehyde dehydrogenase 6 mRNA, complete cds /cds=(52,1590)_/gb=U07919 /gi=995897 /ug=Hs.75746 /len=3442	Cluster Incl U35139:Human NECDIN related protein mRNA, complete cds /cds=(58,1023) /gb=U35139 /gi=1754970 /ug=Hs.50130 /len=1592	Cluster Incl M68840:Human monoamine oxidase A (MAOA) mRNA, complete cds /cds=(73,1656) /gb=M68840 /gi=187352 /ug=Hs.183109 /len=1949	Cluster Incl AF093118:Homo sapiens UP50 mRNA, complete cds /cds=(168,1514) /gb=AF093118 /gl=3676821 /ug=Hs.11494 /len=2019	Cluster Incl U10492:Human Mox1 protein (MOX1) mRNA, complete cds /cds=(29,793) /gb=U10492 /gi=505653 /ug=Hs.438 /len=2315	Cluster Incl AF022797:Homo sapiens intermediate conductance calcium-activated potassium channel (hKCa4) mRNA, complete cds /cds=(396,1679) /gb=AF022797 /gi=2674355 /ug=Hs.10082 /len=2238
i	Cluster#	Hs.96063	Hs.106070	Hs.75746	Hs.50130	Hs.183109	Hs.11494	Hs.438	Hs.10082
	Gene Name	insulin receptor substrate 1	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	aldehyde dehydrogenase 6	necdin (mouse) homolog	monoamine oxidase A	fibulin 5	mesenchyme homeo box 1	potassium intermediate/small conductance calcium- activated channel, subfamily N, member 4
	Genbank	S62539	U22398	U07919	U35139	M68840	AF093118	U10492	AF022797
		41049_at	1787_at	36686_at	36073_at	41772_at	39038_at	36010_at	41106_at
	SegiD	1120	1143	1138	1147	1050	306	1139	291
	##	95	96	26	86	66	100	101	102

						52		10	x/ 0302/0
	p-values	4.12E-07	0.0000904	0.0000232	0.0025	0.00000113	0.000041	0.00041	0.00105
	Fold Change	0.260055335	0.259339901	0.259264106	0.258780062	0.258230155	0.257792937	0.256900234	0.256815942
	Cluster Description	Cluster Incl U17760:Human laminin S B3 chain (LAMB3) gene /cds=(399,3917) /gb=U17760 /gi=2182192 /ug=Hs.75517 /len=4213	M98539 /FEATURE=exon /DEFINITION=HUMPDS03 Human prostaglandin D2 synthase gene, exon 7	Cluster Incl W61005:zd29a11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-342044 /clone_end=3" /gb=W61005 /gi=1367764 /ug=Hs.14896 /len=786"	Cluster Incl J00153:Human alpha globin gene cluster on chromosome 16- zeta gene /cds=(0,428) /gb=J00153 /gi=183794 /ug=Hs. 182374 /len=429	Cluster Incl U61374:Human novel protein with short consensus repeats of six cysteines mRNA, complete cds /cds=(41,1426) /gb=U61374 /gi=1778409 /ug=Hs.15154 /len=1800	Cluster Incl X57025:Human IGF-I mRNA for insulin-like growth factor I /cds=(166,627) /gb=X57025 /gi=33007 /ug=Hs.85112 /len=7236	Cluster Incl M15856:Human lipoprotein lipase mRNA, complete cds /cds=UNKNOWN /gb=M15856 /gi=187209 /ug=Hs.180878 /len=3549	Cluster Incl X00129:Human mRNA for retinol binding protein (RBP) /cds=(51,650) /db=X00129 /gi=35896 /ug=Hs.76461 /len=882
	Cluster#	Hs.75517	Hs.8272	Hs.14896	Hs.251577	Hs.15154	Hs.85112	Hs.180878	Hs.76461
	Gene Name	laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	prostaglandin D2 synthase (21kD, brain)	DHHC1 protein	hemoglobin, alpha 1	sushi-repeat- containing protein, X chromosome	insulin-like growth factor 1 (somatomedia C)	lipoprotein lipase	retinol-binding protein 4, interstitial
	Genbank	U17760	M98539	W61005	J00153	U61374	X57025	M15856	X00129
	Affy	36929_at	216_at	39750_at	31525_s_at	31855_at	38737_at	41209_at	32552_at
	SegID	1141	1060	1191	666	1156	1225	1037	1214
:	#11	103	104	105	106	107	108	109	110

0.000837	0.0321	0.000106	0.000998	0.000037	0.0000523	0.0000179	0.000763
<b>Fold Change</b> 0.256739005	0.251627664	0.251471671	0.251434843	0.250173978	0.249382262	0.248516754	0.242494771
Cluster Description Cluster Incl U41518:Human channel-like integral membrane protein (AQP-1) mRNA, clone AQP-1-2344, partial cds /cds=(0,460) /gb=U41518 /gi=1314305 /ug=Hs.74602 /len=2344	Cluster Incl Y10179:H.sapiens mRNA for prolactin-inducible protein /cds=(36,476) /gb=Y10179 /gi=2292895 /ug=Hs.99949 /len=576	Cluster Inci K03000:Human aldehyde dehydrogenase 1 mRNA /cds=(0,1022) /gb=K03000 /gi=178399 /ug=Hs.76392		Cluster Incl U39447:Human placenta copper monamine oxidase mRNA, complete cds /cds=(160,2451) /gb=U39447 /gi=1399031	X57025 /FEATURE=mRNA /DEFINITION=HSIGFACI Human IGF-I mRNA for insulin-like growth factor I	L07594 /FEATURE= /DEFINITION=HUMTGFB3C Human transforming growth factor-beta type III	Cluster Incl U05861:Human hepatic dihydrodiol dehydrogenase gene /cds=(26,997) /gb=U05861 /gi=487134 /ug=Hs.201967 /len=1222
<b>Cluster#</b> Hs.74602	Hs.99949	Hs.76392	Hs.155376	Hs.198241	Hs.85112	Hs.79059	Hs.275374
Gene Name aquaporin 1 (channel- forming integral protein, 28kD)	prolactin-induced protein	aldehyde dehydrogenase 1, soluble	hemoglobin, beta	amine oxidase, copper containing 3 (vascular adhesion	insulin-like growth factor 1 (somatomedia C)	transforming growth factor, beta receptor lil (betaglycan,	aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20- alpha (3-alpha)- hydroxysteroid dehydrogenase)
Genbank U41518	Y10179	K03000	M25079	U39447	X57025	L07594	U05861
Affy 36156_at	41094_at	37015_at	31687_f_at	33756_at	1501_at	1897_at	32805_at
<b>SeqID</b> 1150	1238	1011	1042	1148	1225	1012	1137
# =====================================	112	113	114	115	116	117	118

					54				
p-values	2.11E-09	0.0000034	3.37E-08	6.59E-10	0.000415	0.031	3.52E-07	0.00000788	0.0000975
Fold Change	0.233878866	0.233549169	0.231782987	0.228960682	0.228917694	0.226749627	0.225166891	0.222238905	0.220336613
Cluster Description	Cluster Incl U81992:Homo saplens C2H2 zinc finger protein PLAGL1 (PLAGL1) mRNA, complete cds /cds=(176,1411) /gb=U81992 /gi=3513452 /ug=Hs.75825 /len=2561	Cluster Incl X93510:H.saplens mRNA for 37 kDa LiM domain protein /cds=(41,1027) /gb=X93510 /gi=1085021 /ug=Hs.79691 /len=1130	Cluster Incl AF039843:Homo sapiens Sprouty 2 (SPRY2) mRNA, complete cds /cds=(390,1337)/gb=AF039843 /gi=2809399 /ug=Hs.18676 /len=2117	Cluster Incl L10373:Human (clone CCG-B7) mRNA sequence /cds=UNKNOWN /gb=L10373 /gi=307287 /ug=Hs.82749 /len=1792	D10667 /FEATURE= /DEFINITION=HUMMHCAAA Homo saplens mRNA for smooth muscle myosin heavy chain, partial cds	Cluster Incl U33147:Human mammaglobin mRNA, complete cds /cds=(60,341) /gb=U33147 /gi=1199595 /ug=Hs.46452 /len=503	Cluster Incl J04076:Human early growth response 2 protein (EGR2) mRNA, complete cds /cds=(203,1423) /gb=J04076 /gi=181986 /ug=Hs.1395 /len=2700	Cluster Incl Y16961:Homo saplens mRNA for KET protein /cds=(27,2069) /gb=Y16961 /gi=3970716 /ug=Hs.137569 /len=4849	Cluster Incl U50410:Human heparan sulphate proteoglycan (OCI5) mRNA, complete cds /cds=(144,1886) /gb=U50410 /gi=1245416 /ug=Hs.119651 /len=226
Cluster#	Hs.75825	Hs.79691	Hs.18676	Hs.82749		Hs.46452	Hs.1395	Hs.137569	Hs.119651
Gene Name	pleiomorphic adenoma gene-like 1	LIM domain protein	sprouty (Drosophila) homolog 2	transmembrane 4 superfamily member 2		mammaglobin 1	early growth response 2 (Krox-20 (Drosophila) homolog)	tumor protein 63 kDa with strong homology to p53	glypican 3
Genbank	U81992	X93510	AF039843	L10373	D10667	U33147	J04076	Y16961	U50410
Affy	36943 <u>r_</u> at	32610_at	33700_at	38408_at	774_g_at	36329_at	37863_at	31791_at	39350_at
SedID	1162	1237	294	1014	096	1146	1003	1241	1152
##	119	120	121	122	123	124	125	126	127

חבוחחחחות שנות החבוחים במ

				33				
p-values	0.00000138	9.64E-09	0.0000527	0.0000209	0.00000443	0.000166	0.0000371	4.51E-07
Fold Change	0.218509986	0.216723881	0.216083178	0.207358276	0.206077576	0.202234909	0.19705452	0.196869236
Cluster Description	Cluster Incl X54162:Human mRNA for a 64 Kd autoantigen expressed in thyroid and extra- ocular muscle /cds=(212,1930) /gb=X54162 /gi≃28968 /ug=Hs.79386 /len=3849	Cluster Incl U69263:Human matrilin-2 precursor mRNA, partial cds /cds=(0,941) /gb=U69263 /gi=2072789 /ug=Hs.19368 /len=1033	Cluster Incl L38486:Human microfibril-associated glycoprotein 4 (MFAP4) mRNA, 3 end of cds /cds=(0,771) /gb=L38486 /gi=790816 /ug=Hs.118223 /len=1757"	Cluster Incl M36820:Human cytokine (GRO beta) mRNA, complete cds /cds=(74,397) /gb=M36820 /gi=183628 /ug=Hs.75765 /len=1110	Cluster Incl U19495:Human intercrine-alpha (hIRH) mRNA, complete cds /cds=(473,742) /gb=U19495 /gi=1754834 /ug=Hs.169672 /len=2244	Cluster Incl X04470:Human mRNA for antileukoprotease (ALP) from cervix uterus /cds=(18,416) /gb=X04470 /gi=28638 /uq=Hs.169793 /len=594		Cluster Incl L13463:Human helix-loop-helix basic phosphoprotein (G0S8) mRNA, complete cds /cds=(32,667) /gb=L13463 /gi=292054 /ug=Hs.78944 /len=1345
Cluster#	Hs.79386	Hs.19368	Hs.118223	Hs.75765	Hs.237356	Hs.251754	Hs.110903	Hs.78944
Gene Name	leiomodin 1 (smooth muscle)	matrilin 2	microfibrillar- associated protein 4	GRO2 oncogene	stromal cell-derived factor 1	secretory leukocyte protease inhibitor (antileukoproteinase)	claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)	regulator of G-protein signalling 2, 24kD
Genbank	X54162	U69263	L38486	M36820	U19495	X04470	AF000959	L13463
Affy	37765_at	32239_at	39066_at	37187_at	32666_at	32275_at	38995_at	37701_at
SeqiD	1223	1157	1026	1045	1142	1218	282	1015
<b>7</b> 15	128	129	130	131	132	133	48	135

			50			
sanlex-d	0.0108	2.64E-10	0.000818	4.71E-08	0.00058	9.21E-08
Fold Change	0.195015273	0.191432122	0.19139473	0.187743879	0.187570884	0.186647173
Cluster Description	Cluster Incl U95626:Homo sapiens ccr2b (ccr2), ccr2a (ccr2), ccr5 (ccr5) and ccr6 (ccr6) genes, complete cds, and lactoferrin (lactoferrin) gene, partial cds /cds=(2,1429) /gb=U95626 /gi=2104517 /ug=Hs.105938 /len=1607	Cluster Incl M18533:Homo sapiens dystrophin (DMD) mRNA, complete cds /cds=UNKNOWN /gb=M18533 /gi=181856 /ug=Hs.169470 /len=13957	Cluster Incl AF044311:Homo sapiens gamma- synuclein gene, complete cds /cds=(52,435) /gb=AF044311 /gi=3347841 /ug=Hs.63236 /len=708	Cluster Incl L34155:Homo sapiens laminin- related protein (LamA3) mRNA, complete cds /cds=(0,5141) /gb=L34155 /gi=551596 /ug=Hs.83450 /len=5433	Cluster Incf M69199:Human G0S2 protein gene, complete cds /cds=(160,471) /gb=M69199 /gi=609453 /ug=Hs.95910 /len=863	Cluster Incl L35594:Human autotaxin mRNA, complete cds /cds=(49,2796) /gb=L35594 /gi=537905 /ug=Hs.174185 /len=3231
Cluster#	Hs.347	Hs.169470	Hs.63236	Hs.83450	Hs.95910	Hs.174185
Gene Name	lactotransferrin	dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272	synuclein, gamma (breast cancer- specific protein 1)	laminin, alpha 3 (niceln (150kD), kalinin (165kD), BM600 (150kD), epilegrin)	putative lymphocyte G0/G1 switch gene	ectonucleotide pyrophosphatase/pho sphodiesterase 2 (autotaxin)
Genbank	U95626	M18533	AF044311	L34155	M69199	L35594
Affy	37149_s_at	40488_at	36555_at	37909_at	38326_at	41124_r_at
SeqID	1168	1038	295	1023	1051	1024
##	136	137	138	139	140	141

						58				
	p-values	0.00506	0.00282	0.0000162	5.79E-09	0.00000648	0.0000201	0.00000235	0.000768	0.0000385
	Fold Change	0.161923599	0.161859881	0.155156674	0.145966282	0.143559713	0.138540058	0.137509192	0.137096706	0.136296847
	Cluster Description	3 Cluster Incl U15979:Human (dlk) mRNA, complete cds /cds=(173,1321) /gb=U15979 /gi=562105 /ug=Hs.169228 /len=1553	K00650 /FEATURE=cds /DEFINITION=HUMFOS Human fos proto- oncogene (c-fos), complete cds	Cluster Incl X03350:Human mRNA for alcohol dehydrogenase beta-1-subunit (ADH1-2 allele) '/cds=(72,1199) /gb=X03350 /gl=28415 /ug=Hs.4 /len=2532	Cluster Incl X64559:H.sapiens mRNA for tetranectin /cds=(93,701) /gb=X64559 /gi=37408 /ug=Hs.65424 /len=848		M57399 /FEATURE= /DEFINITION=HUMHBNF1 Human nerve growth factor (HBNF-1) mRNA, complete cds	M62402 /FEATURE= /DEFINITION=HUMIGFBP4 Human insulin-like growth factor binding protein 6 (IGFBP6) mRNA, complete cds	Cluster Incl M12963:Human class I alcohol dehydrogenase (ADH1) alpha subunit mRNA, complete cds /cds=(72,1199) /gb=M12963 /gi=178089 /ug=Hs.73843 /len=1450	Cluster Incl AB005293:Homo sapiens mRNA for perilipin, complete cds /cds=(124,1692) /gb=AB005293 /gi=3041770 /ug=Hs.103253 /len=2904
i	Cluster#	Hs.169228	Hs.25647	Hs.4	Hs.65424	Hs.74369	HS.44	Hs.274313	Hs.73843	Hs.103253
	Gene Name	delta-like homolog (Drosophila)	v-fos FBJ murine osteosarcoma viral oncogene homolog	alcohol dehydrogenase 2 (class I), beta polypeptide	tetranectin (plasminogen-binding protein)	integrin, alpha 7	pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)	insulin-like growth factor binding protein 6	alcohol dehydrogenase 1 (class I), alpha polypeptide	perilipin
	Genbank	U15979	K00650	X03350	X64559	AF032108	M57399	M62402	M12963	AB005293
	Affy	32648_at	2094_s_at	35730_at	36569_at	.36892_at	234_s_at	1736_at	34637_f_at	37122_at
	SedID	1140	1009	1217	1229	. 293	1047	1048	1032	271
	#11	151	152	153	154	155	156	157	158	159

					5	9		
	<b>p-values</b> 1.19E-07		0.000082	0.0000134	.9.26E-08	9.15E-08	0.000222	0.000439
	<b>Fold Change</b> 0.13521119		0.124249102	0.121953593	0.118530255	0.118243196	0.116969229	0.108941232
:	Cluster Inc. A.1001183:Homo sapiens mRNA	for Sox10 protein /cds=(120,1520) /gb=AJ001183 /gi=2909359 /ug=Hs.44317 /len=2547	Cluster Incl L49169:Human G0S3 mRNA, complete cds /cds=(593,1609) /gb=L49169 /gi=1082037 /ug=Hs.75678 /len=3775	AF001548 /FEATURE=mRNA /DEFINITION=HUAF001548 Human Chromosome 16 BAC clone CIT987SK-A- 815A9. complete sequence				Cluster Incl AA128249:zl29d09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-503345 /clone_end=5" /gb=AA128249 /gi=1688343 /ug=Hs.83213 /len=648"
•	Cluster#		Hs.75678	Hs.78344	Hs.155597	Hs.283750	Hs.195850	Hs.83213
	Gene Name	region Y)-box 10	FBJ murine osteosarcoma viral oncogene homolog B	myosin, heavy polypeptide 11, smooth muscle	D component of complement (adipsin)	tenascin XA	keratin 5 (epidermolysis bullosa simplex, Dowling-	Cockayne types) fatty acid binding protein 4, adipocyte
	Genbank	A300 1 183	L49169	AF001548	M84526	U89337	M21389	AA128249
	Affy	36018_at	36669_at	767_at	40282_s_at	38508_s_at	613_at	38430_at
	SeqID	20 44 50	1029	283	1055	1166	1039	45
	##	160	161	162	163	<u>\$</u>	165	166

ji.

					60			
p-values	9.35E-07	5.83E-07	0.000249	0.00000084	0.0000236	2.66E-08	3.51E-07	0.00000596
Fold Change	0.108244989	0.10121597	0.097312672	0.096634153	0.092826583	0.091111614	0.090848213	0.070781449
Cluster Description	Cluster Incl U pi subunit mR /cds=(156,14; /ug=Hs.70728	Cluster Incl M57399:Human nerve growth factor (HBNF-1) mRNA, complete cds /cds=(395,901) /gb=M57399 /gi=292072 /uq=Hs.44 /len=1029	Cluster Incl X07696:Human mRNA for cytokeratin 15 /cds=(61,1431) /gb=X07696 /gi=34070 /ug=Hs.80342 /len=1709	Cluster Incl M69225:Human bullous pemphigoid antigen (BPAG1) mRNA, complete cds /cds=UNKNOWN /gb=M69225 /gi=179522 /ug=Hs.620 /len=8930	Cluster Incl AF013570:Homo sapiens smooth muscle myosin heavy chain SM2 mRNA, alternatively spliced, partial cds /cds=(0,1767) /gb=AF013570 /gi=2352944 /ug=Hs.78344 /len=2580	Cluster Incl D17408:Homo sapiens mRNA for calponin, complete cds /cds=(92,985) /gb=D17408 /gl=1783204 /ug=Hs.21223 /len=1517	D00654 /FEATURE=cds /DEFINITION=HUMACTSG7 Homo sapiens gene for enteric smooth muscle gamma-actin, exon9, complete cds	
Cluster #	Hs.70725	Hs.44	Hs.80342	Hs.620	Hs.78344	Hs.21223	Hs.77443	Hs.117729
Gene Name	gamma-aminobutyric acid (GABA) A receptor, pi	pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)	keratin 15	bullous pemphigoid antigen 1 (230/240kD)	myosin, heavy polypeptide 11, smooth muscle	calponin 1, basic, smooth muscle	actin, gamma 2, smooth muscle, enteric	keratin 14 (epidermolysis bullosa simplex, Dowling-Meara,
Genbank	U95367	M57399	X07696	M69225	AF013570	D17408	D00654	J00124
Affx	4033	34820_at	37582_at	40304_at	37407_s_at	34203_at	1197_at	39052_at
SedID	1167	1047	1220	1052	288	964	929	866
##	167	168	169	170	171	172	173	174

PRICEOCOLD: -NAC - COCCOCTAGE

<b>p-values</b> 5.77E-09	0.00055334	0.00136502	4.5016E-06	0.00129495	0.00039175	2.7406E-06
<b>Eold Change</b> 0.0564074	7.73694268	4.18	0.282343722	3.871753195	0.308362018	0.227899817
Cluster Incl AF056087:Homo sapiens secreted frizzled related protein mRNA, complete cds /cds=(302,1243) /gb=AF056087 /gi=3033550 /ug=Hs.7306 /len=4458	Cluster Incl. AW007442:wt55g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2511418 /clone_end=3' /gb=AW007442 /gl=5856220 /in=Hs, 235961 /len=424'		Cluster Incl. AA614135:no82f09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1113353 /clone_end=3' /gb=AA614135 /gi=2466269 /inc=Hs 49765 /len=584'		Cluster Incl. AI283888:qk51f12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1872527 /clone_end=3'/gb=AI283888 /gi=3922121	Cluster Incl. AI589804:tm74e11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2163884 /clone_end=3'/gb=AI589804 /gi=4598852 /ug=Hs.12828 /len=508'
Cluster# Hs.7306	Hs.821	Hs.179718	Hs.49765	Hs.151678	Hs.186961	Hs.12828
Gene Name secreted frizzled- related protein 1	zinc finger protein homologous to Zfp92 in mouse	v-myb avian myeloblastosis viral oncogene homolog- like 2	VLCS-H1 protein	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6)	ubiquitin specific protease 25	tweety (Drosophila) homolog 1
Genbank AF056087	AW007442	A1990026	AA614135	AL118633	AI283888	AI589804
<b>Affy</b> 32521_at	74989_at	80675_at	64695_at	59253_at	91419_at	48513_at
SeqID 299	923	843	183	901	411	525
# 175	176	177	178	179	180	181

				•	52			
p-values	0.00017707	1.0421E-05	3.9817E-06	1.5585E-05	7.4333E-10	0.00109754	0.00022486	6.75E-04
Fold Change	6.818460543	4.363660627	4.2443289	4.256819836	9.431588747	5.50	0.149624624	4.122293677
Cluster Description	Cluster Incl. AW003626:wx34e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2545562 /clone_end=3' /gb=AW003626 /gi=5850542 /ug=Hs.234018 /len=707'	Cluster Incl. Al973225:wr53c11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2491412 /clone_end=3 /gb=Al973225 /gi=5770051 /ug=Hs.233704 /len=399'	Cluster Incl. Al990642:ws22g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2497978 /clone_end=3 /gb=Al990642 /gi=5837523 /ug=Hs.233886 /len=591	Cluster Incl. AA026429:ze92a04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-366414 /clone_end=5'/gb=AA026429 /gi=1492330 /uq=Hs.108106 /len=479'	Cluster Incl. AW003286:wq65a02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2476106 /clone_end=3' /gb=AW003286 /gi=5850202 /ug=Hs.232126 /len=773'	Cluster Incl. AA707213:zj32h06.s1 Homo sapiens cDNA, 3 end /clone=452027 /clone_end=3' /gb=AA707213 /gi=2717131 /ug=Hs.14319 /len=527'	Cluster Incl. AI480357:tm51d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2161647 /clone_end=3' /gb=AI480357 /gi=4373525 /ug=Hs.91877 /len=830'	Cluster Incl AA704137:ag47g01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1119984 /clone_end=3" /gb=AA704137 /gi=2714055 /ug=Hs.125359 /len=923"
Cluster#	Hs.159154	Hs.169840	Hs.104019	Hs.108106	Hs.270810	Hs.317	Hs.91877	Hs.125359
Gene Name	tubulin, beta, 4	TTK protein kinase	transforming, acidic coiled-coil containing protein 3	transcription factor	topoisomerase (DNA) Hs.270810 II alpha (170kD)	topoisomerase (DNA) I	thyroid hormone responsive SPOT14 (rat) homolog	Thy-1 cell surface antigen
Genbank	AW003626	Al973225	Al990642	AA026429	AW003286	AA707213	Al480357	AA704137
Affy	57034_at	74593_at	52238_s_at Al990642	63346_at	74096_at	. 90442_at	57778_at	39395_at
SeqID	913	833	847	9	911	208	488	205
##	182	183	184	185	186	187	188	189

()

			03				
<u>p-values</u> 0.00065669	3.1699E-09	0.00058351	3.4432E-06	2.6069E-05	0.00051209	0.00133643	0.0000138
<b>Fold Change</b> 3.418467862	0.284181885	99.9	0.31	4.206790316	3.273076721	0.325281828	0.277326129
Cluster Incl. AA527151:ni07b08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-967287 /clone_end=3' /gb=AA527151 /gi=2269220 /un=Hs 108977 /len=559'	Cluster Incl. Al675177:tm80g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2164472 /clone_end=3' /gb=Al675177 /gi=4875657 /hn=Hs 229620 /len=548'	Cluster Incl. AL036753:DKFZp564I0663_r1 Cluster Incl. AL036753:DKFZp564I0663_r1 Homo sapiens cDNA, 5 end /clone=DKFZp564I0663 /clone_end=5' /gb=AL036753 /gi=5927893 /ug=Hs.133482 /len=617'	Cluster Incl. Al949433:wq11e08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2470982 /clone_end=3' /gb=Al949433 /gi=5741831 /ua=Hs.13562 /len=561'	Cluster Incl. AI285531:qu49b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1968079 /clone_end=3' /gb=AI285531 /gi=3923764 /ua=Hs.106260 /len=598'	Cluster Incl. H10816:ym04e12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-46664 /clone_end=5' /gb=H10816 /gi=875636 /ug=Hs.22065 /len=660'	Cluster Incl. N45415:yw97h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-260219 /clone_end=5' /gb=N45415 /gi=1186581 /ug=Hs.24395 /len=647'	Cluster Incl AI720438:as81g04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2335158 /clone_end=3" /gb=AI720438 /gi=5037694 /ug=Hs.20144 /len=550"
,					- "	.0 0/	0 0
Cluster# BLS.184242 CI	Hs.243678 (s	Hs.32964		Hs.106260	Hs.22065 (	Hs.24395 (	Hs.20144 (
,			sperm surface protein Hs.129872				ible Hs.20144 of the lbfamily A member
Cluster# Hs.184242	Hs.243678	nining Hs.32964		Hs.106260	Hs.22065	Hs.24395	ucible Hs.20144 subfamily A su
sterol-C5-desaturase Hs.184242 (fungal ERG3, delta-5 desaturase)-like	SRY (sex determining Hs.243678 region Y)-box 8	SRY (sex determining Hs.32964 region Y)-box 11	sperm surface protein Hs.129872	sorting nexin 10 Hs.106260	small protein effector Hs.22065 of of Cdc42	small inducible Hs.24395 cytokine subfamily B (Cys-X-Cys), member 14 (BRAK)	small inducible Hs.20144 cytokine subfamily A (Cys-Cys), member 14
Gene Name Cluster# AA527151 sterol-C5-desaturase Hs.184242 (fungal ERG3, delta-5 desaturase)-like	Al675177 SRY (sex determining Hs.243678 region Y)-box 8	AL036753 SRY (sex determining Hs.32964 region Y)-box 11	Al949433 sperm surface protein Hs.129872	Al285531 sorting nexin 10 Hs.106260	H10816 small protein effector Hs.22065 of Cdc42	N45415 small inducible Hs.24395 cytokine subfamily B (Cys-X-Cys), member 14 (BRAK)	Al720438 small inducible Hs.20144 cytokine subfamily A (Cys-Cys), member 14

			•	14			
1.7128E-08	0.000166	5.5177E-07	2.1786E-06	0.02422274	0.00029667	3.31E-03	8.0344E-05
0.13254339	0.147972137	0.279118305	0.113932898	3.52	5.371729632	3.31996447	5.815956961
Cluster Incl. AA102575:zn42c03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-550084 /clone_end=3' /gb=AA102575 /gi=1647767 /ug=Hs.26530 /len=589'			Cluster Incl. AI829385:wk64e08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2420198 /clone_end=3' /gb=AI829385 /gi=5450056 /ug=Hs.59729 /len=480'		Cluster Incl. Al864016:wj53h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2406595 /clone_end=3' /gb=Al864016 /gi=5528123 /ug=Hs.234375 /len=511'	Cluster Incl AA131149:zo16d05.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-587049 /clone_end=5" /gb=AA131149 /gi=1692640 /ug=Hs.2962 /len=464"	Cluster Incl. Al990405:ws20h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2497795 /clone_end=3' /ch=Al990405 /ci=5837286
Hs.26530	Hs.181062	Hs.1327.92	Hs.59729	Hs.279623	Hs.313	Hs.2962	Hs.194691
serum deprivation response (phosphatidylserine-binding protein)	serum amyloid A1	serologically defined colon cancer antigen 43	semaphorin sem2	selenoprotein X	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T- lymphocyte activation 1)	S100 calclum-binding protein P	retinoic acid induced 3
AA102575	AA829286	AI832477	AI829385	W92110	Al864016	AA131149	Al990405
50094_at	33272_at	63580_at	62486_at	78757_at	74815_at	34319_at	57027_at
36	233	732	729	1213	746	46	844
198	199	200	201	202	203	204	205
	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA102575:zn42c03.s1 Homo response sapiens cDNA, 3 end /clone=IMAGE-550084 (phosphatidylserine- /clone_end=3'/gb=AA102575/gi=1647767 binding protein) /ug=Hs.26530 /len=589'	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA102575:zn42c03.s1 Homo 0.13254339 response capiens cDNA, 3 end /clone=IMAGE-550084 (phosphatidylserine-pindling protein) / ug=Hs.26530 /len=589' 0.147972137 sapiens cDNA, 3 end /clone=IMAGE-1420488 /clone=IMAGE-1420488 /clone_end=3" /gb=AA829286 /gi=2902385 /len=559"	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA102575:zn42c03.s1 Homo 0.13254339 response (phosphatidylserine- binding protein)	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA402575:zn42c03.s1 Homo 0.13254339 1.7128E-08 response	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA102575;zn42c03.s1 Homo response respon	39 50094_at AA102575 serum deprivation Hs.26530 Cluster Incl. AA102575xn42c03 st Homo response response response response response response (none=infA0E=580084 red.)	39         50094_at         AA102575         serum deprivation         Hs.26300 Cluster Incl. AA10275572/m.02020         0.12254339         1.712BE-08           233         33272_at         AA829286         (bindup protein)         (idone_and=3*)(bb-AA102576*084)         0.147972137         0.000166           233         33272_at         AA829286         serum amyloid A1         Hs.161092 Cluster Incl AA8292865006801.st Homo on on-order antigen clone, and clone-allMAGE-377248         0.147972137         0.000166           722         63580_at         AI832477         serologically defined         Hs.13792 Cluster Incl. AB822286500681.st Homo on on-order antigen clone, and clone-allMAGE-2377243         0.147972137         0.000166           722         63580_at         AI832477         serologically defined         Hs.13792 Cluster Incl. AB822286500691.st Homo on on-order antigen clone, and clone-allMAGE-2377243         0.177E-07           729         62486_at         AI829385         semaphorin sem2         Hs.59729 Cluster Incl. AB82386*Wide-e60x.rt Homo on on-order antigen clone, and clone-allMAGE-242098         0.13932898         2.1786E-06           1213         78757_at         Wg2110         selenoprotein X         Hs.279629         Hs.59729 Incl. AB82386*Wide-e60x.rt Homo on-order antigen clone, and clone-allMAGE-240086         0.00242274           746         74815_at         AI884016         secreted

/clone\_end=3' /gb=Al990405 /gi=5837286 /ug=Hs.233881 /len=481/~\_\_

p <u>-values</u> 4.5657E-06	0.02812425	0.00031747	4.4105E-06	2.9782E-08	1.3574E-05	2.9836E-06	9.3518E-10
Fold Change 0.18 4	0.30	3.28	4.031107597	6.276196882	0.26701338	0.183592799	5.975488989
Cluster Incl. AL110368:DKFZp564P1078_s1 Homo sapiens cDNA, 3 end /clone=DKFZp564P1078 /clone_end=3' /gb=AL110368 /gi=5865976 /ug=Hs.198353 /len=720'	Cluster Incl. AA147088:zo32c07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-58858 /clone_end=3'/gb=AA147088 /gi=1716461 /ug=Hs.106185 /len=688'	Cluster Incl. AI799107:we98h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2349171 /clone_end=3' /gb=AI799107 /gi=5364579 /uc=Hs.128501 /len=713'	Cluster Incl. AL079372:DKFZp564H1178_s1 Homo sapiens cDNA, 3 end /clone=DKFZp564H1178 /clone_end=3' /gb=AL079372 /gi=5423266 /ug=Hs.23044	Cluster Incl. AI739117:wi18c04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2390598 /clone_end=3'/gb=AI739117 /gi=5101098 /ua=Hs.73625 /len=762'	Cluster Incl. Al858626:wl40g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2427416 /clone_end=3'/gb=Al858626 /gi=5512242 /ug=Hs.30807 /len=617'	Cluster Incl. Al304339:qo58g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1912770 /clone_end=3'/gb=Al304339 /gl=3988028 /ua=Hs.8364 /len=614'	Cluster Incl. AA195614:zr37b09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-665561 /clone_end=5'/gb=AA195614 /gi=1783791 /ug=Hs.5101 /len=635'
<u>Сluster#</u> Нs.12246	Hs.106185	Hs.128501	Hs.23044	Hs.73625	Hs.198281	Hs.8364	Hs.5101
<u>Gene Name</u> reelin	ral guanine nucleotide Hs.106185 dissociation stimulator	RAD54, S. cerevisiae, homolog of, B	RAD51 (S. cerevislae) homolog (E coli RecA homolog)	RAB6 interacting, kinesin-like (rabkinesin6)	pyruvate kinase, muscle	pyruvate dehydrogenase kinase, isoenzyme 4	protein regulator of cytokinesis 1
<u>Genbank</u> AL110368	AA147088	AI799107	AL079372	AI739117	AI858626	Al304339	AA195614
<b>Affy</b> 69473_r_at	91384_at	74300_at	44037_at	46683_at	57173_at	48647_at	45799_at
SeqID 900	19	212	895	620	737	420	. 18
20e	207	208	209	210	211	212	213

					66							101/0	J302/02.	LIU				
p-values	1.0797E-05		5.5208E-05		0.03570463		0.00261362		7.8961E-05			0.00044405			9.7327E-07		6.0939E-06	
Fold Change	0.31		0.181794989		3.638706185		0.158415546		0.062026919			0.19			0.14		5.25	
Cluster Description	Cluster Incl. AI828396:wk84e07.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2422116 /clone_end=3' /gb=Al828396 /gi=5449067 /ug=Hs.201574 /len=465'	Cluster Incl. AI741776:wg22g10.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2365890 /clone_end=3' /gb=Al741776 /gl=5110064 /ug=Hs.8944 /len=641'	Cluster Incl. AA593830:nn17b11.s1 Homo	/clone_end=3' /gb=AA593830 /gi=2408508 /ug=Hs.163833 /len=405'	Cluster Incl. A1863965:wj54b08.x1 Homo	sapiens culvA, 3 end /cione=iiviAs==24000 i 3 ./clone_end=3'/gb=Al863965 /gi=5527996 ./.n=Hs 15285 /len=601'		sapiens cDNA, 3 end /clone=IMAGE-2208241	/clone_end=3' /gb=Al697470 /gi=4985370 /un=Hs. 205126 /len=494'	Cluster Incl. AL044906:DKFZp434K183 r1	Homo sapiens cDNA, 5 end /clone=DKFZp434K183 /clone_end=5'	/gb=AL044906 /gi=5433103 /ug=Hs.211647 /len=485'	Cluster Incl. AI492388:ti27d10.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2131699 /clone_end=3' /gb=Al492388 /gi=4393391 /ug=Hs.145011 /len=477'	Cluster Incl. AA535819:nj79e01.s1 Homo sapiens cDNA /clone=IMAGE-998712 /nh=AA535819 /ni=2280072 /nn≃Hs 238355	/len=522
Cluster#"	Hs.75323		Hs.8944		Hs.163833		Hs.279898		Hs.205126			Hs.75813			Hs.117176		Hs.83883	
Gene Name	prohibitin		procollagen C-	endopeptidase enhancer 2	PRO0611 protein		PRO0529 protein		polymeric	immunoglobulin	receptor	polycystic kidney			poly(A)-binding	protein, nuclear 1	PMEPA1 protein	
Genbank	AI828396		AI741776		AA593830		AI863965		AI697470			AL044906			AI492388		AA535819	
Affy	86573_at		55569_at		84574_r_at		65700_at		45294 at	l		71106 i at	! !		90494_at		91095_s_at	
SeqID	726		625		173		745		607			874			492		161	
##	214		215		216		217		218			219	! !		220		221	

1128

227

738

228

804

229

924

226

SealD

824

225 ## 698

223

705

224

143

225

. :

68																												
p-values	0.00020188		0.00307749			6.6167E-05		0.000479				1.4629E-08				6.7348E-06			4.93E-06					5.3066E-07				
Fold Change	0.199980315		3.316200333			4.64		0.117240353				0.17504844				0.262530591			4.698983711					3.809930405				
Cluster Description	Cluster Incl. Al355848:qu02d09.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-1963601 /clone_end=3' /gb=Al355848 /gi=4096001 /ug=Hs.239464 /len=715'	Cluster Incl. AI935353:wo82d12.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2461847 /clone_end=3' /gb=Al935353 /gi=5674223	/ug=Hs.234669 /len=532'	Cluster Incl. Al479933:tm73b08.x1 Homo sapiens cDNA. 3 end /clone=IMAGE-2163735	/clone_end=3' /gb=AI479933 /gi=4373101 /ua=Hs.223933 /len=465'	Cluster Incl. W48800:zc44f03.r1 Homo sapiens	cDNA, 5 end /clone=IMAGE-325181	/clone_end=5' /gb=W48800 /gi=1336949	/ug=Hs.167297 /len=451'	Cluster Incl. AA427578:zw54b07.s1 Homo	sapiens cDNA, 3 end /clone=IMAGE-773845	/clone_end=3' /gb=AA427578 /gi=2112006	/ug=Hs.220975 /len=525'	Cluster Incl. AI052524:oz27f07.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-1676581	/cione_end=3 /gb=Al022224 /gl=33063 l3 /ug=Hs.4799 /len=537'	Cluster Incl AA418080:zv97h07.s1 Homo	sapiens cDNA, 3 end /clone=IMAGE-767773	/clone_end=3"/gb=AA418080/gi=2079881	/ug=Hs.3972 /len=543"		Cluster Incl. Al742260:wq39q10.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2367522	/clone_end=3' /gb=Al742260 /gi=5110548	/ug=Hs.93847 /len=789'	
Cluster#	Hs.35841		Hs.243886			Hs.159623		Hs.44054				Hs.266902				Hs.3821			Hs.3972					Hs.93847				
Gene Name	nuclear factor I/X	(CCAAT-binding transcription factor)	nuclear autoantigenic	sperm protein (histone-binding)		NK-2 (Drosophila)		ninein				neurotrophin 5	(neurotrophin 4/5)			neurobeachin			NeuAc-alpha-2,3-Gal-	beta-1,3-GalNAc-	alpha-2, 6-	sialyltransferase	alpha2,6-	NADPH oxidase 4				)
Genbank	AI355848		A1935353			AI479933		W48800				AA427578				A1052524			AA418080					AI742260				
Affy	63877_r_at		49666_s_at			72236_at		82657 f at				72026_g_at				56809_at			34778_at					55457 at	; ; ;			
SedID	435		790			486		1188				114				328			105					630				
##	230		231			232		233				234				235			236					237	į			

p-values 4.4362E-07	0.0000139	0.00225117	0.00151003	1.1301E-05	0.0000045	0.00267462	0.0000502
<b>Fold Change</b> 0.32670528	0.168769332	0.288946314	4.848524211	3.068295724	0.23811529	0.23	0.246437105
Cluster Description Cluster Incl. AA526844:ni92d10.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-984307 /clone_end=3 /gb=AA526844 /gi=2268913 /ua=Hs.77310 /len=669'	Cluster Incl AF001548:Human Chromosome 16 BAC clone CIT987SK-A-815A9 /cds=(0,5573) /gb=AF001548 /gi=2104552 /ug=Hs. 78344 /len=6428		Cluster Incl. N78139:yv73d07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-248365 /clone_end=5 /gb=N78139 /gl=1240840 /ug=Hs.239825 /len=656'	Cluster Incl. N27428:yx81h09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-268193 /clone_end=3 /gb=N27428 /gi=1141909 /ing=Hs_221178 /len=407		Hs.177536 Cluster Incl. AA776393:ah16g09.s1 Homo sapiens cDNA, 3 end /clone=1156864 /clone_end=3'/gb=AA776393 /gi=2835727 /ug=Hs.177536 /fen=602'	
<u>Gluster#</u> Hs.211582	Hs.78344	Hs.239663	Hs.42346	Hs.240	Hs.183109	Hs.177536	Hs.279771
Gene Name myosin, light polypeptide kinase	myosin, heavy polypeptide 11, smooth muscle	myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog);	muscle-specific protein	M-phase phosphoprotein 1	monoamine oxidase A	metallocarboxypeptid ase CPX-1	melanoma inhibitory activity,ras-related GTP-binding protein 4b
Genbank AA526844	AF001548	AI814178	N78139	N27428	AA420624	AA776393	AA461365
<b>Affy.</b> 46276_at	32582_at	46743_s_at	.58494_r_at	59624_g_at	41771_g_at	84934_at	39271_at
SeqID 150	283	269	1093	1069	<del>1</del>	222	127
738 738	239	240	241	242	243	244	245

WO 02/059271					•	70				
p-values	6.1415E-06	7. 17. 20.	1.80 July 1.00 J	0.00253759	0.00110724	0.0005914	0.00014885	8.7304E-05	6.1228E-07	
Fold Change	0.196704294	6	7.0	0.307354772	4.366999247	0.247555921	0.214230439	0.322163154	3.542386026	
Cluster Description	Cluster Incl. AI972357:wr37c09.x1 Homo	sapiens cDNA, 3 end /clone=IMAGE-2489872 /clone_end=3' /gb=Al972357 /gi=5769183 /ug=Hs.237874 /len=524'	Cluster Incl. Al459139:tj65e05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146400 /clone_end=3'/gb=Al459139 /gi=4311718 /ug=Hs.235590 /len=519'	Cluster Incl. Al969879:wq76f05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2477217 /clone_end=3'/gb=Al969879 /gi=5766697 /ug=Hs.233610 /len=329'	Cluster Incl. W22091:61F10 Homo sapiens cDNA /clone=(not-directional) /gb=W22091	Cluster Incl. F36908:HSPD34832 Homo sapiens cDNA /clone=sH5-000021-0/A10 /gb=F36908 /gi=4822534 /ug=Hs.97044 /len=408				
Cluster #	Hs. 19368		Hs.56729	Hs.89137	Hs.1770	Hs.97044	Hs.84728	Hs.182965	Hs.279766	
Gene Name	matrilin 2	1	lymphocyte-specific protein 1	low density lipoprotein related protein 1 (alpha-2-macroglobulin	receptor) ligase I, DNA, ATP- dependent	Kv channel- interacting protein 2	Kruppel-like factor 5 (intestinal)	Kruppel-like factor 4 (gut)	kinesin family member 4A	
Genhank	A1079357		Al459139	Al969879	W22091	F36908	AI815057	Al290876	AA004208	
Δffι	75754 24	13234_ai	78644_at	74541_at	74835_r_at	48950_at	47113_at	48587_at	51160_at	
	alkas	6 <b>7</b> 0	480	819	1176	976	669	416	7	
*	# 5	740	247	248	249	250	251	252	253	

DESCRIPTION ASSESSMENT AS I

			7	1			
<b>p-values</b> 3.2252E-06	0.00090706	0.00048007	0.00894957	9.936E-05	4.1926E-05	1.24E-12	1.69E-06
<b>Fold Change</b> 0.189411148	0.317853152	0.28929478	3.778012983	0.231260722	0.20	10.18941323	3.635450964
Cluster Incl. W68504:zd36b01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-342697 /clone_end=5' /gb=W68504 /gl=1377374 /ug=Hs.21288 /len=613'			Cluster Incl. AI073544:ov45e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1640282 /clone_end=3' /gb=AI073544 /gi=3400188 /ua=Hs 120703 /len=481'	Cluster Incl. Al097463:qb90a04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1707342 /clone_end=3 /gb=Al097463 /gi=3447045 /ug=Hs. 21035 /len=464	Cluster Incl. H19400:ym46g07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-51511 /clone_end=5 /gb=H19400 /gi=888095 /ug=Hs.21035 /len=488'	Cluster Incl AB029000:Homo sapiens mRNA for KIAA1077 protein, partial cds /cds=(0,2456) /gb=AB029000 /gi=5689490 /ug=Hs.70823 /len=4834	Cluster Incl AB020713:Homo sapiens mRNA for KIAA0906 protein, partial cds /cds=(0,2772) /gb=AB020713 /gi=4240300 /ug=Hs.56966 /len=4217
Cluster#	Hs.230188	Hs.263395	Hs.62576	Hs.21035	Hs.21035	Hs.70823	Hs.56966
Gene Name KIAA1479 protein	KIAA1396 protein	KIAA1368 protein	KIAA1240 protein	KIÀA1130 protein	KIAA1130 protein	KIAA1077 protein	KIAA0906 protein
<b>Genbank</b> W68504	AA912409	AF063500	Al073544	Al097463	H19400	AB029000	AB020713
<b>Affy</b> 49599_at	88138_at	63393_at	76253_at	52793_at	90920_at	35832_at	41812_s_at
SeqID 1194	250	302	334	350	986	278	276
## 524	255	256	257	258	259	260	261

~·:·

## SeqID Affy Ganbank Gene Name Cluster incl. Arthogographs of 65693_at Ant-2266 KiAAu781 protein Hs.45676 Cluster incl. Arthogographs of 67234 Homo Cluster incl. Arthogographs of 672430659 B 6801E-06 saplars of 0000, 3 and 14,2366 Cluster incl. Arthogographs of 17,2334 Advantage incl. Arthogographs of 17,234 Advantage incl. Arthogographs of 17,237 Advantage incl. Arthogographs of 17,239 Ad		WO 02/0592	2/1		7	2		PC	T/US02/02176
SegID         Affy         Gene Name         Cluster inc.         Activation           58         65583_at         AA142956         KIAA0781 protein         Hs.42676         Cluster Incl. AA1429562443002.s1 Homo sapients cDNA, a and (Jonne-BIMAGE-504722 Incline)           203         68283_r. at         AA701619         KIAA0614 protein         Hs.7314         Aug-Hs.239142 Inche 640         Jug-Hs.239142 Inche 640         Jug-Hs.239142 Inche 640         Jug-Hs.23384         Jug-Hs.239142 Inche 640         Jug-Hs.239142 Inche 640         Jug-Hs.23384         Jug-Hs.239142 Inche 640         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.239142 Inche 640         Jug-Hs.2372         Jug-Hs.23389         Jug-Hs.23389         Jug-Hs.2372	p-values	9.6801E-06	0.04190137	2.62E-08	5.93E-09	5.5307E-05	3.56E-09	0.0000146	0.01054263
SeqID         Afty         Genbank         Gene Name         Cluster#           58         65593_at         AA142956         KIAA0781 protein         Hs.42676           203         68283_r_at         AA701619         KIAA0614 protein         Hs.7314           273         39382_at         AB011089         KIAA0517 protein         Hs.12372           269         39544_at         AB002351         KIAA0353 protein         Hs.115740           961         38116_at         D14657         KIAA0101 gene         Hs.81892           962         34760_at         D14664         KIAA0022 gene         Hs.2441           731         62998_at         AI831452         Keratin 6B         Hs.11758	Fold Change	0.247630859	0.33	0.226047115	0.075355998	0.22	6.816530863	0.325833287	0.3274967
SeqID         Affy         Genbank         Gene Name           58         65593_at         AA142956         KIAA0781 protein           203         68283_r_at         AA701619         KIAA0517 protein           273         39382_at         AB0011089         KIAA0517 protein           269         39544_at         AB002351         KIAA0353 protein           207         91405_at         AA706612         KIAA0101 gene           961         38116_at         D14657         KIAA0022 gene           9731         62998_at         AI831452         Keratin 6B	Cluster Description	Cluster Incl. AA142956:zl43g02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-504722 /clone_end=3'/gb=AA142956 /gi=1712334 /ug=Hs.239142 /len=640'	Cluster Incl. AA701619:zi41f11.s1 Homo sapiens cDNA, 3 end /clone=433389 /clone_end=3'/gb=AA701619 /gi=2704784 /ug=Hs.190382 /len=398'	.Cluster Incl AB011089:Homo sapiens mRNA for KIAA0517 protein, partial cds /cds=(0,2380) /gb=AB011089 /gi=3043557 /ug=Hs.12372 /len=6740	Cluster Incl AB002351:Human mRNA for KIAA0353 gene, partial cds /cds=(0,4125) /gb=AB002351 /gi=2224646 /ug=Hs.10587 /len=6651		Cluster Incl D14657:Human mRNA for KIAA0101 gene, complete cds /cds=(61,396) /gb=D14657 /gi=285938 /ug=Hs.81892 /len=836	Cluster Incl D14664:Human mRNA for KIAA0022 gene, complete cds /cds=(184,696) /gb=D14664 /gi=285952 /ug=Hs.2441 /len=3694	Cluster Incl. AI831452:wj49b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2406125 /clone_end=3'/gb=AI831452 /gi=5452123 /ug=Hs.91539 /len=597'
SeqID         Affy         Genbank         Gene           58         65593_at         AA142956         KIAA0781           203         68283_r_at         AA701619         KIAA0614           273         39382_at         AB011089         KIAA0517           269         39544_at         AB002351         KIAA0353           207         91405_at         AA706612         KIAA0210           961         38116_at         D14657         KIAA0101           962         34760_at         D14664         KIAA0022           731         62998_at         AI831452         keratin 6B	Cluster#	Hs.42676	Hs.7314	Hs.12372	Hs.10587	Hs.115740	Hs.81892	Hs.2441	Hs.111758
58 65593_at Av 58 65593_at Av 203 68283_r_at Av 203 39544_at Av 207 91405_at Av 961 38116_at Dv 962 34760_at Dv 731 62998_at Av	Gene Name	KIAA0781 protein	KIAA0614 protein	KIAA0517 protein	KIAA0353 protein	KIAA0210 gene product	KIAA0101 gene product	KIAA0022 gene product	keratin 6B
203 203 207 207 207 207 207 207 207	Genbank	AA142956	AA701619	AB011089	AB002351	AA706612	D14657	D14664	AI831452
		65593_at	68283 <u>r_at</u>	39382_at	39544_at	91405_at	38116_at	34760_at	62998_at
## 262 263 264 266 266 266 266 269 269 269 3	SedID	28	203	273	569	207	961	962	731
	粗	262	263	264	265	266	267	268	569

<b>p-values</b> 0.00012792	0.0007796	7.6279E-07	1.23E-05	0.01689309	1.29E-07	0.0007917	6.2389E-06
<b>Fold Change</b> 0.18	3.175184161	0.146596341	5.51416519	0.25	0.171820134	0.310324615	0.223459008
Cluster Description Cluster Incl. Al566193:tq69f02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2214075 /clone_end=3 /gb=Al566193 /gi=4524645 /ua=Hs. 196927 /len=393'		Cluster Incl. AW008322:wv53d07.x1 Homo saplens cDNA, 3 end /clone=IMAGE-990848 /clone_end=3 /gb=AW008322 /gi=5857100 /ua=Hs_234145 /len=556*	Cluster Incl AA203213:zx57e04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446622 /clone_end=5" /gb=AA203213 /gi=1798923 /lin=Hs R33 /len=879"	Cluster Incl. Al971748:wr07f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2480871 /clone_end=3'/gb=Al971748 /gi=5768574 /len=841'	Cluster Incl AL021786:Human DNA sequence from PAC 696H22 on chromosome Xq21.1-21.2. Contains a mouse E25 like gene, a Kinesin like pseudogene and ESTs /cds=(0,680) /gb=AL021786 /gi=2853186	Cluster Incl. AW022660:df42a02.y1 Homo sapiens cDNA, 5 end /clone=IMAGE-2485899 /clone_end=5 /gb=AW022660 /gi=5876190 /lin=Hs 236002 /len=505	
<b>Cluster #</b> Hs.196927	Hs.237868	Hs.64310	Hs.833	Hs.85266	Hs.17109	Hs.85112	Hs.143648
Gene Name iroquois homeobox protein 4	interleukin 7 receptor	interleukin 11 receptor, alpha	interferon-stimulated protein, 15 kDa	integrin, beta 4	integral membrane protein 2A	insulin-like growth factor 1 (somatomedia C)	insulin receptor substrate 2
Genbank Al566193	AI655781	AW008322	AA203213	Al971748	AL021786	AW022660	AA031286
<b>Affy</b> 79663_at	63628_at	89921_at	38432_at	73285 <u>_i_</u> at	40775_at	64305_s_at	56338_at
SeqID 518	557	928	82	826	850	942	4
270	27.1	272	273	274	275	276	277

p-values 0.0000161	0.0016656	0.000411	0.00034019	1.7517E-05	3.744E-08
Eold Change p 0.309888618 0.	0.316720069 0	0.23941203 C	0.302724058 0.	10.30345974 1.	0.1264716 3
Cluster Incl AL022726:Human DNA sequence from clone 625H18 on chromosome 6p22.2-23. Contains the gene for ID4 Helix-loop-helix DNA binding protein and part of an alternatively spliced novel gene. Contains ESTs, STSs, GSSs and putative CpG Islands /cds=(368,853) /gb=AL022726 /gi=3676217 /ug=Hs.34853 /len=3859	Cluster Incl. AA152276:zl06e06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-491554 /clone_end=5'/gb=AA152276 /gi=1721679 /un=Hs 204038 /len=618'	Cluster Incl Al660656:wf23c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2351436 /clone_end=3" /gb=Al660656 /gl=4764239 /ug=Hs.76325 /len=522"	Hs.283305 Cluster Incl. Al813866:wk61b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2419853 /clone_end=3' /gb=Al813866 /gi=5425081	Cluster Incl. Al828404:wk84f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2422117 /clone_end=3 /gb=Al828404 /gi=5449075	
<u>Cluster#</u> Hs.34853	Hs.204038	Hs.76325	Hs.283305	Hs.140	Hs.112844
Gene Name inhibitor of DNA binding 4, dominant negative helix-loop- helix protein	indolethylamine N- methyltransferase	immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides	immunoglobulin heavy contant alpha 1	immunoglobulin heavy constant gamma 3 (Gm	marker) hypothetical protein PRO2160
<u>Genbank</u> AL022726	AA152276	AI660656	Al813866	AI828404	AW016235
<b>Affy</b> 41536_at	63798_at	37006_at	75127_f_at	58869 <u>i</u> at	64258_f_at
<u>SeqID</u> 852	29	570	969	727	935
. 278	279	280	281	282	283

senlex-d	2.1399E-07	4.8443E-05	1.7499E-09	5.2039E-08	0.00014333	0.00241384	1.8721E-05	0.00187809
Fold Change	0.297383187	3.983397486	0.047728145	0.289179561	3.336721416	0.32	3.188106939	4.36
Cluster Description	Cluster Incl. AA651733:ns67b07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-1188661 /clone_end=5'/gb=AA651733 /gi=2583385 /ug=Hs.21861 /len=515'	Cluster Incl. N21131:yx52g04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-265398 /clone_end=3'/gb=N21131 /gi=1126301 /ug=Hs.233612 /len=571'	Cluster Incl. AA020743:ze63c11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-363668 /clone_end=3'/gb=AA020743 /gi=1484525 /ug=Hs.234026 /len=626'	Cluster Incl. AA521440:aa69c11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-826196 /clone_end=3'/gb=AA521440 /gi=2261983 /ua=Hs.169764 /len=583'	Cluster Incl. Al276023:qw08h12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1990535 /clone_end=3'/gb=Al276023 /gl=3898297 /ug=Hs.11388 /len=476'			Cluster Incl. AI149537:qc70g02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1714994 /clone_end=3'/gb=AI149537 /gi=3678006 /ug=Hs.203401 /len=527'
Cluster#	Hs.21861	Hs.42949	Hs.271277	Hs.169764	Hs.118552	Hs.267368	Hs.133260	Hs.263081
Gene Name	hypothetical protein MPMGp800C04260Q 003	hypothetical protein HES6	hypothetical protein from EUROIMAGE 363668	hypothetical protein FLJ20701	hypothetical protein FLJ20539	hypothetical protein FLJ20489	hypothetical protein FLJ20354	hypothetical protein FLJ20320
Genbank	AA651733	N21131	AA020743	AA521440	Al276023	AA563601	AA813827	Al149537
Affy		49633_at	50223_at	54742_at	47427_at	91394_at	56634_at	70129 <u>r_a</u> t
SegiD	195	1063	O	144	406	167	231	371
##	284	285	286	287	288	289	290	291

				76			1 0 17 0 5 0 27	02170
<b>p-values</b> 0.00010396	0.00090349	6.097E-08	3.4283E-07	1.2408E-05	0.00013093	9.6896E-05	1.4039E-06	0.00250076
<u>Fold Change</u> 3.437531315	4.739571659	3.646875259	0.299454892	0.263536613	0.223334551	0.142325635	3.915587607	0.33
Cluster Incl. AA181060:zp66h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-625211 /clone_end=3 /gb=AA181060 /gi=1764543 /lua=Hs.239302 /len=607	•	Cluster Incl. AA741298:oc86a07.s1 Homo sapiens cDNA /clone=IMAGE-1356564 /gb=AA741298 /gi=2779890 /ug=Hs.23495 /len=530	Cluster Incl. Al376944:tc34b06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2066483 /clone_end=3'/gb=Al376944 /gi=4186797 /ua=Hs. 6166 /len=492'	Cluster Incl. W27376:28b7 Homo sapiens cDNA /gb=W27376 /gi=1307036 /ug=Hs.8395 /len=596	Cluster Incl. Al971695:wq88e01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2479128 /clone_end=3' /gb=Al971695 /gi=5768521 /ug=Hs.237607 /len=573'	Cluster Incl. AA708740:zl57g12.s1 Homo sapiens cDNA, 3 end /clone=506086 /clone_end=3' /gb=AA708740 /gi=2718658 /ug=Hs.23467 /len=475'	Cluster Incl. AA195220:zr34g09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-665344 /clone_end=5' /gb=AA195220 /gi=1784932 /ug=Hs.26516 /len=637'	Cluster Incl. Al811688:tw44g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2262594 /clone_end=3' /gb=Al8116R8 /gi=5398254 /ug=Hs.128766 /len=455
Cluster# Hs.92254	Hs.161554	Hs.23495	Hs.6166	Hs.8395	Hs.107882	Hs.23467	Hs.26516	Hs.128766
Gene Name hypothetical protein FLJ20163	hypothetical protein FLJ20159	hypothetical protein FLJ11252	hypothetical protein FLJ11196	hypothetical protein FLJ10781	hypothetical protein FLJ10659	hypothetical protein FLJ10633	hypothetical protein FLJ10604	hypothetical protein FLJ10600
Genbank AA181060	AI766666	AA741298	Al376944	W27376	Al971695	AA708740	AA195220	Ai811688
<b>Affy</b> 50280_at	74539_g_at	43439_at	53962_at	55074_at	44855_s_at	44057_at	51130_at	74343_at
SeqID 76	<b></b>	က	445	1179	825	210	62	695
S '	656	213	4	<del>_</del>	89	7	7	99

p-values	0.0022939	4.719E-12	1.3006E-07	9.0609E-08	1.8056E-05	7.6457E-06	0.00028995	5.3484E-07
Fold Change	3.07	9.164231149	3.058813358	4.806177129	3.509937557	0.21534971	3.782457573	0.18625739
Cluster Description	Cluster Incl. AI016073:ov26f11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1638477 /clone_end=3' /gb=AI016073 /gi=3230409 /ug=Hs,131840 /len=561'	Cluster Incl. AI674163:wc09a11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2314652 /clone_end=3' /gb=AI674163 /gi=4874643 /ug=Hs.14559 /len=553'	Cluster Incl. AA134589:zn90b04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-565423 /clone_end=5' /gb=AA134589 /gi=1695586 /ug=Hs.48855 /len=608'	Cluster Incl. AI823992:wj29c06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2404234 /clone_end=3'/gb=AI823992/gi=5444663 /ug=Hs.122579/len=564'		Cluster Incl. AI651535:wb06h08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2304927 /clone_end=3 /gb=AI651535 /gi=4735514 /uq=Hs.43102 /len=587	Cluster Incl. Al949698:wq13h04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2471191 /clone_end=3 /gb=Al949698 /gi=5742008 /ua=Hs.42309 /len=553'	Cluster Incl. AL040063:DKFZp434P0712_r1 Homo sapiens cDNA, 5 end /clone=DKFZp434P0712 /clone_end=5' /gb=AL040063 /gi=5409033 /ug=Hs.22505 /len=557'
Cluster#	Hs.131840	Hs.14559	Hs.48855	Hs.122579	Hs.104650	Hs.106283	Hs.53913	Hs.22505
Gene Name	hypothetical protein FLJ10578	hypothetical protein FLJ10540	hypothetical protein FLJ10468	hypothetical protein FLJ10461	hypothetical protein FLJ10292	hypothetical protein FLJ10262	hypothetical protein FLJ10252	hypothetical protein FLJ10159
Genbank	Al016073	Al674163	AA134589	AI823992	A1037879	AI651535	Al949698	AL040063
Affx	74690_at	58235_at	52966_at	59461_at	54889_at	64666_at	52617_at	49523_at
SealD	313	582	53	715	323	549	801	863
##	301	302	303	304	305	306	307	308

77

				•	78			
p-values	5.8315E-11	0.00017758	0.00279468	1.5285E-06	5.019E-05	5.4416E-07	0.00026772	1.2153E-08
Fold Change	4.802394237	0.27	0.26	0.262634843	0.269743016	0.275006365	0.291337727	0.054106026
Cluster Description	Cluster Incl. AA779101:zj42h12.s1 Homo sapiens cDNA, 3 end /clone=452999 /clone_end=3'/gb=AA779101 /gi=2838432 /ug=Hs.104859 /len=528'	Cluster Incl. Al613455:ty37b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2281229 /clone_end=3 /gb=Al613455 /gi=4622622 /ug=Hs.181658 /len=418'		Cluster Incl. Z78379:HSZ78379 Homo sapiens cDNA /clone=3.18-(CEPH) /gb=Z78379 /gi=1495152 /ug=Hs.224337 /len=1958	Cluster Incl. AL039400:DKFZp434K1210_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434K1210 /clone_end=3' /gb=AL039400 /gi=5928554 /ug=Hs.32352 /len=703'	Cluster Incl. AI632223:tt20d07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2241325 /clone_end=3' /gb=AI632223 /gi=4683553 /ug=Hs.144633 /len=721'	Cluster Incl. AA625897:zu87b02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-744939 /clone_end=3' /gb=AA625897 /gi=2538284 /ug=Hs.222095 /len=252'	Cluster Incl. AA046671:zf12d09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-376721 /clone_end=5'/gb=AA046671 /gi=1524772 /ug=Hs.17917 /len=596'
Cluster #	Hs.104859	Hs.49933	Hs.284280	Hs.279023	Hs.32352	Hs.144633	Hs.24583	Hs.278975
Gene Name	hypothetical protein DKFZp762E1312	hypothetical protein DKFZp762D1011	hypothetical protein DKFZp547H236	hypothetical protein DKFZp434N1928	hypothetical protein DKFZp434K1210	hypothetical protein DKFZp434F2322	hypothetical protein DKFZp434C0328	hyaluronic acid receptor,lymphatic vessel endothelial hyaluronan receptor 1
Genbank	AA779101	AI613455	Al394248	Z78379	AL039400	AI632223	AA625897	AA046671
Affy	48045_at	77581_at	87842_at	63581_at	44682_at	53831_at	72538_at	65731_at
SeqD	225	533	460	1245	859	539	186	56
##	309	310	311	312	313	314	315	316

PNSCOCIO: -WO 02050271A2 L

			4	19			
<i>p-values</i> 2.013E-09	0.00165492	0.00126636	0.00508853	6.2245E-06	1.93E-08	2.4107E-05	0.0031179
<b>Fold Change</b> 7.363245733	0.26	3.975570707	3.439858165	5.704063952	3.965279191	0.285742894	5.05
Cluster Incl. Al990409:wt74a03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2513164 /clone_end=3 /gb=Al990409 /gi=5837290 /ug=Hs.5199 /len=744*	Cluster Incl. F37133:HSPD35222 Homo sapiens cDNA /clone=sH5-000026-0/F04 /gb=F37133 /gi=4822759 /ug=Hs.185302 /len=337	Cluster Incl. Al670876:wa06c12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297302 /clone_end=3 /gb=Al670876 /gi=4850607 /ua=Hs, 44276 /len=798'	Cluster Incl. AW024474:wu76h03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990888 /clone_end=3'/gb=AW024474 /gi=5878004 /lun=Hs. 236884 /len=229'	Cluster Incl. AI525822:PT1.3_06_B10.r Homo sapiens cDNA, 5 end /clone_end=5' /gb=AI525822 /gi=4439957 /ug=Hs.109706 /len=773'	Cluster Incl AA255502:zr85b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-682451 /clone_end=5" /gb=AA255502 /gi=1892406 /ua=Hs.46423 /len=348"	Cluster Incl. AA609509:af14d11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1031637 /clone_end=3'/gb=AA609509 /gi=2457937 /ua=Hs 238503 /len=381'	Cluster Incl. AI125923:qc41f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1712197 /clone_end=3'/gb=AI125923 /gi=3594437 /ug=Hs.239324 /len=512'
Cluster# Hs.5199	Hs.278943	Hs.44276	Hs.44276	Hs.109706	Hs.46423	Hs.180877	Hs.180779
Gene Name HSPC150 protein similar to ubiquitin- conjugating enzyme	HSPC047 protein	homeo box C10	homeo box C10	HN1 protein	H4 histone family, member G	H3 histone, family 3B (H3.3B)	H2B histone family, member B
Genbank Al990409	F37133	AI670876	AW024474	AI525822	AA255502	AA609509	AI125923
<b>Affy</b> 45803_at	78942_at	52117_at	57830_s_at	56428_at	39969_at	90048_at	88155_at
SegID 845	977	573	947	503	91	179	356
317	318	319	320	321	322	323	324

					80				
b-values	1.24E-04	1.5236E-07	3.9853E-10	2.305E-06	8.5076E-08	3.05E-08	2.6578E-09	1.3623E-06	1.8509E-07
Fold Change	3.590913916	0.226916444	4.119810176	0.172426013	12.40	0.259661725	0.233804467	0.17	5.46370987
Cluster Description	Cluster Incl Al885852:wl62d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2429487 /clone_end=3" /gb=Al885852 /gi=5591016 /ug=Hs.795 /len=580"	Cluster Incl. AA115300:zl09d12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-501431 /clone_end=3' /gb=AA115300 /gl=1670497 /ug=Hs.103720 /len=588'	Cluster Incl. U82984:U82984 Homo sapiens cDNA /clone=163g24 /gb=U82984 /gi=2731436 /ug=Hs.23900 /len=1771		Cluster Incl. AA613715:nq25b01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1144873 /clone_end=3' /gb=AA613715 /gi=2463685 /ug=Hs.81795 /len=607'			•	
Cluster #	Hs.795	Hs.23767	Hs.23900	Hs.58589	Hs.5566	Hs.160318	Hs.77889	Hs.239069	Hs.118162
Gene Name	H2A histone family, member O	guanine nucleotide binding protein (G protein), gamma 2	GTPase activating protein	glycogenin 2	gap junction protein, beta 2, 26kD (connexin 26)	FXYD domain- containing ion transport regulator 1 (phospholemman)	Friedreich ataxia region gene X123	four and a half LIM domains 1	fibronectin 1
Genbank	AI885852	AA115300	U82984	D60584	AA613715	AA524547	AA524029	AW024276	AW021977
Affy	32609_at	58445_at	50271_at	55630_f_at	91306_s_at	32109_at	54581_at	80572_at	45557_r_at
SeqID	756	40	1163	696	182	149	145	944	940
##	325	326	327	328	329	330	331	332	333

<del>p-values</del> 5.0303E-07	2.9946E-05	0.00020319	0.00010017	6.067E-07	0.00101117	6.263E-08	7.8076E-06
Eold Change 0.097550234	3.294370164	0.276576877	0.31	0.08111725	0.311274497	0.108158864	0.22460642
Cluster Incl. AA156998:z119e05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-502400 /clone_end=3'/gb=AA156998 /gi=1728613 /ug=Hs.239679 /len=562'		•					
Cluster#************************************	Hs.193053	Hs.43697	Hs.79095	Hs.11713	Hs.21595	Hs.109439	Hs.108924
Gene Name eukaryotic translation initiation factor 4 gamma, 1	eukaryotic translation initiation factor 2C, 2	ets variant gene 5 (ets-related molecule)	epidermal growth factor receptor pathway substrate 15	E74-like factor 5 (ets domain transcription factor)	DNA segment on chromosome X and Y (unique) 155 expressed sequence	DKFZP586P2421 protein	DKFZP586P1422 protein
Genbank AA156998	AI146465	AA224344	Al138998	Al912678	AA557237	AW020116	W72194
<b>Affy.</b> 63893_f_at	56226_at	75258_f_at	78641_at	59390_at	60058_at	43506_at	56409_at
SeqID 70	369	87	. 363	768		937	1197
33#	335	336	337	338	339	340	34.1

				8:	2			
p-values	7.5151E-06	6.4105E-05	0.00232454	0.00000163	6.3581E-06	0.00455471	0.000426	4.57E-06
Fold Change	0.185480277	0.308559272	0.306209896	0.296976926	3.405694621	0.222139001	0.21553985	5.17065685
Cluster Description	Cluster Incl. W78050:zd78c04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-346758 /clone_end=3'/gb=W78050 /gi=1388613 /ug=Hs.235916 /len=446'	Cluster Incl. AW026659:wv15c11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-991047 /clone_end=3 /gb=AW026659 /gi=5880112 /ug=Hs.26358 /len=551'	Cluster Incl. Al984087:wz56d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2562063 /clone_end=3 /gb=Al984087 /gi=5811306 /ug=Hs.235102 /len=479	Cluster Incl AL050024:Homo sapiens mRNA; cDNA DKFZp564D206 (from clone DKFZp564D206) /cds=(0,404) /gb=AL050024 /gi=4884093 /ug=Hs.25956 /len=1409	Cluster Incl. AW007289:wt54f03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2511293 /clone_end=3 /gb=AW007289 /gi=5856067 /ug=Hs.16441 /len=552'	Cluster Incl. Al961431:wt22e08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2508230 /clone_end=3'/gb=Al961431 /gi=5754144 /ug=Hs.9029 /len=696'	Cluster Incl AL049798:Human DNA sequence from clone 797M17 on chromosome 1q22-24.3. Contains the DPT gene for Dermatopontin, ESTs, an STS and GSSs /cds=(9,614) /gb=AL049798 /gi=4995638 /ug=Hs.80552 /len=1705	Cluster Incl AL050118:Homo sapiens mRNA; cDNA DKFZp586C201 (from clone DKFZp586C201) /cds=(0,936) /gb=AL050118 /gi=4884143 /ug=Hs.1846^1 /len=2621
Cluster#	Hs.58419	Hs.26358	Hs.3447	Hs.25956	Hs.16441	Hs.9029	Hs.80552	Hs.184641
Gene Name	DKFZP586L2024 protein	DKFZP566K1924 protein	DKFZP564K1964 protein	DKFZP564D206 protein	DKFZP434H204 protein	DKFZP434G032 protein	dermatopontin	delta-6 fatty acid desaturase
Genbank	W78050	AW026659	A1984087	AL050024	AW007289	Al961431	AL049798	AL050118
Affy	44813_s_at	64180_at	45501_s_at	39577_at	60038_at	48684_at	38057_at	32190_at
SeqID	1208	951	839	891	922	811	886	892
##	342	343	344	345	346	347	348	349

\_\_\_\_

ග	ဖ	7		න න	4	ю
<u>p-values</u> 1.3941E-05	0.00379696	0.00136947	1.9E-08	0.00679779	0.00061484	5.3744E-06
Fold Change 0.23	4.29	0.24	0.121682021	3.01095294 (	3.125264866 (	0.297772176
Cluster Incl. Al459140:tj65e06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146402 /clone_end=3 /gb=Al459140 /gi=4311719 /uq=Hs.129109 /len=499'	Cluster Incl. AA909181:ol12b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1523215 /clone_end=3'/gb=AA909181 /gl=3048586 /ug=Hs_234830 /len=526		Cluster Incl AL038340:DKFZp566K192_s1 Homo sapiens cDNA, 3 end /clone=DKFZp566K192 /clone_end=3" /gb=AL038340 /gi=5407591 /ug=Hs.1940 /len=746"	Cluster Incl. AA127736:zk88c12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-489910 /clone_end=5'/gb=AA127736 /gi=1687099 /ua=Hs.237523 /len=616'		Cluster Incl. Al382415:ta72b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2049583 /clone_end=3'/gb=Al382415 /gi=4195196 /ug=Hs.239510 /len=418'
Cluster # Hs. 74649	Hs.1174	Hs.164866	Hs.1940	Hs.82985	Hs.179573	Hs.75106
Gene Name cytochrome c oxidase subunit VIc	cyclin-dependent kinase inhibitor 2A (melanoma, p16,	cyclin K	crystallin, alpha B	collagen, type V, alpha 2	collagen, type I, alpha Hs.179573 2	clusterin (complement lysis inhibitor, SP- 40,40, sulfated glycoprotein 2, testosterone- repressed prostate message 2, apolipoprotein J)
<b>Genbank</b> Al459140	AA909181	X84721	NM_001885	AA127736	Al610692	Al382415
<b>Affy</b> 74406_at	73132_r_at	90629_at	32242_at	65797_at	49162_f_at	<b>75384_f_at</b>
<b>SegID</b> 481	247	1236	1100	4	531	457
350	351	352	353	354	355	356

		84			
<u>p-values</u> 2.3579E-06	2.5648E-07	0.000347	1.1789E-10	0.00000214	2.8896E-05
<u>Fold Change</u> 0.262336411	4.805037919	0.212939754	8.862541971	0.155185151	3.067793027
Cluster Incl. Al382415:ta72b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2049583 /clone_end=3' /gb=Al382415 /gi=4195196 /ug=Hs.239510 /len=418'	Hs.279905 'Cluster Incl. AA143745;zo31a01,s1 Homo sapiens cDNA, 3 end /clone=IMAGE-588456 /clone_end=3' /gb=AA143745 /gi=1713158 /ug=Hs.62273 /len=649'	Cluster Incl AL049977:Homo sapiens mRNA; cDNA DKFZp564C122 (from clone DKFZp564C122) /cds=UNKNOWN /gb=AL049977 /gi=4884227 /ug=Hs.162209 /len=1071	Cluster Incl. AA534688:nf75c01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-925728 /clone_end=3' /gb=AA534688 /gi=2278941 /ug=Hs.238349 /len=467'	Cluster Incl AL049176:Human DNA sequence from clone 141H5 on chromosome Xq22.1-23. Contains parts of a novel Chordin LIKE protein with von Willebrand factor type C domains. Contains ESTs, STSs and GSSs /cds=(0,767) /gb=AL049176 /gi=4808226 /ug=Hs.82223 /len=3143	Cluster Incl. AA426499:zw02b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-768083 /clone_end=5' /gb=AA426499 /gi=2106744 /ug=Hs.239900 /len=553'
Cluster# Hs.75106	Hs.279905	Hs.162209	Hs.9329	Hs.82223	Hs.81800
Gene Name clusterin (complement lysis inhibitor, SP- 40,40, sulfated glycoprotein 2, testosterone- repressed prostate message 2, apolipoprotein J)	clone HQ0310 PRO0310p1	claudin 8	chromosome 20 open reading frame 1	chordin-like	chondroltin sulfate proteugilyzan 2 (versican)
<u>Genbank</u> Al382415	AA143745	AL049977	AA534688	AL049176	AA426499
<b>Affy</b> 75382_i_at	64489_at	33611_g_at AL049977	45574_g_at	37630_at	45718_at
SeqID 457	09	888	158	885	113
357	358	359	360	361	362

DESCRIPTION AND PROPERTIES IS

<b>p<u>-values</u></b> 7.4702E-06	8.7397E-08	1.4906E-07	7.4051E-05	0.03811473	1.16E-07	0.00000833	3.194E-05
Eold Change 3.05	0.174212976	5.21	0.221161273	3.355023106	0.231001071	0.292109229	0.23945116
Cluster Incl. AA766775:oa35d08.s1 Homo sapiens cDNA /clone=IMAGE-1306959 /gb=AA766775 /gi=2818013 /ug=Hs.163195 /len=440	Cluster Incl. AA545730:HBMSF2G12-REV Homo sapiens cDNA, 5 end /clone=HBMSF2G12 /clone_end=5' /gb=AA545730 /gi=2307100 /ug=Hs.31198 /len=507'	Cluster Incl. AF154332:AF154332 Homo sapiens cDNA /clone=CILCA3 /gb=AF154332 /gi=5055942 /ug=Hs.239736 /len=714	Cluster Incl. AI972237:wr33c02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2489474 /clone_end=3 /gb=AI972237 /gi=5769063 /ug=Hs.233663 /len=354'	Cluster Incl. Al675178:tm80g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2164474 /clone_end=3 /gb=Al675178 /gi=4875658 /ua=Hs.90207 /len=462'	Cluster Incl AB020629:Homo sapiens mRNA for KIAA0822 protein, complete cds /cds=(138,4883) /gb=AB020629 /gi=4240129 /ug=Hs.38095 /len=5677	Cluster Incl AI651024:wa96h06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2304059 /clone_end=3" /gb=AI651024 /gi=4735003 /ug=Hs.15780 /len=657"	Cluster Incl. AA628405:af26b09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1032761 /clone_end=3'/gb=AA628405 /gl=2540792 /ug=Hs.50107 /len=548'
Cluster# Hs.240443	Hs.117582	Hs.184572	Hs.82129	Hs.90207	Hs.38095	Hs.15780	Hs.153961
Gene Name chondroitin 4- sulfotransferase,chon droitin-4- sulfotransferase (C4ST gene)	CGI-43 protein	cell division cycle 2, G1 to S and G2 to M	carbonic anhydrase III, muscle specific	calcium channel, voltage-dependent, gamma subunit 4	ATP-binding cassette, sub-family A (ABC1), member 8	ATP-binding cassette, sub-family A (ABC1), member 6	ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha)
<u>Genbank</u> AA766775	AA545730	AF154332	Al972237	AI675178	AB020629	Al651024	AA628405
<b>Affy</b> 75722_at	50177_at	91194_at	74571_s_at	62987_r_at	35717_at	35390_at	64423_s_at
SeqID 217	164	310	828	586	275	547	188
363	364	365	366	367	368	369	370

			8	36			
<b>p-values</b> 3.3556E-06	1.4825E-06	2.0018E-05	0.000333	0.0000909	2.9261E-05	0.0000126	0.00059716
Eold Change 0.212140139	3.58350616	0.263359832	0.215928239	0.129092155	0.135508105	0.308528713	0.33
Cluster Description Cluster Incl. Al804914:tu43d04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2253799 /clone_end=3'gb=Al804914 /gi=5391504 /ug=Hs.55565 /len=535'	Cluster Incl. Al341261:qx85a07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2009268 /clone_end=3' /gb=Al341261 /gi=4078188 /ug=Hs.62180 /len=538'		Cluster Incl Al381790:te41h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2089315 /clone_end=3" /gb=Al381790 /gi=4194571 /ua=Hs.74120 /len=544"	Cluster Incl H15814:yl28b07.s1 Homo saplens cDNA, 3 end /clone=IMAGE-159541 /clone_end=3" /gb=H15814 /gi=880634 /ug=Hs.80485 /len=453"	Cluster Incl. AA393277:zt74d08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-728079 /clone_end=5' /gb=AA393277 /gi=2046245 /ug=Hs.238152 /len=455'		Cluster Incl. F37480:HSPD36277 Homo sapiens cDNA /clone=sH1-000003-0/G06 /gb=F37480 /gi=4823106 /ug=Hs.221714 /len=408
Cluster# "Hs.55565	Hs.62180	Hs.203299	Hs.74120	Hs.80485	Hs.18268	Hs.158203	Hs.58324
Gene Name ankyrin repeat domain 3	anillin	amylase, alpha 2A; pancreatic	adipose specific 2	adipose most abundant gene transcript 1	adenylate kinase 5	actin binding LIM protein 1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 5
Genbank Al804914	Al341261	Al218026	Al381790	H15814	AA393277	D31883	F37480
<b>Affy</b> 46108_at	46194_at	89031_at	32527_at	40657_r_at	58927_at	40155_at	80160_at
SeqID 685	426	392	455	982	101	965	978
37.1	372	373	374	375	376	377	378

(0	0.20	_		σ <i>1</i>	ဖ	~	ပ
<u>p-values</u> 0.00028766	7.756E-06	0.00049057	1.5774E-06	2.3135E-06	3.4955E-06	2.2368E-07	3.8401E-05
<u>Fold Change</u> 3.46460752	0.14023914	0.288607766	0.310758648	4.823648195	0.241006046	0.156366951	6.80
Cluster Incl. AA13525:zl09e04.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-501438 /clone_end=3' /gb=AA135525 /gi=1696573 /uo=Hs.56009 /len=609'	Cluster Incl. A1088609:qb14e04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1696254 /clone_end=3' /gb=A1088609 /gi=3427668 /ug=Hs.98558 /len=749'	Cluster Incl. AW007983:wv47f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-991064 /clone_end=3' /gb=AW007983 /gi=5856761 /lua=Hs. 236090 /len=211'	Cluster Incl. W37770:zc12g12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-322150 /clone_end=5' /gb=W37770 /gi=1319383 /ug=Hs.9851 /len=573'	Cluster Incl. AA147884:zl50b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-505327 /clone_end=3'/gb=AA147884 /gi=1717300 /ug=Hs.9812 /len=652'	Cluster Incl. Al970823:wr20c05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2488232 /clone_end=3' /gb=Al970823 /gi=5767649 /ua=Hs.97876 /len=452'	Cluster Incl. AW016780:UI-H-BI0p-abm-f-08-0- UI.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-2712350 /clone_end=3' /gb=AW016780 /gi=5865537 /ug=Hs.238149	Cluster Incl. Al935915:wo07g11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2454692 /clone_end=3'/gb=Al935915/gl=5674785 /ug=Hs.188741 /len=405'
<b>Cluster#</b> Hs.56009	Hs.98558	Hs.98518	Hs.9851	Hs.9812	Hs.97876	Hs.97876	Hs.97837
Gene Name 2'-5'oligoadenylate synthetase 3							
Genbank AA135525	A1088609	AW007983	W37770	AA147884	Al970823	AW016780	A1935915
<b>Affy</b> 64450_at	58361_at	75011_at	55720_at	49052_at	63041 <u>i</u> at	45353_s_at	85521_at
SeqID 54	344	927	1184	63	820	936	792
379	380	381	382	383	384	385	386

			8	8			
<u>p-values</u> 1.4682E-05	5.524E-07	8.975E-06	4.8195E-06	0.00058791	0.00034656	0.00068973	2.6139E-08
<b>Eold Change</b> 0.161954139	0.281787455	0.302684307	0.12598837	0.248393008	3.039821602	3.308493975	0.282705156
Cluster Description Cluster Incl. Al659076:tt97 d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2249487 /clone_end=3' /gb=Al659076 /gi=4762646 /ua=Hs.239118 /len=412'	Cluster Incl. Al672356:ty64c02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2283842 /clone_end=3' /gb=Al672356 /gi=4852087 /ug=Hs_96996 /len=495'	Cluster Incl. D55886:HUM405B01B Homo sapiens cDNA, 5 end /clone=GEN-405B01 /clone_end=5' /gb=D55886 /gi=970293 /ug=Hs.9572 /len=553'	Cluster Incl. R54660:yj74b11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-154461 /clone_end=3' /gb=R54660 /gi=819118 /ug=Hs.95511 /len=427'	Cluster Incl. AI743671:wg41e07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367684 /clone_end=3' /gb=AI743671 /gi=5111959 /len=452'		Cluster Incl. Al669212:wc13c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2315058 /clone_end=3' /gb=Al669212 /gi=4833986 /ug=Hs 92127 /len=596'	Cluster Incl. Al972873:wr44f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2490567 /clone_end=3'/gb=Al972873 /gi=5769699 /ug=Hs.9167 /len=594'
Cluster# Hs.97031	Hs.96996	Hs.9572	Hs.95511	Hs.94789	Hs.92679	Hs.92127	Hs.9167
Gene Name							
<u>Genbank</u> Al659076	AI672356	D55886	R54660	AI743671	AA292431	AI669212	Al972873
Affy 51785_s_at	63035_at	47579_at	55484_r_at	47566_at	.46737_s_at	55436_at	65976_g_at
<b>SeqID</b> 564	211	896	1112	635	69	572	832
387	388	389	390	391	392	393	394

			•	9			
<b>p-yalues</b> 3.1056E-07	0.00185863	0.00208182	0.00000576	5.7165E-07	0.00000349	2.6349E-05	0.00010051
<b>Eold Change</b> 0.146420991	3.433762656	0.293369996	0.290791559	0.159849377	0.316621071	0.20131865	0.306142564
Cluster Incl. Al972873:wr44f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2490567 /clone_end=3' /gb=Al972873 /gi=5769699 /ua=Hs.9167 /len=594'	Cluster Incl. AI742239:wg39e09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367496 /clone_end=3' /gb=AI742239 /gi=5110527	Cluster Incl. AI150491:qf36b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1752079 /clone_end=3' /gb=AI150491 /gi=3678960 /ug=Hs. 126635 /len=485'	Cluster Incl AF052142:Homo sapiens clone 24665 mRNA sequence /cds=UNKNOWN /gb=AF052142 /gi=3360451 /ug=Hs.90063 /len=1486	Cluster Incl. AA351076:EST58700 Homo sapiens cDNA, 3 end /clone=ATCC-104314 /clone_end=3' /gb=AA351076 /gi=2003416 /un=Hs 237155 /len=529'	Cluster Incl AL079279:Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 248114 /cds=UNKNOWN /gb=AL079279 /ci=5102585 /uq=Hs.8963 /len=2428	Cluster Incl. AW006898:ws15g04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2497302 /clone_end=3' /gb=AW006898 /gi=5855676 /ug=Hs.234094 /len=228'	Cluster Incl. AA481493:aa34a10.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-815130 /clone_end=3' /gb=AA481493 /gi=2211045 /ug=Hs.88537 /len=406'
Cluster# Hs.9167	Hs.91109	Hs.90756	Hs.90063	Hs.90063	Hs.8963	Hs.88827	Hs.88537
Gene Name							
<u>Genbank</u> Al972873	AI742239	Al150491	AF052142	AA351076	AL079279	AW006898	AA481493
<b>Affy</b> 65975_at	55610_at	77001_at	38803_at	52294_s_at	38786_at	63994_i_at	64813_at
<b>SeqID</b> 832	629	374	297	86	894	919	132
395	396	397	398	399	400	401	402

۱<u>،</u>

				90	)			
p-values	1.3801E-05	6.8126E-06	1.0223E-07	2.2017E-05	4.7993E-06	2.8399E-09	5.6167E-06	1.8002E-06
Fold Change	0.224326303	0.319186626	4.319893329	0.300430737	0.233032608	0.16	0.113945577	0.204459738
Cluster Description	Cluster Incl. AW007080:ws49h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2500579 /clone_end=3 /gb=AW007080 /gi=5855858 /ug=Hs.8817 /len=523'	Cluster Incl. AA927475:om27h03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1542293 /clone_end=3 /gb=AA927475 /gi=3076372 /ug=Hs.88162 /len=536'	Cluster Incl. Al913396:wa11g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297816 /clone_end=3'/gb=Al913396 /gi=5633251 /ug=Hs.86619 /len=503'	Cluster Incl. AA480075:zv42b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-756275 /clone_end=5' /gb=AA480075 /gi=2208226 /ug=Hs.85015 /len=588'			Cluster Incl. Al346341:qp50b09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1926425 /clone_end=3'/gb=Al346341 /gi=4083547 /ug=Hs.82669 /len=549'	
Cluster#	Hs.8817	Hs.88162	Hs.86619	Hs.85015	Hs.84630	Hs.83938	Hs.82669	Hs.81796
Gene Name								
Genbank	AW007080	AA927475	Al913396	AA480075	Al417267	Al288745	Al346341	AI123555
Affy	47138_at	62974_at	48268_at	62952_at	55077_at	91320_at	62942_at	54593_at
SeqID	921	256	770	131	462	415	431	351
##	403	404	405	406	407	408	409	410

			,	<b>'1</b>			
p <u>-values</u> 1.8411E-07	5.4545E-06	2.739E-06	0.00000603	0.00000139	6.8391E-05	7.2051E-06	5.4948E-09
<u>Fold Change</u> 0.29962365	0.280798539	3.262260583	0.27595812	0.277326235	3.506341539	0.29408728	0.222082398
Cluster Incl. W73230:zd56c09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-344656 /clone_end=3'/gb=W73230 /gi=1383364 /uq=Hs.7913 /len=570'			Cluster Incl AL031846:dJ742C19.5 (novel Chromobox protein) /cds=(89,844) /gb=AL031846 /gi=4164368 /ug=Hs.7442 /len=3964			Cluster Incl. N95620:zb66b09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-308537 /clone_end=3' /gb=N95620 /gi=1267890 /uq=Hs,7212 /len=563'	
Cluster# Hs.7913 C	Hs.76605	Hs.76550	Hs.7442	Hs.74034	Hs.73452	Hs.7212	Hs.72089
Gene Name					·		
<b>Genbank</b> W73230	Al692878	AA046853	AL031846	AF070648	AW003215	N95620	AA775711
<b>Affy</b> 54992_at	64747_at	46274_at	36894_at	36119_at	55986_at	57214_at	52844_at
<b>SeqID</b> 1203	601	27	853	304	910	1099	221
# 11	412	413	414	415	416	417	418

			1		9	2			
	p-values	0.00059258	0.00037428	5.5293E-06	2.0222E-07	2.0661E-06	3.7787E-05	1.4531E-07	0.00033754
;	Fold Change	0.272334447	3.317504451	0.313288626	0.311833232	3.820099432	0.307655933	0.20785966	0.321089692
	Cluster Description	Cluster Incl. AA142875:zl49b06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-505235 /clone_end=3 /gb=AA142875 /gi=1712261 /ug=Hs.71719 /len=450'	Cluster Incl. Al742057:wg38d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367383 /clone_end=3'/gb=Al742057 /gi=5110345 /ug=Hs.7155 /len=603'	Cluster Incl. R51371:yg76f03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-39107 /clone_end=3 /gb=R51371 /gi=813273 /ug=Hs.7107 /len=542'	Cluster Incl. Al694389:wd83b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2338173 /clone_end=3'/gb=Al694389 /gi=4971729 /ug=Hs.71058 /len=514'	Cluster Incl. AA056180:zk70f09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-488201 /clone_end=5'/gb=AA056180 /gi=1548518 /ug=Hs.70704 /len=653'	Cluster Incl. AI791751:oq53g10.y5 Homo sapiens cDNA, 5 end /clone=IMAGE-1590114 /clone_end=5'/gb=AI791751 /gi=5339562 /ug=Hs.68505 /len=516'	Cluster Incl. AL039870:DKFZp434F1012_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434F1012 /clone_end=3' /gb=AL039870 /gi=5408867 /ug=Hs.6750 /len=537'	Cluster Incl. Al948551:wp91c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2469132 /clone_end=3'/gb=Al948551 /gl=5740861 /ug=Hs.67317 /len=434'
	Cluster#	Hs.71719	Hs.7155	Hs.7107	Hs.71058	Hs.70704	Hs.68505	Hs.6750	Hs.67317
	Gene Name								
	Genbank	AA142875	AI742057	R51371	A1694389	AA056180	AI791751	AL039870	Al948551
	Affx	53762_at	46659_at	64913_at	46649_at	65999_at	53733_at	46622_at	53724_at
	SedID	56	628	1110	605	28	999	861	799
	#1	419	420	. 421	422	423	424	425	426

<b>p-values</b> 2.84E-04	6.5166E-08	0.00238804	1.7127E-07	1.3008E-05	0.00046176	0.00039039	7.743E-06
<b>Fold Change</b> 0.327537441	0.215531153	3.179888739	0.262677342	0.09523078	0.311206678	0.309546056	0.305213649
Cluster Incl AL050367:Homo sapiens mRNA; cDNA DKFZp564A026 (from clone DKFZp564A026) /cds=UNKNOWN /gb=AL050367 /gi=4914600 /ug=Hs.66762 /len=3938	Cluster Incl. AW026241:wv10d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990954 /clone_end=3' /gb=AW026241 /gi=5879771 -/uq=Hs. 65239 /len=520'	Cluster Incl. Al092936:qa81b05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1693137 /clone_end=3' /gb=Al092936 /gi=3431912 /ug=Hs. 6459 /len=516'	Cluster Incl. Al640524:wa29b02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2299467 /clone_end=3' /gb=Al640524 /gi=4703633 /lua=Hs. 6382 /len=471'	Cluster Incl. AA742697:nx30g04.s1 Homo sapiens cDNA /clone=IMAGE-1257654 /gb=AA742697 /gi=2782203 /ug=Hs.62492 /len=526	Cluster Incl. W68034:zd39e02.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-343034 /clone_end=5 /gb=W68034 /gi=1376903 /lon=Hs.6052 /len=593'	Cluster Incl. AA723692:ah85c11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1325876 /clone_end=3'/gb=AA723692 /gi=2741399 /ug=Hs.5889 /len=491'	Cluster Incl. AI149693:qf42g05.x1 Homo saplens cDNA, 3 end /clone=IMAGE-1752728 /clone_end=3'/gb=AI149693 /gi=3678162 /ug=Hs.58606 /len=505'
Cluster# Hs.66762	Hs.65239	Hs.6459	Hs.6382	Hs.62492	Hs.6052	Hs.5889	Hs.58606
Gene Name						·	
Genbank AL050367	AW026241	A1092936	Al640524	AA742697	W68034	AA723692	AI149693
<b>Affy</b> 36821_at	53687_at	54001_at	46583_at	46200_at	62493_at	53200_at	64720_at
<b>SeqID</b> 893	949	346	544	214	1193	212	373
427	428	429	430	431	432	433	434

	WO 02/059	271		9	94		PC	T/US02/02176
p-values	0.00051417	4.6226E-06	6.2106E-06	7.5477E-08	1.5685E-09	2.5792E-05	1.2863E-05	4.7788E-05
Fold Change	0.241273698	0.206509126	0.168279383	0.179788238	0.068952382	0.28516587	0.323048827	0.274783293
Cluster Description	Cluster Incl. W73386:zd53e05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-344384 /clone_end=3' /gb=W73386 /gi=1383519 /ug=Hs.58303 /len=418'	Cluster Incl. AA044828:zk72c09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-488368 /clone_end=3' /gb=AA044828 /gi=1523031 /ua=Hs.58043 /len=641'	Cluster Incl. A4166620:zo85f08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-593703 /clone_end=3' /gb=A4166620 /gi=1745209 /uq=Hs.55778 /len=597'	Cluster Incl. AA036952:zk30h01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-472081 /clone_end=3'/gb=AA036952 /gi=1510009 /ug=Hs.50841 /len=571'	Cluster Incl. AI799784:wc43b08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2321367 /clone_end=3 /gb=AI799784 /gi=5365256 /ug=Hs.49696 /len=382'	Cluster Incl. AI743925:wg54f04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2368927 /clone_end=3 /gb=AI743925 /gi=5112213 /ug=Hs.4944 /len=505'	Cluster Incl. AA243659:zr68c06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-668554 /clone_end=3' /gb=AA243659 /gi=1874478 /ug=Hs.4863 /len=481'	Cluster Incl. AA082546:ze88h10.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-366115 /clone_end=5'/gb=AA082546 /gi=1624603 /ug=Hs.48516 /len=567'
Cluster.#"	Hs.58303	Hs.58043	Hs.55778	Hs.50841	Hs.49696	Hs.4944	Hs.4863	Hs.48516
Gene Name								
Genbank	W73386	AA044828	AA166620	AA036952	AI799784	AI743925	AA243659	AA082546
Affy	46087_at	54407_at	62213_at	53011_at	64694_at	52986_at	52183_at	45786_at
SeqID	1204	55	74	9	678	637	88	37
##	435	436	437	438	439	440	144	442

			95				
<u>p-values</u> 2.6745E-08	0.00013182	5.9049E-07	1.5186E-06	4.1704E-06	7.1664E-06	6.2406E-11	6.5731E-05
<b>Fold Change</b> 0.074704469	0.237704503	0.10436228	0.279947233	0.324029566	0.276986241	0.07793742	0.298567674
Cluster Incl. Al200456:qf93d03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1757573 /clone_end=3' /gb=Al200456 /gi=3753062 /ug=Hs.235398 /len=347'	Cluster Incl. AA541622:ni86c05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-983720 /clone_end=3'/gb=AA541622 /gi=2288056 /lug=Hs 47447 /len=604'	Cluster Incl. AL046941:DKFZp586I0717_r1 Cluster Incl. AL046941:DKFZp586I0717_r1 Homo saplens cDNA, 5 end /clone=DKFZp586I0717 /clone_end=5' /gb=AL046941 /gi=5435000 /ug=Hs.46531	Cluster Incl. AI768516:wh22g11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2381540 /clone_end=3' /gb=AI768516 /gi=5235025 /uq=Hs.44038 /len=554'	Cluster Incl. N22378:yw37d04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-254407 /clone_end=3' /gb=N22378 /gi=1128512 /ug=Hs.43157 /len=450'	Cluster Incl. AA150501:zl08g02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-491762 /clone_end=3' /gb=AA150501 /gi=1722015 /ug=Hs.43148 /len=645'	Cluster Incl. Al864898:wj66d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2407791 /clone_end=3'/gb=Al864898 /gi=5529005 /ua=Hs.43125 /len=523'	Cluster Incl. Al651212:wa98a10.x1 Homo saplens cDNA, 3 end /clone=IMAGE-2304186 /clone_end=3' /gb=Al651212 /gi=4735191 /ug=Hs.4283 /len=609'
Cluster# <sup></sup> Hs.48516	Hs.47447	Hs.46531	Hs.44038	Hs.43157	Hs.43148	Hs.43125	Hs.4283
Gene Name							
Genbank Al200456	AA541622	AL046941	AI768516	N22378	AA150501	AI864898	AI651212
<b>Affy</b> 51012_at	64407_at	52140_at	62136_at	59014_at	45220_at	52080_at	52075_at
SeqID 383	162	876	658	1065	92	747	548
443	444	445	446	447	448	449	. 450

						96			
	p-values	0.00148036	0.00152421	1.1279E-08	1.5134E-05	3.4237E-06	1.848E-05	6.9772E-05	3.554E-07
	Fold Change	0.317296872	3.149001267	8.270850261	3.94	0.276493253	5.223054257	3.048509737	4.526523002
***	Cluster# Cluster Description	Hs.42586 Cluster Incl. Al934361:wp04g11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2463908 /clone_end=3'/gb=Al934361/gi=5673231 /ug=Hs.42586 /len=588'	Hs.4243 Cluster Incl. Al990483:ws40b12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2499647 /clone_end=3 /gb=Al990483 /gi=5837364 /ug=Hs.4243 /len=541*	Hs.41271 .Cluster Incl. Al557210:PT2.1_14_H10.r Homo sapiens cDNA, 3 end /clone_end=3' /gb=Al557210 /gi=4489573 /ug=Hs.41271 /len=867'	Hs.41271 Cluster Incl. AI751438:cn10a03.y1 Homo sapiens cDNA /clone=NHTBC_cn10a03-(random) /gb=AI751438 /gl=5129702 /ug=Hs.182827 /len=513	Hs.41067 Cluster Incl. AL079707:DKFZp434F1430_r1	Hs.40479 Cluster Incl. N25267;yx74h01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-267505 /clone_end=3'/gb=N25267 /gi=1139417 /ug=Hs.40479 /len=460'	Hs.39421 Cluster Incl. W89022:zh72e09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-417640 /clone_end=3 /gb=W89022 /gi=1403908 /ug=Hs.39421 /len=515'	Hs.38178 Cluster Incl. AA921830:om44b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1543855 /clone_end=3' /gb=AA921830 /gi=3069139 /ug=Hs.38178 /len=516'
	Gene Name Clu	HS.	Å.	Hs.	Hs.4	Hs,4	Hs.4	Hs.3	<b>HS.3</b>
	Genbank	Al934361	Al990483	Al557210	AI751438	AL079707	N25267	W89022	AA921830
	Affy	45779_at	45203_at	52019_at	85126_at	45179_at	46372_at	46365_at	51970_at
	SegID	787	846	512	140	988		1212	254
	##	451	452	453	454	455	456	457	458

,al	9	90 90	22	98 27	Ε	62		· 약
b-values	4.1587E-06	5.9115E-06	1.4632E-05	0.00063822	0.00321371	0.00228259	0.00321198	0.00016645
Fold Change	0.286699064	0.171580051	0.196081354	0.287881302	0.324205584	0.227579801	0.309546276	0.283008853
Cluster Description	Cluster Incl. Al913749:wa13d11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297973 /clone_end=3' /gb=Al913749 /gi=5633604 /ug=Hs.32241 /len=564'	•	Cluster Incl. AL040912:DKFZp434J0215_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434J0215 /clone_end=3' /gb=AL040912 /gi=5409856 /ug=Hs.31595 /len=665'	Cluster Incl. AA921922:om40h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1543547 /clone_end=3' /gb=AA921922 /gi=3069231 /ug=Hs.31412 /len=488'			Cluster Incl. AA195251:zr36d03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-665477 /clone_end=3' /gb=AA195251 /gi=1784951 /ug=Hs.30835 /len=810'	
Cluster#	Hs.32241	Hs.32135	Hs.31595	Hs.31412	Hs.31297	Hs.31297	Hs.30835	Hs.30156
Gene Name								
Genbank	Al913749	W07043	AL040912	AA921922	Al557360	AI743715	AA195251	A1093702
Affx	44679_at	64238_at	44575_at	61681_at	43591_r_at	50955_at	65651_s_at	50658_s_at
SealD	774	1173	865	255	513	636	80	347
##	467	468	469	470	471	472	473	474

				,	,			
p-values	5.309E-12	7.704E-05	0.0041327	0.00030044	2.469E-12	0.00021707	1.3716E-06	4.6046E-08
Fold Change	13.96572736	0.274066497	0.321891202	0.20	4.243716901	0.259103459	0.211477764	0.131870144
j	7792 Cluster Incl. AA059458:zl96g05.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-512504 /clone_end=5 /gb=AA059458 /gi=1553317 /ug=Hs.28792 /len=572'	-						·
<u>Cluster</u> #	Hs.28792	Hs.28625	Hs.286228	Hs.286216	Hs.286117	Hs.285995	Hs.285966	Hs.285966
Gene Name								
Genbank	AA059458	AI806324	Al439628	H54254	AA705188	AA126704	AA131648	Ai680541
Affy	65626_at	44025_at	91773_at	78617_at	53490_at	52999_at	56211_at	50408_at
SealD	33	687	474	895	206	4	49	288
##	475	476	477	478	479	480	481	482

<b>VV O 02/03</b> 2	7& / I		, 1	100	PCT/US02/02176		
<u>p-values</u> 0.00017459	0.00011017	0.00024096	0.0008652	6.1606E-11	0.00027317	5.8287E-05	5.0013E-05
Fold Change 0.30	0.262417057	3.603536057	0.327647494	11.21387388	0.18	0.326231649	0.22
Cluster Description Cluster Incl. Al656062:tt43b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2243503 /clone_end=3'/gb=Al656062 /gi=4740041 /ug=Hs.239724 /len=525'		-			Cluster Incl. Al983045:wz30c01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2559552 /clone_end=3'/gb=Al983045/gi=5810264 /ug=Hs.237789 /len=566'	Cluster Incl. Al963873:wt86b08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2514327 /clone_end=3'/gb=Al963873 /gi=5756586 /ug=Hs.227032 /len=704'	Cluster Incl. Al557450:PT2.1_7_D12.r Homo sapiens cDNA, 3 end /clone_end=3' /gb=Al557450 /gi=4489813 /ug=Hs.235996 /len=565'
<b>Cluster #</b> Hs.285834	Hs.285785	Hs.285590	Hs.285570	Hs.285473	Hs.285414	Hs.285247	Hs.285233
Gene Name							
Genbank Al656062	W02823	Al458306	W19285	AA669106	Al983045	Al963873	Al557450
<b>Affy</b> 88239_i_at	50990_at	59070_at	65988_at	48083_at	87998_at	60842_at	78103_at
<b>SeqID</b> 558	1171	478	1175	198	838	815	514
<b>₩</b>	484	485	486	487	488	489	490

\*

	WO 02/059	271		. 10	)1		PC	T/US02/02176
p-values	1.8665E-06	0.00150517	8.0203E-05	3.4232E-05	8.7733E-05	0.00121855	2.5913E-05	0.00082565
Fold Change	4.466366979	0.31	0.254762986	4.911742129	0.27	0.23	0.30	4.06
cluster Description	220 Cluster Incl. Al869951:wl63a07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2429556 /clone_end=3'/gb=Al869951 /gi=5543919 /ug=Hs.20854 /len=752'	<ul> <li>209 Cluster Incl. N31046;yx51h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-265307 /clone_end=5' /gb=N31046 /gi=1151445 /ug=Hs.154536 /len=422'</li> </ul>	269 Cluster Incl. AA824349:aj30f10.s1 Homo sapiens cDNA, 3 end /clone=1391851 /clone_end=3' /gb=AA824349 /gi=2896419 /ug=Hs.40300 /len=888'	713 Cluster Incl. AA584310:nn79g01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1090128 /clone_end=3' /gb=AA584310 /gi=2368919 /ug=Hs.99769 /len=582'	360 Cluster Incl. Al435443:th94e06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2126338 /clone_end=3' /gb=Al435443 /gi=4303218 /ug=Hs.149084 /len=475'	252 Cluster Incl. AA143491:zo31a09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-588472 /clone_end=5' /gb=AA143491 /gi=1712862 /ug=Hs.239308 /len=552'	594 Cluster Incl. AI188749:qd11c05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1723400 /clone_end=3' /gb=AI188749 /gi=3739958 /ug=Hs.181742 /len=467'	530 Cluster Incl. Al446168:tj07h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2140861 /clone_end=3' /gb=Al446168 /gi=4293320 /ug=Hs.176708 /len=435'
Cluster#	Hs.285220	Hs.285009	Hs.284269	Hs.283713	Hs.276860	Hs.274252	Hs.271594	Hs.271530
Gene Name								
Genbank	AI869951	N31046	AA824349	AA584310	Al435443	AA143491	AI188749	AI446168
Affy	63460_at	83506_at	51999_at	48774_at	83118_at	78658_at	67167_at	84893_at
SegiD	749	1070	232	171	470	29	379	476
##	491	492	493	494	495	496	497	498

				10	)2		10	170302/02170
p-values	0.00710567	0.01228173	5.7601E-05	9.3673E-05	0.00017276	0.00654385	0.01366367	0.00854584
Fold Change	0.315940639	3.07	0.18	4.593843245	0.250833383	0.247069023	4.683322065	0.28
Cluster# Cluster Description	Hs.271363 Cluster Incl. R17937:ye90f06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-125027 /clone_end=3 /gb=R17937 /gi=771547 /ug=Hs.61734 /len=386'	Hs.271157 Cluster Incl. AA677864:zi13d12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-430679 /clone_end=3' /gb=AA677864 /gi=2658386 /ug=Hs.222705 /len=384'	Hs.270549 Cluster Incl. W72407:zd67c03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-345700 /clone_end=3' /gb=W72407 /gi=1382424 /ug=Hs.118607 /len=651'	Hs.270524 Cluster Incl. AI743516:wf72b10.x2 Homo sapiens cDNA, 3 end /clone=IMAGE-2361115 /clone_end=3' /gb=AI743516 /gi=5111804 /ug=Hs.205320 /len=663'	Hs.270235 Cluster Incl. Al418596:tg37d02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2110947 /clone_end=3' /gb=Al418596 /gi=4264527 /ug=Hs.187926 /len=431'	Hs.270027 Cluster Incl. Al683911:tw54f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2263527 /clone_end=3' /gb=Al683911 /gi=4894093 /ug=Hs.145791 /len=497'	Hs.269628 ·Cluster Incl. AA773348:ab65g04.s1 Homo sapiens cDNA, 3 end /clone=845718 /clone_end=3' /gb=AA773348 /gi=2824919 /ug=Hs.193254 /len=508'	Hs.269392 Cluster Incl. R69584:yl40e04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-141726 /clone_end=3' /gb=R69584 /gi=843101 /ug=Hs.183359 /len=379'
Gene Name								
Genbank	R17937	AA677864	W72407	AI743516	Al418596	Al683911	AA773348	R69584
Affy	1103 .60202 <u>.i.</u> at	72092 <u>f_</u> at	76208_at	69687_at	87016_at	91206_at	88243 <u>r_</u> at	78883_at
SedID	1103	199	1200	633	466	591	219	1115
#1	499	200	501	502	503	504	505	206

				103				
senlex-d	9.1918E-06	3.1637E-07	7.5535E-05	0.00045064	6.5167E-06	0.00715494	0.00127676	0.01815078
Fold Change	0.142950221	0.27	0.092486133	0.194270285	0.27933205	3.052533662	3.03	0.310940166
	6 Cluster Incl. R20784:yh18b08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-130071 /clone_end=3' /gb=R20784 /gi=775565 /ug=Hs.227815 /len=452'		4 Cluster Incl. R53594:yj71c01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-154176 /clone_end=3' /gb=R53594 /gi=815496 /ug=Hs.221424 /len=465'	Cluster Incl. AI524085:th01e09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2117032 /clone_end=3' /gb=AI524085 /gi=4438220 /ug=Hs.25391 /len=509'	Cluster Incl. Al659533:tu12a12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2250814 /clone_end=3' /gb=Al659533 /gi=4763103 /ug=Hs.25248 /len=654'			
Cluster#	Hs.268286	Hs.265499	Hs.260164	Hs.25391	Hs.25248	Hs.250879	Hs.250594	Hs.24898
Gene Name								
Genbank	R20784	AW014647	R53594	Al524085	AI659533	AI742002	AI672389	R67627
Affy	49549_at	80401_at	42913_f_at	64057_at	50411_at	61333_at	78487_at	51886_at
SealD	1104	932	1111	200	566	627	578	1114
##		909	209	210	511	512	513	514

518

517

519

520

521

522

/clone\_end=3' /gb=AA909818 /gi=3050617

'ug=Hs.225822 /len=406'

515

516

				U.S				
<u>p-values</u> 4.329E-05	1.5567E-06	2.5531E-05	9.8105E-06	4.0549E-05	1.9829E-05	0.00035218	0.00788877	1.7239E-06
<b>Fold Change</b> 0.313634138	0.232069434	0.31162811	4.191125642	0.325095547	0.24	3.938205017	0.20	0.290657123
Cluster Incl. C16443:C16443 Homo sapiens cDNA, 5 end /clone=GEN-321F12 /clone_end=5 /gb=C16443 /gl=1571150 /ug=Hs.24144 /len=456'	Cluster Incl. AI797276:we86f09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2348009 /clone_end=3' /gb=AI797276 /gi=5362748 /ine=Hs 23912 /len=516'	Cluster Incl. Al421837:tf55c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2103186 /clone_end=3' /gb=Al421837 /gl=4267768 /ua=Hs.23869 /len=573'			•			
Cluster# Hs.24144	Hs.23912	Hs.23869	Hs.237809	Hs.23630	Hs.235920	Hs.235758	Hs.235390	Hs.234898
Gene Name						·		
<b>Genbank</b> C16443	AI797276	AI421837	AA948319	N57539	AA629715	Al362288	W26589	Al970898
Affy 50001_at	43502_at	56624_at	52615_at	56574_at	73233_at	66131_at	78622 <u>r</u> at	43427_at
<b>SeqID</b> 956	674	468	262	1086		438	1178	822
£ \$23	524	525	526	527	528	529	530	531

				10	06			
p-values	1.2854E-06	8.7469E-08	1.2339E-07	6.6059E-07	4.4094E-06	0.00181461	0.01016812	2.4083E-06
Fold Change	0.268475458	4.250714876	3.197888571	3.85742898	3.322756779	3.320734927	0.233986843	0.280053615
Cluster# Cluster Description	Hs.234898 Cluster Incl. Al057637:oy31h06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1667483 /clone_end=3' /gb=Al057637 /gi=3331503 /ug=Hs.21305 /len=599'	Hs.234545 Cluster Incl. Al015982:ou95e06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1635586 /clone_end=3' /gb=Al015982 /gi=3230318 /ug=Hs.96992 /len=495'	Hs.234545 Cluster Incl. AA383718:EST97358 Homo sapiens cDNA, 3 end /clone=ATCC-188064 /clone_end=3'/gb=AA383718/gi=2036227 /ug=Hs.234545/len=311'	Hs.23448 Cluster Incl. AA133979:zn88b09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-565241 /clone_end=5' /gb=AA133979 /gi=1691065 /ug=Hs.23448 /len=593'	Hs.233634 Cluster Incl. AI970896:wr21b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2488317 /clone_end=3' /gb=AI970896 /gi=5767722 /ug=Hs.233634 /len=514'	Hs.233310 Cluster Incl. Al978650:wr57g08.x1 Homo sapiens cDNA, 3 end /clone=iMAGE-2491838 /clone_end=3' /gb=Al978650 /gi=5803680 /ug=Hs.233310 /len=516'	Hs.232177 Cluster Incl. Al208691:qg56b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1839151 /clone_end=3' /gb=Al208691 /gi=3770633 /ug=Hs.232177 /len=369'	Hs.23202 Cluster Incl. AI419030:tf53b01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2102953 /clone_end=3'/gb=AI419030 /gl=4264961 /ug=Hs.23202 /len=473'
Gene Name Clus	Hs.2	Hs.2	Hs.2	Hs.2	Hs.2.	Hs.2.	Hs.2	HS.2
Genbank	A1057637	Al015982	AA383718	AA133979	Al970896	Al978650	AI208691	Al419030
Affy	49452_at	55504_at	64282_at	44055_at	44974_at	74340_at	74162 <u>r</u> at	43046_at
SedID	332	312	100	52	821	834	390	467
##	532	533	534	535	536	537	538	539

/clone\_end=3' /gb=Al339240 /gl=4076154

	108								
p-values	0.012637	7.7241E-05	0.00071317	1.0609E-07	2.5827E-06	3.9564E-05	0.00147634	0.00020743	
Fold Change	3.51886622	3.531852021	0.306661245	0.085100991	0.2674744	0.286772796	0.22	0:30	
# Gluster Description	97 Cluster Incl. AA251131:zs03b12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-684095 /clone_end=3' /gb=AA251131 /gi=1886093 /ug=Hs.220697 /len=365'		•		37 Cluster Incl. Al911149:wd24b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2329037 /clone_end=3' /gb=Al911149 /gi=5630885 /ug=Hs.218037 /len=432'		15 Cluster Incl. Al935522:wo97e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2463290 /clone_end=3' /gb=Al935522 /gi=5674392 /ug=Hs.9225 /len=845'		
Cluster#	Hs.220697	Hs.22011	Hs.21914	Hs.218707	Hs.218037	Hs.214906	Hs.21415	Hs.213923	
Gene Name									
Genbank	AA251131	Al344312	Al949833	N63913	Al911149	AI610837	A1935522	Al917447	
Affy	71839_at	42988_at	60813_at	44210_at	71668_at	71524_at	91345_at	87161_s_at	
SedID	06	430	802	1090	765	532	791	774	
##	548	549	550	551	552	553	554	555	

				10	19			
p-values	0.00795029	7.8969E-05	0.03460633	0.00010506	0.00648177	1.3875E-05	1.5821E-06	0.00062149
Fold Change	0.292836533	3.74	0.302753776	3.62	3.047280178	0.23	6.957639593	3.289367551
Cluster Description	Cluster Incl. Al888493:wn32e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2447162 /clone_end=3'/gb=Al888493 /gi=5593657 /ug=Hs.212709 /len=473'			Cluster Incl. Al989871:ws36e12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2499310 /clone_end=3' /gb=Al989871 /gi=5836752 /ug=Hs.210467 /len=722'	Cluster Incl. Al800529:tc12a08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2063606 /clone_end=3' /gb=Al800529 /gi=5366001 /ug=Hs.209235 /len=439'			
Cluster#	Hs.212709	Hs.211535	Hs.211129	Hs.210467	Hs.209235	Hs.209078	Hs.208912	Hs.208854
Gene Name								
Genbank	AI888493	AI823649	AI825341	Al989871	AI800529	Al351653	Al381686	Н68822
Affy	71153 <u>. i_</u> at	87102_at	70733_r_at	80045_at	70350_at	70704_i_at	64145_at	70219_at
SealD	759	714	717	842	680	433	454	994
##	556	557	558	559	260	561	562	563

569

760

570

493

571

875

566

567

567

647

568

187

565

## 5<sup>6</sup>

clone\_end=3' /gb=Al492879 /gi=4393882

/ug=Hs.203879 /len=5211

	WO 02/0592	271		11	1		PC	T/US02/02176
p-values	7.7642E-05	0.00187143	0.00030428	0.00090022	0.01216522	2.9782E-06	0.00527403	0.00084162
Fold Change	4.96	3.17	3.64	0.29	4.11	0.263799925	0.300766236	0.322154385
Cluster# Cluster Description	Hs.202259 Cluster Incl. AI700646:we38h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2343421 /clone_end=3'/gb=AI700646 /gi=4988546 /ug=Hs.202259 /len=466'	Hs.202040 Cluster Incl. Al937060:wp72f01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2467321 /clone_end=3'/gb=Al937060 /gi≈5675930 /ug=Hs.202040 /len=522'	Hs.201875 Cluster Incl. AI825713:wb75g02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2311538 /clone_end=3'/gb=AI825713/gl=5446384 /ug=Hs.201875/len=445'	Hs.199996 Cluster Incl. AI804054:tc60g03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2069044 /clone_end=3'/gb≂AI804054 /gi=5369526 /ug=Hs.199996 /len=459'	Hs.199713 Cluster Incl. Al921685:wo28g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2456706 /clone_end=3 /gb=Al921685 /gl=5657649 /ug=Hs.199713 /len=427	Hs.19827 Cluster Incl. W72511:zd64f08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-345447 /clone_end=3'/gb=W72511 /gi=1382168 /ug=Hs.19827 /len=601'	Hs.197676 Cluster Incl. Al653487:tq94h03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2216501 /clone_end=3 /gb=Al653487 /gi=4737466 /ug=Hs.197676 /len=306'	Hs.197643 Cluster Incl. Al962986:wt25g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2508538 /clone_end=3'/gb=Al962986 /gi=5755699 /ug=Hs.197643 /len=391'
Gene Name								
Genbank	AI700646	Al937060	AI825713	AI804054	Al921685	W72511	Al653487	Al962986
Affx	75961_at	86612_at	69876_at	69600_at	79751_at	59623_at	68663_at	88622_at
SealD	611	795	718	684	776	1201	554	813
₹£	572	573	574	575	576	222	578	579

			, 1	12			
<u>p-values</u> 5.3291E-06	8.2878E-07	0.00678174	1.1628E-06	0.00380632	0.00223833	5.2381E-08	3.5251E-06
Fold Change 0.26	0.08	4.74	5.05	0.318361618	0.32	3.13	0.19
Cluster Incl. Al860484:wl03b06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2423795 /clone_end=3' /gb=Al860484 /gi=5514100 /ug=Hs.194274 /len=485'				-			
Cluster#	Hs.194093	Hs.193745	Hs.193602	Hs.193491	Hs.193142	Hs.192872	Hs.192671
Gene Name							
<u>Genbank</u> Al860484	A1968379	AA419260	AI761782	AA701600	AI825806	AA719022	Al678986
<b>Affy</b> 69069_at	86154_at	67440 <u>r</u> at	88814_at	88268_at	.85986_at	85943_at	68671_at
SeqID 741	817	108	651	202	719	211	587
28 ## 280	581	582	583	584	585	586	587

				11	13			
p-values	0.00126246	0.00214022	0.00044234	0.00178098	3.57E-05	0.00013261	0.0021469	1.0173E-06
Fold Change	0.309129194	4.256875625	3.32	3.428921588	3.57	0.212242354	0.23399829	0.25
Cluster # Cluster Description	Hs.192174 Cluster Incl. AA778816:zj38a10.s1 Homo sapiens cDNA, 3 end /clone=452538 /clone_end=3' /gb=AA778816 /gi=2838147 /ug=Hs.192174 /len=505'	Hs.191935 Cluster Incl. R11248;yf41c02.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-129410 /clone_end=5' /gb=R11248 /gl=763983 /ug=Hs.191935 /len=456'	Hs.189284 Cluster Incl. AA936632:om58b03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1551341 /clone_end=3' /gb=AA936632 /gi=3094550 /ug=Hs.189284 /len=505'	Hs.189040 Cluster Incl. AI031557:ow48d01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1650049 /clone_end=3' /gb=AI031557 /gi=3249769 /ug=Hs.189040 /len=721'	Hs.188952 Cluster Incl. Al692624;wd86a10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2338458 /clone_end=3' /gb=Al692624 /gi=4969964 /ug=Hs.188952 /len=569'	Hs.18861 Cluster Incl. AA039324;zk39d07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-485197 /clone_end=3' /gb=AA039324 /gl=1515602 /ug=Hs.188861 /len=488'	Hs.188120 Cluster Incl. Al283643:qj67c11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1864532 /clone_end=3' /gb=Al283643 /gi=3921876 /ug=Hs.188120 /len=447'	Hs.187319 Cluster Incl. Al624103:ts41h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2231197 /clone_end=3'/gb=Al624103/gl=4649034 /ug=Hs.187319/len=432'
Gene Name Clus	Hs.19	Hs.18	Hs.16	Hs.18	Hs.16	Hs.18	Hs.18	Hs.1
Genbank	AA778816	R11248	AA936632	A1031557	AI692624	AA039324	AI283643	Al624103
Affx	68288_at	63131 <u>i</u> at	68047_at	67962_g_at	79037_at	46962_at	87087_at	67650_at
SeqID	224	1102	260	320	298	21	410	535
#H	588	589	290	591	592	593	594	595

					114				
	p-values	1.2795E-06	0.00081831	0.00021905	0.02428683	0.00016473	0.00072735	1.4344E-05	3.5825E-06
	Fold Change	3.57	3.31	0.21	3.34	3.50	3.60	0.24	0.32
1	Cluster# Cluster Description	Hs.186579 Cluster Incl. T79574:yd71a01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-113640 /clone_end=3' /gb=T79574 /gi=698083 /ug=Hs.186579 /len=533'	Hs.185798 Cluster Incl. AA420590:nc61b10.s1 Homo sapiens cDNA /clone=IMAGE-745723 /gb=A4420590 /gi=2094496 /ug=Hs.185798 /len=501	Hs.185708 Cluster Incl. Al381930:te72f02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2092251 /clone_end=3' /gb=Al381930 /gi=4194711 /ug=Hs.185708 /len=639'	Hs.184343 Cluster Incl. AL037594:DKFZp564J0372_s1	Hs.183918 Cluster Incl. AA846091:ak83e05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1414496 /clone_end=3'/gb=AA846091 /gi=2932231 /ug=Hs.183918 /len=464'	Hs.183412 Cluster Incl. W05248:za83a08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-299126 /clone_end=5' /gb=W05248 /gi=1277998 /ug=Hs.183412 /len=473'	Hs.183409 Cluster Incl. Al653441:tq94b09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2216441 /clone_end=3' /gb=Al653441 /gi=4737420 /ug=Hs.183409 /len=448'	Hs.182809 Cluster Incl. Al985653:wt19b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2507901 /clone_end=3' /gb=Al985653 /gi=5812930 /ug=Hs.182809 /len=765'
	Gene Name								
	Genbank	T79574	AA420590	Al381930	AL037594	AA846091	W05248	Al653441	Al985653
	Affy	85338_at	78954_at	78945_at	92031_g_at	90745_at	67311_at	85168_at	89329_at
	SedID	1129	110	456	856	239	1172	553	840
	##	596	597	598	599	009	601	602	603

			115				
p- <u>values</u> 8.1089E-05	6.5741E-07	1.8689E-07	0.00011263	0.0000283	5.8955E-06	3.4377E-07	0.00108233
Fold Change 0.22	0.209357681	0.143530024	3.036525383	0.268423966	0.309887046	3.92	0.214928901
- Cluster Description Cluster Incl. Al083598:ox61c09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1660816 /clone_end=3'/gb=Al083598 /gl=3422021 /ud=Hs.239551 /len=449'			Cluster Incl. AA004622:zh87b06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-428243 /clone_end=3' /gb=AA004622 /gl=1448469 /ug=Hs.18214 /len=509'				
Cluster# Hs.182364	Hs.182364	Hs.182364	Hs.18214	Hs.181104	Hs.180178	Hs.179891	Hs.179673
Gene Name							
Genbank Al083598	AL044670	Al962647	AA004622	Al312646	AA284268	AI741880	AA027103
<b>Affy</b> 91173_at	58999_at	61317_f_at	59812_at	40642_at	54826_at	84983_at	63270_at
SegID 341	873	812	ო	421	85	626	<del></del>
## 604	605	909	209	809	609	610	611

Fold Change sapiens cDNA, 3 end /clone=IMAGE-1845372 sapiens cDNA, 3 end /clone=IMAGE-1884216 sapiens cDNA, 3 end /clone=IMAGE-1759728 sapiens cDNA, 3 end /clone=IMAGE-2148483 sapiens cDNA, 3 end /clone=IMAGE-2137956 sapiens cDNA, 3 end /clone=IMAGE-276538 sapiens cDNA, 3 end /clone=IMAGE-726353 sapiens cDNA, 3 end /clone=IMAGE-429293 /clone\_end=3' /gb=AA292789 /gi=1941611 Cluster Incl. Al215667:qm39e01.x1 Homo Cluster Incl. AA007367:zh98b03.s1 Homo Cluster Incl. AA297789:zt56d09.s1 Homo /clone\_end=3' /gb=AI206063 /gi=3764735 /clone\_end=3' /gb=AI218358 /gi=3798173 /clone\_end=3' /gb=Al215667 /gi=3784708 Cluster Incl. Al206063:qg16g01.x1 Homo Cluster Incl. Al218358:qh21g07.x1 Homo /clone\_end=3' /gb=Al522299 /gi=4436434 /clone\_end=3' /gb=A!472331 /gi=4334421 /clone\_end=3' /gb=N39104 /gi=1162311 Cluster Incl. AI472331:tj87d02.x1 Homo Cluster Incl. Al522299:ti76e07.x1 Homo Cluster Incl. N39104:yy45g06.s1 Homo Cluster Description /ug=Hs.179222 /len=510\* /ug=Hs.176067 /len=504\* /ug=Hs.175048 /len=411' /ug=Hs.175044 /len=461\* /ug=Hs.173975 /len=574' /ug=Hs.179153 /len=428' /ug=Hs.173369 /len=490' Hs.173975 4s.179222 Hs.179153 Hs.175048 Hs.175044 Hs.173369 Hs.173088 Hs.176067 Cluster# Gene Name Genbank AA292789 AA007367 AI206063 AI218358 AI522299 AI215667 AI472331 N39104 78821\_at 92131\_at 85591\_at 92091\_at 77540 at Aff 85706\_at 85702 at 62643\_at SealD 1073 389 393 499 483 391 94 4 613 614 615 616 618 619 617 612 ₩

				1.	17			
p-values	6.0474E-07	0.00090761	0.00358521	8.8677E-08	0.00028322	0.02233069	0.00013456	8.779E-05
Fold Change	0.246578758	3.484499631	0.241109168	0.289343463	0.17	3.274952213	5.310804413	0.300177072
Cluster Description	Cluster Incl. Al672101:ty63d10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2283763 /clone_end=3' /gb=Al672101 /gi=4851832 /ug=Hs.17296 /len=554'	Cluster Incl. Al458858:tj55b07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2145397 /clone_end=3'/gb=Al458858 /gi=4311437 /ug=Hs.172548 /len=485'	Cluster Incl. AI499334:to10d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2178639 /clone_end=3'/gb=AI499334 /gi=4391316 /ug=Hs.171959 /len=462'	Cluster Incl. Al693178:wd68d11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2336757 /clone_end=3' /gb=Al693178 /gi=4970518 /ug=Hs.171939 /len=531'			Cluster Incl. Al498957:tn01c09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2166352 /clone_end=3 /gb=Al498957 /gi=4390939 /ug=Hs.170861 /len=425	
Cluster#	Hs.17296	Hs.172548	Hs.171959	Hs.171939	Hs.171205	Hs.170935	Hs.170861	Hs.169943
Gene Name	·							
Genbank	AI672101	AI458858	Al499334	AI693178	A1039722	AI540204	Al498957	AA480009
Affx	58916_at	83000_at	85486_at	58428_at	84627_at	92007_at	85341_at	47972_r_at
SeqID	576	479	498	602	325		495	130
##	620	621	622	623	624	625	626	627

				1	18			
p-values	0.00347986	0.00289855	3.6415E-07	1.1163E-05	0.00107381	3.5001E-06	6.4421E-05	0.00236446
Fold Change	0.285068791	3.047322219	3.315735415	0.232010725	0.31	5.499256795	0.265071246	3.725341684
:# Cluster Description	41 Cluster Incl. Al911346:wd16a11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2328284 /clone_end=3' /gb=Al911346 /gi=5631082 /ug=Hs.168941 /len=396'							<ul> <li>505 Cluster Incl. AL044366:DKFZp434C022_s1</li> <li>Homo sapiens cDNA, 3 end</li> <li>/clone=DKFZp434C022 /clone_end=3'</li> <li>/gb=AL044366 /gi=5432588 /ug=Hs.165805</li> <li>/len=668'</li> </ul>
Cluster#	Hs.168941	Hs.167899	Hs.167771	Hs.166784	Hs.166674	Hs.165909	Hs.165885	Hs.165805
Gene Name								
Genbank	Al911346	AI032972	AI656807	AI264299	AI681307	AA424160	AI590385	AL044366
Affv	62309_at	85068_at	58354_at	84903_f_at	84314_at	62277_at	82441_f_at	84763_at
SealD	766	322	559	402	589	112	528	871
#	628	629	930	631	632	633	634	635

			1.	19			
<u>p-values</u> 2.4112E-05	0.00054065	1.2564E-07	7.3767E-05	0.00288569	0.00073954	0.01192547	0.00162269
<b>Fold Change</b> 0.280524611	0.278599395	3.548116214	3.26	5.533470597	0.298063122	3.258423603	3.012339056
Cluster Incl. N21031:yx46f05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-264801 /clone_end=3' /gb=N21031 /gi=1126201 /ug=Hs.164779 /len=554'	Cluster Incl. Al039005:ox24g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1657304 /clone_end=3' /gb=Al039005 /gi=3278199 /ua=Hs.164680 /len=483'	Cluster Incl. AI436670:th91b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2125999 /clone_end=3'/gb=AI436670 /gi=4283458 /ug=Hs, 164369 /len=393'	Cluster Incl. Al436297;th81c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2125074 /clone_end=3'/gb=Al436297 /gi=4309200 /ug=Hs.164226 /len=435'	Cluster Incl. AA610522:np93h10.s1 Homo sapiens cDNA /clone=IMAGE-1133923 /gb=AA610522 /gi=2458950 /ug=Hs.162697 /len=364	Cluster Incl. N46855:yy73e01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-279192 /clone_end=3'/gb=N46855 /gi=1188021 /ug=Hs.16262 /len=524'	Cluster Incl. AA565654:nk25h12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1014599 /clone_end=3' /gb=AA565654 /gi=2337293 /ug=Hs.162130 /len=218'	
Cluster#"	Hs.164680	Hs.164369	Hs.164226	Hs.162697	Hs.16262	Hs.162130	Hs.159983
Gene Name							
Genbank N21031	A1039005	AI436670	Al436297	AA610522	N46855	AA565654	AA993566
<b>Affy</b> 62707_at	62259_at	84701_at	75740_at	84323_at	62701_at	84264_at	81810_at
<b>SeqID</b> 1062	324	473	472	180	1078	168	268
636 636	637	638	639	640	641	642	643

	WO 02/059271 120					PC	T/US02/02176	
p-values	2.8623E-06	0.0140631	4.5784E-06	2.7534E-07	0.00027572	0.00025369	0.00039332	0.02404954
Fold Change	0.15	3.577532367	0.275099238	0.220904269	0.198202182	3.99	0.305190872	3.01
E Cluster Description	7 Cluster Incl. T64637:yc12h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-80507 /clone_end=5' /gb=T64637 /gi=673682 /ug=Hs.159367 /len=546'	2 Cluster Incl. Al631850:wa36h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2300221 /clone_end=3' /gb=Al631850 /gi=4683180 /ug=Hs.158992 /len=491'	Hs.158984 ·Cluster Incl. Al380583:tf95g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2107066 /clone_end=3'/gb=Al380583 /gi=4190436 /ug=Hs.158984 /len=314'		1 Cluster Incl. AW026553:wv14h08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990994 /clone_end=3' /gb=AW026553 /gi=5880083 /ug=Hs.158741 /len=522'		8 Cluster Incl. Al924465:wn56e01.x1 Homo sapiens cDNA, 3 end /clone=iMAGE-2449464 /clone_end=3' /gb=Al924465 /gi=5660429 /ug=Hs.158258 /len=384'	
Cluster#	Hs.159367	Hs.158992	Hs.158984	Hs.158832	Hs.158741	Hs.158549	Hs.158258	Hs.158113
Gene Name		·				·		
Genbank	T64637	Al631850	Al380583	Al928037	AW026553	Al916544	Al924465	H15868
Affy	83908_at	91596_at	83727_at	81659_at	81648_at	90603_at	81591_r_at Al924465	77316_at
SegID	1127	238	451	783	950		780	983

eph.

## 644 444

/clone\_end=3' /gb=Al341602 /gi=4078529

'ug=Hs.152932 /len=461'

/ug=Hs.147562 /len=460

SeqID

##

622

999

1117

662

177

661

569

663

543

664

900

665

889

999

736

299

/ug=Hs.146042 /len=492'

899

#4

	WO 02/059	271		12	24		PC	T/US02/02176
p-values	0.00209424	0.01380957	1.7637E-06	6.6343E-05	0.04200059	9.1255E-05	0.00044029	0.00040144
Fold Change	0.26	0.15	0.30	0.309293968	0.24	0.23	0.231031663	0.28
Cluster# Cluster Description	Hs.145989 Cluster Incl. AW006499:wt05d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2506583 /clone_end=3' /gb=AW006499 /gi=5855277 /ug=Hs.145989 /len=513'	Hs.145068 Cluster Incl. Al821472:nj04c07.x5 Homo sapiens cDNA, 3 end /clone=IMAGE-985356 /clone_end=3' /gb=Al821472 /gi=5440551 /ug=Hs.145068 /len=500'	Hs.144871 Cluster Incl. Al686114:tt92c02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2248994 /clone_end=3'/gb=Al686114 /gi=4897408 /ug=Hs.144871 /len=495'	Hs.144864 Cluster Incl. AW052142:wx26d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2544783 /clone_end=3' /gb=AW052142 /gi=5914501 /ug=Hs.144864 /len=549'	Hs.144151 Cluster Incl. AI668620:yo53h06.x5 Homo sapiens cDNA, 3 end /clone=IMAGE-181691 /clone_end=3' /gb=AI668620 /gi=4827928 /ug=Hs.144151 /len=617'	Hs.143995 Cluster Incl. AI570222:to76e03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2184220 /clone_end=3' /gb=AI570222 /gi=4533596 /ug=Hs.143995 /len=458'	Hs.143873 Cluster Incl. AI740621:wg23e12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2365966 /clone_end=3'/gb=AI740621/gi=5108909 /ug=Hs.143873/len=457'	Hs.143789 Cluster Incl. AI694059;wd67c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2336658 /clone_end=3'/gb=AI694059 /gi=4971399 /ug=Hs.143789 /len=540'
Gene Name Cli	Hs.	Ř	₹	Ä.	Hs.	H.	. <del>Š</del>	Ę.
Genbank	AW006499	AI821472	Al686114	AW052142	AI668620	AI570222	AI740621	AI694059
Affy	82860_at	89087_at	77106_at	79803_at	77077_at	.82595_at	79618_at	77053_at
SeqID	918	712	593	954	571	519	623	604

# 676

<b>p-values</b> 9.8109E-05	4.2869E-07	0.00038894	0.00182392	5.382E-07	0.00918651	0.0002078	0.00024859
Fold Change 6.44	0.22	3.543032267	0.326197997	0.29	0.33	0.29343002	3.063096074
Cluster Incl. AA633203:nq57b02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1147947 /clone_end=3' /gb=AA633203 /gi=2556617	/ug=Hs.14258 /len=570' Cluster Incl. AL040178:DKFZp434F0213_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434F0213 /clone_end=3' /gb=AL040178 /gi=5409143 /ug=Hs.142003			Cluster Incl. W63684;zd30d04,s1 Homo sapiens cDNA, 3 end /clone=IMAGE-342151 /clone_end=3 /gb=W63684 /gi=1371265 /ug=Hs.13821 /len=662'		Cluster Incl. AA015613:ze20f12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-359567 /clone_end=3 /gb=AA015613 /gi=1476661	
Cluster# Hs.14258 (	Hs.142003	Hs.141024	Hs.140996	Hs.13821	Hs.137907	Hs.13766	Hs.137447
Gene Name							
Genbank AA633203	AL040178	Al963725	AA412205	W63684	AI018237	AA015613	Al539443
<b>Affy</b> 90421_at	90389_at	69928_at	75277_f_at	91422_at	75195_at	65185_g_at	61191_at
SeqID 193	864	814	103	1192	316	ဖ	507
# 684	685	989	687	688	689	069	691

•			13	26		10	170502/02170
<b>p-values</b> 1.3855E-05	0.00011435	0.00068507	0.00145442	0.00038716	0.02123852	0.03600705	8.8297E-05
<b>Eold Change</b> 0.31404932	0.25	0.24	5.00	0.127900019	3.05	4.015935457	0.260125725
##		57 Cluster Incl. AA534591:nf81b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-926287 /clone_end=3' /gb=AA534591 /gi=2278844 /ug=Hs.135657 /len=492'		05 Cluster Incl. AI057450:ow80c03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1653124 /clone_end=3' /gb=AI057450 /gi=3331316 /ug=Hs.135405 /len=379'	56 Cluster Incl. H06350:yl79g02.r1 Homo saplens cDNA, 5 end /clone=IMAGE-44306 /clone_end=5' /gb=H06350 /gi=869902 /ug=Hs.201607 /len=551'		
Cluster# Hs.137262	Hs.137003	Hs.135657	Hs.13561	Hs.135405	Hs.135056	Hs.134665	Hs.134110
Gene Name							
Genbank N49591	Al242023	AA534591	AI819340	AI057450	H06350	AI673818	AI078121
<b>Affy</b> 79133_at	82436_at	82385_at	78442 <u>_</u> at	78844_at	86587_at	78668 <u>r_</u> at	78555_at
<b>SeqID</b> 1080	396	157	708	331	626	581	337
## 695	693	694	695	969	269	869	669

/clone\_end=3' /gb=A1031771 /gi=3249983

/ug=Hs.132586 /len=454

				12	28			
p-values	6.3592E-07	0.00126632	0.00124922	1.7752E-05	2.9214E-05	0.00029449	4.2586E-09	0.01303714
Fold Change	0.16	3.09	0.271854365	0.30	0.080787812	7.28	0.103783146	3.015818659
er#" Cluster Description	1987 Cluster Incl. Al890418:wm85a12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2442718 /clone_end=3'/gb=Al890418 /gi=5595582 /ug=Hs.131987 /len=516'	1886   Cluster Incl. AW003102:wr03e03.x1   Homo sapiens cDNA, 3 end /clone=IMAGE-2480476			<ul> <li>// Septimes Color</li></ul>	<ul> <li>// Albano</li> <li>// Albano</li></ul>	<ul> <li>Jegg Cluster Incl. AA621478:af92e12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1055278 /clone_end=3' /gb=AA621478 /gi=2525417 /ug=Hs.130699 /len=398'</li> </ul>	
e Cluster#	Hs.131987	Hs.131886	Hs.131170	Hs.131044	Hs.130893	Hs.130853	Hs.130699	Hs.130316
Gene Name								
Genbank	AI890418	AW003102	A1937390	Al631301	AI124631	AI810266	AA621478	Al572156
Affy	76703_at	74698_at	77926_at	82120_at	59911_f_at	82094 <u>i_a</u> t	47481_at	90691_at
SegID	763	606	797	537	353	693	184	521
##	708	602	710	711	712	713	714	715

/clone\_end=3' /gb=AA975530 /gl=3151322

				13	30		10	170502702170
p-values	1.2217E-06	2.3169E-05	0.00040139	7.0947E-06	4.2446E-06	4.7816E-06	1.6889E-06	4.0015E-05
Fold Change	0.19	3.31847909	5.050317981	3.297301166	0.26	0.169055931	0.25	0.32
Cluster# Cluster Description	Hs.126768 Cluster Incl. AI589858:tm81b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2164509 /clone_end=3' /gb=AI589858 /gi=4598906 /ug=Hs.126768 /len=495'	Hs.126733 Cluster Incl. AA913703:ol38e01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1525752 /clone_end=3'/gb=AA913703/gi=3053095 /ug=Hs.126733 /len=507'	Hs.126672 Cluster Incl. AI792817:ol64f01.y5 Homo sapiens cDNA, 5 end /clone=IMAGE-1534393 /clone_end=5' /gb=AI792817 /gi=5340533 /ug=Hs.126672 /len=306'	Hs.126390 Cluster Incl. AA905481:ok01h09.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1506593 /clone_end=3'/gb=AA905481/gi=3040604 /ug=Hs.126390 /len=461'	Hs.125780 Cluster Incl. Al934342:wp04e12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2463886 /clone_end=3'/gb=Al934342/gi=5673212 /ug=Hs.125780 /len=521'	Hs.125376 Cluster Incl. AA584403:nn81a05.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1090256 /clone_end=3' /gb=AA584403 /gi=2369012 /ug=Hs.125376 /len=512'	Hs.124436 Cluster Incl. AA844007:ai91d09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1388177 /clone_end=3' /gb=AA844007 /gl=2930458 /ug=Hs.124436 /len=310'	Hs.124250 Cluster Incl. AA848010:od24g07.s1 Homo sapiens cDNA /clone=IMAGE-1368924 /gb=AA848010 /gi=2934528 /ug=Hs.124250 /len=415
Gene Name								
Genbank	AI589858	AA913703	AI792817	AA905481	A1934342	AA584403	AA844007	AA848010
Affx	90069_at	46538_at	77013_at	90479_at	73933_at	76770_at	73801_at	73794_at
SegID	526	252	699	244	786	172	238	240
##	724	725	726	727	728	729	730	731

			13	71			
p-values 4.4423E-07	1.5522E-06	4.2459E-08	1.9577E-06	2.1736E-10	0.00094679	7.1425E-07	0.00166257
<b>Fold Change</b> 0.09	5.302996355	0.100992647	0.21246828	0.17	3.60100109	0.24	0.29523189
Cluster Description Cluster Incl. Al458003:tj66c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146476 /clone_end=3 /gb=Al458003 /gi=4312021 /ug=Hs.124141 /len=531			Cluster Incl. AA707308:zj27a11.s1 Homo sapiens cDNA, 3 end /clone=451484 /clone_end=3'/gb=AA707308 /gi=2717226 /ug=Hs.12369 /len=566'				
<u>Cluster#</u> Hs.124141	Hs.124015	Hs.123933	Hs.12369	Hs.122593	Hs.121532	Hs.121518	Hs.120959
Gene Name							
Genbank Al458003	Al953838	AI809953	AA707308	AL037998	AA033764	H41870	Al278074
<b>Affy</b> 90009_at	59471_at	57605_at	65155_at	81670_at	90316_at	81589_at	74760_s_at
SeqID 477	807	691	209	828	91	686	409
732	733	734	735	736	737	738	739

			13	32		-	
<u>p-values</u> 3.0941E-06	1.5413E-05	2.9798E-06	0.00104631	4.3863E-08	0.00159704	1.3663E-05	1.5912E-05
<b>Fold Change</b> 0.22	0.285003866	0.239883875	0.24	0.198179833	3.768700804	0.204140593	0.240592502
Cluster Incl. Al201982:qs79e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1944314 /clone_end=3' /gb=Al201982 /gi=3754588 /ug=Hs.123318 /len=480'		Hs.120568 · Cluster Incl. Al302387:qn50g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1901720 /clone_end=3' /gb=Al302387 /gi=3961733 /ug=Hs.120568 /len=396'					
Cluster#	Hs.120785	Hs.120568	Hs.120388	Hs.12024	Hs.118599	Hs.118513	Hs.118502
Gene Name							
Genbank Al201982	W73890	Al302387	AI742521	R42914	AI821005	Al161367	AW052186
<b>Affy</b> 76326_at	57550_at	66390_at	88669_at	61879_at	90251_at	52946_at	76076_at
SeqID 387	1207	419	632	1107	710	377	955
740	741	742	743	744	745	746	747

DEICHOOLD AND MOROSTERS IS

					13	3			
	p-values	3.2934E-06	3.2676E-06	0.00404612	0.00013207	0.00138841	0.00090085	0.00320729	1.5411E-07
	Fold Change	0.223181865	3.141681584	0.314306045	0.305498776	0.325353873	0.26	0.322106515	0.090939502
1 ***	•	Hs.118392 Cluster Incl. Al824037:wj29h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2404275 /clone_end=3' /gb=Al824037 /gi=5444708 /ug=Hs.118392 /len=603'	Hs.118338 Cluster Incl. N24987:yx16d11.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-261909 /clone_end=5' /gb=N24987 /gi=1139137 /ug=Hs.118338 /len=582'	Hs.118262 Cluster Incl. Al698243:wa70g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2301560 /clone_end=3'/gb=Al698243/gi=4986143 /ug=Hs.118262 /len=431'	Hs.118121 Cluster Incl. AI124882:am57f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1539687 /clone_end=3' /gb=AI124882 /gi=3593396 /ug=Hs.118121 /len=406'	Hs.11782 Cluster Incl. AI823572:wh55g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2384698 /clone_end=3' /gb=AI823572 /gi=5444243 /ug=Hs.11782 /len=538'	Hs.117687 Cluster Incl. AI766029:wh67b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2385775 /clone_end=3' /gb=AI766029 /gi=5232538 /ug=Hs.117687 /len=704'	Hs.117474 Cluster Incl. R49146;yg69h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-38818 /clone_end=3' /gb=R49146 /gi=820214 /ug=Hs.117474 /len=435'	Hs.116123 Cluster Incl. Al016755:ov27c06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1638538 /clone_end=3'/gb=Al016755/gi=3231091 /ug=Hs.116123/len=477'
	Gene Name	I	Ι	Ι.	I	_	1	_	1
	Genbank	Al824037	N24987	AI698243	AI124882 '	AI823572	AI766029	R49146	Al016755
	Affy	57528_at	47434_at	76029_at	76015_at	57517_at	.76163_at	66305_at	66240_s_at
	SedID	716	1066	609	354	713	655	1108	315.
	##	748	749	750	751	752	753	754	755

1	34	1

			13	34			
<b>p-values</b> 7.063E-09	2.0933E-09	0.00377036	6.3947E-05	5.4104E-05	5.4138E-06	0.00036834	0.00069299
<b>Fold Change</b> 0.139924253	8.54	4.52	0.21	0:30	0.25	0.18	0.262512195
Cluster Incl. Al916626:wa28h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2299443 /clone_end=3' /gb=Al916626 /gi=5636481 /ug=Hs.116110 /len=487'	Cluster Incl. AI275140:qI70h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1877715 /clone_end=3'/gb=AI275140/gi=3897414 /ug=Hs.116104 /len=444'						Cluster Incl. T64447:yc10g02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-80306 /clone_end=3'/gb=T64447 /gi=668312 /ug=Hs.11455 /len=563'
Cluster#	Hs.116104	Hs.115838	Hs.115497	Hs.115315	Hs.115173	Hs.114889	Hs.11455
Gene Name							
<u>Genbank</u> Al916626	Al275140	Al344053	AI498375	Al978710	Al418405	AI797063	T64447
<b>Affy</b> 90168_at	88580_at	8856 <b>7_s_a</b> t	76118_at	81061_at	89807_at	81039_at	54983_at
SeqID 773	405	429	494	835	464	673	1126
756	757	758	759	092	761	762	763

			13	93			
p <u>-values</u> 1.6712E-08	5.1114E-07	1.9391E-08	2.882E-07	6.2396E-05	0.00068815	2.0122E-05	0.00718188
<b>Fold Change</b> 0.093652816	0.200282848	0.20	0.202348411	0.084843922	3.166594901	0.116868505	0.269236792
Cluster Incl. Al091154:0018a08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1566518 /clone_end=3' /gb=Al091154 /gi=3430213 /ua=Hs.113750 /len=437'				•			
Cluster # Hs.113750	Hs.112885	Hs.112572	Hs.110406	Hs.11006	Hs.109653	Hs.109525	Hs.107253
Gene Name							
Genbank Al091154	AI742490	AA628467	AA452295	AI732274	N91175	AI871044	AA059401
<b>Affy</b> 75585_at	57022_at	80917_at	56941_at	48115_at	42353_at	56910_at	63344_at
SeqID 345	631	189	124	618	1098	750	32
764	765	766	767	768	769	770	771

			1	36			
0.00333978	3.0927E-05	3.2707E-05	2.4582E-06	0.04026278	6.4561E-05	4.2545E-05	7.7541E-05
<b>Fold Change</b> 0.289956429	0.212581687	0.25026049	3.113529847	0.31991901	0.194470029	0.147540619	0.29
Cluster Incl. AA173572:zp04e02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-595418 /clone_end=3' /gb=AA173572 /gi=1753704 /ug=Hs.10683 /len=595'							
Cluster# Hs.10683 Clussap	Hs.106771	Hs.103395	Hs.103305	Hs.102793	Hs.102541	Hs.102367	Hs.10198
Gene Name							
Genbank AA173572	AA806965	AA147751	AI885164	AI707589	AI752682	W72347	Al201965
Affy 48063_at	58174_at	48040_at	56190_at	58429_at	·63315_at	48032_at	87970_at
SeqID 75	229	62	753	615	642	1199	386
772	773	774	775	776	777	778	622

781

783

784

785

786

787

sapiens cDNA, 5 end /clone=GEN-501F10

'clone\_end=5' /gb=D63177 /gi=966846

780

##

DEICHOOMING AMON MORNOTHAN I S

			138			101/0	)302/021 / <b>0</b>
<b>p-values</b> 8.1229E-05	0.00070373	9.1295E-07	1.7708E-06	3.3328E-06	7.1154E-05	1.3678E-06	5.8223E-06
<b>Fold Change</b> 3.149965078	0.32	0.317111476	0.297990459	0.264521584	0.233645562	0.185193232	0.182339389
Cluster Incl. A1025199:ov40f01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1639801 /clone_end=3' /gb=A1025199 /gi=3240812 /ug=Hs,131604 /len=427'	Cluster Incl. AA081045:zn33e02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-549242 /clone_end=3' /gb=AA081045 /gl=1623033 /ug=Hs.193281 /len=522'	Cluster Incl. W44656:zc29a09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-323704 /clone_end=5' /gb=W44656 /gi=1330176 /ug=Hs.14627 /len=599'	Cluster Incl. AL043089:DKFZp434C1123_r1 Homo sapiens cDNA, 5 end /clone=DKFZp434C1123 /clone_end≈5' /gb=AL043089 /gl=5422506 /ug=Hs.3807 /len=762'	Cluster Incl. W56090:zc56g03.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-326356 /clone_end=5' /gb=W56090 /gi=1357999 /ug=Hs.12319 /len=620'	Cluster Incl. AA007390:zh99a06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-429394 /clone_end=5' /gb=AA007390 /gi=1463628 /ug=Hs.166944 /len=555'	Cluster incl. AA430314:zw68h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-781403 /clone_end=5' /gb=AA430314 /gi=2113524 /ug=Hs.95296 /len=579'	Cluster Incl. W07304;za97b10.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-300475 /clone_end=5' /gb=W07304 /gi=1281502 /ug=Hs.12927 /len=578'
Cluster# CI CI Se Se /CI							
Gene Name							
Genbank Al025199	AA081045	W44656	AL043089	W56090	AA007390	AA430314	W07304
<b>Affy</b> 66998_at	79496_r_at	47889_at	65867_at	57586_at	82582_at	48927_at	53793_at
<b>SeqID</b> 319	36	1186	869	1190	သ	117	1174
## 2488	789	790	791	792	793	794	795

p-values	6.1089E-05	2.7057E-06
Fold Change	0.14	0.110161171
Cluster Description	Cluster Incl. N50065:yz10h03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-282677 /clone_end=3' /gb=N50065 /gi=1191231 /ug=Hs 169732 /len=550'	Cluster Incl. R70255:yj81f06.s1 Homo sapiens 0.110161171 2.7057E-06 cDNA, 3 end /clone=IMAGE-155171 /clone_end=3' /gb=R70255 /gi=843772 /ug=Hs.25150 /len=367'
Cluster#		
Gene Name		
Genbank	N50065	R70255
Affx	3453	52449_at
SealD	1081	1116
##	962	797

4: 1

orley-d	-Value	5.020000E-05	3.510000E-07	2.660000E-08	202000000000000000000000000000000000000	Z.30000E-03	7 4244E 06	1.124404E-00		1.340000E-05		6.210594E-06		4.710000E-08	1.380000E-06	4.050474E-06	7.807645E-06	4 150000E-04	to-1000001:t	1.318202E-04	•	4.120000E-07	3.247311E-05	1.610000E-04	1.518608E-06	3.900000E-07	2.613853E-08	7.205058E-06	1.770803E-06	4.329042E-05		1.000000E-04	4.436191E-07	2.373819E-06	1.093627E-04	1 086072E_05	1,00001
Eold Change (ratio)	old Chairye Hatto	0.246437105	0.090848213	0.091111614	0 003808000	0.032020303	0 44005500	0.110033030		0.121953593		0.168279383		0.187743879	0.218509986	0.221960648	0.22460642	0 228917694	1001100	0.237704503		0.260055335	0.264360188	0.279338963	0.279947233	0.281207961	0.282705156	0.29408728	0.297990459	0.313634138		0.323566748	0.32670528	0.36717276	0.415471413	0.407000585	0.401 999000
		-4.06	-11.01	-10.98	1107	-10.1	ć	30.8-	-	-8.20		-5.94		-5.33	-4.58	-4.51	-4 45	25.4	10.7	-4.21		-3.85	-3.78	-3.58	-3.57	-3.56	-3,54	-3.40	-3.36	-3.19		-3.09	-3.06	-2.72	-2.41	) 1E	) 64.7-
	melanoma inhibitory activity,ras-related	GTP-binding protein 4b	actin, gamma 2, smooth muscle, enteric	calponin 1, basic, smooth muscle	myosin, neavy polypeptide 11, silloutil	muscle	eukaryotic translation initiation factor 4	gamma, 1	myosin, heavy polypeptide 11, smooth	muscle	eukaryouc translation illitiation lactor +	gamma, 1	laminin, alpha 3 (nicein (150kD), kalinin	(165kD), BM600 (150kD), epilegrin)	leiomodin 1 (smooth muscle)		DKE7D586D1409 protein				laminin, beta 3 (nicein (125kD), kalinin	(140kD), BM600 (125kD))		myosin, light polypeptide kinase		inositol polyphosphate-1-phosphatase					RNA-binding protein gene with multiple	splicing	myosin, light polypeptide kinase		phosphatidic acid phosphatase type 2A	RN nding protein gene with multiple	spiicing
er node 2761X	Genbank	AA461365	D00654	D17408		AF0135/0		AI380979		AF001548		AA156998		L34155	X54162	AA034289	10122101	W/2194	799010	AA541622		U17760	AI658662	U48959	AI768516	1.08488	A1972873	N95620	AI 043089	C16443		D84110	AA526844	AB007972	AF014402		D84111
Table 3: 35 Genes from HCA cluster node 2761X	AIIV	39271 at	1197_at	34203_at		37407_s_at		58774_at		767_at		63893_f_at		37909 at	37765 at	60532 at	56400 pt	20409_at	7/3_at	64407_at	ı	36929 at	50361_at	32847 at	62136_at	41524 at	65975 at	57214 at	65867_at	50001 at	1	38048 at	46276 at	41137 at	34797_at		34162_at
35 Genes	Sedin	127	959	964	;	288	į	453		283		2		1023	1223	17	1077	/81	960	162		1141	561	1151	658	1013	832	1099	869	928		973	150	272	289	į	974
Table 3:	#:I	_	8	က		4	ı	S		9		7		∞	σ.	Ç		Ξ :	12	5		14	15	9	1	. œ	<u> </u>	20	7	2 :		23	24	25	8	į	27

p-value 2.789025E-04	5.432773E-06	1.694770E-05	3.251490E-06	1.715459E-03	4.653880E-06	4.038920E-05	3.551680E-04
Fold Change (ratio) 0.389097343	_	0.473538178	0.47055836	0.458611832	0.348051542	0.367062886	0.406092748
Fold Change F-2.57	-2.62	-2.11	-2.13	-2.18	-2.87	-2.72	-2.46
Gene Name				CGI-43 protein	DKFZP564B0769 protein		
Genbank AA843926	AI379892	AI571525	AI744109	A1912571	W72919	W87690	W88427
Aff <u>v</u> 66529 at	49540_at	49300_at	65734_at	46653_at	49349_at	47076_at	54668_at
SeqID 237	449	520	638	767	1202	1210	1211
## 88 1##	59	30	31	32	33	34	35

Tab	le 4: BREA	ST / INFILTRA	Table 4: BREAST / INFILTRATING DUCT CARCINOMA	VOMA			
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1	1	AA001250					340.76+/-99.54
			×	×	×	×	N1=40, N2=10
			•				Fold Change: 2.01
							P-value: .00096
7	7	AA017070	218.33+/-195.52			218.33+/-195.52	218.33+/-195.52
			75.87+/-104.51			49.83+/-71.53	28.53+/-33.27
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.8			Fold Change: 3.67	Fold Change: 5.14
			P-value: 0			P-value: 0	P-value: 0
3	11	AA027103	252.16+/-278.17		252.16+/-278.17	252.16+/-278.17	252.16+/-278.17
			53.89+/-220.22		47.94+/-61.86	14.48+/-36.79	15.58+/-46.81
			N1=39, $N2=168$	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.64		Fold Change: 3.3	Fold Change: 4.51	Fold Change: 4.88
			P-value: 0		P-value: .01164	P-value: 0	P-value: 0
4	12	AA029437	221.16+/-280.96			221.4+/-284.63	
			57.63+/-138.17			86.7+/-207.7	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 3.25			Fold Change: 2.95	
			P-value: 0			P-value: .00006	
ĸ	13	AA029735					581.98+/-218.36
)	}						246.82+/-189
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.76
							P-value: .00174
9	15	AA031790					336.45+/-181.35
							122.36+/-61.84
		•	×	×	×	×	N1=40, N2=10
							Fold Change: 2.82
							P-value: .0009
7	17	AA034289	203,74+/-150.5		203.74+/-150.5	203.74+/-150.5	203.74+/-150.5
			30.48+/-63.02		56.05+/-43.37	41.75+/-90.59	-7.27+/-28.68
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 4.19		Fold Change: 2.69	Fold Change: 3.95	Fold Change: 6.91
			P-value: 0		P-value: .00466	F-value: 0	F-value: 0

PRICEOGREP - MACO - CONTROL A A A A

259  68  X  X  X  X  X  X  X  X  X  X  X  X  X		į,			Mossie Mollomont	Mountain Stone I	Normal ve Stage II	Normal ve Stage III
18 AA03418 1774-175.09  19 N1=40, N2=168	,	Sed Th	Сепрапк	NOFILIAI VS ALI	IVOLUIAI VS IVIAIIBIIAIIL	TOT HERE AS STARGET	Morning vs Dungo at	Cr July 1. Co all
20 AA044828		18	AA034418	370.77+/-175.09			367.92+/-176.43	367.92+/-176.43
20 AA047766  X X X X  Fold Change: 2.41  21 AA044828 228.224-120.36  22 AA044830 228.224-120.36  23 AA044830 38.463+-138.59  195.744-112.66  N1=40, N2=168  N1=40, N2=6  P-value: 0  P-value: 00032  N1=40, N2=6  Fold Change: 2.42  P-value: 0008  P-value: 0008  P-value: 0008  P-value: 0008				171.84+/-132.49			145.41+/-92.73	148.75+/-103.92
Poid Change: 2.41  P-value: 0  20  AA037766  X				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
20 AA037766  X X X  22 AA044828 228.224-/120.36  81.18+/-75.97 N1=40, N2=168 Pold Change: 2.87 P-value: 0  24 AA045145 261.46+/-178.02 P-value: 0  25 AA046853 200.27+/-13.41 X X X N1=40, N2=6 P-value: 0  26 AA046853 200.27+/-13.62 X X X N1=40, N2=6 Pold Change: 3.35 P-value: 0  27 AA046853 200.27+/-136.52 P-value: 0  28 344-/-118.02 P-value: 0  29 S38.34+/-118.03 P-value: 0  20 254.96+/-154.86 P-value: 0  27 AA046853 200.27+/-136.52 P-value: 0  28 385.33+/-229.71 P-value: 0  29 P-value: 0  26 P-value: 0  27 P-value: 0  27 P-value: 0  28 385.33+/-229.71 P-value: 0				Fold Change: 2.41	!		Fold Change: 2.76	Fold Change: 2.55
20 AA037766  X X X  21 AA044828 228.224-120.36  22 AA044830				P-value: 0			P-value: 0	P-value: .00125
X X X X X X X X X X X X X X X X X X X		20	AA037766				217.99+/-102.27	
X X X X X X X X X X X X X X X X X X X		ì					98.41+/-70	
22 AA044928 228.224/-120.36 81.18+/-75.97 N1=40, N2=168 Fold Change: 2.87 Fold Change: 3.45 Fold Change: 2.4 Fold Change: 2.4 Fold Change: 2.4 Fold Change: 2.07 Fold Change:				×	×	×	N1=39, N2=31	×
22 AA044828 228.224-1.20.36 81.184-7.75.97 N1-40, N2=168 X Fold Change: 2.87 P-value: 0 23 AA044830 384.63+1.18.59 P-value: 0 24 AA045145 261.46+1.12.66 N1=40, N2=168 X N1=40, N2=168 X N1=40, N2=168 X N1=40, N2=168 X X N1=40, N2=6 Fold Change: 2.4 P-value: 0 254.96+1.154.86 91.58+1.20.82 X X N1=40, N2=6 Fold Change: 2.4 P-value: 0.0032 N1=40, N2=168 X X N1=40, N2=6 Fold Change: 2.4 P-value: 0.0032 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.4 P-value: 0.0032 P-value: 0.0032 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.4 P-value: 0.0032							Fold Change: 2.21	
22 AA044828 228.22+/-120.36 81.18+7-5.97 N1=40, N2=168							P-value: 0	
81.18+/-75.97 N1=40, N2=168 Rold Change: 2.87 P-value: 0 24 AA045145 Signature: 0 24 AA045145 Signature: 0 25 AA046857 Signature: 0 27 AA046853 Signature: 0 27 AA046853 Signature: 0 27 AA046853 Signature: 0 28 3.44-196.52 Signature: 0 29 A-value: 0 25 AA046853 Signature: 0 26 Air Change: 2.07 Signature: 0 27 AA046853 Signature: 0 28 385.33+/-196.52 Signature: 0 29 Aa046853 Signature: 0 20 Signature: 0 20 Signature: 0 20 Signature: 0 20 Signature: 0 30 Signat	_	22	AA044828	228.22+/-120.36			228.25+/-121.93	228.25+/-121.93
N1=40, N2=168		ł		81.18+/-75.97		•	68.84+/-62.87	30.55+/-34.05
Fold Change: 2.87  P-value: 0  23 AA044830 384.63+/189.59  195.74+/-112.66  N1=40, N2=168  P-value: 0  24 AA045145 83.44+/-180.2  P-value: 0  25 AA046457  X  X  X  X  X  X  X  N1=40, N2=6  Fold Change: 2.44  P-value: 0.0032  27 AA046853 200.27+1-196.52  N1=40, N2=168  N1=40, N2=168  P-value: 0.0032  P-value: 0.0032  P-value: 0.0032  P-value: 0.0032  P-value: 0.0032  P-value: 0.0032				N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
23 AA044830 384.63+1.189.59 195.74+1.12.66 N1=40, N2=168 X Fold Change: 2.09 P-value: 0 P-value: 0 P-value: 0 24 AA045145 261.46+1.178.02 83.44+1.183.41 N1=40, N2=168 X R Fold Change: 3.35 P-value: 0 P-value: 0 25 AA046857 X X X X X X X X X X X X X X X X X X X				Fold Change: 2.87			Fold Change: 3.18	Fold Change: 5.8
23 AA044830 384.63+1.189.59 195.74+1.112.66 N1=40, N2=168				P-value: 0			P-value: 0	P-value: 0
195.74+/-112.66 N1=40, N2=168 N1=40, N2=168 Fold Change: 2.09 P-value: 0 24 AA045145 261.46+/-178.02 Rold Change: 3.35 P-value: 0 P-value: 0  25 AA046457 X X X X X X X X X X X X X X X X X X X	1	23	A A 044830	384.63+/-189.59			387.92+/-190.91	387.92+/-190.91
24 AA045145 261.464-i-178.02 24 AA045145 261.464-i-178.02 25 AA046457  25 AA046853 200.27+i-196.52 27 AA046853 200.27+i-196.52 28 AA046853 200.27+i-196.52 29 AA046853 200.27+i-196.52 201.69+i-198.89 27 AA046853 200.27+i-196.52 28 A60.89+i-152.52 N1=40, N2=6 Fold Change: 2.07 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0008		}		195.74+/-112.66			142.87+/-73.75	148.94+/-75.02
Fold Change: 2.09  P-value: 0  24		•		N1=40, N2=168	×	×	NI=40, N2=31	N1=40, N2=10
24 AA045145 261.46+/-178.02				Fold Change: 2.09			Fold Change: 2.81	Fold Change: 2.65
24       AA045145       261.46+/-178.02       X         83.44+/-183.41       X       X         Fold Change: 3.35       Fold Change: 3.35         P-value: 0       254.96+/-154.86         91.58+/-30.86       X         X       X         N1=40, N2=6       Fold Change: 2.4         P-value: .00032       200.27+/-196.52         N1=40, N2=168       X         N1=40, N2=6       Fold Change: 2.42         P-value: .0008       P-value: .0008         P-value: .0008       P-value: .0008				P-value: 0			P-value: 0	P-value: .00182
83.44+/-183.41 N1=40, N2=168 Fold Change: 3.35 P-value: 0  25 AA046457 X X X X X N1=40, N2=168 91.58+/-30.86 91.58+/-30.86 7 AA046853 200.27+/-196.52 27 AA046853 200.27+/-196.52 N1=40, N2=168 N1=40, N2=168 N1=40, N2=168 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0008		24	AA045145	261.46+/-178.02			262.21+/-180.28	262.21+/-180.28
Fold Change: 3.35  P-value: 0  P-value: 0  AA0464S7  AA0464S7  AA046853  Z00.27+/-196.52  N1=40, N2=6  Fold Change: 2.4  P-value: 0  Z54.96+/-154.86  91.58+/-30.86  X  X  X  X  N1=40, N2=6  Fold Change: 2.4  P-value: 0  P-value: 0008  P-value: 0008  P-value: 0  P-value: 0008		1		83.44+/-183.41			63.71+/-149.37	8.27+/-106.8
Fold Change: 3.35  P-value: 0  P-value: 0  P-value: 0  X  X  X  X  N1=40, N2=6  Fold Change: 2.4  P-value: 0  P-value: 0  Z54.96+/-154.86  91.58+/-30.86  X  X  X  N1=40, N2=6  Fold Change: 2.4  P-value: 0  P-value: 0008				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0  P-value: 0  X  X  X  X  N1=40, N2=6  Fold Change: 2.4  P-value: 0.0032  27  AA046853  200.27+/-196.52  N1=40, N2=6  Fold Change: 2.07  P-value: 0.008  P-value: 0.008				Fold Change: 3.35			Fold Change: 4	Fold Change: 5.08
25 AA046457  X X X III=40, N2=6 91.58+/-30.86  X N1=40, N2=6 Fold Change: 2.4 P-value: 0.0032  X A046853 200.27+/-196.52  X N1=40, N2=6 Fold Change: 2.4 Fold Change: 2.7 Fold Change: 2.7 P-value: 0.008 P-value: 0.008		•		P-value: 0		:	P-value: 0	P-value: .00018
X X N1=40, N2=6 N1=40, N2=6 Fold Change: 2.4 P-value: .00032 27 AA046853 200.27+/-196.52 385.33+/-229.71 N1=40, N2=168 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.07 P-value: .0008	1	25	AA046457			254.96+/-154.86		254.96+/-154.86
X X N1=40, N2=6 Fold Change: 2.4 P-value: .00032 27 AA046853 200.27+/-196.52 385.33+/-229.71 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.07 P-value: .0008						91.58+/-30.86		99.01+/-89.62
Fold Change: 2.4  P-value: .00032  27 AA046853 200.27+/-196.52  385.33+/-229.71 201.69+/-198.89  A06.89+/-152.52  N1=40, N2=168 X N1=40, N2=6  Fold Change: 2.07 Fold Change: 2.42  P-value: .0008				×	×	N1=40, N2=6	×	N1=40, N2=10
27 AA046853 200.27+/-196.52 P-value: .00032 385.33+/-229.71 201.69+/-198.89 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.07 Fold Change: 2.42 P-value: .0008						Fold Change: 2.4		Fold Change: 2.75
27 AA046853 200.27+/-196.52 201.69+/-198.89 385.33+/-229.71 406.89+/-152.52 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.07 Fold Change: 2.42 P-value: 0 P-value: 0008						P-value: .00032		P-value: .00204
385,33+/-229,71 N1=40, N2=168 X N1=40, N2=6 Fold Change: 2.07 P-value: 0	1_	27	AA046853	200.27+/-196.52		201.69+/-198.89	201.69+/-198.89	201.69+/-198.89
X N1=40, N2=6 Fold Change: 2.42 P-value: .0008				385,33+/-229,71		406.89+/-152.52	428.46+/-216.88	370.09+/-174.14
Fold Change: 2.42 P-value: .0008				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
P-value: .0008				Fold Change: 2.07		Fold Change: 2.42	Fold Change: 2.44	Fold Change: 2.06
				P-value: 0		P-value: .0008	P-value: 0	P-value: .00306

RNSDOCID- (WO 02059271A2 | >

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
15	28	AA056180					80.83+/-48.85 254.08+/-148.48
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.07 P-value: .00013
16	29	AA056755			243+/-190.55	243+/-190.55	
					413.4+/-148.7	476.92+/-268.57	
			×	×	N1=40, N2=6	N1=40, N2=31	×
					Fold Change: 2.12	Fold Change: 2.22	
					P-value: .00235	P-value: .00002	
17	30	AA058578				282.9+/-254.52	282.9+/-254.52
						100.56+/-94.65	62.96+/-63.59
			×	×	×	N1=40, N2=31	NI=40, N2=10
						Fold Change: 2.24	Fold Change: 3.01
						P-value: .00272	P-value: .00335
18	31	AA059396	383.9+/-126.38			383.25+/-127.97	383.25+/-127.97
			184.18+/-88.67			195.3+/-91.8	164.81+/-71.68
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.2			Fold Change: 2.03	Fold Change: 2.37
			P-value: 0			P-value: 0	P-value: .00006
119	32	AA059401	444.15+/-409.74		450.12+/-413.33	450.12+/-413.33	450.12+/-413.33
			108.09+/-137.58		84.82+/-108.93	78.85+/-105.76	4.41+/-98.3
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.84		Fold Change: 4.32	Fold Change: 5.13	Fold Change: 7.56
			P-value: 0		P-value: .01621	P-value: 0	P-value: 0
20	33	AA059458	73.64+/-89.7		74.76+/-90.6	74.76+/-90.6	74.76+/-90.6
			421.17+/-253.37		328.32+/-224.02	373.99+/-269.57	399.15+/-254.81
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.85		Fold Change: 4.88	Fold Change: 5.56	Fold Change: 5.85
			P-value: 0		P-value: .00774	P-value: 0	P-value: .00035
21	34	AA075632				331.71+/-236.88	331.71+/-236.88
						176.14+/-256.71	125.73+/-212.88
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.48	Fold Change: 4.1
						7100: :0mm	, mine: .0000

:

DEIDDOOID, AND MOCONTANT I

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
22	35	AA079839				399.21+/-217.44	399.21+/-217.44
						178.24+/-173.52	1/3.1+/-209.18
			×	×	×	N1=39, N2=31	N1=39, N2=6
						Fold Change: 2.2	Fold Change: 2.61
						P-value: .00001	P-value: .00239
23	37	A A 082546	272.4+/-223.42			275.39+/-225.53	275.39+/-225.53
}	5		105.34+/-63.79			93.91+/-47.44	74.83+/-36.32
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.35			Fold Change: 2.55	Fold Change: 3.23
			P-value: 0			P-value: 0	P-value: .00005
24	×.	AA101125				99.756+/-99.029	670.66+/-337.66.
;	2					325+/-154.53	292.03+/-126.99
			×	×	×	N1=40, N2=31	N1=40, N2=10
			<b>;</b>			Fold Change: 2.01	Fold Change: 2.27
						P-value: 0	P-value: .00091
35	41	AA126704	314.32+/-135.99			312.64+/-137.34	312.64+/-137.34
}	!		107.92+/-81.49			77.02+/-71.72	78.95+/-75.5
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.17			Fold Change: 4.14	Fold Change: 3.75
			P-value: 0			P-value: 0	P-value: .00032
36	42	AA127718	238.22+/-357.2			240.21+/-361.64	
}	!		82.46+/-76.05			87.69+/-80.58	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.53			Fold Change: 2.39	
			P-value: 0			P-value: .00006	
27	43	AA127727	214.24+/-122.15		212.97+/-123.48	212.97+/-123.48	212.97+/-123.48
			81.63+/-51.81		89.92+/-52.2	66.11+/-40.88	51.85+/-29.44
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.72		Fold Change: 2.29	Fold Change: 3.29	Fold Change: 3.99
_			P-value: 0		P-value: .00795	P-value: 0	P-value: .00001
28	47	AA131456	642.53+/-392.68			650.36+/-394.64	
			325.78+/-211.65			340.69+/-188.84	
			N1=40, N2=168	×	×	N1=40, N2=31	×
_			Fold Change: 2.13			Fold Change: 2.01	
			P-value: 0			F-value: 0	

RNSDOCID: <WO 02059271A2 | >

ţ

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
29	48	AA131632	×	×	×	376.43+/-162.83 185.82+/-88.41 N1=40, N2=31 Fold Change: 2.11 P-value: 0	×
30	50	AA131894	×	×	<b>×</b>	×	125,64+/-46.19 310.35+/-183.98 N1=40, N2=10 Fold Change: 2.19 P-value: .00585
31	51	AA133248	401.89+/-133.14 193.81+/-109.33 N1=40, N2=168 Fold Change: 2.26 P-value: 0	X	× ·	×	400.91+/-134.73 182.12+/-50.15 N1=40, N2=10 Fold Change: 2.15 P-value: 0
32		AA137038	X	×	×	122.53+/-86.86 266.01+/-205.87 N1=40, N2=31 Fold Change: 2.11 P-value: .00008	×
33	57	AA142913	302.75+/-219.97 88.13+/-60.53 N1=40, N2=168 Fold Change: 3.49 P-value: 0	×	302,34+/-222.83 104,62+/-49.26 N1=40, N2=6 Fold Change: 2.6 P-value: .00174	302.34+/-222.83 84.31+/-62.54 N1=40, N2=31 Fold Change: 3.74 P-value: 0	302.34+/-222.83 83.75+/-83.82 N1=40, N2=10 Fold Change: 4.01 P-value: .00014
34	65	AA143491	491.76+/-382.75 278.14+/-268.9 N1=40, N2=168 Fold Change: 2.1 P-value: .00012	<b>X</b> .	×	×	485.72+/-385.82 206.94+/-269.35 N1=40, N2=10 Fold Change: 3.02 P-value: .02186
35	62	AA147751	480.16+/-205.12 247.19+/-214.23 N1=40, N2=168 Fold Change: 2.38 P-value: 0	×	×	478.2+/-207.42 284.09+/-237.65 N1=40, N2=31 Fold Change: 2.21 P-value: .00015	×

:

DEICHOOLIN- JAIN MINEDOTANO I .

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
36	63	AA147884	46.57+/-54.48 235.82+/-200.06 N1=40, N2=168 Fold Change: 4.33 P-value: 0	×	×	×	×
37	64	AA149312	377.26+/-139.17 193.77+/-99.25 N1=40, N2=168 Fold Change: 2.04 .P-value: 0	×	×	374+/-139.43 170.47+/-78.83 N1=40, N2=31 Fold Change: 2.29 P-value: 0	374+/-139.43 140.83+/-37.98 N1=40, N2=10 Fold Change: 2.57 P-value: 0
38	99	AA150501	213.29+/-103.88 89.09+/-51.7 N1=40, N2=168 Fold Change: 2.45 P-value: 0	×	215.8+/-104 97.8+/-28.03 N1=40, N2=6 Fold Change: 2.01 P-value: .00034	215.8+/-104 74.57+/-38.51 N1=40, N2=31 Fold Change: 2.85 P-value: 0	215.8+/-104 41.35+/-30.37 N1=40, N2=10 Fold Change: 4.75 P-value: 0
39	99	AA151346	×	×	×	180.8+/-85.07 392.04+/-178.92 N1=39, N2=31 Fold Change: 2.13 P-value: 0	×
94	89	AA155914	400.19+/-405.95 143.7+/-119.6 N1=40, N2=168 Fold Change: 2.56 P-value: 0	×	×	407.07+/-408.89 135.07+/-104.23 N1=40, N2=31 Fold Change: 2.69 P-value: .00009	×
14	69	AA155952	×	×	×	343.72+/-239.12 136.91+/-62.46 N1=40, N2=31 Fold Change: 2.23 P-value: 0	343.72+/-239.12 111.1+/-55.68 N1=40, N2=10 Fold Change: 2.77 P-value: .00005
42	71	AA158731	288.7+/-238.19 93.33+/-144.72 N1=40, N2=168 Fold Change: 3.48 P-value: 0	×	×	287.72+/-241.22 95.77+/-117.6 N1=40, N2=31 Fold Change: 3.08 P-value: .00001	287.72+/-241.22 183.13+/-413.53 N1=40, N2=10 Fold Change: 3.9 P-value: .01612

176.564-116.87   176.564-117.38   176.	4	Esa III	Coukon	Normal ve All	Normal we Malianant	Normal ve Stage I	Normal ve Stage II	Normal vs Stage III
AA105701   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+110.01   17.0.707+10.01   1	,[	250	A A 1 CE TO 1	176 56±/ 116 07	Ivolulial to transguare.	176 56±/-116 87	176 56+/-116 87	176 56+/-116 87
Nation	_	S	10/C0TWA	1/0.001/-110.0/		277 40±/ 172 1	200 01±7.121.22	200 08±/-142 67
Fig. 10				355./4+/-147.31	;	322.407/-1/3.1	77:101-1-10:07	10.241-142.00
Fold Change: 2.21   Fold Change: 2.14   Fold Change: 2.14   Fold Change: 2.10				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	NI=40, NZ=10
A AA166620   227.064+165.92   247.064+				Fold Change: 2.21		Fold Change: 2.14	Fold Change: 2.01	Fold Change: 2.05
T4   AA16620   227.06+1165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+165.92   227.06+19.41   11-30.04-16.88   Ni=30, N2=10   Ni=30,				P-value: 0		P-value: .0095	P-value: .00002	P-value: .00163
Ni	_	74	AA166620	227.06+/-165.92		227.06+/-165.92	227.06+/-165.92	227.06+/-165.92
NI=39, N2=168				100.03+/-194.31		88.27+/-25.59	85.25+/-119.41	38.81+/-22.68
Fold Change: 2.58   Fold Change: 2.98					×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
P-value; 0   P-value; 0   P-value; 0   P-value; 0				Fold Change: 2.58		Fold Change: 2.06	Fold Change: 2.98	Fold Change: 4.89
75   AA173572   368.06+/-171.39   368.073+/-173.58   132.74+/171.15   105.87+/-793.3   132.74+/-121.15   105.87+/-793.3   105.87+/-793.3   105.87+/-793.3   105.78+/-793.3   105.78+/-793.3   105.78+/-793.3   105.78+/-793.3   105.78+/-7040   P-value: 0   P-value: 0   P-value: 0   P-value: 0   P-value: 0   222.51+/-105.8   X   X   X   X   X   X   X   X   X				P-value: 0		P-value: .00143	P-value: 0	P-value: 0
132.74/121.15	l	75	AA173572	368.06+/-171.39			368.73+/-173.58	368.73+/-173.58
Ni = 40, N2 = 168		!		132.7+/-121.15			105.87+/-79.3	162.1+/-222.38
Fold Change: 3.31   Fold Change: 3.94     P-value: 0				N1=40, N2=168	×	×	N1=40, N2=31	NI=40, N2=10
7.7         AA188763         109.78+/-67.46         P-value: 0         P-value: 0           7.7         AA193340         X         X         X           7.8         AA193340         X         X         X           8.5         AA211369         X         X         X           8.5         AA227778         250.35+/-164.31         X         X         X           8.8         AA227778         250.35+/-164.31         X         X         X         X           8.9         P-value: 0         P-value: 00001         P-value: 00002         P-value: 00001         P-value: 00001				Fold Change: 3.31			Fold Change: 3.94	Fold Change: 3.72
77         AA188763         109,78+/-67.46           78         AA193340         X <th< td=""><th></th><td></td><td></td><td>P-value: 0</td><td></td><td></td><td>P-value: 0</td><td>P-value: .0091</td></th<>				P-value: 0			P-value: 0	P-value: .0091
223.51+/-105.81 N1=40, N2=168		77	AA188763	109 78+/-67 46				109.94+/-68.33
Ni=40, N2=168		•		223.51+/-105.81				210.03+/-82.61
Fold Change: 2.13  P-value: 0  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=40, N2=168	×	×	×	N1=40, N2=10
78         AA193340         P-value: 0         338.82+/-318.56           135.54+/-138.52         X         X N1=40, N2=31           85         AA211369         X         X           8         AA227778         250.35+/-164.31         X         X           88         AA227778         250.35+/-164.31         X         X           N1=40, N2=16         N1=40, N2=31         Fold Change: 3.07         Fold Change: 3.09           P-value: .00002         P-value: .00002         P-value: .00002				Fold Change: 2.13				Fold Change: 2.06
78         AA193340         X         X         135.54+'-318.56           135.54+'-138.52         NI=40, N2=31         Fold Change: 2.47           85         AA211369         X         X         X           88         AA227778         250.35+'-164.31         X         X         X           88         AA227778         250.35+'-164.31         254.32+'-164.5         157.31+'-463.97           N1=40, N2=168         X         NI=40, N2=31         Fold Change: 3.09         P-value: .00002           P-value: 0         P-value: 0         P-value: .00002         P-value: .00002				P-value: 0				P-value: .00159
SS   AA211369   X   X   X   N1=40, N2=31		78	AA193340				338.82+/-318.56	338.82+/-318.56
85         AA211369         X         X         N1=40, N2=31           85         AA21778         X         X         X           88         AA227778         250.35+/-164.31         X         X         X           88         AA227778         250.35+/-164.31         X         X         X           N1=40, N2=168         X         N1=40, N2=31         Fold Change: 3.07         Fold Change: 3.09           P-value: 0         P-value: 0         P-value: .00002		) •					135.54+/-138.52	65.09+/-44.54
85         AA211369         X				×	×	×	N1=40, N2=31	N1=40, N2=10
85 AA211369  X  X  X  X  X  X  X  X  X  X  X  X  X						-	Fold Change: 2.47	Fold Change: 4.45
85 AA211369  X  X  X  X  X  X  X  X  X  X  X  X  X							P-value: .00001	P-value: .00006
88 AA227778 250.35+/-164.31 254.32+/-164.5 157.31+/-463.97 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.07 P-value: 0 P-value: 0		85	AA211369					495.8+/-374.32
88 AA227778 250.35+/-164.31 254.32+/-164.5  N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.07 P-value: 0 P-value: 0								166.56+/-142.09
88 AA22778 250.35+/-164.31 254.32+/-164.5 103.23+/-228.68 X X N1=40, N2=31 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.07 P-value: 0				×	×	×	×	N1=40, N2=10
88 AA22778 250.35+/-164.31 254.32+/-164.5 103.23+/-228.68 157.31+/-463.97 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.07 Fold Change: 3.09 P-value: 0								Fold Change: 2.75
88 AA227778 250.35+/-164.31 103.23+/-228.68 N1=40, N2=168 Fold Change: 3.07 P-value: 0								P-value: .00161
163.23+/-228.68 X X N1=40, N2=31 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.09 P-value: 0		88	AA227778	250.35+/-164.31			254.32+/-164.5	254.32+/-164.5
X N1=40, N2=31 Fold Change: 3.09 P-value: .00002		}		103.23+/-228.68			157.31+/-463.97	92.7+/-116.55
Fold Change: 3.09 P-value: .00002				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: .00002				Fold Change: 3.07			Fold Change: 3.09	Fold Change: 2.93
				P-value: 0			P-value: .00002	P-value: .00666

....

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
20	95	AA295451		×	×	428.38+/-345.54 191.85+/-157.04 N1=40, N2=31 Fold Change: 2.05 P-value: .0027	×
22	96	AA310786	X	×	<b>x</b>	242.07+/-109.49 509.52+/-191.41 N1=40, N2=31 Fold Change: 2.19 P-value: 0	242.07+/-109.49 578.59+/-173.41 N1=40, N2=10 Fold Change: 2.55 P-value: 0
22	97	AA312905	×	X	×	270.53+/-105.99 554.04+/-183.58 N1=40, N2=31 Fold Change: 2.06 P-value: 0	×
23	66	AA369887	×	×	×	×	326.24+/-259.48 88.98+/-90.46 N1=40, N2=10 Fold Change: 4.05 P-value: .00073
45	102	AA400080	×	×	X	89.66+/-112.79 246.79+/-233.75 N1=40, N2=31 Fold Change: 2.21 P-value: .0043	×
55	104	AA417813	846.09+/-411.44 570.86+/-624.96 N1=40, N2=168 Fold Change: 2.01 P-value: 0	×	<b>X</b>	849.01+/-416.4 499.89+/-596.68 N1=40, N2=31 Fold Change: 2.44 P-value: .00007	×
56	106	AA418636	244.96+/-112.2 85.16+/-53.2 N1=39, N2=168 Fold Change: 2.92 P-value: 0	×	244.96+/-112.2 107.39+/-80.98 N1=39, N2=10 Fold Change: 2.43 P-value: .02032	244.96+/-112.2 62.82+/-36.83 N1=39, N2=31 Fold Change: 3.75 P-value: 0	244.96+/-112.2 57.15+/-13.69 N1=39, N2=6 Fold Change: 3.86 P-value: 0

107   AA418995	#	Coo II	Conhonly	Normal ne All	Mountain Malianont	Normal ve Chan I	Mormol ve Chan II	Normal an Charlet
107   AA418995	٤	11000	GCHUAIIR	INOI IIIAI VS AII	MOUNTAIN VS INTAINBILAINT	Normal vs Stage I	Ivorillal vs Stage II	Normal vs Stage LL
109   AA419263   X	21	107	AA418995					276.52+/-180.68
109   AA419263   X								89.94+/-34.01
112   AA42160   72.764-123.26   34.264-124.68   34.264-124.68   34.264-124.68   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.34   34.264-34.32   34.264-360.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.32   34.264-34.33   34.264-34.33   34.264-36.32				×	×	×	×	N1=40, N2=10
112   AA42963   X								Fold Change: 2.64
112   AA424160   72.764-123.26								P-value: 0
112   AA424160   72.764-123.26   73.824-124.68   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-123.26   74.264-144.29   76.16 Change: 5.39   76.16 Change: 5.08   76.16 Change: 5.08   76.16 Change: 5.08   76.16 Change: 5.09   76.16 Change: 2.09   76.16 Change: 2.47   76.16 Change: 2.47   76.16 Change: 3.88   76.16 Change: 4.16   76.16 Change: 4.16   76.16 Change: 3.88   76.16 Change: 4.16   76.16 Change: 4.16   76.16 Change: 3.88   76.16 Change: 4.16   76.16 Change: 2.16   76.16 Change: 2.18   76.16 Ch	58	109	AA419263					547.83+/-148.39
112   AA424160   72.764+123.26   73.824+124.68   73.824+124.68   73.824+124.68   73.824+124.68   73.824+124.68   73.824+124.68   73.824+124.68   73.824+124.23   73.824+124.								268.37+/-114.78
112				×	×	×	×	NI=40, N2=10
112								Fold Change: 2.12
112   AA424160   72.764-123.26   73.824-124.68   344.264-347.34   72.194+2060.32   X   X   X   X   X   X   X   X   X								P-value: .00021
The color of the	59	112	AA424160	72.76+/-123.26			73.82+/-124.68	73.82+/-124.68
NI = 40, N2 = 18				241.99+/-260.32			344.26+/-347.34	405.04+/-245.91
Fold Change: 3.39 Fold Change: 5.08 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0 115 AA429308 124.384/-144.29 116 AA430300 X X X X X X X X X X X X X X X X X				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
115   AA429308   242.38+/-144.29   237.83+/-143.23   124.83+/-144.29   237.83+/-143.23   124.83+/-144.29   237.83+/-143.23   124.83+/-150.06   X				Fold Change: 3.39			Fold Change: 5.08	Fold Change: 7.49
115   AA429308   242.384/-144.29   237.834/-143.23     124.83+/-150.06   X   X   N1=40, N2=31     N1=40, N2=168   X   N1=40, N2=31     N1=40, N2=168   X   X   X   X     N1=40, N2=10.00089     N1=40, N2=10.0089   N1=40, N2=31     N1=40, N2=10.0089   N1=40, N2=31     N1=40, N2=10.0089   N1=40, N2=31     N1=40, N2=31   N2=40,				P-value: 0			P-value: 0	P-value: 0
124.83+/-150.06	9	115	AA429308	242.38+/-144.29			237.83+/-143.23	237.83+/-143.23
N1=40, N2=168				124.83+/-150.06			88.15+/-43.75	65.39+/-41.56
Fold Change: 2.04 P-value: 0  The AA430300  The AA430314  The AA430318  The AA430318  The AA430318  The AA430318  The AA430330  The AA43030  The AA4303				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
116 AA430300  X  X  X  X  X  X  X  X  X  X  X  X				Fold Change: 2.04			Fold Change: 2.47	Fold Change: 3.5
116 AA430300  X  X  X  X  X  X  X  X  X  X  X  X				P-value: 0			P-value: 0	P-value: .00009
117   AA430314   265.864/-187.91   259.574/-186.05     117   AA430314   265.864/-187.91   259.574/-186.05     65.064/-109.36   X   X   X   X   X   X   X   X   X	61	116	AA430300					511.45+/-201.77
117   AA430314   265.86+/-187.91   259.57+/-186.05     117   AA430314   265.86+/-109.36   259.57+/-186.05     118   AA436185   S-value: 0   253.53+/-335.89     118   AA436185   X								242.83+/-223.58
117 AA430314 265.86+/-187.91 259.57+/-186.05 65.06+/-109.36 X X N1=40, N2=31 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.88 Fold Change: 4.16 P-value: 0 P-value: 0 253.53+/-335.89 70.15+/-61.86 X X N1=40, N2=31 Rold Change: 2.38 P-value: 0 253.53+/-335.89 P-value: 0 253.53+/-335.89 P-value: 0 253.53+/-01.86 X X N1=40, N2=31 P-value: 0.0089				×	×	×	×	N1=40, N2=10
117 AA430314 265.86+/-187.91 259.57+/-186.05 65.06+/-109.36 X X X X X X X X X X X X X X X X X X X								Fold Change: 2.55
117 AA430314 265.864/-187.91 65.064/-109.36 N1=40, N2=168 X N1=40, N2=168 Fold Change: 4.16 P-value: 0 P-value: 0  118 AA436185 X X X X N1=40, N2=31 Fold Change: 4.16 P-value: 0  253.53+/-335.89 70.15+/-61.86 X X P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0.0089								P-value: .00275
65.06+/-109.36  N1=40, N2=168  X  N1=40, N2=31  Fold Change: 3.88  P-value: 0  P-value: 0  253.53+/-335.89  70.15+/-61.86  X  X  X  X  N1=40, N2=31  Fold Change: 4.16  P-value: 0  253.53+/-335.89  70.15+/-61.86  P-value: .00089	62	117	AA430314	265.86+/-187.91			259.57+/-186.05	259.57+/-186.05
N1=40, N2=168 X X N1=40, N2=31 Fold Change: 3.88 Fold Change: 4.16 P-value: 0  118 AA436185 X X X N1=40, N2=31  70.15+/-61.86 X N1=40, N2=31 Fold Change: 2.38 P-value: 0  253.53+/-335.89 P-value: 0.0089				65.06+/-109.36			59.77+/-101.82	-4.03+/-59
Fold Change: 3.88  P-value: 0  P-value: 0  118  AA436185  X  X  X  X  Fold Change: 4.16  P-value: 0  253.53+/-335.89  70.15+/-61.86  X  X  X  Fold Change: 2.38  P-value: .00089				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0 P-value: 0 P-value: 0 253.53+/-335.89 70.15+/-61.86 X X X X X N1=40, N2=31 Fold Change: 2.38 P-value: .00089				Fold Change: 3.88			Fold Change: 4.16	Fold Change: 6.66
118 AA436185 253.53+/-335.89 70.15+/-61.86 X X N1=40, N2=31 Fold Change: 2.38 P-value: .00089				P-value: 0			P-value: 0	P-value: 0
X X N1=40, N2=31 Fold Change: 2.38 P-value: .00089	63	118	AA436185				253.53+/-335.89	
Fold Change: 2.38 P-value: .00089				×	×	×	N1=40, N2=31	×
							Fold Change: 2.38 P-value: .00089	

						Management	Mountain Change III
<b>∓</b> ±	Seq ID	Genbank	Normal vs Ali	Normal vs Mangnant	Normal Vs Stage 1	NOTHIAL VS Stage II	Itoliliai va Stage III
49	119	AA436250				213.31+/-226.04 84.53+/-80.67	
			×	×	×	N1=40, N2=31 Fold Change: 2.03 P-value: .00323	×
65	120	AA447015	227.33+/-171.55 82.62+/-74.49			226.67+/-173.74 66.02+/-51.23	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.51			Fold Change: 2.87 P-value: 0	
99	122	A A 450090	285.47+/-226.15			285.47+/-226.15	
3	777	o Concerna	133.85+/-131.49			125.82+/-152.5	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.57			Fold Change: 2.88	
			P-value: 0			P-value: 0	
15	124	AA452295	227.07+/-122.52		220.36+/-116.43	220.36+/-116.43	220.36+/-116.43
;			44.21+/-53.65		97.66+/-165.2	39.86+/-35.12	45.22+/-26.99
			N1=40. N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.1		Fold Change: 3.73	Fold Change: 5.14	Fold Change: 4.25
			P-value: 0		P-value: .03669	P-value: 0	P-value: 0
8	125	A A 455877				295.74+/-130.76	295.74+/-130.76
3						131.5+/-76.16	102.29+/-56
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.4	Fold Change: 3.08
						P-value: 0	P-value: .0007
69	126	AA456099					375.25+/-161.56
						;	163.63+/-115.9/
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.5
							P-value: .00094
70	128	AA464792					244.42+/-163.62
							77.5+/-57.57
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.92
							P-value: .00105

#	Sec 10	Cenhank	Normal ve All	Normal ve Malianant	Normal ve Stage I	Normal ve Stage II	Normal ve Stage III
17	129	AA479033	104.1+/-260.94		TOTAL SE CHIEF TO		TOTALIS TO SUBJECT III
			492.38+/-952.15 N1=40, N2=168 Fold Change: 2.62	×	×	×	×
22	131	AA480075	331.51+/-157.28 155.12+/-117.94 N1=40, N2=168 Fold Change: 2.34 P-value: 0	×	×	331.5+/-159.34 119.29+/-99.73 N1=40, N2=31 Fold Change: 3.04 P-value: 0	331.5+/-159.34 97.24+/-36.96 N1=40, N2=10 Fold Change: 3.11 Parahae: 0
13	133	AA486366	237.55+/-149.6 115.8+/-122.37 N1=39, N2=168 Fold Change: 2.09 P-value: 0	×	×	237.55+/-149.6 102.26+/-105.5 N1=39, N2=31 Fold Change: 2.18 P-value: .0001	237.55+/-149.6 20.97+/-35.35 N1=39, N2=6 Fold Change: 4.64 P-value: 0
47	135	AA48889	298.27+/-192.46 99.12+/-55.38 N1=40, N2=168 Fold Change: 2.64 P-value: 0	×	×	298.86+/-194.94 90.94+/-37.43 N1=40, N2=31 Fold Change: 2.8 P-value: 0	298.86+/-194.94 118.43+/-135.55 N1=40, N2=10 Fold Change: 2.62 P-value: .00133
27	136	AA496142	×	×	×	223+/-72.35 113.96+/-51.66 N1=39, N2=31 Fold Change: 2.03 P-value: 0	×
92	137	AA501987	202.15+/-87.72 123.46+/-65.5 N1=39, N2=168 Fold Change: 1.68 P-value: 0	· <b>X</b>	×	×	×
77	138	AA502943	438.99+/-109.54 262.83+/-186.3 N1=40, N2=168 Fold Change: 2.11 P-value: 0	×	×	439.24+/-110.96 250.93+/-145.84 N1=40, N2=31 Fold Change: 2.17 P-value: .00002	X

MODOOID: ING. COCCOST

						#	Manual and Others ITT
#±	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Moriual vs Stage Lix
78	139	AA504253					394.39+/-105.44
							121.134/-09.32
			×	×	×	×	N1=40, N2=10
			!				Fold Change: 2.81
							P-value: .00011
e e	140	A A \$08106	475 57+/-315 6			475.57+/-315.6	475.57+/-315.6
۲,	7	DCT00CT-	700 07 1 1 1 7 000			207 81+/-174.35	184.11+/-120.65
			10.041-/-140.04		>	N1=40 N2=31	N1=40 N2=10
			NI=40, NZ=108	<	<b>&lt;</b>	10 201 (OL 101	17 ( )
			Fold Change: 2.02			Fold Change: 2.39	Fold Change: 2.31
		•	P-value: 0			P-value: .00002	P-value: .00343
00	141	A A 513002	156 4+/-98 44			156,4+/-98.44	
8	141	TOO CTOUT	785 00±/-134 83			282.09+/-129.91	
			CO.FCI-// CC.COZ	>	>	N1=39 N2=31	×
			NI=39, NZ=100	<	<	10 11 (C) 111 C	
			Fold Change: 2.05			Fold Change: 2.03	
			P-value: 0			r-value, .00001	1027 051/ 707 66
~	146	AA524095					00.102-1700.1001
5	)						517.53+/-221.07
			<b>&gt;</b>	×	×	×	N1=40, N2=10
			<b>*</b>	1	,		Fold Change: 2.08
							P-value: .00018
3	177	A A ED ADEO	227 04/ 122 73			340.18+/-134.68	340.18+/-134.68
78	/+1	0C747CWW	100 07±1/16/10			149 6+/-62.5	98.23+/-47.07
			N1-40 N7=168	*	×	N1=40, N2=31	N1=40, N2=10
			Eold Change: 2 02	4	1	Fold Change: 2.28	Fold Change: 3.58
			P-value: 0			P-value: 0	P-value: .00001
83	148	AA524536	304.34+/-210.76		298.68+/-210.41	298.68+/-210.41	
}			116,11+/-126.7		87.05+/-113.19	113.27+/-115.65	
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 2.64		Fold Change: 3	Fold Change: 2.42	
			P-value: 00001		P-value: .03651	P-value: .00101	
84	151	A A 526961	415.49+/-234.41			417.14+/-237.24	417.14+/-237.24
5	! }		178.69+/-118.79			163.41+/-149.82	119.79+/-62.48
			N1=40, N2=168	×	×	NI=40, N2=31	N1=40, N2=10
			Fold Change: 2.31			Fold Change: 2.62	Fold Change: 3.37
			P-value: 0			P-value: 0	F-value: .0000/

RNSDOCID <WO 02059271A2 1 >

	Con TD	Conhonly		Morrison to Moliveront	Mountain Ctore I	Mountain Otton II	Mountain Charlet
ŧ۱	ord trac	Gennank	MOUNTAIN VS AU	Normal vs Mangnam	Normal vs Stage I	Normal VS Stage II	Normal Vs Stage III
82	153	AA527180					336.44+/-180.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.03
98	154	AA527298	121.15+/-82.59				
			N1=39, N2=168	×	×	×	×
			Fold Change: 1.92 P-value: 0	•			
87	155	AA533272				345.7+/-116.17	
						171.66+/-72	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.1	
						P-value: 0	
88	159	AA534724				143.93+/-57.72	143.93+/-57.72
						325.98+/-117.74	353.03+/-109.1
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.31	Fold Change: 2.56
						P-value: 0	P-value: 0
68	160	AA535218	323.08+/-135.81			322.09+/-137.43	
			155.95+/-97.92			178.24+/-126.11	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.27			Fold Change: 2.06	
			P-value: 0			P-value: .00002	
06	163	AA543076				109.8+/-95.15	
						365.31+/-441.38	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.58	
						P-value: .00003	
91	165	AA555312					215.48+/-192.29
			×	×	×	×	40.38+/-31.93 N1=40, N2=10
							Fold Change: 3.68
							P-value: .00006

i

*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
8	169	AA568397	243.4+/-227.66		243.4+/-227.66	243.4+/-227.66	243.4+/-227.66
*	ì		92.45+/-68.55		86.44+/-37.31	74.95+/-70.23	52.06+/-33.54
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.27		Fold Change: 2.12	Fold Change: 2.77	Fold Change: 3.85
			P-value: 0		P-value: .00208	P-value: 0	P-value: .00005
93	170	AA570519	200.18+/-172.78				200.18+/-172.78
<u> </u>	)		77.04+/-65.26				48.77+/-33
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.26				Fold Change: 3.04
			P-value: 0		•		P-value: .00005
46	171	AA584310	398.21+/-320.55			402.55+/-323.55	402.55+/-323.55
:			1296.13+/-716.97		•	1058.09+/-583.59	1089.78+/-475.55
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.84			Fold Change: 3.12	Fold Change: 3.31
			P-value: 0			P-value: 0	P-value: .00032
20	172	AA584403	593.26+/-1291.79			593.26+/-1291.79	593.26+/-1291.79
<u>}</u>	l i		85.5+/-209.13			113.63+/-199.33	77.07+/-76.22
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.61	•		Fold Change: 2.7	Fold Change: 3.14
			P-value: 0			P-value: .00077	P-value: .00412
96	174	AA595800				405.39+/-344.1	
	I					167.2+/-159.75	
	•		×	×	×	N1=40, N2=31	×
_						Fold Change: 2.2	
	•					P-value: .00334	
6	176	AA602521					258.64+/-109.45
:	)				٠		92.33+/-57.89
			×	×	×	×	N1=39, N2=6
							Fold Change: 3.01
							P-value: .00015
86	178	AA609310	289.22+/-160.55			285.39+/-160.8	285.39+/-160.8
			106.23+/-108.02			81.33+/-54.9	139.85+/-180.52
_			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.16			Fold Change: 3.57	Fold Change: 2.65
			P-value: 0			F-value: 0	F-value: .00931

‡	Coo II	Conhonly	Mountain All	M.c	N	N	100
•	m hac	Gennank	NOTINAL VS ALI	Normal vs Mangnant	Normal Vs Stage I	Normal Vs Stage II	Normal vs Stage III
66	180	AA610522	803+/-768.74		803+/-768.74	803+/-768.74	
			2527.25+/-2163.34		1730.2+/-869.55	1878.88+/-1670.25	
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 3.75		Fold Change: 3.78	Fold Change: 2.57	
			P-value: 0		P-value: .00045	P-value: .00552	
100	181	AA612864			÷	228.36+/-116.88	228.36+/-116.88
						495.29+/-290.05	440.68+/-155.22
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.03	Fold Change: 2.03
						P-value: 0	P-value: .00004
101	184	AA621478	394.08+/-322.25		398.69+/-325.12	398.69+/-325.12	398.69+/-325.12
			60.41+/-84.83		79.9+/-118.32	53.41+/-82.79	18+/-20.91
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.59		Fold Change: 5.51	Fold Change: 7.48	Fold Change: 11.4
			P-value: 0		P-value: .00526	P-value: 0	P-value: 0
102	185	AA625387				92.36+/-35.34	92.36+/-35.34
						208.73+/-105.36	231.14+/-178.29
			×	×	×	N1=39, N2=31	N1=39, N2=6
						Fold Change: 2.15	Fold Change: 2.24
						P-value: 0	P-value: .00162
103	189	AA628467	1150.97+/-497.25			1145.06+/-502.33	1145.06+/-502.33
			290.19+/-235.1			274.87+/-259.13	122.9+/-92.36
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.65			Fold Change: 4.99	Fold Change: 9.81
			P-value: 0			P-value: 0	P-value: 0
104	192	AA631215		!		190.98+/-126.92	
			×	×	*	N1=40, N2=31	*
			<u>.</u>	!		Fold Change: 2.05	
						P-value: .00057	
105	193	AA633203	127.67+/-220.56			130.61+/-222.66	130.61+/-222.66
			389.82+/-388.38			451.59+/-365.56	413.97+/-273.89
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.74			Fold Change: 5.08	Fold Change: 4.59
			P-value: 0			P-value: 0	P-value: .00196

7	T See	Conbonk	Normal ve All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	oed 110	Centrality	IVOI III III VS CALI	TOT WHEN TO THE THE		07 007 7 : 00 000	
106	194	AA634799	763.44+/-619.75			/39.38+/-008.02	
			367.84+/-431.55			440.74+/-650.81	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 241			Fold Change: 2.26	
			P-value: 00001			P-value: .00284	
101	106	A A 659561					238.89+/-114.83
/01	130	TOCOCONY					110.57+/-54.76
			*	×	×	×	N1=40, N2=10
			47	1			Fold Change: 2.02
							P-value: .00612
100	100	A A 669106	82 72+/-129.9			84.29+/-131.22	84.29+/-131.22
100	130	001/00574	202 67+/-186 26			383.96+/-227.86	381.34+/-202.47
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.65			Fold Change: 6.02	Fold Change: 6.04
			P-value: 0			P-value: 0	P-value: 0
90	000	1 A A 700K21	467 51+/-455 09		467.51+/-455.09	467.51+/-455.09	467.51+/-455.09
707	201	1000	66.85+/-123.51		87.68+/-141.47	36.61+/-66.8	26.41+/-35.67
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.01		Fold Change: 4.72	Fold Change: 7.35	Fold Change: 8.68
	(		P-value: 0		P-value: .02358	P-value: 0	P-value: 0
110	204	A A 703262				1213.89+/-750.28	1213.89+/-750.28
-						519.38+/-282.83	361.77+/-193.77
	)		×	×	×	N1=40, N2=31	N1=40, N2=10
			į			Fold Change: 2.09	Fold Change: 3.02
						P-value: .00044	P-value: .00125
Ξ	214	AA742697	1009.7+/-1062.61			1026.03+/-1071.41	1026.03+/-1071.41
! !			222.47+/-326.55			238.53+/-383.92	142.42+/-134
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.19			Fold Change: 4.18	Fold Change: 5.09
			P-value: 0			P-value: .00001	P-value: .00012
112	215	AA747315				448.86+/-190.26	448.86+/-190.26
•						258.21+/-198.98	135.53+/-84.89
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.02	Fold Change: 3.66
						P-value: .00001	P-value: .0001

Seq ID Genbank	Genban		Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
AA760767		2	100.23+/-83.19			101.93+/-83.58	101.93+/-83.58
		245	245.71+/-246.25			273.79+/-236.49	388.04+/-242.5
NI	Ä	Ë	N1=40, N2=168	×	×	N1=40, N2=31	NI=40, N2=10
Fold	Fold	Fold	Fold Change: 2.06			Fold Change: 2.59	Fold Change: 3.64
		_	P-value: 0			P-value: .00001	P-value: .00384
218 AA772278							137.98+/-96.56
			;	i	;	,	296.31+/-168.39
			×	×	×	×	NI=40, N2=10
							Fold Change: 2.42
							P-value: .00585
220 AA775180	AA775180						264.55+/-193.81
					•	;	84.64+/-55.48
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.66 P-value: .00029
223 AA777369	AA777369					104.24+/-57.98	
			;	) 7	Þ	211.807/-126.02 311-40 312-21	<b>*</b>
			×	<b>×</b>	⊀ .	N1=40, N2=31 Fold Chanαe: 2 02	<
						P-value: 0	
226 AA779795	AA779795						493.39+/-168.5
							227.18+/-95.72
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.25
•							P-value: .00072
227 AA788946 568.73-		568.73	568.73+/-336.98				
1313.0	1313.0	1313.0	1313.01+/-867.03				
N1=39	N1=39	N1=39	N1=39, N2=168	×	×	×	×
Fold C	Fold C	Fold CP	Fold Change: 2.15				
P-V	P-v	P-v	P-value: 0				
228 AA789332 120.9		120.9	120.94+/-61.86			120.94+/-61.86	
221.5	221.5	221.5	221.57+/-96.99	i	;	228.17+/-103.03	;
N1=3	N1=3	N1=3	N1=39, N2=168	×	×	NI=39, NZ=31	×
Fold C	Fold C	Fold C	Fold Change: 1.91			Fold Change: 1.94	
ų.	.H.	<u>-</u>	P-value: 0			r-value: .00007	

ENGULCIU- MU USUCOSTIAS 1 2

	į,	O. P. L. L.	Missing 1 and 1	Mountain Malianent	Normal ve Stage I	Normal ve Stage II	Normal vs Stage III
ŧ	Sed III	упидае	Normal vs All	IVOI Mai VS IVIAUGNAM	Ivoluial 13 Stage 1	Tagma of inition	TACATION OF THE PARTY
120	230	AA807154	271.93+/-107.94			273.39+/-108.95	273.39+/-108.95
			150.18+/-94.12			115.85+/-82.09	137.82+/-101.26
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.01			Fold Change: 2.55	Fold Change: 2.3
			P-value: 0			P-value: 0	P-value: .00953
121	235	AA830844	93.3+/-120.3			94.7+/-121.54	94.7+/-121.54
•	)		272.03+/-321.32			320.78+/-455.06	361.79+/-369.37
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.64	,	ę	Fold Change: 2.9	Fold Change: 3.88
			P-value: 0			P-value: .00003	P-value: .00167
122	236	AA838843					1133.4+/-889.08
ļ					•		503.96+/-209.26
			×	×	×	×	N1=40, N2=10
							Fold Change: 2
							P-value: .00069
123	239	AA846091	83.83+/-80.09		84.12+/-81.11	84.12+/-81.11	
			254.24+/-227.12		271.23+/-192.47	226.57+/-179.06	
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 2.88		Fold Change: 3.44	Fold Change: 2.75	
			P-value: 0		P-value: .01151	P-value: 0	
124	241	AA875998					144.49+/-132.98
	!						225.7+/-97.08
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.02
							P-value: .00162
125	246	AA909042				166.1+/-92.52	166.1+/-92.52
}	) 					345.62+/-200.16	375.51+/-207.38
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.07	Fold Change: 2.2
						P-value: 0	P-value: .00481
126	249	AA909958		5		304.09+/-148.66	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.04	
						7 - v azav	

#	Sea 10	Genhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
و ا		010000	THE CLEANING THE				270 55±/ 102
171	167	AA913079					3/9.334/-192 810/704/
						1	019./27/-391.0
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.18
							P-value: .00102
128	254	AA921830	91.7+/-113.88			92,93+/-115.1	92.93+/-115.1
,			226.43+/-153.69			257.36+/-191.81	324.58+/-186.68
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.9			Fold Change: 3.24	Fold Change: 4
			P-value: 0			P-value: 0	P-value: .0002
129	255	AA921922	312.62+/-288.86			312.44+/-292.63	312.44+/-292.63
			76.08+/-72.69			75.75+/-54.61	36.4+/-15.92
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.16			Fold Change: 3.86	Fold Change: 6.83
			P-value: 0		i	P-value: 0	P-value: 0
130	257	AA928698					979.86+/-357.7
							383.02+/-284.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.22
							P-value: .00199
131	258	AA928776	334.78+/-156.59			334.78+/-156.59	334.78+/-156.59
			126.01+/-82.79			129.6+/-115.01	91.05+/-43.12
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.72			Fold Change: 2.74	Fold Change: 3.62
			P-value: 0			P-value: 0	P-value: .00002
132	259	AA928876			*	279.93+/-242.15	
			ij	;	;	118.83+/-118.61	ì
			×	×	×	NI=40, N2=31	×
						Fold Change: 2.37	
-						P-value: .00023	0 200 7 100 200
133	260	AA936632	124.77+/-125.66			125.03+/-127.3	125.03+/-127.3
			335.73+/-304.1			307.81+/-176.76	325.44+/-181.42
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.65			Fold Change: 2.68	Fold Change: 3
			P-value: 0			P-value: 0	F-value: .00001

Sed ID	1	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
196		A A 0.47173	7000/462	è		287 11+/-00 81	287 11+/-00 81
<b>.</b>		ALL THE STATE OF T	135.96+/-76.03			108.39+/-64.68	106.79+/-57.35
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.34			Fold Change: 2.88	Fold Change: 3.03
			P-value: 0			P-value: 0	P-value: .00116
263		AA968657	120.64+/-123.71				
			221.47+/-188.53				
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.02				
			P-value: .00055				
264	~	AA969863					154.92+/-62.69
							335+/-158.01
			×	×	<b>×</b>	×	N1=40, N2=10
							Fold Change: 2.11
							P-value: .00058
7 997	~	AA976064	363.92+/-151.16				
			165./+/-101.29	ļ	;	;	,
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.17				
			P-value: 0				
792	7	AA977204			-		159.24+/-78.21
							300.74+/-74.19
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.02
							P-value: 0
272	ייו	AB007972	317.37+/-102.68			317.37+/-102.68	317.37+/-102.68
			141.41+/-56.37			127.42+/-50.63	110.2+/-25.69
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.26			Fold Change: 2.49	Fold Change: 2.75
			P-value: 0			P-value: 0	P-value: 0
280		AC004010				237.41+/-101.03	
						119.13+/-50.91	
			×	×	×	N1=39, N2=31	×
						Fold Change: 2.01	
	ł					P-value: 0	

#	Sed ID	Conhank	Normal ve All	Normal ve Malianant	Normal ve Stage I	Normal ve Stone II	Normal vo Ctage III
		Companie	Mar California Volume	TO MAIN 19 MAINEMAIN	Morning vs Diagor	TOT HIGH AS DUBECTE	TIOI III A STABE III
141	281	AC004770	116.54+/-76.22			116.54+/-76.22	116.54+/-76.22
			231.2+/-112.79			258.92+/-95.73	353.08+/-90.31
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.41	Fold Change: 3.44
			P-value: 0			P-value: 0	P-value: 0
142	286	AF007150					560.67+/-252.85
							244.22+/-118.81
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.3
							P-value: .00021
143	287	AF009314	280.81+/-113.17				280.81+/-113.17
			138.34+/-66.55				90.09+/-43.95
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.04				Fold Change: 3.18
			P-value: 0				P-value: .00003
144	297	AF052142	307.17+/-169.55			307.17+/-169.55	307.17+/-169.55
			136.07+/-86.42			134.05+/-84.74	131.75+/-87.96
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.28			Fold Change: 2.25	Fold Change: 2.44
			P-value: 0			P-value: 0	P-value: .00309
145	300	AF058075					-15.62+/-107.9
							355.75+/-489.88
	•		×	×	×	×	N1=40, N2=10
							Fold Change: 3.73
							P-value: .0394
146	304	AF070648	1031.52+/-429.52			1031.52+/-429.52	1031.52+/-429.52
			432.03+/-213.34			357.01+/-152.1	292.72+/-163.49
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.41			Fold Change: 2.82	Fold Change: 3.62
			P-value: 0			P-value: 0	P-value: .00002
147	309	AF150174	211.02+/-104.05			211.02+/-104.05	211.02+/-104.05
			86.63+/-46.76			86.92+/-51.98	78.32+/-31.52
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.26			Fold Change: 2.26	Fold Change: 2.38
			r-value, o			r-value. o	I -value. 0

RNSDOCID- WO DODGOTTAD 1 >

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
148	311	AI002238					254.67+/-91.81 105.29+/-71.62
			×	×	×	×	N1=40, N2=10
•							Fold Change: 2.72
							P-value: .00083
149	314	AI016604			•	502.7+/-255.95	502.7+/-255.95
						262.05+/-145.41	226.05+/-112.74
			×	×	×	NI=40, N2=31	N1=40, N2=10
						Fold Change: 2.02	Fold Change: 2.18
						P-value: .00002	P-value: .00111
150	317	AI018523	422.08+/-187.64		•	422.08+/-187.64	422.08+/-187.64
			94.36+/-123.53			77.78+/-105.86	44.08+/-59.8
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.56			Fold Change: 6.54	Fold Change: 9.77
			P-value: 0			P-value: 0	P-value: 0
151	321	AI031771	85.9+/-105.07			85.9+/-105.07	
			257.24+/-405.17			298.84+/-697.75	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.53			Fold Change: 2.33	
			P-value: 0			P-value: .00142	
152	324	AI039005	201.84+/-130.44			203.54+/-131.69	203.54+/-131.69
			77.34+/-61.5			61.56+/-42.38	44.43+/-54.48
			N1=40, N2=168	×	×	NI=40, N2=31	N1=40, N2=10
			Fold Change: 2.58			Fold Change: 3.03	Fold Change: 3.97
			P-value: 0			P-value: 0	P-value: .0001
153	325	AI039722	990.63+/-1152.38			1007.24+/-1162.59	1007.24+/-1162.59
			438.37+/-1004.04			232.49+/-466.94	207.73+/-245.94
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.87	•		Fold Change: 6.17	Fold Change: 5.76
			P-value: 0			P-value: 0	P-value: .00392
154	326	AI049549	653.84+/-535.62			653.84+/-535.62	653.84+/-535.62
			267.97+/-227.53			226.29+/-141.74	155.78+/-116.9
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.36			Fold Change: 2.5	Fold Change: 3.66
			P-value: 0			P-value: .00001	P-value: .00006

	6		M 4 U	Mountain Malianout	Mormal we Stone I	Normal ve Stage II	Normal ve Stage III
#	Sed III	Cennank	Normal VS All	NOTHIAL VS INTANGUALIT	Ivol illal vs Stage I	Morning 13 Stage II	TOT WHILE 13 DEREC LAN
155	327	. AI049973					391.85+/-108.68
							199.36+/-52.62
			×	×	×	×	N1=39, N2=6
_			<b>!</b>				Fold Change: 1.95
							P-value: .00002
156	330	AT056241	241.39+/-152.04		241.39+/-152.04	241.39+/-152.04	241.39+/-152.04
3	3		67 68+/-55 35		93.33+/-104.89	49.94+/-43.13	45.49+/-48.07
			N1=39 N2=168	×	N1=39, N2=10	N1=39, N2=31	NI=39, N2=6
			Fold Change: 2.88		Fold Change: 2.9	Fold Change: 3.33	Fold Change: 4.03
			P-value: 0		P-value: .03101	P-value: 0	P-value: .00003
15.7	331	A1057450	381.32+/-1572.07			381.32+/-1572.07	381.32+/-1572.07
	Š		20.72+/-180.68			27.5+/-176.72	10.16+/-47.15
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.92			Fold Change: 2.87	Fold Change: 2.99
			P-value: .00006			P-value: .00026	P-value: .00095
158	332	A1057637	568.22+/-502.47		573.52+/-507.9	573.52+/-507.9	573.52+/-507.9
}			153.6+/-81.89		163.69+/-59.04	129.31+/-59.91	124.36+/-39.47
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.29		Fold Change: 2.9	Fold Change: 3.79	Fold Change: 3.81
			P-value: 0		P-value: .0001	P-value: 0	P-value: 0
150	336	AT078033	454.77+/-280.5			454.77+/-280.5	454.77+/-280.5
}	3		203.08+/-158.36			183.47+/-128.31	129.56+/-78.11
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.27			Fold Change: 2.42	Fold Change: 3.22
			P-value: 0			P-value: 0	P-value: .00008
169	337	A1078121	267.92+/-121.01				267.92+/-121.01
3	}		129.6+/-75.04				124.52+/-39.11
			N1=39, N2=168	×	<b>×</b>	×	N1=39, N2=6
			Fold Change: 2.01				Fold Change: 2.05
_			P-value: 0				P-value: .00004
161	338	AI079545			248.94+/-138.38		
					463.39+/-104.61	;	;
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.14 P-value: .00004		

		Control of	Normal we All	Normal ve Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	Sed III	Genoank	IVOI IIIAI VS AII	AND MAR VS MARINE		11576+/-14171	
162	339	AI079558				214.96+/-122.84	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.3 P-value: .00001	
5	241	A 1002500	344 81+/-787 52			339,56+/-289.33	339.56+/-289.33
103	140	A1003370	74.07/170.72			210.77+/-736.98	31.3+/-28.36
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.75	•	•	Fold Change: 4.41	Fold Change: 6.76
			P-value: 0			P-value: 0	P-value: 0
164	242	AT086614	300.02+/-151.08			301.2+/-152.86	301.2+/-152.86
5	745	1000000	127 26+/-88.54			96.79+/-68.03	68.08+/-44.9
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.5			Fold Change: 3.25	Fold Change: 3.7
			P-value: 0			P-value: 0	P-value: 0
165	343	AI087975	137.52+/-92.28				
) )	!		277.44+/-204.79			!	;
			N1=39, N2=168	×	×	×	×
			Fold Change: 1.96	٠			
			P-value: 0			10000110000	700 751/ 500 21
166	344	AI088609	711.92+/-592.71		•	709.25+7-600.21	/09.25+/-600.21
			327.21+/-706.4			163.7+/-218.98	78.97+/-52.81
			N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.75			Fold Change: 4.73	Fold Change: 6.93
			P-value: 0			P-value: 0	P-value: 0
167	345	AI091154	351.29+/-406.17		351.29+/-406.17	351.29+/-406.17	351.29+/-406.17
			73.95+/-133.05		87.21+/-103.53	86.99+/-153.12	62.86+/-69.84
			N1=40. N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.29		Fold Change: 3.04	Fold Change: 3.61	Fold Change: 3.91
			P-value: 0		P-value: .0365	P-value: 0	P-value: .00107
168	346	AI092936	185.51+/-150.9			186.98+/-152.58	
			417.08 + 7.227.3	×	×	N1=40, N2=31	×
			Fold Change: 2.2	<b>;</b>		Fold Change: 2.35	
			r-value. o			10000: :onthe	

_	<del>,</del>	<del></del>		<del></del>			<del></del>
Normal vs Stage III	x	354.78+/-131.25 184.82+/-126.35 N1=40, N2=10 Fold Change: 2.08 P-value: .00216	300+/-164.6 55.08+/-36.39 N1=40, N2=10 Fold Change: 4.97 P-value: .00001	297.76+/-110.04 120.8+/-50.92 N1=39, N2=6 Fold Change: 2.46 P-value: .00002	X	220.92+/-142.18 366.48+/-123.56 N1=40, N2=10 Fold Change: 2.01 P-value: .00008	X
Normal vs Stage II	X	×	300+/-164.6 67.15+/-70.68 N1=40, N2=31 Fold Change: 4.66 P-value: 0	297.76+/-110.04 152.58+/-82.32 N1=39, N2=31 Fold Change: 2.04 P-value: 0	69.28+/-126.42 215.91+/-164.16 N1=39, N2=31 Fold Change: 2.27 P-value: .00023	X	230.52+/-149.31 872.58+/-881.67 N1=40, N2=31 Fold Change: 2.85 P-value: .00002
Normal vs Stage I	×	×	300+/-164.6 91.12+/-67 N1=40, N2=6 Fold Change: 3.22 P-value: .00482	×	×	· X	×
Normal vs Malignant	X	×	X	×	×	X	X
Normal vs All			300.32+/-162.49 75.22+/-66.82 N1=40, N2=168 Fold Change: 4.19 P-value: 0	297.76+/-110.04 156.35+/-127.73 N1=39, N2=168 Fold Change: 2.06 P-value: 0	69.28+/-126.42 217.42+/-192.92 N1=39, N2=168 Fold Change: 2.31 P-value: 0	×	×
Genbank	AI094535	AI096389	AI123555	AI123738	AI125252	AI126237	AI127289
Seq ID	348	349	351	352	355	357	358
#	169	170	171	172	173	174	175

BNSDOCID: -WO 0205027440 I

Seq	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1		4 T1 10010	125 6247 00 11			70 00 / \(\tau \) / / / / / / / / / / / / / / / / / /	90 00 /TCV VCC
50%		070071	101.84+/-66.82			96.42+/-39.89	82.27+/-38.37
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.29			Fold Change: 2.29	Fold Change: 2.85
			P-value: 0			P-value: 0	P-value: .0008
360		AI129320	462.88+/-248.98			462.06+/-252.18	462.06+/-252.18
			223.69+/-111.28			218.45+/-156.49	242.37+/-237.11
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.08			Fold Change: 2.3	Fold Change: 2.23
			P-value: 0		•	P-value: 0	P-value: .00458
362		AI131078	299.48+/-223.81			299.48+/-223.81	299.48+/-223.81
			105.31+/-56.6		•	102.41+/-57.3	99.18+/-37.7
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.51			Fold Change: 2.6	Fold Change: 2.48
			P-value: 0			P-value: 0	P-value: .00001
365		AI140764	241.9+/-66.27				241.9+/-66.27
			127.44+/-57.54				119.16+/-48.86
			N1=39, N2=168	×	×	×	N1=39, N2=6
			Fold Change: 2.03	•	-		Fold Change: 2.11
			P-value: 0				P-value: .00026
367		AI141556					297.58+/-90.49
							101.69+/-39.39
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.97
Ī							P-value: 0
368		AI144477	560.95+/-250.34			564.89+/-252.35	
			250.3+/-192.18	!		332.2+/-2/5.56	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.61		-	Fold Change: 2.04	
			P-value: 0			P-value: .00003	
370		AI148006	241.32+/-191.01			241.17+/-193.5	241.17+/-193.5
			84.05+/-116.71			51.87+/-67.91	25.24+/-42.83
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.99			Fold Change: 4.03	Fold Change: 5.56
			r-value: 0			r-vaiue: 0	r-vaine: 0

٠.	:										••																								
Normal vs Stage III	. 223.18+/-91.72	113.09+/-116.05	N1=39, N2=6	Fold Change: 2.37	P-value: .00396	243+/-112.73	111.62+/-39.76	N1=40, N2=10	Fold Change: 2.04	P-value: .00009	301.58+/-452.1	76.68+/-82.57	N1=40, N2=10	Fold Change: 2.77	P-value: .00751			×		7 101 1 200	. 284./+/-101.6	127.96+/-60.39	N1=40, N2=10	Fold Change: 2.41	P-value: .00278	205.71+4'81.06	101.78+/-59.91	N1=40, N2=10	Fold Change: 2.2	P-value: .00676	290.63+/-103.17	100.98+/-38.82	N1=40, N2=10	Fold Change: 2.9	P-value: .00001
Normal vs Stage II	223.18+/-91.72	107.58+/-66.58	NI=39, N2=31	Fold Change: 2.25	P-value: 0			×			301.58+/-452.1	76.69+/-52.21	N1=40, N2=31	Fold Change: 2.46	P-value: .00013			×					×					×			290.63+/-103.17	141.14+/-64.83	N1=40, N2=31	Fold Change: 2.13	P-value: 0
Normal vs Stage I			×					×		!			×					×					×			-		×					×		
Normal vs Malignant			×				-	×					×	•				×					×					×	•				×		
Normal vs All	223.18+/-91.72	95.74+/-62.93	N1=39, N2=168	Fold Change: 2.5	P-value: 0			×			301.58+/-452.1	77.97+/-71.53	N1=40, N2=168	Fold Change: 2.61	P-value: .00001	356.99+/-119.9	188.39+/-84.68	N1=39, N2=168	Fold Change: 1.94	P-value: 0			×					*	4				×	!	
Genbank	AI149693					AI160811					AT161049					AI168057					AI189011					AI189255					AT190755				
Seq ID	373					375					376					378					380					381	1				382	1			
*	183					184					185	1				186					187				-	188	}	_			180	}			

				AT	Married an Otomo I	Normal ve Stone II	Normal ve Stage III
#	Seq ID	Genbank		Normai vs Mangnant	Normal vs Stage I	Ivol mai vs stage at	20 010 / 100 00
190	384	AI200954	529.23+/-316.46			524.84+/-319.36	524.84+/-319.36
						219.57+/-119.93	165.98+/-93.19
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2 07	{		Fold Change: 2.28	Fold Change: 3.18
			P-value: 0			P-value: .00001	P-value: .00195
101	295	AT201273	535 25+1-296.2			533.25+/-299.79	533.25+/-299.79
	20	CONTRACTO	238 85+/-188 24			203.14+/-125.12	125.11+/-95.45
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.5	i i		Fold Change: 2.61	Fold Change: 4.56
			P-value: 0			P-value: 0	P-value: .0001
100	386	AT201965	237 22+/-148.65			234.24+/-149.37	234.24+/-149.37
	200	COCTOTIVE	107 53+/-70.7			100.47+/-56.35	65.63+/-51.87
			N1=40 N7=168	×	×	.N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.18	Ţ		Fold Change: 2.19	Fold Change: 3.63
			P_value. 0			P-value: .00001	P-value: .00031
1	207	AT201082	279 97+/-146 77			279.97+/-146.77	279.97+/-146.77
25	/00	A1601704	114 06+/-74 45			121.58+/-55.99	121.2+/-81.62
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Hold Change: 2 45	!		Fold Change: 2.14	Fold Change: 2.51
			P-value: ()			P-value: 0	P-value: .00327
707	200	ATOMOTA	213 72+/-107 69			211.4+/-108.08	211.4+/-108.08
	200	-10000714	81 38+/-54 34			80.55+/-42.41	60.05+/-31.32
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.63	-		Fold Change: 2.54	Fold Change: 3.36
			P-value: 0			P-value: 0	P-value: .00001
195	389	AI206063	133.1+/-160.7		-	133.1+/-160.7	
			339.26+/-339.95			353.59+/-366.06	;
			NI=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.57			Fold Change: 2.7	
			P-value: .00002			P-value: .00061	
196	393	AI218358	210.74+/-117.83		210.74+/-117.83	210.74+/-117.83	210.74+/-117.83
			87.3+/-105.07		82.51+/-91.18	76.3+/-97.56	74.44+/-133.85
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, NZ=6
			Fold Change: 2.43		Fold Change: 2.74	Fold Change: 2.64	Fold Change: 3.62
			P-value: 0		P-value: .0333	P-value: 0	F-value: .00101

_							······································
Normal vs Stage III	×	×	425.47+/-356.02 148.1+/-83.25 N1=40, N2=10 Fold Change: 2.51 P-value: .00165	250.33+/-314.52 20.13+/-36.3 N1=40, N2=10 Fold Change: 4.49 P-value: 0	246.38+/-130.33 97.95+/-69.13 N1=40, N2=10 Fold Change: 2.68 P-value: .00126	657.85+/-222.05 309.8+/-83.6 N1=40, N2=10 Fold Change: 2.09 P-value: .00001	×
Normal vs Stage II	431.73+/-162.38 143.7+/-81.33 N1=40, N2=31 Fold Change: 3.23 P-value: 0	×	X	250.33+/-314.52 34.79+/-48.59 N1=40, N2=31 Fold Change: 4.13 P-value: 0	×	X	26.4+/-47.96 232.81+/-210.09 N1=40, N2=31 Fold Change: 6.41 P-value: 0
Normal vs Stage I	×	<b>×</b>	×	X	×	×	×
Normal vs Malignant	×	×	×	×	×	×	· ×
Normal vs All	431.73+/-162.38 169.82+/-117.43 N1=40, N2=168 Fold Change: 2.81 P-value: 0	320.5+/-159.05 170.68+/-74.58 N1=39, N2=168 Fold Change: 1.73 P-value: 0	×	250.33+/-314.52 40.01+/-55.99 N1=40, N2=168 Fold Change: 3.88 P-value: 0	×	×	×
Genbank	AI222594	AI242160	AI244908	A1247837	AI264135	AI266650	AI275140
Seq ID	394	397	398	399	401	403	405
#	197	198	199	200	201	202	203

BNSDOCID: <WO 02059271A2 I >

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
204	407	A1276259	10	×	×	121.51+/-224.22 245.37+/-268.39 N1=40, N2=31 Fold Change: 2.09 P-value: .00466	×
205	408	AI277612	1009.49+/-899.38 93.86+/-163.03 N1=40, N2=168 Fold Change: 9.23 P-value: 0	×	1022.91+/-907.07 163.73+/-156.36 N1=40, N2=6 Fold Change: 5.12 P-value: .00592	1022.91+/-907.07 82.75+/-117.04 N1=40, N2=31 Fold Change: 10.43 P-value: 0	1022.91+/-907.07 40.07+/-27.26 NI=40, N2=10 Fold Change: 16.08 P-value: 0
506	413	AI285970	×	· ×	×	269.01+/-274.71 88.12+/-54.51 N1=40, N2=31 Fold Change: 2 P-value: .00393	×
207	414	AI288586	×	×	×	313.32+/-139.2 113.39+/-56.77 N1=39, N2=31 Fold Change: 2.6 P-value: 0	313.32+/-139.2 107.36+/-49.96 N1=39, N2=6 Fold Change: 2.94 P-value: .00028
208	415	AI288745	276.49+/-146.02 108.9+/-73.82 N1=39, N2=168 Fold Change: 2.51 P-value: 0	×	×	276.49+/-146.02 104.75+/-63.19 N1=39, N2=31 Fold Change: 2.5 P-value: 0	276.49+/-146.02 67.42+/-24.06 N1=39, N2=6 Fold Change: 3.69 P-value: 0
209	417	AI300876	601.83+/-985.51 74.02+/-258.41 N1=40, N2=168 Fold Change: 6.47 P-value: 0	×	×	601.83+/-985.51 54.33+/-149.24 N1=40, N2=31 Fold Change: 6.66 P-value: 0	601.83+/-985.51 13.6+/-22.13 N1=40, N2=10 Fold Change: 8.67 P-value: 0
210	422	AI333767	×	*	×	×	201.68+/-104.32 104.93+/-75.04 N1=40, N2=10 Fold Change: 2 P-value: .00805

٦	E	O. P. Land	N	N	M. C. C.	New Color I	Manager Change
*	OF Dac	Gendank	Normal vs Ali	Normal vs Mangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
211	423	AI333987	×	×	×	208.53+/-320.79 57.06+/-100.56 N1=40 N2=31	×
			∢	¢	<b>4</b>	Fold Change: 2.4 P-value: .00125	<b>&lt;</b>
212	424	AI338536					548.6+/-192.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.31 P-value: 0
213	427	AI341602	135.16+/-276.86		137.44+/-280.1	137.44+/-280.1	137.44+/-280.1
			593.58+/-944.91		438.85+/-447.12	723.06+/-652.3	580.91+/-380.87
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.46		Fold Change: 3.86	Fold Change: 6.28	Fold Change: 6.09
			P-value: 0		P-value: .03152	P-value: 0	P-value: .00062
214	428	AI342169					496.19+/-393.99
							1347.53+/-986.09
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.64 P-value: .0043
215	430	AI344312	84.72+/-57.63				
			209.71+/-134.29				
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.33				
216	431	AI346341	640.59+/-422.41			635.18+/-426.52	635.18+/-426.52
			155.96+/-203.21			120.31+/-143.98	104.05+/-133.87
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.26			Fold Change: 4.92	Fold Change: 5.89
			P-value: 0			P-value: 0	P-value: .00006
217	432	AI351043	236.73+/-93.44			236.3+/-94.62	236.3+/-94.62
			109.27+/-56.02			98.05+/-50.78	73.16+/-38.18
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.23			Fold Change: 2.47 P-value: 0	Fold Change: 3.35 P-value: 00009
			1 - value. o				

	Conhoni	Mormol ve All	Normal ve Malianant	Normal vs Stage I	Normal vs Stage []	Normal VS Stage III
)ec 117	Genoalik	IVOI IIIAI VS AII	TO MAR 13 TAMBER	9	222 69 4/-144 28	222.69+/-144.28
434	1/17cc1A				77 40+/-85 14	51 96+/-71 13
				• 7	F1:50-1.65.11	A-CIK 0C-11K
		×	×	×	N=39, N=31	NI=59, N2=0
					Fold Change: 2.28	Fold Change: 2.86
					P-value: 0	P-value: .00032
436	91357639					103.44+/-82.21
2	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\					229.26+/-76.25
		×	×	×	×	N1=40, N2=10
		<b>(</b>	:			Fold Change: 2.51
						P-value: 0
437	AT361002				226.33+/-66.64	209.31+/-66.11
P					131.77+/-56.91	116.1+/-36.28
		×	×	×	N1=39, N2=31	N1=39, N2=6
		•			Fold Change: 1.8	Fold Change: 1.82
					P-value: 0	P-value: .00118
441	A1369275	412 08+/-182 64			404.52+/-178.58	404.52+/-178.58
Ė		160.8+/-88.56			156.69+/-71.33	124.99+/-48.08
		N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.56			Fold Change: 2.52	Fold Change: 3.09
		P-value: 0			P-value: 0	P-value: 0
443	AI375115	215.71+/-84.93			211.26+/-81.18	211.26+/-81.18
<u>:</u>		107.21+/-43.49			101.07+/-42.95	95.25+/-21.17
		N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.02			Fold Change: 2.07	Fold Change: 2.08
		P-value: 0			P-value: 0	P-value: 0
446	AI377937				360.06+/-360.99	360.06+/-360.99
					150.11+/-76.77	160.98+/-94.5
		×	×	×	N1=40, N2=31	N1=40, N2=10
					Fold Change: 2.07	Fold Change: 2
					P-value: .00001	P-value: .0091
447	AI378584	837.48+/-393.22			815.22+/-371.96	815.22+/-371.96
:		288.6+/-150.82			263.18+/-114.79	231+/-80.99
		N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.77			Fold Change: 2.89	Fold Change: 3.19
		P-value: 0			P-value: 0	P-value: 0

ENGULCIU - MU 1005007140 1 >

225 448 AI379723 226 450 AI380204 227 452 AI380932 228 456 AI381930 229 458 AI393356 230 461 AI401832	386.86+/-176.47 126.18+/-143.63 N1=40, N2=168 Fold Change: 3.46 P-value: 0	××	380.22+/-173.64 136.6+/-134.47 N1=40, N2=6 Fold Change: 3.5 P-value: .03454	380.22+/-173.64 87.51+/-60.3 N1=40 N2=21	380,22+/-173,64
458 458 458 461 462	386.86+/-1/6.4/ 126.18+/-143.63 N1=40, N2=168 Fold Change: 3.46 P-value: 0	* *	380.224-173.64 136.64/-134.47 N1=40, N2=6 Fold Change: 3.5 P-value: .03454 X	380.22+/-173.64 87.51+/-60.3 N1=40 N2=21	380.22+/-173.64
450 450 456 458 461 462	126.18+/-143.63 N1=40, N2=168 Fold Change: 3.46 P-value: 0	×	136.6+/-134.47 N1=40, N2=6 Fold Change: 3.5 P-value: .03454 X	87.51 + /-60.3	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
450 452 458 458 461 462	N1=40, N2=168 Fold Change: 3.46 P-value: 0  X	×	N1=40, N2=6 Fold Change: 3.5 P-value: .03454 X	N1=40 N2-21	68.16+/-48.01
450 452 456 461 462	Fold Change: 3.46 P-value: 0 X	×	Fold Change: 3.5 P-value: .03454 X	10-71,04-11	N1=40, N2=10
450 452 456 461 462	P-value: 0 X	×	P-value: .03454 X	Fold Change: 4.24	Fold Change: 5.51
450 456 456 461 462	×	×	×	P-value: 0	P-value: 0
456 456 461 462	×	×	×	194.43+/-169.86	
456 456 461 462	×	×	×	361.5+/-246.51	
456 456 461 462				N1=40, N2=31	×
452 456 456 461 462				Fold Change: 2.15	
452 458 461 462		•		P-value: .00078	
456 461 462					191.48+/-96.27
458 461 462					387.31+/-138.62
456 461 462	×	×	×	×	N1=40, N2=10
458 461 462					Fold Change: 2.16
458 461 462	260 01+/ 245 06		260 01+1-245 06	260 01+1-245 06	760 01±/ 245 06
458	00.042-1110.002		00:01-2-1-10:00	00:047-1:1070	00.042-11.002
458 461 462	44.47+/-65.54		63.86+/-29.55	34.22+/-46.82	62.78+/-171.44
458 461 462	N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
458 461 462	Fold Change: 3.7		Fold Change: 3.2	Fold Change: 3.85	Fold Change: 3.91
458	P-value: 0		P-value: .00133	P-value: 0	P-value: .0021
461				74.44+/-64.03	
461				339.43+/-658.29	
461	×	×	×	N1=40, N2=31	×
461		i i		Fold Change: 2.18	ļ
461				P-value: .00164	i
462				72.16+/-151.56	
462				408.66+/-668.16	
462	×	×	×	N1=40, N2=31	×
462				Fold Change: 2.63	
462				P-value: .00745	
	927.3+/-482.64		933.35+/-487.41	933.35+/-487.41	933.35+/-487.41
	259.61+/-119.48		387.97+/-131.13	238.15+/-85.44	240.55+/-123.45
	N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
,	Fold Change: 3.36		Fold Change: 2.11	Fold Change: 3.54	Fold Change: 3.74
	P-value: 0		P-value: .0003	P-value: 0	P-value: .00001

BNEDOCID -WO COCCOCT AC .

1				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	N	Moreon we Stone II	Normal ve Stone III
- 1	Sed ID	Genbank	Normal VS All	Normal vs Manghant	Normal vs Stage I	Ivol mai vs Stage at	Morning 43 Stage Lin
l	463	AI417917	564.39+/-315.14			567.47+/-318.65	567.47+/-318.65
			271.17+/-167.23			218.33+/-110.93	115.26+/-82.27
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.25			Fold Change: 2.61	Fold Change: 5.16
			P-value: 0			P-value: 0	P-value: .00005
233	465	AI418481				77.52+/-60.1	
	3					257.35+/-253.01	
			×	×	×	N1=40, N2=31	×
			<u> </u>			Fold Change: 2.83	
						P-value: 0	
234	466	AI418596					229.67+/-120.12
							43.69+/-43.08
			×	×	×	×	N1=39, N2=6
			<b>!</b>				Fold Change: 3.79
							P-value: 0
235	467	A1419030	446.12+/-255.78			445,97+/-259.12	445.97+/-259.12
	è		158 41+/-132 36			133.67+/-123.4	81.99+/-31.49
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.03			Fold Change: 3.56	Fold Change: 4.69
			P-value: 0			P-value: 0	P-value: 0
236	468	AI421837	294.7+/-145.9			293.96+/-147.73	293.96+/-147.73
	}		111.04+/-64.19			102.42+/-57.12	109.78+/-55.53
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.62			Fold Change: 2.8	Fold Change: 2.62
			P-value: 0			P-value: 0	P-value: .00166
237	469	AI431799			463.05+/-382.43		
					658.8+/-240.03		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2		
					P-value: .00993		
238	471	AJ435828				587.69+/-414.14	587.69+/-414.14
						299.14+/-333.14	119.57+/-42.81
			×	×	×	N1=40, N2=31	N1=40, N2=10
					•	Fold Change: 2.52	Fold Change: 3.9
						r-value: .00001	r-value: .00001

RNSDOCID: <WO 02059271A2 | >

(ID Genbank Normal	uk Normal vs All Normal vs Malignant	vs All Normal vs Malignant		Normal vs Stage	-	Normal vs Stage II	Normal vs Stage III
À	383.04+/-264.2 935.53+/-916.21	À		<b>,</b>		383.04+/-264.2 987.66+/-795.06	À
N1=40, N2=168 X Fold Change: 2.29 P-value: 0	×	×		×	:	N1=40, N2=31 Fold Change: 2.53 P-value: 0	×
476 AI446168 216.67+/-584.58	216.67+/	216.67+/-584.58				220.39+/-591.75	220.39+/-591.75
561.08+/-695.63 N1=40 N2=168 X	*	*		×		606.41 + 7.908.81	603.11 + -527.41 $N1 = 40$ $N2 = 10$
	!	!				Fold Change: 3.51	Fold Change: 3.91
P-value: 0	P-value: 0	P-value: 0				P-value: 0	P-value: .00476
477 AI458003 276.51+/-201.47 280.16+/-202.76	276.51+/-201.47		280.16+/-20	280.16+/-20	12.76	280.16+/-202.76	280.16+/-202.76
				81.96+/-8	9.4	43.42+/-152.26	4.43+/-42.79
×	×	×		N1=40, N	9=2	N1=40, N2=31	N1=40, N2=10
5.07 F			Fold Change	Fold Change	3.22	Fold Change: 4.35	Fold Change: 7.36
482 AI468491 r-value. USAGE	r-value, o		r-value.	r-value.	2040	r-value: 0	256.57+/-264.41
							84.09+/-113.95
X X	×	×		×		×	N1=40, N2=10
							Fold Change: 2.68 P-value: .00796
487 AI480215 122.23+/-104.86		122.23+/-104.86	-			125.66+/-103.93	
295.22+/-297.68	295.22+/-297.68	295.22+/-297.68				321.02+/-262.5	-
N1=40, N2=168 X			×		×	N1=40, N2=31	×
Fold Change: 2.15	Fold Change: 2.15	Fold Change: 2.15				Fold Change: 2.49	
	P-value:	P-value: ,00005				P-value: .0002	
489 AI492051 384.45+/-175.99		384.45+/-175.99				382.34+/-177.78	382.34+/-177.78
176.84	176.84	176.84				91.96+/-44.92	154.08+/-202.28
×	×	×			×	N1=40, N2=31	N1=40, N2=10
Fold Change: 3.12	Fold Change: 3.12	Fold Change: 3.12				Fold Change: 4.08	Fold Change: 3.91
P-value: 0	P-valu	P-value: 0				P-value: 0	P-value: .0032
490 AI492091	AI492091						146.39+/-59.05
						;	321.61+/-116.38
X			×		×	×	N1=40, N2=10
							Fold Change: 2.22 P-value: 00005

בו כבולרנים האום האוביסידום ו

#	Sea 1D	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
						0,027,100,000	010101010
246	493	AI492879	214.23+/-650.46		219.42+/-658.12	219.42+/-658.12	219.42+/-028.12
			465.24+/-396.65		277.88+/-265.92	663.74+/-488.43	771.71+/-307.65
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.22		Fold Change: 3.72	Fold Change: 9.89	Fold Change: 14.12
			P-value: 0		P-value: .01903	P-value: 0	P-value: 0
247	494	AI498375	244.41+/-203.11		244.41+/-203.11	244.41+/-203.11	244.41+/-203.11
; ! 			46+/-55.84		47.6+/-45.95	43.16+/-57.68	48.55+/-41.9
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	NI=39, N2=6
			Fold Change: 3.62		Fold Change: 3.32	Fold Change: 3.62	Fold Change: 3.45
			P-value: 0		P-value: .00134	P-value: 0	P-value: .00002
248	498	AI499334	236,34+/-181.29		236.34+/-181.29		236.34+/-181.29
			117.03+/-221.42		83.26+/-88.81		16.68+/-51.22
			N1=39, N2=168	×	N1=39, N2=10	×	N1=39, N2=6
			Fold Change: 2.28		Fold Change: 2.68		Fold Change: 4.22
			P-value: 0		P-value: .0244		P-value: 0
249	500	AJ524085	380.84+/-525.16		388.89+/-529.52	388.89+/-529.52	388.89+/-529.52
:			54.03+/-109.2		35.06+/-63.65	36.84+/-79.16	8.33+/-48.11
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.48		Fold Change: 4.76	Fold Change: 5.39	Fold Change: 7
			P-value: 0	•	P-value: .00065	P-value: 0	P-value: 0
250	501	AI525044	319.4+/-142.13			316.89+/-143.08	316.89+/-143.08
			131.06+/-178.35			121.55+/-76.85	65.73+/-20.84
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.93			Fold Change: 2.83	Fold Change: 4.61
			P-value: 0			P-value: 0	P-value: 0
251	502	AI525601					223.25+/-101.98
							605.18+/-406.21
			×	×	×	×	N1=40, N2=10
				٠			Fold Change: 2.43
							P-value: .00221
252	504	AI535997	526.38+/-278.8			527.18+/-282.39	527.18+/-282.39
			203.43+/-127.91			182.64+/-99.43	177.05+/-109.73
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.55		•	Fold Change: 2.76	Fold Change: 2.81
			r-value. 0			r-value. 0	r -vaine: .00003

Normal vs Malignant Normal vs Stage I
×
×
×
×
90.74+/-52.8 232.59+/-162.79 X N1=40, N2=6 Fold Change: 2.54 P-value: .00734
X
×

*	Seg ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III.
	213	ATECOIEO				249.15+/-159.54	249,15+/-159.54
07	010	ALSOULS				475,18+/-183.53	849.92+/-667.24
			>	*	×	N1=40. N2=31	N1=40, N2=10
			<	<b>&lt;</b>	<b>:</b>	Fold Change: 2.08	Fold Change: 3.13
						P-value: 0	P-value: .00061
261	517	AI566038	257.62+/-109.32			436.1+/-150.59	
•			154 67+/-104.12			302.74+/-153.34	
			N1=39, N2=168	×	×	N1=39, N2=31	×
			Fold Change: 1.94			Fold Change: 1.57	
			P-value: 0		•	P-value: .00104	
262	523	A1583942	231.62+/-1223.34			237.55+/-1238.75	
			574.26+/-2305.76			1788.59+/-4779.29	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.18			Fold Change: 4.69	
			P-value: .00076			P-value: .00099	
263	524	A1587178					222.78+/-143.35
3							88.43+/-75.43
			×	×	×	×	N1=40, N2=10
	•						Fold Change: 2.64
				•			P-value: .00579
264	576	A1589858	296 87+/-162.49			296.87+/-162.49	296.87+/-162.49
			138 95+/-123			143.85+/-108.99	121.61+/-47.86
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.17			Fold Change: 2.1	Fold Change: 2.31
			P-value: 0			P-value: .00002	P-value: .00132
265	527	AI590093	316.95+/-171.55			314.33+/-172.98	314.33+/-172.98
			167.02+/-141.99			149.67+/-84.85	121.07+/-88.54
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.1			Fold Change: 2.08	Fold Change: 2.91
			P-value: 0			P-value: .00003	P-value: .00504
266	529	AI598252				417.54+/-196.25	
						833.81+/-317.16	ţ
			×	×	×	N1=39, N2=31	×
						Fold Change: 2.06	
						F-value: 0	

BNSDOCID: <WO\_02059271A2\_I\_>

ı	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
267	530	AI601149	270.5+/-122.37			267.15+/-122.1	267.15+/-122.1
			115.84+/-107.17			101.95+/-53.86	55.7+/-20.35
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.62			Fold Change: 2.69	Fold Change: 4.57
			P-value: 0			P-value: 0	P-value: 0
268	532	AI610837	2072.69+/-1692.17			2072.69+/-1692.17	2072.69+/-1692.17
			724.59+/-659.17	•		544+/-358.27	319.79+/-159.71
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.65	•		Fold Change: 3.17	Fold Change: 4.66
			P-value: 0			P-value: 0	P-value: 0
569	534	AI620381			-		610.77+/-316.3
							1217.36+/-274.04
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.16
							P-value: 0
270	535	AI624103	289.59+/-159.89		289.59+/-159.89	289.59+/-159.89	289.59+/-159.89
			123.14+/-143.73		116.4+/-81.91	82.42+/-59.19	71.19+/-34.34
			N1=39. N2=168	×	N1=39, N2=10	NI=39, N2=31	N1=39, N2=6
			Fold Change: 2.74		Fold Change: 2.65	Fold Change: 3.4	Fold Change: 3.74
			P-value: 0		P-value: .03426	P-value: 0	P-value: 0
271	537	AI631301	328.42+/-165.41			328.42+/-165.41	328.42+/-165.41
			126.68+/-74.53		,	111+/-70.99	58.7+/-32.01
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.52			Fold Change: 2.8	Fold Change: 5.02
			P-value: 0			P-value: 0	P-value: 0
272	538	AI631850				26.13+/-35.18	
						224.44+/-595.61	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.14	
						P-value: .00784	
273	540	AI634852				278.07+/-162.92	
						171.54+/-216.03	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.18	
I						r-value: .0011	

RNSDOCID: <WO 02059271A2 L

7	The state of	Conhonly	Normal us All	Normal ve Malianant	Normal ve Stage I	Normal vs Stage II	Normal vs Stage III
*	or bac	Genualik	IVOI MIRI VS AMI	1101 luar 13 trangilant	TOTAL STATES	010 00 1 00 01	010 22 1 03 64
274	541	AI635774	212.33+/-93.64			212.33+/-93.64	212.33+/-93.64
			92.03+/-51.47			93.14+/-61.28	89.02+/-26.68
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.39			Fold Change: 2.5	Fold Change: 2.62
			P-value: 0			P-value: 0	P-value: .00169
275	546	AI650514	108.33+/-162.01		110.57+/-163.5	110.57+/-163.5	110.57+/-163.5
1	)		321.96+/-278.48		306.38+/-174.2	495.16+/-349.41	380.44+/-266.81
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.14		Fold Change: 3.3	Fold Change: 5.31	Fold Change: 3.44
			P-value: 0		P-value: .02515	P-value: 0	P-value: .01035
276	550	A1651732					200.01+/-105.06
2	3					•	67.38+/-39.88
			×	×	×	×	N1=40, N2=10
				1			Fold Change: 3.01
							P-value: .00028
777	551	A1652058					182.73+/-51.39
-	100						384.98+/-89.44
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.14
							P-value: 0
27.8	552	A1652459					724.8+/-344.86
2							274.16+/-175.44
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.8
							P-value: .00159
279	554	AI653487	251.37+/-223.37		251.37+/-223.37	251.37+/-223.37	251.37+/-223.37
			44.78+/-81.85		41.71+/-73.61	30.69+/-76.04	4.44+/-69.04
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.04		Fold Change: 3.36	Fold Change: 3.36	Fold Change: 4.16
			P-value: 0		P-value: .00441	P-value: 0	P-value: .00002
280	555	AI654035	227.06+/-388.81			227.06+/-388.81	
			65.4+/-275.63	1	;	56.3+/-242.23	,
			N1=40, N2=168	×	×	N1=40, N2=31	*
			Fold Change: 2.9			Fold Change: 3.21	
			r-vame: .00003			r-value: .0001	

₹	Con III	Conhonly	Moumol w All	Mountain Malianont	Moumol we Ctone I	Mormal we Stone II	Noumal so Chan III
	135	CCHUAIIN	LIOT FIRM VS PAIL	IVOI III AI IVIAII ERANI	TOT HIGH AS DIGEOT	TOTHING 13 DIABOTE	MOLITICAL VS DIABE III
281	556	AI655499	46.97+/-125.7			47.75+/-127.24	
			313.1+/-881.21			453.25+/-957.09	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.28			Fold Change: 2.89	
			P-value: 0	!	-	P-value: .00225	
282	260	AI656836					496.58+/-144.86
							242.93+/-91.56
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.07
							P-value: .00005
283	295	AI658925	545.69+/-343.76			542.56+/-347.67	542.56+/-347.67
			259.08+/-213.04			233.63+/-187.46	164.54+/-115.15
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.3			Fold Change: 2.42	Fold Change: 3.62
			P-value: 0			P-value: .00001	P-value: .00181
284	563	AI658928	230.91+/-89.43			230.91+/-89.43	230.91+/-89.43
			89.62+/-64.08			75.71+/-63.86	130.21+/-102.4
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.76			Fold Change: 3.17	Fold Change: 2.16
			P-value: 0			P-value: 0	P-value: .02073
285	565	AI659418					261.02+/-116.11
							125.48+/-61.12
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.05
							P-value: .00057
286	999	AI659533	566.04+/-199.44			563.4+/-201.34	563.4+/-201.34
			260.59+/-219.32			289.88+/-264.96	161.05+/-65.87
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.68			Fold Change: 2.58	Fold Change: 3.49
			P-value: 0			P-value: 0	P-value: 0
287	568	AI659927				-	427.88+/-182.76
							161.17+/-86.36
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.71
1							r-value: .00004

ENGRACIO - NO CONTROL S

Normal vs Stage III	119.06+/-130.86 357.85+/-302.39 N1=39, N2=6 Fold Change: 2.63 P-value: .01212	X	112+/-77.42 229.83+/-111.91 N1=40, N2=10 Fold Change: 2.3 P-value: .00034	172.75+/-104.93 326.06+/-163.08 N1=40, N2=10 Fold Change: 2.1 P-value: .00523	×	×	X
Normal vs Stage II	×	1443.34+/-1731.78 1028.64+/-1669.79 N1=40, N2=31 Fold Change: 2.82 P-value: .01542	X	×	285.7+/-185.25 643.27+/-468.95 N1=40, N2=31 Fold Change: 2.17 P-value: .00012	281.86+/-139.36 128.43+/-98.38 N1=40, N2=31 Fold Change: 2.34 P-value: .00001	278.54+/-168.6 119.84+/-49.46 N1=40, N2=31 Fold Change: 2.13 P-value: 0
Normal vs Stage I	×	×	<b>X</b>	X	X	X	X
Normal vs Malignant	×	×	×	×	X	×	×
Normal vs All	119.06+/-130.86 277.49+/-246.97 N1=39, N2=168 Fold Change: 2.1 P-value: 0	×	×	×	×	X	×
Genbank	AI660245	AI668620	AI671836	AI671984	AI673539	AI673735	AI674603
Sea ID	569	571	574	575	579	280	583
#	288	589	290	291	292	293	294

7	E See	7-1-1-		M	NI CALL	10 11	100
*	or hac	Centrank	Normal vs All	Normal vs Mangnant	Normal vs Stage I	Normal Vs Stage II	Normal Vs Stage III
295	584	A1675106	353.92+/-130.58 188.82+/-101.49 N1=39, N2=168 Fold Change: 2.02 Pavalue: 0	×	×	×	×
296	588	AI680541	516.15+/-202.37 138.66+/-107.52 N1=40, N2=168 Fold Change: 4.19 P-value: 0	×	×	510.08+/-201.29 149.24+/-129.55 N1=40, N2=31 Fold Change: 3.77 P-value: 0	510.08+/-201.29 101.96+/-86.37 N1=40, N2=10 Fold Change: 5.63 P-value: .00001
297	590	AI683036	106.33+/-110.74 328.16+/-267.3 N1=39, N2=168 Fold Change: 2.81 P-value: 0	×	×	106.33+/-110.74 296.92+/-224.37 N1=39, N2=31 Fold Change: 2.63 P-value: 0	×
298	591	AI683911	241.46+/-200.89 35.47+/-57.1 N1=40, N2=168 Fold Change: 4.64 P-value: 0	×	×	241.46+/-200.89 28.41+/-33.49 N1=40, N2=31 Fold Change: 5.05 P-value: 0	241.46+/-200.89 29.45+/-35.37 N1=40, N2=10 Fold Change: 5.29 P-value: 0
299	592	AI684457	96.99+/-74.31 233.36+/-405.3 N1=40, N2=168 Fold Change: 2 P-value: .00001	×	×	×	×
300	593	AI686114	375.54+/-271.13 158.93+/-158.15 N1=40, N2=168 Fold Change: 2.67 P-value: 0	×	×	374.48+/-274.59 155.96+/-124.29 N1=40, N2=31 Fold Change: 2.4 P-value: .00006	×
301	594	AI686316	255.25+/-97.58 102.19+/-93.67 N1=39, N2=168 Fold Change: 2.55 P-value: 0	×	255.25+/-97.58 120.04+/-93.28 N1=39, N2=10 Fold Change: 2.52 P-value: .0397	255.25+/-97.58 79.78+/-67.6 N1=39, N2=31 Fold Change: 2.99 P-value: 0	255.25+/-97.58 51.42+/-78.59 N1=39, N2=6 Fold Change: 3.34 P-value: .00001

-,}

#	Coa III	Conhonly	Normal ve All	Normal we Malianant	Normal ve Stone I	Normal ve Stage II	Normal ve Stage
ŧ	250	GCIIDAIIR	IVOI HIGH VS AM	TOT HAT TO ITABLISHALL	Ivol mar vs Stage A	MOLINIAL VS DIABOAL	TANK MINER TO DEED TOT
302	595	AI689747	229.57+/-81.34			229.57+/-81.34	229.57+/-81.34
			113.53+/-98.71			120.42+/-76.86	74.4+/-34.38
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.2			Fold Change: 2.07	Fold Change: 2.9
			P-value: 0			P-value: 0	P-value: 0
303	597	AI691077	201.9+/-110.51				
			84.62+/-106.12				
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.35				
304	400	A1692687	r-value. 0				215.65+/-82.22
	}						106.33+/-67.45
			×	×	×	×	N1=39, N2=6
							Fold Change: 2.27
							P-value: .00376
305	603	AI693690					187.55+/-153.71
							419.84+/-166.89
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.84
			•				P-value: .00002
306	604	AI694059	256.63+/-189.71			256.63+/-189.71	256.63+/-189.71
			63.49+/-68.69			45.9+/-74.24	24.83+/-23.88
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.4			Fold Change: 3.8	Fold Change: 5.35
			P-value: 0			P-value: 0	P-value: 0
307	909	AI695684		-			284.08+/-85.43
							138.19+/-31.83
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.01
							P-value: 0
308	809	AI698134	801.15+/-394.52		803.86+/-399.3	803.86+/-399.3	803.86+/-399.3
			295.3+/-157.04		305.4+/-156.08	238.5+/-98.66	290.26+/-225.95
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.66		Fold Change: 2.52	Fold Change: 3.16	Fold Change: 3.23
			P-value: 0		P-value: .00483	P-value: 0	P-value: .00182

#	Chor III	Conhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1000	200	AT700484	78 PUE /+0V VUV		404 49+/-304.86	404.49+/-304.86	404.49+/-304.86
202	010	AL / 00404	140 08±7.02 82		151 52+/-60.91	139.3+/-55.78	132.26+/-50.46
			N1=40 N2=168	*	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.59	Ī	Fold Change: 2.49	Fold Change: 2.66	Fold Change: 2.75
			P-value: 0		P-value: .00796	P-value: 0	P-value: 0
310	612	AT701034					215.78+/-96.65
210							101.91+/-38.36
			×	×	×	×	N1=40, N2=10
			<i>t</i> 1	Į.			Fold Change: 2.03
							P-value: .00018
211	613	AT703441				166.32+/-110.39	166.32+/-110.39
777	3	71.00/170				348.27+/-255.22	332.43+/-137.78
			×	×	×	N1=40, N2=31	N1=40, N2=10
			4			Fold Change: 2	Fold Change: 2.31
						P-value: .00052	P-value: .00003
312	614	AI703451				58.72+/-154.11	
-						479.31+/-977.92	
			×	×	×	N1=40, N2=31	×
			<b>!</b>			Fold Change: 3.05	
						P-value: .00313	
212	615	A1707589	446 78+/-668 95			414.9+/-646.18	414.9+/-646.18
CTC	3	100101	350 77+/-1435 2			236.79+/-693.96	-8.82+/-71.63
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.73	1		Fold Change: 2.49	Fold Change: 4.36
			P-value: .00099			P-value: .01893	P-value: .00006
317	617	A1720763					216.2+/-123.53
1	10						94.49+/-39.1
			*	×	×	×	N1=40, N2=10
			į				Fold Change: 2.05
							P-value: .00026
216	610	ATT2777A	076 554/-085 51		947.08+/-989.69	947.08+/-989.69	947.08+/-989.69
crc	010	F132617	133 4+7.773 85		92.83+/-139.88	17.45+/-85.58	25.59+/-138.38
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 7.17	1	Fold Change: 8.37	Fold Change: 13.2	Fold Change: 14.18
			P-value: 0		F-value: .00451	r-value. v	T -Value: O

BNG00010--WO 0205027182 1 5

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
			0 000 - 110 000		00 303 / 10 300	11 505 /TO 3CC	375 04/-506 22
316	619	AI733679	319.55+/-589.9		372.9+/-296.77	525.94/-590.22	525.94/-590.22
			41.3+/-61.11		26.3+/-20.79	23.3+/-13.87	22.92+/-14.21
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3 96		Fold Change: 4.56	Fold Change: 5.05	Fold Change: 5.39
			P-value: 0		P-value: .00001	P-value: 0	P-value: 0
317	621	A1740483					519.7+/-165.79
	<b>i</b>						245.74+/-94.64
			×	×	×	×	N1=39, N2=6
			ŀ				Fold Change: 2.11
							P-value: .00011
318	622	AI740516	23.68+/-49.95			24.14+/-50.52	
			230.26+/-254.07			211.05+/-266.38	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 5.25			Fold Change: 4.63	
			P-value: 0			P-value: 0	
319	623	AI740621	231,84+/-247.13			231.84+/-247.13	· 231.84+/-247.13
ì			51.4+/-63.67			55.89+/-78.15	58.59+/-71.76
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.99			Fold Change: 2.92	Fold Change: 2.89
			P-value: 0	٠		P-value: .00006	P-value: .00645
320	624	AI741026	324.97+/-140.14			321.67+/-140.4	
			152.41+/-75.46			156.42+/-93.26	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.1			Fold Change: 2.06	
			P-value: 0			P-value: 0	
321	627	AI742002	109.12+/-131.8		111.78+/-132.43	111.78+/-132.43	111.78+/-132.43
			356.63+/-240.05		392.25+/-219.22	395.11+/-278.86	430.05+/-236.92
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.82		Fold Change: 4.18	Fold Change: 3.97	Fold Change: 4.87
			P-value: 0		P-value: .00524	P-value: 0	P-value: 0
322	628	AI742057	200.43+/-229.58			203.47+/-231.77	203.47+/-231.77
			445.89+/-295.68			460.52+/-275.2	448.38+/-232.46
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.37			Fold Change: 2.6	Fold Change: 2.46
			P-value: 0			P-value: 0	P-value: .00303

7	E Co.	Conbont	Mormal we All	Normal ve Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	oed TT	Gennauk	IVOI MAI VO FAII	TIOT THE 13 TYREED THE	8	150 71 / 100 11	
323	629	AI742239	160.34+/-196.79			139./04/-139.32	
			321.12+/-260.74			420.92+/-297.86	
			N1=40 N2=168	×	×	N1=40, N2=31	×
			T-13 OF 1-17			Fold Change: 3.17	
			Fold Change: 2.24 P-velue: 00004			P-value: .00002	
7.00	531	A 1742400	608 25±1.253 14			601.57+/-252.84	601.57+/-252.84
<del>1</del> 76	160	A1/42470	044 6 17 205.14			202.34+/-107.23	135.78+/-110.24
			244.84/-205.92	>	>	N1=40 N2=31	N1=40 N2=10
			NI=40, NZ=108	<		E-14 Change: 2.01	Fold Change: 5.03
			Fold Change: 2.99			Fold Change, 5.01	D-volve: 00005
			P-value: 0			r-value: 0	r-value00003
325	229	AI742521	213.11+/-232.57		215.93+/-234.91	215.93+/-234.91	215.93+/-234.91
3			75 67+1-56 27		60.9+/-90.73	35.9+/-49	21.54+/-22.52
			N1=40 N2=168	*	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Eald Change: 3.02	4	Fold Change: 3.31	Fold Change: 3.94	Fold Change: 4.49
			rold Change, 3.32		P-value: 02617	P-value: 0	P-value: 0
į	20)	1771071	£70 011/215 16			582.82+/-317.91	582.82+/-317.91
370	035	A1/430/1	01/015-/+17-01/0		•	172 55+/-151 01	150.6+/-109.83
			77.7.7.4/-183.47	;	ř	M1-40 M2-21	N1=40 N2=10
			N1=40, N2=168	×	*	IC-7N, OF-1N	01-40, 142
			Fold Change: 2.79			Fold Change: 3.82	Fold Change: 3.98
			P-value: 0			P-value: 0	P-value: .0009
207	763	A1742715	320 58+/-241 61			312.02+/-238.55	312.02+/-238.55
176	20	MAINS LA	00 04+/-151 07			78.92+/-130.98	17.92+/-64.11
			N1=0 N2=168	*	×	N1=40, N2=31	N1=40, N2=10
			E.14 Change: 3 54			Fold Change: 4.04	Fold Change: 6.18
			Fold Change, 3.34 P-value: 0			P-value: 0	P-value: .00001
328	637	AI743925	665.72+/-305.69	·			
			344.09+/-309.12			;	) P
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.33				
			P-value: ()				
329	639	AJ745624	1			210.12+/-81.11	
			;	;	>	116.93+/-65.22 N1=20 N2=31	<b>*</b>
			<b>×</b>	<	<b>&lt;</b>	Fold Change: 1.89 P-value: 0	<b>:</b>

					Ministration Office I	Normal ve Stage II	Normal vs Stage III
#	Seq ID	Genbank		Normal vs Malignant	Normal vs Stage 1	Cor oc : Of 44	607 86+1.754 44
330	640	AI750575	702.71+/-253.03			697.86+/-254.44	275 21+1-286 22
			412.71+/-328.09			3//.634/-296.23	21.0.2.1.1.2.2.1.2 21.0.2.1.1.2.1.2
			N1=40 N2=168	×	×	N1=40, N2=31	NI=40, NZ=IO
			Eold Change: 2 14			Fold Change: 2.36	Fold Change: 3.89
			Pavalue: 0			P-value: .00005	P-value: .00699
3	150	AT721420	141 85+/-187 15			144.67+/-188.73	144.67+/-188.73
331	140	AL/31430	62. 101-11 CO.141			466.36+/-471.12	306.05+/-201.86
			FC.F2/-/1.20.0C0	*	×	N1=40, N2=31	N1=40, N2=10
			Eold Change: 4.71	•		Fold Change: 3.51	Fold Change: 2.79
		•	rota Change, 4.71			P-value: 0	P-value: .00492
	,	00,000	r-value: 0			369.82+/-189.17	369.82+/-189.17
332	642	AI/52682	3/3.204/-109.0/			148.94+/-124.57	76.67+/-82.11
			100.227/-155.04 N14-40 N79-168	<b>&gt;</b>	×	N1=40, N2=31	N1=40, N2=10
			101-40, 102-106	4		Fold Change: 2.85	Fold Change: 5.81
			Fold Change: 5.01			P-value: .00001	P-value: .00014
			osconii cen 44		833 57+/-68 83	833.52+/-665.83	833.52+/-665.83
333	643	AI758223	830.0/+/-03/.44		215 0+/-314 77	164.76+/-581.67	52.12+/-64.89
			155.81+/-450.44	>	N1=40 N2=6	N1=40. N2=31	N1=40, N2=10
			001-7N, 05-1N	<	Eold Change: 6.2	Fold Change: 10.99	Fold Change: 14.24
			Fold Change: 9.32		P-value: .02859	P-value: 0	P-value: 0
		0070000	r-value. 0				383.82+/-126.82
334	644	AL758408					188.25+/-213.28
			Þ	*	×	×	N1=40, N2=10
			<	d X			Fold Change: 3.58
							P-value: .01039
100	24.5	A17C0210	708 60±/±65 34		208.69+/-65.34	208.69+/-65.34	208.69+/-65.34
335	040	AL/00317	105 79+/-40 89		102.62+/-62.32	102.48+/-38.82	104.41+/-52.84
			N1=30 N7=168	*	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Told Change. 7	į	Fold Change: 2.02	Fold Change: 2.07	Fold Change: 2.13
			Fold Change: 2 D walne: 0		P-value: .01579	P-value: 0	P-value: .00136
	- 1	0 T T T T T T T T T T T T T T T T T T T	I -value. V			691.21+/-512.28	691.21+/-512.28
330	940	AL/003/0				259.02+/-226.94	142.47+/-133.11
			<b>×</b>	×	×	N1=40, N2=31	N1=40, N2=10
			<b></b>	·		Fold Change: 2.3	Fold Change: 4.03
						P-value: .00272	P-value: .00082

#	Sea 10	Genbank	Normal vs All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
337	648	AI760589	X	×	×	81.29+/-140.48 214.53+/-216.44 N1=40, N2=31 Fold Change: 3.26 P-value: 0	×
338	649	AI761241	891.41+/-331.82 417.19+/-273.72 N1=40, N2=168 Fold Change: 2.32 P-value: 0	×	×	883.3+/-332.12 352.83+/-245.83 N1=40, N2=31 Fold Change: 2.7 P-value: 0	883.3+/-332.12 238.36+/-101.2 N1=40, N2=10 Fold Change: 3.83 P-value: .00005
339	650	AI761274	346.01+/-181.77 114.5+/-91.9 N1=40, N2=168 Fold Change: 3.44 P-value: 0	X	×	342.36+/-182.65 121.75+/-92.05 N1=40, N2=31 Fold Change: 3.23 P-value: 0	342.36+/-182.65 77.48+/-76.11 N1=40, N2=10 Fold Change: 4.73 P-value: .00028
340	651	AI761782	×	×	×	×	41.02+/-103.08 282.44+/-98.22 N1=39, N2=6 Fold Change: 6.26 P-value: 0
341	652	AI761844	284.64+/-141.48 117.61+/-150.43 N1=40, N2=168 Fold Change: 2.8 P-value: 0	X	×	278.83+/-138.41 132.4+/-302.8 N1=40, N2=31 Fold Change: 3.35 P-value: 0	278.83+/-138.41 94.71+/-60.55 N1=40, N2=10 Fold Change: 3.05 P-value: .0007
342	654	AI763298	247.25+/-99.93 113.86+/-100.53 N1=40, N2=168 Fold Change: 2.6 P-value: 0	×	×	242.06+/-95.62 148.77+/-173.93 N1=40, N2=31 Fold Change: 2.29 P-value: .00002	242.06+/-95.62 84.64+/-67.22 N1=40, N2=10 Fold Change: 3.32 P-value: .00045
343	655	A1766029	265.74+/-522.75 15.92+/-35.83 N1=40, N2=168 Fold Change: 3.94 P-value: 0	×	271.74+/-528.19 11.19+/-13.38 N1=40, N2=6 Fold Change: 4.33 P-value: 0	271.74+/-528.19 4.73+/-8.61 N1=40, N2=31 Fold Change: 4.64 P-value: 0	271.74+/-528.19 8.83+/-25.01 N1=40, N2=10 Fold Change: 4.09 P-value: 0

DEIGNOON JAIN MOSMITTAN E

659 A 661 AJ 662 AI 665 AI 669 AI7	#	Seq ID	Genbank	Normal va All	**			
X	344	629	AJ768777	LIOI IIIGI VS AIII	ivormal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
5 661         A1769559         X         X         101.34+7.62.5           5 662         A1770080         450.33+7.335.5         X         NII=9, N2=31           6 662         A1770080         450.33+7.335.5         X         NII=9, N2=31           6 662         A1770080         450.33+7.335.5         X         X         P-value: 0         P-value: 0         P-value: 0         H-value: 0         H-value: 0         H-value: 0         H-value: 0         H-value: 0         P-value: 0 <td></td> <td></td> <td></td> <td>×</td> <td>×</td> <td>×</td> <td>×</td> <td>263.99+/-143.63 686.1+/-326.01 N1=40, N2=10 Fold Change: 2.67</td>				×	×	×	×	263.99+/-143.63 686.1+/-326.01 N1=40, N2=10 Fold Change: 2.67
Secondary   Seco	345	661	AI769559				212 1617 00 7	P-value: .00011
6 662         AI770080         450.33+7.335.5         Feature: 0           1 66.16+1.90.29         1 66.16+1.90.29         X         1 2.24-1.07.13           1 N1=40, N2=168         X         X         N1=40, N2=31           P-value: 0         76.1.5+9.47.17         P-value: 0         P-value: 0           665         AI783490         76.1.5+9.47.17         X         X           Poid Change: 2.14         X         X         X           P-value: 0.0537         P-value: 0.0537         X         X           665         AI791632         2.55.06+1.50.68         X         X           Rold Change: 2.22         X         X         X           Fold Change: 2.22         X         X         X           Fold Change: 2.22         X         X         X           Rold Change: 2.22         X         X         X           P-value: 0         P-value: 0         93.82+/112.78           SS 02.01+/224.89         X         X           Rold Change: 2.22         X         X           P-value: 0         P-value: 0.0448         558.02.91+/224.89           Rold Change: 3.34         X         X           Rold Change: 3.33         X         X </td <td></td> <td></td> <td></td> <td>×</td> <td>×</td> <td>×</td> <td>213.1074-92.0 101.344/-76.51 N1=39, N2=31 Fold Change: 2.13</td> <td>×</td>				×	×	×	213.1074-92.0 101.344/-76.51 N1=39, N2=31 Fold Change: 2.13	×
166.164+190.29   143.24+107.13     166.164+190.29   X   X   143.24+107.13     166.164+190.29   X   X   143.24+107.13     166.3   A1783490   767.154+947.17     151.3384-2167.1   X   X   X   X     151.3384-2167.1   X   X   X   X     151.3384-2167.1   X   X   X   X     122.844-86.83   X   X   X   X   X     122.844-86.83   X   X   X   X   X     122.844-86.83   X   X   X   X   X   X     122.844-86.83   X   X   X   X   X   X   X     123.847-143.52   X   X   X   X   X   X   X   X     123.847-143.52   X   X   X   X   X   X   X   X   X     123.847-143.52   X   X   X   X   X   X   X   X   X	346	799	AI770080	450.33+/-335.5			P-value: 0	
Fold Change: 2.79				166.16+/-190.29			455.96+/-339.09	453.96+/-339.09
Fold Change: 3.2   Fold Change: 3.2				N1=40, N2=168 Fold Change: 2 70	×	×.	N1=40, N2=31	N1=40. N2=10
March   Marc				P-value: 0			Fold Change: 3.2	Fold Change: 4.55
1513.38+/-2167.1   N1=40, N2=168	47	663	AI783490	767.15+/-947.17			P-value: 0	P-value: .00046
665         A1791632         Proid Change: 2.14         X         X         X           665         A1791632         255.064-150.68         X         X         X           122.844-86.83         X         X         X         X           Fold Change: 2.22         X         X         X         X           Fold Change: 2.22         X         X         X         X           Fold Change: 2.22         X         X         X         X           Fold Change: 2.02         X         X         X         N1=40, N2=31           Fold Change: 3.97         X         X         X         P-value: .00448           Fold Change: 3.33         X         X         X         X         P-value: .00448           Fold Change: 3.33         X         X         X         X         N1=40, N2=31           Fold Change: 3.37         P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0		•		1513.38+/-2167.1				
665 AI791632 255.064-150.68  122.844-k8.683				N1=40, N2=168	×	×	*	<b>&gt;</b>
665         AI791632         255.06+/-150.68         X <td></td> <td></td> <td></td> <td>Ford Change: 2.14 P-value: .00537</td> <td>٠.</td> <td></td> <td>•</td> <td>&lt;</td>				Ford Change: 2.14 P-value: .00537	٠.		•	<
122.84+/-86.83 N1=40, N2=168 Fold Change: 2.22 P-value: 0  667. AI792405  X X X X X X X X X X X X X X X X X X	8	999	AI791632	255.06+/-150.68				
N1=40, N2=168				122.84+/-86.83				255.06+/-150.68
667. AI792405  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=40, N2=168 Fold Change: 2.22	×	×	×	96.82+/-63.86 N1=40, N2=10
667. AI792405  X  X  X  X  X  X  X  X  X  X  X  X  X				P-value: 0				Fold Change: 2.58
93.82+/-112.78  202.01+/-224.89  N1=40, N2=31  Fold Change: 2.02  P-value: 0.0448  S58.02+/-937.45  Fold Change: 3.33  Fold Change: 3.97	<u></u>		AI792405					P-value: .00084
669 AI792817 112.38+/-143.52 Fold Change: 2.02  558.02+/-937.45 N1=40, N2=168 Fold Change: 3.33 Fold Change: 3.33 Fold Change: 3.37 P-value: 0  P-value: 3.70 P-value: 3.7				*	Þ		93.82+/-112.78 202.01+/-224.89	
669 AI792817 112.38+/-143.52 P-value: 0.0448 558.02+/-937.45 N1=40, N2=168 X N1=40, N2=31 Fold Change: 2.02 P-value: 0 P-value: 0.0448 112.38+/-143.52 510.79+/-557.67 N1=40, N2=31 Fold Change: 3.97				\$	≺	×	N1=40, N2=31	×
669 AI792817 112.38+/-143.52 558.02+/-937.45 N1=40, N2=168 X N1=40, N2=31 Fold Change: 3.33 P-value: 0 P-value: .00448 P-value: .00448  112.38+/-143.52 510.79+/-557.67 N1=40, N2=31 Fold Change: 3.97							Fold Change: 2.02	•
X X N1=40, N2=31 Fold Change: 3.97			AI792817	112.38+/-143.52			P-value: .00448	
X X N1=40, N2=31 Fold Change: 3.97				558.02+/-937.45			112.38+/-143.52	112.38+/-143.52
Fold Change: 3.97				N1=40, N2=168	×	≽	510.79+/-557.67	849.79+/-711.76
D wellies O				Fold Change: 3.33		€	N1=40, N2=31 Fold Change: 2 07	NI=40, N2=10
				P-value: 0			D Condition	Fold Change: 7.3

							100
#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
,	3	ATTOROGO	77 000 110 000		407 2±7.778 56	407 3+1-278 56	407.3+/-278.56
32	0/0	AL/9555	401.34/-2/8.30		00:0/7-/:0:/0+	00:017-7:07-001	127 64 / 122 70
			146.44+/-111.32		173.14+/-117.81	177.01+/-2/./8	15/.04+/-125./8
			N1=39, $N2=168$	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Eald Change 2 62		Fold Change: 2.32	Fold Change: 2.89	Fold Change: 3.16
			P-value: 0		P-value: .03224	P-value: 0	P-value: .00069
357	11.9	AT796083			114.7+/-66.6		
					207.1+/-77.72		
			×	×	N1=40, N2=6	×	×
			•	:	Fold Change: 2.06		
					P-value: .00108		
353	672	A1796210	300 25+/-171 19			300.25+/-171.19	300.25+/-171.19
3		2000	136 47+/-160 54			142.27+/-164.88	68,23+/-32.91
				×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.45	1		Fold Change: 2.36	Fold Change: 3.93
			P-value: ()			P-value: 0	P-value: 0
25,4	673	A1707063	217 39+/-201 68			220.19+/-203.53	220.19+/-203.53
5			181 18+/-462 43			161.62+/-454.65	58.77+/-92.21
			N1=40 N2=168	*	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2 2	1		Fold Change: 3.09	Fold Change: 3.3
			P-value: 00014			P-value: .00028	P-value: .00535
355	674	A1797276	270 66+/-135.07		271.48+/-136.73	271.48+/-136.73	271.48+/-136.73
3			91.42+/-65.13		110.91+/-50.09	84.22+/-53.14	51.53+/-37.65
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.1		Fold Change: 2.28	Fold Change: 3.2	Fold Change: 5.08
			P-value: 0		P-value: .00368	P-value: 0	P-value: 0
356	675	A1707788					268.73+/-161.42
3	2						121.99+/-102
			>	*	×	×	N1=40, N2=10
			4	•			Fold Change: 2.27
							P-value: .00827
357	929	AI798144	74.39+/-112.61				
			$243.81 + \frac{1}{2}08.55$	*	×	<b>×</b>	×
			Fold Change: 2.13	<b>:</b>			
			r-value. o				

	F		74	N. J. J. L. J. J. J. L. J. L. J. L. J. J. J. L. J. J. J. L. J. J. J. L. J. J. J. J. L. J. J. J. J. L. J. J. J. J. L. J. L. J.		10	
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
358	849	AJ799784	599.82+/-379.39		603.99+/-383.42	603.99+/-383.42	603.99+/-383.42
			67.15+/-81.53		148.43+/-186.96	63.08+/-91.29	38.2+/-47.49
			NI=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 9.18		Fold Change: 5.77	Fold Change: 10.41	Fold Change: 14.19
			P-value: 0		P-value: .01759	P-value: 0	P-value: 0
359	681	AI801545					107.72+/-63.11
							240.16+/-135.66
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.33
							P-value: .00036
360	682	AI803208					358.64+/-152.22
							196.65+/-140.61
			×	×	×	×	N1=39, N2=6
							Fold Change: 2.05
							P-value: .01446
361	683	AI803648	107.03+/-109.9				
			295.41+/-304.62				
			N1=39, N2=168	×	×	×	×
			Fold Change: 2.31	•	•	1	•
			P-value: 0				
362	684	AI804054	307.23+/-232.94			302.97+/-234.41	302.97+/-234.41
			92.54+/-103.69			73.14+/-50.57	43.17+/-28.15
			NI=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.71			Fold Change: 3.81	Fold Change: 5.95
			P-value: 0			P-value: 0	P-value: 0
363	989	AI806221	206.98+/-125.27		206.98+/-125.27	206.98+/-125.27	206.98+/-125.27
			57.8+/-39.92		64.87+/-57.18	49.38+/-39.25	31.17+/-27.12
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.4		Fold Change: 2.98	Fold Change: 3.82	Fold Change: 5.54
			P-value: 0		P-value: .00675	P-value: 0	P-value: 0
364	<b>289</b>	AI806324	214.04+/-130.5			211.46+/-131.17	211.46+/-131.17
			64.16+/-76.08			48.58+/-64.25	21.48+/-26.9
			NI=40, N2=168	×	×	NI=40, N2=31	N1=40, N2=10
			Fold Change: 3.61			Fold Change: 4.36	Fold Change: 6.44
			P-value: 0			P-value: 0	P-value: 0

					•		
*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
365	069	AI809925				283.79+/-467.54 95.99+/-60.68	283.79+/-467.54 72.84+/-38.61
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.37	Fold Change: 3.03
						P-value: .00001	P-value: .00019
366	691	AI809953	383.3+/-186.88			383.43+/-189.32	383.43+/-189.32
			78.06+/-108.22			59.3+/-98.99	19.05+/-40.62
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.91			Fold Change: 7.01	Fold Change: 10.5
			P-value: 0		•	P-value: 0	P-value: 0
367	692	AI810042					494.45+/-173.8
					,		211.09+/-46.06
			×	×	× •	×	N1=40, N2=10
							Fold Change: 2.24
							P-value: 0
368	693	AI810266	68.69+/-105.28		68.88+/-106.64	68.88+/-106.64	68.88+/-106.64
			955.73+/-1984.55		1044.03+/-865.49	1634.45+/-2196.2	521.04+/-362.47
				×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.41		Fold Change: 16.18	Fold Change: 13.8	Fold Change: 9.22
			P-value: 0	•	P-value: .00033	P-value: 0	P-value: 0
369	694	AI810764				202.16+/-159.83	
						408.84+/-303.87	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.01	
						P-value: .00293	
370	700	AI816806	551.09+/-313.71			560.99+/-311.41	560.99+/-311.41
			267.19+/-176.02			242.91+/-135.88	221.89+/-110.66
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.1			Fold Change: 2.3	Fold Change: 2.4
			P-value: 0	•		P-value: 0	P-value: .00018
371	701	AI816835	360.85+/-289.77			360.85+/-289.77	360.85+/-289.77
			146.43+/-155.9			158.38+/-181.37	80.71+/-87.22
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.82			Fold Change: 2.55 P-value: 00002	Fold Change: 4.99 P-value: 00046
			r-vainc. O				

\_ į

Phichocals, also consocrated to

#	Coo III	Conhonk	Normal ve All	Normal ve Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
372	702	AI817448		X	X	×	241.5+/-87.57 116.59+/-51.83 N1=40, N2=10 Fold Change: 2.2 P-value: .003
373	703	AI817698	×	X	X	879.11+/-582.6 519.31+/-493.58 N1=40, N2=31 Fold Change: 2.38 P-value: .0048	×
374	706	AI818579	396.29+/-225.56 181.53+/-192.42 N1=40, N2=168 Fold Change: 2.49 P-value: 0	·×	×	394,08+/-228.07 173.3+/-120.25 N1=40, N2=31 Fold Change: 2.39 P-value: .00004	×
375	707	AI819198	X	×	×	24.28+/-46.39 341.95+/-719 N1=40, N2=31 Fold Change: 2.75 P-value: .00243	X
376	708	AI819340	60.25+/-126.35 301.57+/-342.95 N1=40, N2=168 Fold Change: 3.51 P-value: 0	×	63.25+/-126.56 247.5+/-201.27 N1=40, N2=6 Fold Change: 3.53 P-value: .04505	63.25+/-126.56 468.97+/-447.94 N1=40, N2=31 Fold Change: 5.82 P-value: 0	63.25+/-126.56 450.47+/-509.91 N1=40, N2=10 Fold Change: 4.85 P-value: .00541
377	709	AI820661	-117.72+/-96.27 255.76+/-788.64 N1=40, N2=168 Fold Change: 2.95 P-value: 0	×	×	×	×
378	711	AI821432	×	×	×	349.15+/-245.88 114.84+/-86.63 N1=40, N2=31 Fold Change: 2.66 P-value: .00004	349.15+/-245.88 55.83+/-64.32 N1=40, N2=10 Fold Change: 5.96 P-value: .00004

#	Sed II	Conhonic					
37.0	Tage Tage	Gennalik	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
3/3	717	AI821472	524.32+/-685.96		519.11+/-694.13	519 11+/-694 13	
			227.66+/-1932.77		10.64+/-179.34	83.31+/-629.25	
			N1=40, N2=168	×	N1=40 N2=6	N1=40 N2=31	>
			Fold Change: 5.78	1	Eold Change 4 41	10-7v1, 04-1v1	≺
			P-value: 0		Four Change: 4.41 P-value: .02894	rold Change: 5./6	
380	713	AI823572	231.34+/-193.19			232 21+/-195 63	
			124.55+/-179.13			80 48+/-58 66	
			N1=40, N2=168	×	×	N1=40 N2=31	>
			Fold Change: 2.37		•	To 14 Change 2 00	<
			P-value: 0			rold Change: 2.82 P-value: 0	
381	714	AI823649	88.12+/-78.99			88.12+/-78.99	88 124/ 78 00
			225.47+/-213.09			223.88+/-174.27	730 734/-737 02
			N1=39, N2=168	×	×	N1=39, N2=31	N=30 N2=K
			Fold Change: 2.16			Fold Change: 2.31	Fold Change: 2.2
500	300		P-value: 0			P-value: 0	P-value: .01309
700	07/	A1825877				418.53+/-162.52	418.53+/-162.52
			į			174.35+/-58.42	183.59+/-84.31
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.28	Fold Change: 2.23
56	22.5	1 7007 / 004				P-value: 0	P-value: .00011
200	77/	A1826437	44.87+/-117.62			45.86+/-118.99	
			241.17+/-525.8			347.56+/-551.29	
			NI=40, N2=168	×	×	N1=40, N2=31	×
			Ford Change: 2.29 P-value: 0			Fold Change: 3.07	
384	723	AI827230	711 88+1.768			r-value: .00134	
			325.69+/-167.35			708.38+/-270.57	708.38+/-270.57
			N1=40 N2=168	Þ	7	200.08+/-114.65	273.56+/-97.64
			Eold Chance, 2 22	<	≺	NI=40, N2=31	N1=40, N2=10
			rond Change: 2.22			Fold Change: 2.67	Fold Change: 2.5
205	707	A TORROLL	r-value: 0			P-value: 0	P-value: 0
000	<del>4</del> 7/	A182/248					1009.54+/-892.35
			>	>	ř	i	424.88+/-561.45
			<b>&lt;</b>	<	⊀	×	N1=40, N2=10
							Fold Change: 3.8
							P-value: .0309

BNSDOCID: WO MONEOSTIAS I

	Canhank	Normal ve All	Normal ve Malianant	Normal ve Stage I	Normal ve Stage II	Normal ve Stage III
725	₹			999		55.74+/-25.88 208.73+/-146.52
		×	×	×	×	N1=40, N2=10 Fold Change: 3.44 P-value: .0001
730	AI829520	78.95+/-63.55 221.75+/-308.11 N1=39, N2=168 Fold Change: 2.05 P-value: 0	×	×	×	×
733	AI833102	X	X	×	×	152.23+/-73.43 301.22+/-134.13 N1=40, N2=10 Fold Change: 2.05 P-value: .00005
734	A1857788	×	X	×	×	201.77+/-88.15 79.71+/-43.65 N1=40, N2=10 Fold Change: 2.61 P-value: .00082
735	A1857856	×	×	×	157.81+/-89.37 341.48+/-151.28 N1=39, N2=31 Fold Change: 2.22 P-value: 0	157.81+/-89.37 329.17+/-128.25 N1=39, N2=6 Fold Change: 2.15 P-value: .00013
739	AI859620	47.7+/-100.9 335.29+/-308.39 N1=39, N2=168 Fold Change: 4.1 P-value: 0	×	×	47.7+/-100.9 292.66+/-218.11 N1=39, N2=31 Fold Change: 4.09 P-value: 0	47.7+/-100.9 289.43+/-181.71 N1=39, N2=6 Fold Change: 3.84 P-value: .00203
740	AI860012	X	×	<b>×</b>	91.22+/-72.75 226.82+/-105.84 N1=39, N2=31 Fold Change: 2.64 P-value: 0	91.22+/-72.75 232.58+/-120.25 N1=39, N2=6 Fold Change: 2.58 P-value: .00185

BNSDOCID: <WO 02059271A2 ! >

7	E - Co	Carteril	Mercal and All	Mountain Malianant	Normal ve Ctore I	Normal ve Cton II	Normal we Const III
*	Than	Cellualin	1101 IIIai vs Aui	IVOLINAL VS IVIAIIBIIAIIL	Mol mal vs Stage 1	1101 Iliai vs Stage II	Not illat vs Stage Lit
393	742	AI860651				183.59+/-123.14 449.58+/-384.81	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.2 P-value: 0	
394	743	AI863166			225.98+/-111.31		
<u> </u>	<u>:</u>				101.21+/-69.32		
			×	×	N1=39, N2=10	×	×
					Fold Change: 2.4		
					F-value: .04/3		
395	747	AI864898	406.1+/-256.59			401.86+/-258.51	401.86+/-258.51
			54.76+/-81.97			39.21+/-56.87	31.77+/-56.32
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 8.17			Fold Change: 9.5	Fold Change: 10.87
			P-value: 0			P-value: 0	P-value: 0
396	748	A1868289				386.08+/-242.58	386.08+/-242.58
						184.36+/-111.4	156.1+/-103.22
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.22	Fold Change: 2.54
						P-value: .00003	P-value: .00207
397	750	AI871044	777.08+/-499.12			766.39+/-500.99	766.39+/-500.99
			185.08+/-242.68			180.1+/-276.48	112.03+/-106.51
			N1=40, N2=168	×	×	N1=40, N2=31	NI=40, N2=10
			Fold Change: 4.86			Fold Change: 5.2	Fold Change: 6.31
			P-value: 0			P-value: 0	P-value: 0
398	751	AI872267	267.23+/-203.1			267.23+/-203.1	267.23+/-203.1
			574.94+/-319.02			557.03+/-278.09	504.87+/-295.04
_			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.41			Fold Change: 2.36	Fold Change: 2.17
			P-value: 0			P-value: .00001	P-value: .00277
399	753	AI885164					99.32+/-89.64
			;	,	;	;	276.5+/-111.42
			×	*	<	<	NI=40, NZ=10
							Fold Change: 2.94 P-value: 00002
							20000 :

#	Sea ID	Genhank	Normal vs All	Normal ve Malionant	Normal ve Stage I	Normal ve Stage II	Normal ve Stage III
400	754	AI885498	220.94+/-153.32 574.07+/-702.09 N1=40, N2=168 Fold Change: 2.02 P-value: .00005	×	×	×	X
401	755	AI885781	×	×	×	219.35+/-109.49 556.06+/-397.8 N1=40, N2=31 Fold Change: 2.14 P-value: .00015	219.35+/-109.49 582.43+/-483.5 N1=40, N2=10 Fold Change: 2.47 P-value: .00109
402	757	AI887362	X	×	×	817.12+/-289.64 355.42+/-140.94 N1=40, N2=31 Fold Change: 2.26 P-value: 0	817.12+/-289.64 243.89+/-105.11 N1=40, N2=10 Fold Change: 3.29 P-value: 0
403	758	AI888322	×	X	×	319.22+/-320.74 161.88+/-221.65 N1=40, N2=31 Fold Change: 2.73 P-value: .00024	319.22+/-320.74 108.01+/-133 N1=40, N2=10 Fold Change: 3.9 P-value: .00657
404	761	AI889178	X	×	372.23+/-146.77 183.45+/-70.01 N1=39, N2=10 Fold Change: 2.03 P-value: .00518	372.23+/-146.77 196.21+/-126.54 N1=39, N2=31 Fold Change: 2.04 P-value: 0	372.23+/-146.77 194.59+/-97.59 N1=39, N2=6 Fold Change: 2.03 P-value: .00236
405	762	AI889959	X	×	×	140.79+/-151.42 298.84+/-296.55 N1=40, N2=31 Fold Change: 2.11 P-value: .00028	140.79+/-151.42 319.25+/-177.44 N1=40, N2=10 Fold Change: 2.62 P-value: .00302
406	763	AI890418	218.25+/-140.58 37.18+/-39.2 N1=39, N2=168 Fold Change: 3.82 P-value: 0	×	218.25+/-140.58 76.35+/-66.16 N1=39, N2=10 Fold Change: 3.02 P-value: .02078	218.25+/-140.58 35.49+/-32.04 N1=39, N2=31 Fold Change: 3.92 P-value: 0	218.25+/-140.58 26.22+/-48 N1=39, N2=6 Fold Change: 4.12 P-value: 0

#	Clean II	Canbonk	Normal ve All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
407	<b>4</b>	AI890488					498.18+/-173.26
!							235.59+/-100.47
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.19
							P-value: .00095
408	760	A1912772					124.98+/-38.73
2	è						344.88+/-151.12
			×	×	×	×	N1=40, N2=10
			<b>:</b>	!			Fold Change: 2.65
							P-value: .00005
400	777	A1916544	150 68+/-161 18			151.27+/-163.24	151.27+/-163.24
6	3	TLCOY CTU	440 12+/-478 52			548.66+/-436.19	636.35+/-560.17
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2 97			Fold Change: 3.81	Fold Change: 3.69
			P-value: 0			P-value: 0	P-value: .01086
410	775	A TO1 7901	501 38+/-804 54		601.53+/-812.45	601.53+/-812.45	601.53+/-812.45
110		10011000	76 34/200 26		57.95+/-67.95	32.64+/-44.74	15.05+/-18.69
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.07		Fold Change: 4.77	Fold Change: 6.97	Fold Change: 9.62
			P-value: 0		P-value: .00228	P-value: 0	P-value: 0
411	776	A1921685	102 15+/-191 42			104.01+/-193.56	
1	2	20018/11/	374 73+/-772 23			633.55+/-1087.03	
			N1=40. N2=168	×	×	NI=40, N2=31	×
			Fold Change: 2.03			Fold Change: 3.3	
			P-value: .0025			P-value: .00274	
412	111	AI922892				203.33+/-90.32	203.33+/-90.32
	:					481.16+/-300.69	498.39+/-402.89
			×	×	×	N1=39, N2=31	N1=39, N2=6
			<b>!</b>			Fold Change: 2.13	Fold Change: 2.02
						P-value: 0	P-value: .02385
413	778	AI923108				245.08+/-135.84	
			,	>	>	N1=40 N2=31	×
			<	<b>&lt;</b>		Fold Change: 2.16	l
						r-value. o	

*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
414	67.1	AI924028					426.33+/-126.02 190+/-63.01
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.25
415	780	A1924465	448.27+/-478.27		448.27+/-478.27	448.27+/-478.27	448.27+/-478.27
			123.26+/-122.11		110.32+/-53.45	104.34+/-104.06	46.51+/-27.28
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.18		Fold Change: 2.73	Fold Change: 3.88	Fold Change: 6.5
			P-value: 0		P-value: .00317	P-value: 0	P-value: 0
416	781	AI924794				132.27+/-116.84	132.27+/-116.84
						324.59+/-170.2	321.46+/-186.7
			×	×	×	N1=39, N2=31	N1=39, N2=6
	•					Fold Change: 2.6	Fold Change: 2.5
						P-value: 0	P-value: .0029
417	782	AI927695					624.33+/-219.53
							287.2+/-131.6
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.22
							P-value: .00029
418	784	AI928296		!	-		146.02+/-113.56
							281.82+/-97.95
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.05
							P-value: .00016
419	785	AI928393	302.49+/-122.77			297.26+/-119.77	297.26+/-119.77
			166.83+/-119.33			142.57+/-77.64	130.31+/-96.66
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.17	Fold Change: 2.67
			P-value: 0			P-value: 0	P-value: .0034
420	787	AI934361	215.99+/-241.37		220.01+/-243.16	220.01+/-243.16	220.01+/-243.16
			49.3+/-62.57		47.28+/-26.36	33.19+/-18.11	32.04+/-24.58
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.48		Fold Change: 3.18	Fold Change: 4.31	Fold Change: 4.29
			P-value: 0		P-value: .00079	P-value: 0	P-value: 0

BNSDOCID: <WO 02059271A2 ! >

	5	1	Monthly All	Normal ve Malianant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
*	Sed ID	Сепрапк	NOTITIAL VS ALL	IVOI IIIAI VS IVIAIIBLIAIIL	Column 13 Diago	9	100 611/100 02
421	788	AI934407					377.54+/-147.2
			*	*	×	×	N1=40, N2=10
			<b>4</b>	•			Fold Change: 2.61
							P-value: .00001
422	707	AT035015	26 52+/-106 71			28.01+/-107.68	28.01+/-107.68
771	40	CT/22/TU	267 11+/-334 72			364.49+/-370.15	510.1+/-498.57
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.41	1		Fold Change: 6.74	Fold Change: 8.29
			P-value: 0			P-value: 0	P-value: .00153
422	702	A1036600				769.05+/-392.56	769.05+/-392.56
C7+	661	ALCOURT,				344.85+/-187.03	208.46+/-65.42
			*	×	×	N1=40, N2=31	N1=40, N2=10
			•	!		Fold Change: 2.04	Fold Change: 3.07
						P-value: .00007	P-value: 0
5	707	A1026973					109.06+/-86.01
+7+	<u>.</u>	C700CCTW					210.69+/-119.04
			×	×	×	×	N1=40, N2=10
			•				Fold Change: 2.33
							P-value: .00059
425	705	A1937060	73 53+/-63 87			73.53+/-63.87	73.53+/-63.87
7		20016	221 63+/-200 57			275.58+/-253.28	293.86+/-212.3
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2 37			Fold Change: 2.86	Fold Change: 3.17
			P-value: 0			P-value: 0	P-value: .00776
426	962	AI937365	458.68+/-248.47		461.09+/-251.24	461.09+/-251.24	
			1357.16+/-1303.29	*	N1=40 N2=6	N1=40, N2=31	×
			NI-40, INZ-100		To 14 Change 2 91	Fold Change: 7 37	
			Fold Change: 2.31		Fold Change: 5.61 P-value: .03322	P-value: .00007	
424	700	A1030507	I -value. 0				67.26+/-38.98
} 	967	100/07				;	211.34+/-144.81
			×	×	×	×	NI=40, NZ=10
							Fold Change: 2.91 P-value: .00102

#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
428	803	AI950023				335.59+/-291.5	335,59+/-291.5
						129.73+/-80.19	94.45+/-69.77
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.04	Fold Change: 2.9
						P-value: .00084	P-value: .00112
429	805	AI952965				161.89+/-108.6	161.89+/-108.6
						347.01+/-159.99	461.65+/-262.27
_			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.38	Fold Change: 2.78
					•	P-value: 0	P-value: .00455
430	908	AI953053					96.66+/-61.58
							403.41+/-323.73
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.33
							P-value: .00265
431	808	AI954874			209.46+/-107.86		
					96.19+/-23.42		
			×	×	N1=40, N2=6	×	*
					Fold Change: 2 01	4	4
					P-value: .00017		
432	810	A1961206				46 06+1-77 63	46 06±1.77 63
}	)					2017/-/100	10.7/1-7/100.04
			,	,	,	204.267/-102.53	4.501-/-105.4
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 3.96	Fold Change: 4.13
						P-value: 0	P-value: .00043
433	817.	AI968379	296.71+/-383.1			295.46+/-388.02	295.46+/-388.02
			45.24+/-243.3			104.96+/-424.91	-12.25+/-22.65
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.99			Fold Change: 4.47	Fold Change: 6.3
			P-value: 0		-	P-value: .00001	P-value: 0
434	818	AI968904	744.48+/-291.11			738.79+/-292.65	
			370.58+/-143.78			373.44+/-151.46	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2			Fold Change: 2.01	
			P-value: 0			P-value: 0	

- 10

#	Seq ID	Genbank	Normal vs All	Normal vs Malionant	Normal ve Stage I	Normal va Ctage	
435	822	A1070808	· 505 50±/ 422 11	Amargament of tarretor	Aloninal Vs Stage 1	MOLINAL VS STABE II	Normal vs Stage III
?		0.000	143 241, 54 20		509.53+/-426.92	509.53+/-426.92	509.53+/-426.92
			142.34+/-84.59		155.46+/-70.61	116.99+/-60.55	117.04+/-63.48
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40 N2=10
			Fold Change: 3.33		Fold Change: 2.81	Fold Change: 3.87	Eold Change, 2 00
			P-value: 0		P-value: 00097	Prvalue: 0	Total Change: 5.66
436	823	AI971441			274 36-1-458 15	77 754 750 15	DOA DOLLOGO SE
					C1.9C7-1.9C1.72	224.30T/-238.I3	224.36+/-258.15
			>	,	25.49+/-91	44.4+/-132.79	-63.46+/-142.66
			<	<b>×</b>	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
					Fold Change: 3.79	Fold Change: 2.75	Fold Change: 4.45
127	200	A TOPEON A			P-value: .01447	P-value: .0003	P-value: .0004
<u>.</u>	/70	AL9/1914					121.63+/-64.27
			,	i			329.2+/-298.85
			≺	×	×	×	N1=40, N2=10
							Fold Change: 2.25
430	020	A TO-70 400	100000				P-value: .00832
2	000	A19/2498	72.111.77		٠	286.51+/-112.64	286.51+/-112.64
			134.28+/-/1.62	!		124.7+/-61.16	109.37+/-47.71
			NI=40, NZ=168	, ×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.22			Fold Change: 2.3	Fold Change: 2.7
15	100	777 0000	F-value: 0			P-value: 0	P-value: .00057
404	100	AL972661				482.12+/-600.67	
						177.9+/-209.56	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.24	
						P-value: .01047	
440	832	AL972873	437.97+/-212.54		436.16+/-215	436.16+/-215	436.16+/-215
			117.56+/-101.2		164.58+/-155.74	126.68+/-109.81	75.01+/-128.01
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40 N2=10
			Fold Change: 4.55		Fold Change: 3.37	Fold Change: 4 14	Fold Change: 8 78
			P-value: 0		P-value: .021	P-value: 0	P-value: 00006
441	836	AI979261				145.88+/-125.11 301.16+/-194.23	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.17	
						***************************************	

DEIGNOCIN JAKO MONEDOTELAN I

		-	NT A.10	M. Malianout	Moumol so Chang I	Normal ve Stage II	Normal vs Stage III
*	Sed ID	Genbank	Normal vs All	NOTHER VS IVIAIIBLIAIIL	Ivol mai vs Stage I	Mol mar vs Dungs At	Contract to the contract to th
442	837	AJ982669				352.73+/-154.77	352.73+/-154.77
!						769.65+/-400.6	839.63+/-451.94
			*	×	×	N1=39, N2=31	N1=39, N2=6
			4			Fold Change: 2.11	Fold Change: 2.2
						P-value: 0	P-value: .00452
443	838	A1983045	282.14+/-333.79		281.02+/-338.08	281.02+/-338.08	281.02+/-338.08
2	8		5 19-/+08 6-		6.46+/-26.18	-12.28+/-33.2	-25.74+/-23.32
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.23	•	Fold Change: 6.38	Fold Change: 6.91	Fold Change: 7.49
			P-value: 0		P-value: 0	P-value: 0	P-value: 0
444	840	A1985653				243.4+/-112.77	243.4+/-112.77
	2					111.29+/-55.01	81.33+/-38.99
			<b>×</b>	×	×	N1=39, N2=31	N1=39, N2=6
			1			Fold Change: 2.12	Fold Change: 2.93
						P-value: 0	P-value: 0
445	841	AI989588			160.57+/-119.71		
2	! !				240.25+/-78.81		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.01		
					P-value: .00445		
446	846	AI990483				35.21+/-34.58	
:	?					207.82+/-290.06	
			×	×	×	N1=40, N2=31	×
			:	-		Fold Change: 2.5	
						P-value: .00091	
447	853	AL031846	446.58+/-157.69			446.58+/-157.69	446.58+/-157.69
:	}		203.55+/-90.87			182,45+/-74.24	148.67+/-68.99
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.21			Fold Change: 2.41	Fold Change: 3.01
			P-value: 0			P-value: 0	P-value: .00002
448	855	AL037368					576.75+/-132.07
			>	*	*	*	296.13+/-132.53 N1=40, N2=10
			<b>&lt;</b>	ŧ	<b>;</b>	<b>:</b>	Fold Change: 2.12
							F-value: .0014

Action   A	٦	1	-					
S67   AL037805   264.14-168.3   X   X   X   28.58+7.14.29     S60   AL039870   229.33+1-19.68   X   X   X   X   X   X   X   X   X	*	Sed III	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
S60   AL03945   N1=40, N2=18	449	857	AL037805	624.14+/-319.31			614 2+/-317 15	614 24/ 317 15
S60   AL03945   Ni=60, N2=163   X   X   X   X   X   X   X   X   X				281 044/ 168 3			0.0110-1-2110	01-7-7-10
Ni = 40, N2 = 108				201-7+4-100.3	4		228.28+/-142.99	168.59+/-62.09
R60   AL039445   P-value: 0   P-value: 0				NI=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
S60   AL039445   P-value: 0   P-value: 0				Fold Change: 2.29			Fold Change: 2.38	Fold Change: 3.3
S61   AL039870   229.33+119.68   X	1			P-value: 0			P-value: 0	P-value: 0
National Section	2	99g	AL039445					103.65+/-39.97
Section								204.36+/-54.58
861         AL039870         229.33+4-119.68         X         X         NI=40, N2=31           862         AL039977         229.33+4-119.68         X         X         NI=40, N2=31           864         AL040178         277.18+1-128.12         277.18+1-128.12         277.18+1-128.12           865         AL040912         277.18+1-28.12         277.18+1-128.12         277.18+1-128.12           865         AL040912         31.14+7.13.52         86.94+6.64         NI=39, N2=16         NI=39, N2=31           866         AL040912         31.14+7.13.72         Pold Change: 2.79         Pold Change: 3.76         Pavalue: 0           866         AL041815         257.28+1-104.74         S57.28+1-106.11           100 AL041815         257.28+1-104.74         S57.28+1-106.11           100 AL041816         129.57+4-68.69         NI=40, N2=31           100 AL041816         129.57+4-68.69         NI=40, N2=31           100 Change: 2.04         Pavalue: 0         Pavalue: 0           100 Change: 2.04         Pavalue: 0         Pavalue: 0           101 Change: 2.04         Pavalue: 0         Pavalue: 0           101 Change: 2.04         Pavalue: 0         Pavalue: 0				×	×	×	×	N1=40, N2=10
861         AL039870         229.33+/-119.68         X         X         226.44+/-119.79           862         AL039917         X         X         X         NI=40, N2=54           862         AL049178         277.18+/-128.12         P-value: 0         P-value: 0           864         AL040178         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12           865         AL040912         311.14+/-137.52         S9.11+/-47.84         NI=39, NZ=10           866         AL041815         277.28+/-104.74         S6.44+/-106.11         S0.11+/-47.84           866         AL041815         277.28+/-104.74         S7.28+/-106.11         S7.28+/-106.11           866         AL041815         257.28+/-104.74         S7.28+/-106.11         S7.28+/-106.11           866         AL041815         257.28+/-104.74         S7.28+/-106.11         S7.38+/-106.11           866         AL041815         257.28+/-104.74         S7.28+/-106.11         S7.28+/-106.11           866         AL041815         257.28+/-106.11         S7.28+/-106.11           866         AL041815         X         NI=40, NZ=31           867         P-value: 0         P-value: 0         P-value: 0           868         AL041815								Fold Change: 2.03
861         AL039870         229.33+7.119.68*         26.47+719.79           862         AL039917         X </td <th></th> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>P-value: 0</td>								P-value: 0
104 084-f.62.24	21	861	AL039870	229.33+/-119.68			226.4+/-119.79	226.4+/-119.79
NI=40, N2=168				104.08+/-62.24			95.07+/-69.54	85.61+/-45.98
Fold Change: 2.19   Fold Change: 2.41				N1=40, N2=168	×	×.	N1=40, N2=31	N1=40, N2=10
862         AL039917         X				Fold Change: 2.19			Fold Change: 2.41	Fold Change: 2.58
862         AL039917         X         Y         X         X         X				P-value: 0			P-value: 0	P-value: .0005
864         AL040178         277.18+/-128.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12         277.18+/-138.12	25	862	AL039917					190.41+/-139.22
864         AL040178         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         X	ı							427.64+/-204.38
864         AL040178         277.184/-128.12         277.184/-138.12				×	×	×	×	N1=40, N2=10
864         AL040178         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         277.18+/-128.12         39.11+/-47.84         N1=39, N2=10         N1=39, N2=31         N1=39, N2=31         N1=39, N2=31         Prold Change: 2.79         Fold Change: 3.76         Prold Change: 3.77         Prold Change: 3.77 </td <th></th> <td>•</td> <td></td> <td></td> <td>•</td> <td></td> <td></td> <td>Fold Change: 2.48</td>		•			•			Fold Change: 2.48
864         AL040178         277.18+/-128.12         278.14/-47.84         277.18+/-128.12         278.14/-47.84         278.14/-47.84         278.14/-47.84         278.14/-47.84         278.14/-47.84         278.14/-47.84         278.14/-137.78         278.14/-1					•			P-value: .00467
865         AL040912         31.14+.47.84         N1=39, N2=16         S9.11+.47.84           866         AL041815         257.28+.104.74         X         N1=40, N2=31         Fold Change: 2.04         P-value: 0         P-value: 0           866         AL041815         257.28+.104.74         X         X         N1=40, N2=31         Fold Change: 4.66         P-value: 0         P-value: 0           866         AL041815         257.28+.104.74         X         N1=40, N2=31         Fold Change: 4.66         P-value: 0         P-value: 0         P-value: 0           866         AL041815         257.28+.104.74         X         N1=40, N2=31         Fold Change: 4.66         P-value: 0           P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0	53	864	AL040178	277.18+/-128.12		277.18+/-128.12	277.18+/-128.12	277.18+/-128.12
865         AL040912         N1=39, N2=168         X         N1=39, N2=31           866         AL041815         257.28+/-104.74         X         N1=39, N2=10         N1=39, N2=31           866         AL041815         257.28+/-104.74         X         N1=40, N2=31         P-value: 0           866         AL041815         257.28+/-104.74         X         N1=40, N2=31         P-value: 0           866         AL041815         257.28+/-104.74         X         N1=40, N2=31         P-value: 0           N1=40, N2=168         X         X         N1=40, N2=31         P-value: 0         P-value: 0           866         AL041815         257.28+/-104.74         X         N1=40, N2=31         P-value: 0           P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0				73.94+/-56.64		106.38+/-90.67	59.11+/-47.84	44.44+/-29.67
865         AL040912         Fold Change: 3.48         Fold Change: 3.76           865         AL040912         311.14+/-137.52         P-value: 0         P-value: 0           865         AL040912         311.14+/-137.52         Recompleted on the control of th				NI=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
865         AL040912         P-value: 0         P-value: 0         P-value: 0           865         AL040912         311.14+/-137.52         86.94+/-86.46         X         P-value: 0         P-value: 0           860         AL041815         257.28+/-104.74         X         N1=40, N2=31         P-value: 0           866         AL041815         257.28+/-104.74         257.35+/-106.11         124.69+/-56.27           N1=40, N2=168         X         X         N1=40, N2=31           Fold Change: 2.04         P-value: 0         P-value: 0           P-value: 0         P-value: 0         P-value: 0				Fold Change: 3.48		Fold Change: 2.79	Fold Change: 3.76	Fold Change: 4.57
865         AL040912         311.14+/-137.52         304.56+/-132.78           86.94+/-86.46         X         X         N1=40, N2=31           Fold Change: 4.08         X         N1=40, N2=31           Fold Change: 4.08         Fold Change: 4.66         P-value: 0           866         AL041815         257.28+/-104.74         257.35+/-106.11           129.57+/-68.69         X         N1=40, N2=31           Fold Change: 2.04         Fold Change: 2           P-value: 0         P-value: 0				P-value: 0		P-value: .01209	P-value: 0	P-value: 0
866 AL041815 257.28+/-104.74  866 AL041815 257.28+/-104.74  Fold Change: 2.04  Fold Change: 2.04  Roll Change: 2.04  Fold Change: 2.04	<b>X</b>	865	AL.040912	311.14+/-137.52			304.56+/-132.78	304.56+/-132.78
Fold Change: 4.08   Fold Change: 4.66				80.94+/-80.46			69.8+/-53.68	52.07+/-61.09
Fold Change: 4.08 P-value: 0  866 AL041815 257.28+/-104.74 129.57+/-68.69 N1=40, N2=168 Fold Change: 2.04 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 4.66 P-value: 0 P-value: 0 P-value: 4.66 P-value: 0 P-value: 0 P-value: 0 P-value: 0 P-value: 0				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
866         AL041815         257.28+/-104.74         P-value: 0           129.57+/-68.69         X         124.69+/-56.27           N1=40, N2=168         X         N1=40, N2=31           Fold Change: 2.04         Fold Change: 2           P-value: 0         P-value: 0				Fold Change: 4.08			Fold Change: 4.66	Fold Change: 6.69
866 AL041815 257.28+/-104.74 257.35+/-106.11 129.57+/-68.69 X X 124.69+/-56.27 N1=40, N2=168 X N1=40, N2=31 Fold Change: 2.04 P-value: 0 P-value: 0				P-value: 0			P-value: 0	P-value: ,00001
124.69+/-56.27 X N1=40, N2=31 Fold Change: 2 P-value: 0	22	998	AL041815	257.28+/-104.74			257.35+/-106.11	
X N1=40, N2=31 Fold Change: 2 P-value: 0				129.57+/-68.69			124.69+/-56.27	
Fold Change: 2 P-value: 0				N1=40, N2=168	×	×	N1=40, N2=31	×
				Fold Change: 2.04			Fold Change: 2	1
				P-value: 0			P-value: 0	

DEICHOCIN- JAIN - 000E0071A2 I -

I D Genbank	Genbank Normal vs All		Normal vs	Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
867 AL042492 801.96+/-843.5 56.95+/-101.91		801.96+/-843.5 56.95+/-101.91			809.69+/-853.09 101.65+/-170.57	809.69+/-853.09 40.59+/-106.87	809.69+/-853.09 11.79+/-18.8
N1=40, N2=168	N1=40, N2=168	N1=40, N2=168		×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
Fold Change: 12.71 P-value: 0	Fold Change: 12.71 P_value: 0	Fold Change: 12.71			Fold Change: 8.78 P-value: 00362	Fold Change: 15 P-value: 0	Fold Change: 20.99
868 AL042923							3125.4+/-1239.9
×	×	×		×	×	×	N1=40, N2=10
							Fold Change: 2.07 P-value: .00207
870 AL043980	AL043980					498.96+/-198.25	498.96+/-198.25
	;			;	į	248.27+/-101.89	206.45+/-96.76
×	×	×		×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.06 P-value: 0	Fold Change: 2.43 P-value: .00002
871 AL044366 137.98+/-186.9		137.98+/-186.9	j 1				
N1=40, N2=168 Fold Change: 2.23 P-value: .00018	N1=40, N2=168 Fold Change: 2.23 P-value: .00018	N1=40, N2=168 Fold Change: 2.23 P-value: .00018		×	×	×	×
872 AL044613							304+/-112.89
							102.49+/-79.71
×	×	×		×	×	×	N1=40, N2=10
							Fold Change: 3.15
							P-value: .00076
876 AL046941 425.75+/-236.48	425.75+/-	425.75+/-236.48				428.58+/-238.89	428.58+/-238.89
53.79+/-102.7	53.79+/-102.7	53.79+/-102.7				34.11+/-80.54	-23.64+/-33.24
N1=40, N2=168	N1=40, N2=168	N1=40, N2=168		×	×	N1=40, N2=31	NI=40, N2=10
Fold Change: 8.01	Fold Change: 8.01	Fold Change: 8.01				Fold Change: 9.66	Fold Change: 16.81
P-value: 0	P-value: 0	P-value: 0				P-value: 0	P-value: 0
877 AL046946	AL046946						713.56+/-217.52
×	×	×		×	×	×	N1=40, N2=10
							Fold Change: 2.57
							P-value: .00006

ENGLACIO AMO GODEOSTIAS I

18,40

#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
463	878	AL048304					308.79+/-74.62
							97.9+/-114.69
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.99
							P-value: .00402
464	879	AL048386	233.2+/-107.71			232.52+/-109.03	232.52+/-109.03
			118.45+/-83.53			94.13+/-59.17	73.94+/-51.55
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.19			Fold Change: 2.63	Fold Change: 3.32
			P-value: 0			P-value: 0	P-value: .00019
465	880	AL048399				768.94+/-280.35	768.94+/-280.35
						336.8+/-159.66	378.81+/-201.68
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.37	Fold Change: 2.22
						P-value: 0	P-value: .00292
466	881	AL048962	951.97+/-353.33			944+/-354.29	944+/-354.29
			498.61+/-346.17			469.14+/-334.1	400.6+/-283.17
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.17	Fold Change: 2.45
			P-value: 0			P-value: 0	P-value: .00012
467	883	AL049257				258.77+/-104.32	258.77+/-104.32
						110.97+/-53.29	104.27+/-37.82
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.35	Fold Change: 2.34
				•		P-value: 0	P-value: 0
468	884	AL049423				385,45+/-146.45	385.45+/-146.45
						176.43+/-82.21	131.88+/-33.79
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.19	Fold Change: 2.73
						P-value: 0	P-value: 0
469	885	AL049471				585.55+/-164.83	585.55+/-164.83
						312.66+/-134.95	304.04+/-127.09
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.01	Fold Change: 2.01
						D section O	D 000064

#	Sea ID	Genhank	Normal ve 411	N	,		
476	887	AI,049949	TAOLIURI VS ALI	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
						525.51+/-234.08	525.51+/-234.08
			×	>	ř	218.01+/-118.84	184.51+/-151.36
			•	<	×	NI=40, N2=31	N1=40, N2=10
						Fold Change: 2.27	Fold Change: 3.21
471	888	AL049957				P-value: 0	P-value: .00178
						664.06+/-250.51	
			>	*	į	339.26+/-164.3	
			<	<	×	N1=39, N2=31	×
						Fold Change: 1.98	
472	890	AI.050002				P-value: 0	
							320.95+/-114.96
			>	à P			152.33+/-60.11
			<	≺	×.	×	N1=40, N2=10
							Fold Change: 2.08
473	893	AT 050267	757 501 1 77 75				P-value: .00017
)		10cocococ	23/.39#/-1/./5			257.59+/-77.75	
			155+/-120.63			117 16+/-76 86	
			N1=40, N2=168	×	*	M1-40 M2-21	;
			Fold Change: 2		<b>&lt;</b>	Te-14 Cu - 10 10	×
			P-value: 0			roid Change: 2.49	
474	894	AL079279	313.49+/-189.76		212 401/ 180 20	r-value: 0	
			108.29+/-83.88		013.494/-189./0	313.49+/-189.76	313.49+/-189.76
			N1=40 N7=168	>	1147/-/0.08	86.73+/-51.4	49.04+/-28.4
			Fold Change: 287	<	NI=40, NZ=6	N1=40, N2=31	N1=40, N2=10
			P-value: 0		Fold Change: 2.51	Fold Change: 3.29	Fold Change: 5.69
475	968	AL079707	258 01+1-224 37		F-value: .00823	P-value: 0	P-value: 0
			67.86+/-48.3		261.69+/-226.08	261.69+/-226.08	261.69+/-226.08
			N1=40 N2=168	>	82.89+/-41.99	48.17+/-30.27	78.83+/-21.26
			Fold Change: 2.55	<	NI=40, N2=6	N1=40, N2=31	N1=40, N2=10
			D mange, 0.00		Fold Change: 2.73	Fold Change: 4.63	Fold Change: 2.7
476	897	AI.079769	108 26±/ 265 40		P-value: .0013	P-value: 0	P-value: 0
			337 38+/.218 01			201.74+/-268.02	201.74+/-268.02
			N1=40 N2=168	>	;	451.36+/-269.91	415.85+/-142.87
			Fold Change: 2.06	<	×	N1=40, N2=31	N1=40, N2=10
			P-value: 0			Fold Change: 2.73	Fold Change: 2.88
						P-value: 0	P-value: 0

#	Sea ID	Cenhank	Mormol no All	M			
1		Connain	IVOI mai vs Au	Normal vs Mangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
//4	898	AL079949				382.36+/-135.98	382.36+/-135.98
			;	;	i	172.14+/-65.04	160.74+/-65.7
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.21	Fold Change: 2.34
470	000	AT 000100				P-value: 0	P-value: .00001
4 / Ø	899	AL080192				103.54+/-69.27	
			;	ì		242.17+/-111.66	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.54	
1						P-value: 0	
479	903	AL120446	304.54+/-95.79			302.81+/-96.4	302.81+/-96.4
			151.01+/-51.13			143.68+/-46.25	137.13+/-46.57
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2			Fold Change: 2.07	Fold Change: 2.16
			P-value: 0			P-value: 0	P-value: .00001
480	904	AW000899	255.52+/-122.34			255.52+/-122.34	
			125.26+/-107.3			136.12+/-122.63	
			N1=39, N2=168	×	×	N1=39, N2=31	*
			Fold Change: 2.23			Fold Change: 2.06	41
			P-value: 0			P-value: .00003	
481	907	AW002846	282.39+/-199.06				283.14+/-201.6
			139.23+/-115.04				97.8+/-63.96
			NI=40, N2=168	×	×	×	N1=40, N2=10
	•		Fold Change: 2.15				Fold Change: 2.7
18	010		F-value: 0				P-value: .00045
704	716	AW003362			211.57+/-81.24 89.06+/-83.95		
			×	×	N1=39, N2=10	×	×
					Fold Change: 2 32	•	€
					P-value: .02046		-
483	914	AW005418				205.57+/-234.3	205.57+/-234.3
			;			67.1+/-110.71	10.33+/-83.48
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.41	Fold Change: 3.7
						r-value: .00065	F-value: .00052

RNSDOCID->WO 02050271A2 L>

#	Seo ID	Genhank	Normal vs All	Normal ve Malienant	Normal vs Stage I	Normal ve Stage II	Normal ve Stage
484	915	AW005814	X	X	146.08+/-90.43 310.43+/-106.68 N1=40, N2=6 Fold Change: 2.4 P-value: .00072	X	X
485	916	AW006235	344.79+/-207.97 103.81+/-60.65 N1=40, N2=168 Fold Change: 3.17 P-value: 0	×	346.9+/-210.26 126.57+/-35.39 N1=40, N2=6 Fold Change: 2.35 P-value: .00014	346.9+/-210.26 95.72+/-56.93 N1=40, N2=31 Fold Change: 3.43 P-value: 0	346.9+/-210.26 99.92+/-23.08 N1=40, N2=10 Fold Change: 2.94 P-value: 0
486	919	AW006898	841.88+/-394.55 331.12+/-203.65 N1=40, N2=168 Fold Change: 2.68 P-value: 0	×	×	835.42+/-397.56 305.25+/-163.97 N1=40, N2=31 Fold Change: 2.7 P-value: 0	835.42+/-397.56 305.65+/-212.32 N1=40, N2=10 Fold Change: 2.91 P-value: .00883
487	920	AW006998	X	×	×	79.75+/-104.09 221.43+/-283.12 N1=40, N2=31 Fold Change: 2.76 P-value: .00002	×
488	921	AW007080	226.13+/-116.85 62.58+/-55.91 N1=40, N2=168 Fold Change: 3.65 P-value: 0	X	×	223.2+/-116.87 55.48+/-39.27 N1=40, N2=31 Fold Change: 3.79 P-value: 0	223.2+/-116.87 48.27+/-49.28 N1=40, N2=10 Fold Change: 4.6 P-value: .00008
489	925	AW007586	552.57+/-493.88 992.94+/-672.01 N1=40, N2=168 Fold Change: 2.04 P-value: .00003	· X	×	552.57+/-493.88 1388.39+/-797.65 N1=40, N2=31 Fold Change: 2.99 P-value: 0	×
490	927	AW007983	308.57+/-180.09 124.89+/-104.9 N1=39, N2=168 Fold Change: 2.45 P-value: 0	×	308.57+/-180.09 120.02+/-133.67 N1=39, N2=10 Fold Change: 3.11 P-value: .02642	308.57+/-180.09 98.43+/-60.3 N1=39, N2=31 Fold Change: 2.82 P-value: 0	308.57+/-180.09 57.05+/-49.19 N1=39, N2=6 Fold Change: 4.11 P-value: 0

7	E	Conhonit	Moumol ve All	Normal ve Malignant	Normal ve Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	Sed III	Gennank	NOTHIAI VS AN	IVOI IIIAI VO IVIAIIBIIAIII	TANIMA WALLEY		
491	929	AW009505					210.48+/-63.01
			>	>	<b>&gt;</b>	×	N1=40 N2=10
			<b>&lt;</b>	<	<b>:</b>	•	Fold Change: 2.06
							P-value: ,00023
492	930	AW013949			228.98+/-140.11		
				!	720.717/-241.61	*	Þ
			×	×	N1=40, N2=6	≺	<b>≺</b>
					Fold Change: 2.49 P-value: .00743		
403	032	AW014647	222 93+/-95 23			222.93+/-95.23	222.93+/-95.23
2	707	1101101101	93 53+/-66.06			87.53+/-67.66	103.61+/-77.88
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2 35			Fold Change: 2.48	Fold Change: 2.1
			P-value: 0			P-value: 0	P-value: .00171
707	033	AW014764	299 88+/-160.3			299.88+/-160.3	
5	)		148 29+/-123 67			143.2+/-104.38	
	-		N1=30 N2=168	*	×	N1=39, N2=31	×
			Eald Change: 2 03	4	•	Fold Change: 2.02	
			P-value: 0			P-value: 0	
404	934	AW015571					648.86+/-400.58
-	1	TICCTOILE					174.43+/-228.74
			*	×	×	×	N1=40, N2=10
			•				Fold Change: 6.15
							P-value: .00262
496	938	AW021108	220,45+/-143.17			220.45+/-143.17	220.45+/-143.17
:			97 68+/-75 55			87.82+/-65.1	76.42+/-41.74
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.37			Fold Change: 2.67	Fold Change: 2.68
			P-value: 0			P-value: 0	P-value: .00045
407	030	AW021169	256 18+/-141 26				254.1+/-142.48
}	<u> </u>		128.88+/-175.65				131+/-172.12
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.2			•	Fold Change: 2.58
			P-value: 0				P-value: .00997

7		Normal ve All	Normal ve Malianant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
	1	IVOI IIIIAI VS AMI	Mornial 13 Manghan	Tolume 13 Single	- H - C - C - C - C - C - C - C - C - C	3 100 / 63 / 60
941	AW022607				820.58+/-231.5 436.42+/-247.61	384.68+/-242.39
		×	×	×	N1=40, N2=31	N1=40, N2=10
		•			Fold Change: 2.16	Fold Change: 2.39
					P-value: 0	P-value: .00116
943	AW023188				290.36+/-132.68	
					130.36+/-49.53	
		×	×	×	N1=39, N2=31	×
					Fold Change: 2.07	
9.46	2007400114				1 - value. o	250.28+/-98.87
£.	AW024203					572.73+/-295.31
		×	×	×	<b>×</b>	N1=40, N2=10
		4	<b>!</b>			Fold Change: 2.27
						P-value: .00009
946	AW024434	790.91+/-331.85			789.9+/-336.13	
		452.03=/15/ N100 N2=168	<b>?</b>	<b>&gt;</b>	N1=40 N2=31	×
		Fold Change: 2.03	<	₹	Fold Change: 2.21	
		P-value: 0			P-value: 0	
948	AW024795					194.61+/-162.76
?						374.26+/-130.52
		×	×	×	×	NI=40, N2=10
		-				Fold Change: 2.22
						P-value: .00004
952	AW044663					216.92+/-78.22
						104.46+/-39.86
		×	×	×	×	N1=40, N2=10
						Fold Change: 2.01
						P-value: .00001
953	AW051492	440.5+/-328.97			442.65+/-332.99	442.65+/-332.99
		200.34+/-109.37	•		174.66+/-95.13	133.38+/-80.06
		N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.03			Fold Change: 2.4	Fold Change: 3.04
		P-value: 0			P-value: 0	P-value: .00008

בו כבודכמבחכה השי הוצירושים

#	Sea ID	Conhonk	Normal and All	M.			
808	950	A 11/062102	200 20 1 1 1 2 2 20	Normal vs Mangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
coc	733	AW052180	200.32+/-119.43		200.32+/-119.43	200.32+/-119.43	200.32+/-119.43
			08.25+/-52.36		83.05+/-58.17	62.34+/-42.9	45.67+/-44.89
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.47		Fold Change: 2.54	Fold Change: 2.68	Fold Change: 3 64
1			P-value: 0		P-value: .0089	P-value: 0	P-value: .00001
206	956	C16443	470.61+/-305.63		470.75+/-309.62	470.75+/-309.62	470.75+/-309.62
			179.69+/-105		197.91+/-113.36	144.75+/-66.63	143.41+/-109 79
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40 N2=10
			Fold Change: 2.63		Fold Change: 2.24	Fold Change: 3.13	Fold Change: 3.40
			P-value: 0		P-value: .00778	P-value: 0	P-value: 00021
207	957	C17781	233.51+/-142.32				1 - Value: .00031
			116.34+/-81.47				
			N1=40, N2=168	×	×	>	>
			Fold Change: 2.05	ľ	:	€	<
			P-value: 0				
208	296	D55884				231.13+/-145.06	
						105.18+/-64.42	
·			×	×	×	N1=40, N2=31	×
						Fold Change: 2.13	
209	970	D63177	72.4+/-72.56			1 - value, .00004	
			225.06+/-178.61				
			N1=40, N2=168	*	>	>	,
			Fold Change: 3.08	<b>ŧ</b>	<	<	≺
1			P-value: 0				
Arc	9/1	D/9487					215.9+/-67.18
			;				84.24+/-31.19
			×	×	×	×	N1=39, N2=6
							Fold Change: 2.6
3	700						P-value: .00001
116	981	H11724				321.52+/-187.56	321.52+/-187.56
			;			158.38+/-76	124.97+/-54.73
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2	Fold Change: 2.5
						F-value: 0	P-value: .00011

. )

			N	Moumal as Malianant	Normal ve Stage I	Normal vs Stage II	Normal vs Stage III
*	Sed ID	Gendank	Normal vs All	IVOLUITAL VS IVIALIE MAIL	Tol Mai 19 Stage		
512	.983	H15868	347.4+/-390.17		344.41+/-394.81 967.69+/-1057.17		
			N1=40, N2=168	×	N1=40, N2=6	×	×
			Fold Change: 2.13		Fold Change: 3.28 P-value: 02477		
5	700	706710	r-value000+2				812.95+/-387.97
cic	407	F1077					295.8+/-82.15
			<b>&gt;</b>	*	×	×	N1=40, N2=10
			<b>4</b>	1			Fold Change: 2.51
					•		P-value: 0
1	200	H16568	203 47+/-211 85			288.53+/-212.27	288.53+/-212.27
914	200	H10300	CO:112-1-14:CC7		•	46.38+/-45.45	38.38+/-26.86
			N1=40 N2=168	*	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.74	<b>:</b>		Fold Change: 4.69	Fold Change: 5.41
			Pavalue.			P-value: 0	P-value: 0
1	200	D137040	221 24±/_117 87			221.34+/-117.87	221.34+/-117.87
CIC	707	D.6/240	86.40+/-44.22			80.01+/-37.66	76.82+/-36.99
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
	•		Fold Change: 2 46		•	Fold Change: 2.42	Fold Change: 2.75
			P-value: 0			P-value: 0	P-value: .00004
71.2	000	TA2085					405.54+/-244.99
OTC	220						174.03+/-102.69
			*	×	×	×	N1=40, N2=10
			•				Fold Change: 2.17
	•						P-value: .00064
517	991	H43374					588.83+/-221.87
	1						314.31+/-230.39
			×	×	×	×	N1=40, N2=10
			•				Fold Change: 2.1
			-				P-value: .00493
218	000	H54254	370.85+/-679.27		377.04+/-687.01	377.04+/-687.01	377.04+/-687.01
210	•		33.63+/-58.23		31.69+/-34.95	21.83+/-62.85	12.93+/-28.05
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.23		Fold Change: 4.88	Fold Change: 6.53	Fold Change: 6.25
			P-value: 0		P-value: .00045	P-value: 0	r-value: 0

BUSCOTTO--WO 0205027182 1 >

E	,	١	_	21						-	2		_	- 92	2			_	55				_	- 12						٠,		_	-
Normal vs Stage III	201 08±/_130 62	53.32+/-25	N1=40, N2=10	Fold Change: 3.21	P-value: 0			×			344.38+/-141.72	134.11+/-57.31	NI=40, NZ=10	Fold Change: 2.56	P-value: .00005	92.04+/-95.24	210.74+/-113.1	N1=40, N2=10	Fold Change: 2.65	P-value: .00009	308.47+/-138.2	118.5+/-63.44	N1=40, N2=10	Fold Change: 2.77	P-value: .00098		×			156.39+/-61.76	332.92+/-151.29	N1=40, N2=10	Fold Change, 2 1
Normal vs Stage II	201 08±1.130 62	64.47+/-33.26	N1=40, N2=31	Fold Change: 2.77	P-value: 0	822.97+/-445.6	356.31+/-294.65	'N1=40, N2=31	Fold Change: 2.5	P-value: .00002			×			92.04+/-95.24	206.91+/-82.99	N1=40, N2=31	Fold Change: 2.71	P-value: 0			×				×					×	
Normal vs Stage I	0		×		!			×					×					×					×				×					×	
Normal ve Malionant			*	ļ				×					×					×					×				×	!				×	
Normal ve All	202 114/ 127 00	82 30+/-48 64	N1=40 N2=168	Fold Change: 2.25	P-value: 0			×					×					×					×			26.22+/-51.01	N1=40, N2=168	Eold Change: 5.07	rold Change, 5.07 P-value: 0			×	
Conhank	THEORUG	A38008				N21030					N21424					N24987					N25096					N25267				N31946			
Coo H		566				1061					1064					1066					1067					1068				1071			
#	14	έΤς				520			_		521					522					523					524				525			_

-

.

- 1	W 5	Garbari.		Mound to Molimont	Normal we Stone I	Normal ve Stage II	Normal vs Stage III
- 1	Sed III	Сепрапк	INOUTHING AND	IVOI IIIAI VS IVIAIIBUAUL	MOI III AI STABE I	Month of Stage A	The second second
	1072	N32254					116.51+/-51.56 249.15+/-168.21
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.03 P-value: .0051
	1074	N42752	63.26+/-47.52			63.77+/-48.02	
			203.51+/-259.92			251.31+/-284.54	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.23			Fold Change: 2.74 P-value: .00008	
1	1075	N45224					574.83+/-196.53
							208.47+/-108.26
			×	×	×	×	N1=40, N2=10
			ł				Fold Change: 2.79
							P-value: .00004
529	1076	N45320	365.77+/-123.03			359.46+/-117.88	359.46+/-117.88
			164.05+/-84.04			163.46+/-78.87	150.13+/-52.84
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.35			Fold Change: 2.36	Fold Change: 2.34
			P-value: 0			P-value: 0	P-value: .00001
530	1079	N48809			130.33+/-82.96		130.33+/-82.96
					233.51+/-111.27		249.11+/-95.4
			×	×	N1=40, N2=6	×	N1=40, N2=10
				•	Fold Change: 2.03		Fold Change: 2.14
					P-value: .00829		P-value: .00153
1	1082	N51335				108.78+/-93.56 222.06+/-201.45	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2	
						P-value: .00003	
532	1083	N52086	289.83+/-310.5			289.83+/-310.5	289.83+/-310.5
			106.77+/-102.27			95.72+/-73.59	77.86+/-63.6
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.07			Fold Change: 2.16	Fold Change: 2.55
			r-value00114			1-4auc. :002-1/	T danc.

RNSDOCID < WO 02059271A2 L >

X		1	11	Morrool at All	Normal ve Malianant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1085   N52352   X	#	oed TID	Gendank		MOI III A MARKET			268 01+/-82 24
1085   N56877   109.54-80.79   109	533	1084	N52352					136.01.17.02.21
1085   N56877   109.54-80.79   109							1	150.45-7-150.1
1085   N56877   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.70   109.54-80.70   109.54-100.42   109.54-10				×	×	×	×	N1=40, N2=10
1085   N56877   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.70   109.54-270.27   109.				•				Fold Change: 2.09
1085   N56877   109.54-/80.79   109.54-/80.79   1109.54-/80.79     N14-40, N2-2168								P-value: .0074
1086   NS7539   225.43+7.101.42   P-value: 0   P-value: 0	25	1005	77832N	100 5+/-80 79			109.5+/-80.79	109.5+/-80.79
No. 10.25.7   No. 10.25.7	2	CONT	//00CVI	200 02-/- 200 02-			327.79+/-348.66	306.18+/-259.39
New York   Fold Change: 2.15   Payalue: 0.0281				N1-40 N2=168	<b>&gt;</b>	×	N1=40, N2=31	N1=40, N2=10
P-value: 0.0281				Fold Change: 2 45	4		Fold Change: 2.15	Fold Change: 2.68
1086   N57539   225.43+1-101.42   106.354+101.42   106.354+101.42   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.14   106.354+100.13   106.				rold Change, 2.45		•	P-value: .00281	P-value: .00382
1086   N5/539   1,03,314-100.42   N1=39, N2=16		,	Contract	775 42±/ 101 42			225.43+/-101.42	225.43+/-101.42
Ni = 59, N2 = 31	Ç	1080	666/6N	253,434/-101.42		•	106.35+/-190.86	96.95+/-76.68
No. 1087   N. 1089   N.				105.71.7-1168 N1-74 05-116	>	×	N1=39, N2=31	N1=39, N2=6
P-value: 0   P-value: 0				Eold Change: 237	4	<b>!</b>	Fold Change: 2.94	Fold Change: 2.43
1087         N59432         r-Value. O         237.954/-107.53         237.954/-107.53           1088         N62126         X				rold Change: 4.37			P-value: 0	P-value: .00273
1089 N63237 217.51+/-156.97 8		1007	ME0403	r-value. o		237.95+/-107.53	237.95+/-107.53	237.95+/-107.53
No. 1080   No. 1080   No. 1080   No. 1080   No. 1080	50	108/	7646CNI			71.26+/-38.6	105.02+/-65.3	110.93+/-111.49
Fold Change: 3.32   Fold Change: 2.39   P-value: 0.0156   P-value: 0.0159   P-valu				>	*	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
N62126   N62126   N63126   N63126   N63126   N63237   217.51+/-156.97   S2.65+/-34.21   S2.57+/-33.35   S2.67+/-314.65   S3.67+/-314.65   S3.67+/-314.65   S3.67+/-314.65   S3.67+/-316.71   S3.67+/-316.71   S3.67+/-316.71   S3.67+/-316.81   S3.67				∢	•	Fold Change: 3,32	Fold Change: 2.39	Fold Change: 2.61
1088         N62126         X						P-value: .00159	P-value: 0	P-value: .00543
1089 N63237 217.51+/-156.97 217.51+/-136.97 P-value: 0 P-value:	1	0007	NICOLOG					280.04+/-181.07
N63237   217.51+1.156.97   S2.57+1.23.3.5   N1=39, N2=10   N1=39, N2=31   P-value: 0   P-v	2	2201	07170N					109.11+/-74.94
1089 N63237 217.51+/-156.97 217.51+/-156.97 217.51+/-156.97 52.65+/-34.21 52.57+/-33.35 N1=39, N2=168 X N1=39, N2=10 N1=39, N2=31 Fold Change: 2.5 P-value: 0 P-value				>	*	×	×	N1=40, N2=10
1089 N63237 217.51+/-156.97 217.51+/-156.97 217.51+/-156.97 52.65+/-34.21 52.65+/-33.35				<b>&lt;</b>	4			Fold Change: 2.59
1089         N63237         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         22.65+/-34.21         52.65+/-34.21         52.57+/-33.35         52.57+/-33.35         NI=39, N2=10         NI=39, N2=31         NI=39, N2=31         NI=39, N2=31         Fold Change: 2.9         P-value: 0         P-value: 0         P-value: 0         P-value: 0         P-value: 0         A58.01+/-316.71         R7.05+/-105.81         R7.05+/-105.81         R01-40, N2=31         Rold Change: 5.25         P-value: 0								P-value: .00734
1009 N63913 (5.57+/-34.21 52.57+/-33.35 (6.3.12+/-54.35	100	1000	NESSS	717 51+/-156 07		217.51+/-156.97	217.51+/-156.97	217.51+/-156.97
N1=39, N2=168	230	1007	167501	62 12+/-54 35		52.65+/-34.21	52.57+/-33.35	24.34+/-38.62
Fold Change: 2.55 Fold Change: 2.55 Fold Change: 2.55 Fold Change: 2.57 Fold Change: 2.55 Fold Change:				05.12/1.20 N1-20 N2=168	*	N1=39, $N2=10$	N1=39, N2=31	N1=39, N2=6
1090 N63913 463.66+/-314.65  R8.17+/-134.91  N1=40, N2=168  Fold Change: 5.84 P-value: 0  458.01+/-316.71  87.05+/-105.81  N1=40, N2=31  Fold Change: 5.25 P-value: 0				Es14 Change: 7 55	4	Fold Change: 3.16	Fold Change: 2.9	Fold Change: 3.83
1090 N63913 463.664/-314.65 88.17+/-134.91 X N1=40, N2=31 N1=40, N2=168 X Solution Fold Change: 5.84 P-value: 0				Fold Change, 2.33		P-value: .00096	P-value: 0	P-value: .00001
88.17+/-134.91 N1=40, N2=168 Fold Change: 5.84 P-value: 0	3	000,	MC2012	A63 66±/ 314 65			458.01+/-316.71	458.01+/-316.71
X N1=40, N2=31 Fold Change: 5.25 P-value: 0	337	1020	CTCCONT	98 17+/ 134 01			87.05+/-105.81	65.18+/-127.89
Fold Change: 5.25 P-value: 0				N1=40 N3=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0				Fold Change: 5.84			Fold Change: 5.25	Fold Change: 7.57
				P-value: 0			P-value: 0	P-value: .00008

*	Cog ID	Conbonk	Normal ve All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1	1001	N64648	Mornial 13 cm	TOTAL CONTROL OF		262 87+/-87 71	262.87+/-87.71
04c	1691	0+0+01				129.76+/-54.11	114.48+/-29.26
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.09	Fold Change: 2.21
						P-value: 0	P-value: 0
541	1092	N76867				210.78+/-96.34	
						106.18+/-57.67	
			×	×	×	N1=39, N2=31	×
						Fold Change: 1.97	
Ş	1004	N79004					93.29+/-75.16
7 + 6	1024	10000					273.05+/-182.9
			×	×	×	×	N1=40, N2=10
			ļ				Fold Change: 2.79
							P-value: .00222
543	1095	N80935	266.86+/-83.21				266.66+/-84.29
!			143.94+/-87.39				130.9+/-68.88
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.01				Fold Change: 2.17
			P-value: 0				P-value: .00097
544	1096	N90525	117.6+/-226.89			118.22+/-229.82	
			226.51+/-203.72			255.32+/-119.15	
	•		N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.23			Fold Change: 2.98	
			P-value: .00001			P-value: 0	
545	1101	R08000	501.45+/-685.59		502.76+/-694.51	502.76+/-694.51	502.76+/-694.51
			78.58+/-101		79.82+/-77.61	57.68+/-127.95	65.51+/-107.84
			N1=40, N2=168	×	N1=40, N2=6	NI=40, N2=31	N1=40, N2=10
			Fold Change: 4.96		Fold Change: 4.45	Fold Change: 7.21	Fold Change: 6.92
			P-value: 0		P-value: .0049	P-value: 0	P-value: .00004
546	1102	R11248				114.31+/-112.68	114.31+/-112.68
						295.22+/-374.37	538.23+/-597.4
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.09	Fold Change: 3.42
						P-value: .00187	P-value: .01362

Seq ID   Genbank   Normal vs Malignant   N					1	Mountain Office I	Noumal ve Chara II	Normal we Stage III
1104   R20784   1107 23+4833 81   1117 844-243.96   1112.7184+234.96   1117 844-234.96   1117 844-234.96   1117 844-234.96   1117 84694   1107 14-83.38   1117 84694   1107 14-83.38   1118 862346   1118 862346   1119 862346	<b>#</b> ±	Seq ID	Genbank	Normal vs All	Normal vs Mangnant	Normal vs Stage 1	Moi iliai vs Stage II	Molinal vs Stage III
Ni = 40, N2 = 11	7	1104	R20784	1107.23+/-833.81		1112.78+/-843.96	1112.78+/-843.96	1112.78+/-843.96
Ni = 40, N2 = 168	•	•		264 46+/-256.11		257.86+/-243.05	168.78+/-236.94	123.27+/-153.07
Fold Change: 4.88   Fold Change: 4.54   Fold Change: 7.78   Fold Change: 4.88   Fold Change: 7.78   Fold Change: 4.88   Fold Change: 4.89   Fold Change: 4.81   Fold Change: 2.05   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.110.51   156.98+/.120.51   156.98+/.1				N1=40 N2=168	<b>×</b>	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
110   R49392   P-value: 0   P-value: 0.0794   P-value: 0.0110   R49392   P-value: 0.0110   R49392   P-value: 0.0110   P-value: 0.0110   P-value: 0.0020				Fold Change: 4 88	1	Fold Change: 4.54	Fold Change: 7.78	Fold Change: 10.71
1109   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R44-110.51   R44-110.51   R44-110.51   R44-110.51   R44-110.51   R44-110.51   R44-110.51   R49.14-12.38   R49.14-13.38   R49.14-13.39   R49.1				P-value: 0		P-value: .00794	P-value: 0	P-value: .00001
1112   R54660   X	0 V	1100	B40302				267.35+/-98.92	267.35+/-98.92
Ni	2	2011					156.98+/-110.51	143.02+/-95.35
1112 R54660   P-value: 0.0002				>	*	×	N1=40, N2=31	N1=40, N2=10
1112   R54660   R54600   R54660   R54				4	1		Fold Change: 2.05	Fold Change: 2.14
1112   R54660   X							P-value: .00002	P-value: .0067
Ni	97	1112	D54660			200.26+/-133.86	200.26+/-133.86	200.26+/-133.86
N1=40, N2=6	ì	7117				49.74+/-62.98	16.03+/-23.1	6.98+/-15.78
Fold Change: 4.34 Fold Change: 5.96  P-value: .00827				×	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
1113   R62346   92.55+/48.64   P-value: .00827   P-value: 0     1113   R62346   92.55+/48.64   P-value: 0     1114   R67627   R67627   R69584   P-value: 0     1115   R69584   211.19+/227.25   214.32+/229.35   214.32+/229.35     1116   R70255   241.03+/179.01   Rold Change: 2.91   P-value: 0     1116   R70255   R70342+ R6.44   R70342   R64 Change: 2.91   R64 Change: 3.62   R64 Change: 3.62   R64 Change: 3.62   R64 Change: 3.63   R64 Change: 3.64   R64 Change: 3.64				•	!	Fold Change: 4.34	Fold Change: 5.96	Fold Change: 6.74
1113   R62346   92.55+/48.64   PC   PC   PC   PC   PC   PC   PC   P						P-value: .00827	P-value: 0	P-value: 0
218.34+/108.48	65	1113	B62346	92 55+/-48.64			92.55+/-48.64	
Ni = 39, N2 = 16	3	CIT	2	218.35+/-108.48			218.34+/-122.05	
Fold Change: 2.17  P-value: 0  P-value: 0  To 3.42+1.425.8  To 3.42+1.425.8  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=39 N2=168	×	×	N1=39, N2=31	×
1114   R67627   P-value: 0   P-value: 0   P-value: 0   703.42+/-425.8				Fold Change: 2.17	}		Fold Change: 2.14	
1114   R67627   R69584   R611.194/-227.25   R69584   R611.194/-227.25   R69584   R611.194/-227.25   R69584   R611.194/-227.25   R69584   R614.324/-229.35   R614.324/-229.35   R614.324/-229.35   R614.324/-229.35   R614.324/-229.35   R614.324/-229.35   R614.324/-229.35   R614.324/-23.04   R70255   R71794/-84.48   R614.294/-181.34   R614.294/-				P-value: 0			P-value: 0	
X   X   X   X   X   X   X   X   X   X	14	1114	R67627				703.42+/-425.8	
The color of the	1						319.29+/-199.18	
Fold Change: 2.32 P-value: 0 P-value: 0.0001 P-value: 0.0002 P-value: 0 P-value: 0 P-value: 0 P-value: 0.0002 P-value: 0				×	×	×	N1=40, N2=31	×
P-value: 0   P-value: 0				<b>:</b>			Fold Change: 2.32	
1115         R69584         211.19+/-227.25         214.32+/-229.35         214.32+/-229.35           1115         R70584         211.19+/-227.25         30.89+/-23.04         37.79+/-84.48           1116         R70255         P-value: .00001         P-value: .0002         P-value: .0           1116         R70255         241.03+/-179.01         P-value: .0002         P-value: .0           1116         R70255         241.03+/-179.01         X         N1=40, N2=31           Fold Change: 5.3         Fold Change: 5.24         P-value: 0         P-value: 0							P-value: 0	
53.06+/-91.11 X N1=40, N2=168 N1=40, N2=31 Fold Change: 2.91 P-value: .0002 P-value: 0  1116 R70255 241.03+/-179.01 P-value: .0002 P-value: 0	1	1115	R69584	211.19+/-227.25		214.32+/-229.35	214.32+/-229.35	214.32+/-229.35
N1=40, N2=168		2		53.06+/-91.11		30.89+/-23.04	37.79+/-84.48	6.84+/-26.67
Fold Change: 2.91 P-value: .0002 P-value: .0002 P-value: 00001 P-value: .0002 P-value: 0 241.29+/-181.34 33.3+/-86.44 N1=40, N2=168 Fold Change: 5.3 Fold Change: 5.24 P-value: 0				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
1116 R70255 241.03+/-179.01 P-value: .0002 P-value: 0  P-value: .00001 P-value: 0  241.29+/-181.34  241.29+/-181.34  241.29+/-181.34  25.72+/-39.39  X N1=40, N2=31  Fold Change: 5.3 P-value: 0				Fold Change: 2 01		Fold Change: 3.38	Fold Change: 3.62	Fold Change: 4.76
1116 R70255 241.03+/-179.01 241.29+/-181.34 33.3+/-86.44 X N1=40, N2=31 Fold Change: 5.3 Fold Change: 5.24 P-value: 0				D-value: 00001		P-value: .0002	P-value: 0	P-value: 0
25.72+/-39.39 33.3+/-86.44 X N1=40, N2=31 N1=40, N2=168 X Fold Change: 5.24 Fold Change: 5.3 Fold Change: 5.24 P-value: 0	553	1116	B70255	241 03+/-179 01			241.29+/-181.34	241.29+/-181.34
X N1=40, N2=31 Fold Change: 5.24 P-value: 0	3	7111		33 3+/-86 44			25.72+/-39.39	17.97+/-75.13
Fold Change: 5.24 P-value: 0				N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0				Fold Change: 5.3			Fold Change: 5.24	Fold Change: 5.55
				P-value: 0			P-value: 0	F-value: .00003

BNG00000 - WO 000007140 1 5

Seq ID		Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1	1	R73518	397.68+/-234.48			397.68+/-234.48	397.68+/-234.48
			142.17+/-86.32			129.97+/-75.3	130.92+/-91.05
			N1=39, N2=168	×	×	NI=39, N2=31	N1=39, N2=6
			Fold Change: 2.61			Fold Change: 2.92	Fold Change: 2.93
			P-value: 0			P-value: 0	P-value: .00003
1118		R74561				425.23+/-350.96	
						871.35+/-705.04	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.06	
						P-value: .00036	
1119		R83604	294.9+/-858.81		304.76+/-867.74	304.76+/-867.74	304.76+/-867.74
ı			-49.34+/-85.75		-70.76+/-37.34	-62.65+/-38.9	-42.74+/-57.17
			N1=40, N2=168	×	NI=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.18		Fold Change: 3.74	Fold Change: 3.74	Fold Change: 3.25
			P-value: .00005		P-value: .00001	P-value: .00001	P-value: .0002
1121		T16144				67.72+/-60.08	67.72+/-60.08
!						246.32+/-239.25	213.1+/-108.52
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 3.16	Fold Change: 3.43
						P-value: 0	P-value: .00004
1122		T57042				286.11+/-193.74	286.11+/-193.74
						114.39+/-69.74	125.4+/-63.01
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.34	Fold Change: 2.01
						P-value: 0	P-value: .00122
1123		T57670				404.19+/-128.46	404.19+/-128.46
						212.97+/-107.98	186+/-108.03
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.03	Fold Change: 2.39
						P-value: 0	P-value: .00117
1124		T57773				-	214.22+/-119.35
							76.17+/-87.27
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.27
Ì							F-value: .002

‡	E 203	Conhoni	Moumol 22 A 11	Mountain Malianant	Mount in Chan	Normal via Chane III	Maumal 20 Ctone III
*	och m	Gendank	NOTHER VS ALI	Normal VS Mailgnant	Normal vs Stage 1	Normal vs Stage II	Normal vs Stage III
561	1125	T61106	164.66+/-104.9			164.66+/-104.9	164.66+/-104.9
			345.33+/-209.56			339.88+/-198.04	341.68+/-227.02
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.21			Fold Change: 2.11	Fold Change: 2.17
			P-value: .00001			P-value: .00077	P-value: .01513
295	1126	T64447	216.31+/-152.39		216.31+/-152.39	216.31+/-152.39	216.31+/-152.39
			41.01+/-92.12		39.2+/-138.62	17.71+/-47.39	-19.08+/-58.11
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.99		Fold Change: 3.8	Fold Change: 5.18	Fold Change: 7.39
			P-value: 0		P-value: .01694	P-value: 0	P-value: 0
563	1130	T79945	266.46+/-143.28				
			196.1+/-275.3				٠
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.04				
			P-value: 0				
564	1133	T92947	370.07+/-299.38			359.82+/-296.09	359.82+/-296.09
			173.72+/-164.88			134.2+/-88.77	113.03+/-41.6
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.08			Fold Change: 2.39	Fold Change: 2.36
			P-value: .00004			P-value: .00007	P-value: .00008
595	1134	T93570				344.83+/-197.39	344.83+/-197.39
						156.26+/-76.45	137.27+/-55.02
			×	×	×	N1=40, N2=31	N1=40, N2=10
	•					Fold Change: 2.12	Fold Change: 2.27
				;		P-value: 0	P-value: .0001
995	1170	W02608	83.49+/-56.33			82.66+/-56.82	82.66+/-56.82
			238.33+/-117.55			216.35+/-112.51	206.9+/-95.19
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.06			Fold Change: 2.77	Fold Change: 2.61
			P-value: 0			P-value: 0	P-value: .00124
292	1171	W02823	220.34+/-88.04			217.4+/-87.18	217.4+/-87.18
			83.44+/-86.86			71.46+/-47.57	107.28+/-72.66
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
_			Fold Change: 2.96			Fold Change: 3.16	Fold Change: 2.32
			P-value: 0			r-value: 0	P-value: .00987

i

\*

Normal vs Stage III	200 21 + 1-164 12	21:401-1:17:26	00000-111000	NI=40, NZ=10	Fold Change: 5.11	P-value: 0	1139.71+/-444.58	291.49+/-262.25	NI=40, N2=10	Fold Change: 5.29	P-value: .00046	172.41+/-85.84	443.37+/-353.68	N1=40, N2=10	Fold Change: 2.22	P-value: .00917			×					×			720.17+/-951.89	39.22+/-65.55	N1=40, N2=10	Fold Change: 7.71	P-value: 0	100.04+/-68.17	213+/-119.61	N1=40, N2=10	Fold Change: 2.14 P-value: .00375
Normal vs Stage II	200 21±7 164 12	56.7+1-41.66 56.7+1-41.66	00:14-7-700	N1=40, N2=31	Fold Change: 4.81	P-value: 0	1139.71+/-444.58	. 244.74+/-245.86	N1=40, N2=31	Fold Change: 5.59	P-value: 0			×			314.68+/-111.87	147.05+/-53.04	N1=39, N2=31	Fold Change: 2.14	P-value: 0	67.04+/-84.41	322.95+/-770.03	N1=40, N2=31	Fold Change: 2.05	P-value: .00441	720.17+/-951.89	169.52+/-503.24	N1=40, N2=31	Fold Change: 4.62	P-value: 0			×	
Normal vs Stage I	200 21±7 164 12	100 65±/ 140 45	100.01-/-10.40	N1=40, N2=6	Fold Change: 3.51	P-value: .03256			×		٠			×					×					×					×					×	•
Normal vs Malignant	8		;	×					×					×					×					×					×					×	
Normal vs All	201 (11 / 100 00	201-/+10776	01.14+1-32.09	N1=40, N2=168	Fold Change: 4.19	P-value: 0	1144.81+/-440.02	379.83+/-343.79	N1=40 N2=168	Fold Change: 3.79	P-value: 0			×		!			×					×			707.63+/-942.95	144.29+/-433.7	N1=40, N2=168	Fold Change: 5.42	P-value: 0			×	
Genbank	07 00011	. WU/U43					W07304					W22264					W28281					W31919					W32480					W55924			
Sea ID		. 2/11					1174					1177					1181					1182					1183					1189			
#		208					569					570	:				571					572	!				573				_	574			

......

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
575	1195	W72062	381.86+/-163.16			380.68+/-165.12	380.68+/-165.12
			N1=40 N2=169	>	>	175.047/-50.16	N1-40 N2-10
			NI-40, INZ-108	<	<	15-7N '0#-INI	01=7NI -40, INZ=10
			Fold Change: 2.03			Fold Change: 2.04	Fold Change: 2.07
			· P-value: 0			P-value: 0	P-value: .00001
216	1196	W72182					83.09+/-49
							231.34+/-134.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.71
							P-value: .00094
577	1199	W72347	367.98+/-155.29			368.08+/-157.32	368.08+/-157.32
			146.12+/-193.47			94.65+/-155.82	261.92+/-468.76
			N1=40, N2=168	×	<b>×</b>	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.46			Fold Change: 5.14	Fold Change: 3.22
			P-value: 0			P-value: 0	P-value: .03608
878	1200	W72407	235.27+/-157.67			234.77+/-159.7	
			63.55+/-76.04			85.52+/-101.27	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 3.77			Fold Change: 3.02	
			P-value: 0			P-value: .00001	
579	1201	W72511	995.7+/-434.28			988.5+/-437.53	988.5+/-437.53
			430.04+/-283.24			418.47+/-331.96	250.59+/-208.45
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.53			Fold Change: 2.63	Fold Change: 4.54
			P-value: 0			P-value: 0	P-value: .00008
280	1203	W73230	526.33+/-307.22			524.48+/-311.01	524.48+/-311.01
			205.2+/-108.64			185.59+/-79.06	164.36+/-67.2
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.58			Fold Change: 2.72	Fold Change: 3
			P-value: 0			P-value: 0	P-value: 0
581	1204	W73386	242.96+/-399.57	469.37+/-905.14	248.29+/-403.35	248.29+/-403.35	248.29+/-403.35
			16.99+/-76.53	95.29+/-88.61	3.09+/-55.26	-16.75+/-32.9	-2.29+/-42.09
			N1=40, N2=168	N1=17, N2=49	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.25	Fold Change: 3.43	Fold Change: 4.79	Fold Change: 5.86	Fold Change: 4.92
			P-value: 0	P-value: .00019	P-value: .000/9	P-value: 0	P-value: 0

4	Clad III	Cenhank	Normal ve All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
±	350	Gennaun	TOT THE LOW			000 100 100	003 501 / 02 10
582	1205	W73819				993.58+/-625.18	793.284/-023.18
						399.14+/-205.47	277.46+/-140.58
			×	×	×	N1=40, N2=31	N1=40, N2=10
			1			Fold Change: 2.23	Fold Change: 3.36
						P-value: 0	P-value: .00039
583	1206	W73855				201.45+/-105.43	
}						87.02+/-86.49	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.72	
		-				P-value: 0	
584	1207	W73890	223.3+/-129.09			223.01+/-130.77	223.01+/-130.77
3			73.33+/-44.79			65.62+/-33.81	62.68+/-63.75
_			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.96			Fold Change: 3.14	Fold Change: 3.85
			P-value: 0			P-value: 0	P-value: .00019
585	1209	W80496	221.23+/-140.42			214.3+/-135.15	214.3+/-135.15
}			105.98+/-75.28			95.94+/-55.75	53.76+/-58.28
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.11			Fold Change: 2.13	Fold Change: 3.87
			P-value: 0			P-value: .00004	P-value: .00029
586	1211	W88427	669.14+/-243.38			661.21+/-241.27	661.21+/-241.27
,			316.73+/-233.88			304.22+/-202.92	187.14+/-59.43
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.35			Fold Change: 2.35	Fold Change: 3.45
			P-value: 0			P-value: 0	P-value: 0
587	1246	Z99386	615.03+/-208.26		•	611.71+/-209.91	611.71+/-209.91
			262.6+/-122.89			245.54+/-120.4	231.83+/-120.93
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.48			Fold Change: 2.66	Fold Change: 3.04
	,		P-value: 0			P-value: 0	P-value: .00124

226
Table 5: BREAST / INFILTRATING LOBULAR CARCINOMA

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
1	7	AA017070	218.33+/-195.52		•
			77.15+/-79.13	•	
			N1=40, N2=17	X	X
			Fold Change: 2.53		
			P-value: .00187		
2	15	AA031790	336.45+/-181.35		
			156.08+/-81.33		
			N1=40, N2=17	X	x
			Fold Change: 2.16		
			P-value: .00003		
3	23	AA044830	387.92+/-190.91	•	
			188.55+/-88.55		
			N1=40, N2=17	X	· <b>x</b>
			Fold Change: 2.14		
			P-value: .00023		
4	24	AA045145	262.21+/-180.28		
•	•		76.07+/-123.14		
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 3.26		
		•	P-value: .00038		
5	25	AA046457	254.96+/-154.86		
			128.89+/-118.57		
			N1=40, N2=17	X	X
			Fold Change: 2.3		
			P-value: .00176		
6	31	AA059396	383.25+/-127.97		383.25+/-127.97
٠.	<b>01</b>		170.7+/-70.05		120.28+/-48.53
		•	N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.32		Fold Change: 3.22
			P-value: 0		P-value: .01218
7	33	AA059458	74.76+/-90.6		74.76+/-90.6
•	-		314.12+/-111.83		344.29+/-46.75
			N1=40, N2=17	$\mathbf{x}$	N1=40, N2=17
			Fold Change: 5.79		Fold Change: 6.82
			P-value: 0		P-value: 0
8	41	AA126704	312.64+/-137.34		
-		<b></b>	130.96+/-82.96		
			N1=40, N2=17	X	X
			Fold Change: 2.5	- <del>-</del>	
			P-value: .00009		
9	42	AA127718	240.21+/-361.64		
-			75.73+/-121.03		
			N1=40, N2=17	X	x
			Fold Change: 3.09		
			P-value: .00005		
10	43	AA127727	212.97+/-123.48		
			100.07+/-53.82		
			N1=40, N2=17	X	x
			Fold Change: 2.1		
			P-value: .00014		
11	51	AA133248	400.91+/-134.73		
	~~	THEOLEG	201.52+/-119.8		
	•		N1=40, N2=17	X	X
			Fold Change: 2.24	21	42
			BUILT DANGE, 1 14		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
12	57	AA142913	302.34+/-222.83		302.34+/-222.83
			104.53+/-62.4		68.29+/-31.77
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.84		Fold Change: 4.03
			P-value: 0		P-value: .00871
13	62	AA147751	478.2+/-207.42		
			245.52+/-144.78		
			N1=40, N2=17	X	X
			Fold Change: 2.03		
			P-value: .00015		
14	63	AA147884	46.86+/-55.16		
l			212.3+/-151.24		
			N1=40, N2=17	X	X
			Fold Change: 3.93		
L _			P-value: .00001		
15	64	AA149312	374+/-139.43		
1			179.7+/-77.1		
l			N1=40, N2=17	X	X
l			Fold Change: 2.18		
			P-value: .00003		
16	65	AA150501	215.8+/-104		
			97.75+/-48.53		
l			N1=40, N2=17	X	X
			Fold Change: 2.27		
L			P-value: .00006		
17	71	AA158731	287.72+/-241.22		
·			94.76+/-99	·	
1			N1=40, N2=17	X	X
1			Fold Change: 3.29		
<u> </u>			P-value: .00036		
18	72	AA160156	630.23+/-274.77		
			297.85+/-166.73	37	<b>3</b> 7
			N1=40, N2=17	X	X
			Fold Change: 2.39		
10		1 1 1 5 5 5 5 5	P-value: .00076		368.73+/-173.58
19	75	AA173572	368.73+/-173.58		
1			140.6+/-66.1	x	101.84+/-30.25
			N1=40, N2=17	^	N1=40, N2=17 Fold Change: 3.17
Ī			Fold Change: 2.52		P-value: .00053
100	0.4	1 1 202 ( (2)	P-value: .00001		r-value00033
20	84	AA203663	288.39+/-92.75		
1			151.54+/-90.12	X	X
1			N1=40, N2=17	Λ	^
			Fold Change: 2.19 P-value: .00062		
1	00	A A GOMMAN			
21	88	AA227778	254.32+/-164.5 129.32+/-121.52		
1			N1=40, N2=17	X	X
			Fold Change: 2.21	Λ.	Α
			P-value: .00551		
122	00	AA369887	326.24+/-259.48		
22	99	AA30700/	326.24+/-239.48 1569.71+/-1564.61		
			N1=40, N2=17	X	X
			Fold Change: 3.13	Λ	2 <b>L</b>
			P-value: .00723		
			F-Value: .00/23		

PHIPPOPID: 1410 - 000F007440 F .

#	Seq ID	. Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
23	117	AA430314	259.57+/-186.05		259.57+/-186.05
			94.12+/-84.62		51.43+/-32.49
			N1=40, N2=17	<b>x</b> .	N1=40, N2=17
)			Fold Change: 2.81		Fold Change: 4.33
			P-value: .00057		P-value: .0109
24	120	AA447015	226.67+/-173.74		226.67+/-173.74
			86.47+/-87.06		49.75+/-49
l			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.44		Fold Change: 3.69
			P-value: .00239		P-value: .04932
25	121	AA448195	82.22+/-92.11		
			252.38+/-226.28		
			N1=40, N2=17	X	x
İ			Fold Change: 2.56		
			P-value: .00561		
26	122	AA450090	285.47+/-226.15		285.47+/-226.15
			121.51+/-105.64		80.74+/-67.6
ļ			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.56		Fold Change: 3.67
			P-value: .00017		P-value: .04277
27	124	AA452295	220.36+/-116.43		220.36+/-116.43
l			43.55+/-34.23		27.93+/-7.95
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.8		Fold Change: 6.64
			P-value: 0		P-value: 0
28	129	AA479033	105.96+/-264.08		
[			699.96+/-1244.37		
			N1=40, N2=17	X	X
ļ			Fold Change: 3.25		
			P-value: .01862	·	
29	131	AA480075	331.5+/-159.34		
ļ			170.51+/-174.22		
			N1=40, N2=17	X	X
1			Fold Change: 2.36		
<u></u>			P-value: .00065		
30	134	AA486731	417.18+/-216.76		
			258.38+/-279.38		}
			N1=40, N2=17	X	X
J			Fold Change: 2.26		
			P-value: .0077		
31	135	AA488889	298.86+/-194.94		
			114.61+/-41.42		
			N1=40, N2=17	X	X
1			Fold Change: 2.16		
			P-value: .00001		
32	138	AA502943	439.24+/-110.96		
			200.97+/-110.89		
			N1=40, N2=17	X	X
1			Fold Change: 2.41		
			P-value: 0		
33	140	AA508196	475.57+/-315.6		
1			208.59+/-128.6		
			N1=40, N2=17	X	X
			Fold Change: 2.29		
			P-value: .0014		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
34	142	AA516420	208.7+/-209.98		
			762.28+/-919.5		
1			N1=40, N2=17	X	x
1			Fold Change: 2.83		
			P-value: .00199		
35	151	AA526961	417.14+/-237.24		
			139.33+/-66.58		
			N1=40, N2=17	X	х
l			Fold Change: 2.89		
			P-value: 0		
36	156	AA534456	1130.9+/-759.82		
			504.53+/-276.17		
1			N1=40, N2=17	X	x
1			Fold Change: 2.23		
			P-value: .00282		
37	160	AA535218	322.09+/-137.43		
			130.51+/-83.58		
			N1=40, N2=17	X	x
l			Fold Change: 2.69		
1			P-value: .00001		
38	171	AA584310	402.55+/-323.55		İ
1			1185.08+/-725.81		
			N1=40, N2=17	X	X
			Fold Change: 3.27		
			P-value: .00003		
39	172	AA584403	593.26+/-1291.79		593.26+/-1291.79
			73.69+/-113.44		46.94+/-41.5
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.63		Fold Change: 4.08
			P-value: .0001		P-value: .01967
40	175	AA601511	2941.11+/-4823.41		
1			8196.8+/-10494.86		
1			N1=40, N2=17	X	X
			Fold Change: 3.59		
			P-value: .04627		
41	178	AA609310	285.39+/-160.8		·
1			103.37+/-63.8		
1			N1=40, N2=17	X	X
			Fold Change: 2.73		
		_	P-value: .00003		
42	180	AA610522	803+/-768.74		803+/-768.74
			2236.91+/-2047.57		1948.9+/-1536.5
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.15		Fold Change: 3.65
			P-value: .00504		P-value: .04632
43	184	AA621478	398.69+/-325.12		
			105.85+/-99.55		***
1			N1=40, N2=17	X	X
			Fold Change: 3.76		
<u></u>		<del></del>	P-value: .00002		1145 061/ 500 22
44	189	AA628467	1145.06+/-502.33		1145.06+/-502.33
1			483.55+/-276.22	37	263.82+/-233.17
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.59		Fold Change: 5.48
L			P-value: .00016		P-value: .04561

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
45	191	AA631047	615.9+/-364.24		
			335.52+/-248.64		
l			N1=40, N2=17	X	X
•			Fold Change: 2.12		
			P-value: .00214		
46	194	AA634799	739.38+/-608.62		
			265.99+/-273.02		
			N1=40, N2=17	X	X
i			Fold Change: 3.37		
		····	P-value: .00153		
47	198	AA669106	84.29+/-131.22		
l			224.41+/-230.31		
			N1=40, N2=17	X	x
			Fold Change: 3.18		
			P-value: .00001		
48	200	AA700621	467.51+/-455.09		467.51+/-455.09
			127.5+/-198.7		65.41+/-73.63
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.36		Fold Change: 4.6
10			P-value: .00047		P-value: .03306
49	214	AA742697	1026.03+/-1071.41		1026.03+/-1071.41
l			497.89+/-1362.07	37	72.76+/-23.65
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.28		Fold Change: 7.24 P-value: 0
50	253	AA921809	P-value: .00238		r-value: 0
טכ	253	AA921809	459.15+/-1266.29 1144.77+/-1121.05		
			N1=40, N2=17	X	. <b>x</b>
1			Fold Change: 2.76	A	
			P-value: .00483		
51	254	AA921830	92.93+/-115.1		92.93+/-115.1
51	254	24A)21030	214.98+/-154.53		328.17+/-235.36
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.53		Fold Change: 4.07
1			P-value: .00048		P-value: .03148
52	255	AA921922	312.44+/-292.63	······································	312.44+/-292.63
1			101.23+/-57.27		79.08+/-33.3
1			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.73		Fold Change: 3.21
	•		P-value: .00001		P-value: .00566
53	260	AA936632			125.03+/-127.3
					341.96+/-182.6
			X	X	N1=40, N2=17
1					Fold Change: 3.13
					P-value: .02208
54	266	AA976064	363.9+/-153.14		
			150.7+/-67.67		
			N1=40, N2=17	X	X
			Fold Change: 2.48	·	
	404		P-value: 0		000 041/ 4 50 04
55	281	AC004770			222.34+/-159.84
l			47	47	51.7+/-14.58
			X	X	N1=40, N2=17
			,	r	Fold Change: 3.51
L		<del></del>			P-value: .00008

WO 02/059271 PCT/US02/02176

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
56	297	AF052142	307.17+/-169.55		
			101.7 <del>6+</del> /-54.87		
			N1=40, N2=17	X	X
			Fold Change: 2.92		
			P-value: 0		
57	317	AI018523	422.08+/-187.64		
			137.17+/-133.59	37	v
			N1=40, N2=17	X	X
			Fold Change: 3.55		
	201	AX021551	P-value: .00002 85.9+/-105.07		
58	321	AI031771	273.11+/-256.97		
ĺ			N1=40, N2=17	X	x
			Fold Change: 2.82		
			P-value: .00563		
59	324	AI039005	203.54+/-131.69		
		120,000	79.78+/-68.07		
			N1=40, N2=17	X	X
			Fold Change: 2.7		
			P-value: .00048		
60	325	AI039722			1007.24+/-1162.59
					71.46+/-83.95
			X	X	N1=40, N2=17
1					Fold Change: 11.94
<u></u>		17075450	201 221/1572 07		P-value: .00965 381.32+/-1572.07
61	331	AI057450	381.32+/-1572.07 -3.82+/-29.02		-11.17+/-8.38
l			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.3	71	Fold Change: 3.63
			P-value: .00001		P-value: 0
62	333	AI073394	124.23+/-101.36		
-			255.64+/-158.11		
			N1=40, N2=17	X	X
			Fold Change: 2.2		
			P-value: .00025		·
63	335	AI073992	110.23+/-145.3		
1			533.62+/-785.24		
			N1=40, N2=17	X	X
			Fold Change: 3.22		
-	220	A TOBOL 45	P-value: .00574		
64	338	AI079545	248.94+/-138.38 465.02+/-171.05		
1			N1=40, N2=17	<b>X</b>	X
			Fold Change: 2.01	A	<b>A</b>
			P-value: .00007		
65	341	AI083598	339.56+/-289.33		339.56+/-289.33
"	J 1.1	111000000	75.11+/-72.52		38.38+/-30.41
			N1=40, N2=17	X	N1=40, N2=17
}			Fold Change: 3.79		Fold Change: 5.72
L			P-value: .00003		P-value: .00274
66	342	AI086614	301.2+/-152.86		
			128.33+/-84.7	•	
			N1=40, N2=17	X	X
			Fold Change: 2.51		
L			P-value: .00041		

#	Seq ID	Genbank	Normal vs Ali	Normal vs Malignant	Normal vs SII and SIII
67	343	AI087975	68.87+/-58.02		
			211.46+/-250.57		
			N1=40, N2=17	X	X
			Fold Change: 2.28		
			P-value: .00976		
68	344	AI088609	709.25+/-600.21		
			265.96+/-356.75		
			N1=40, N2=17	X	X
			Fold Change: 3.21		
			P-value: .00094		
69	345	AI091154	351.29+/-406.17		351.29+/-406.17
			74.97+/-110.43		12.49+/-5.56
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.1		Fold Change: 8.99
			P-value: .00011		P-value: 0
70	351	AI123555	300+/-164.6		300+/-164.6
			65.25+/-46.06		48.57+/-47.56
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.55		Fold Change: 6
			P-value: 0		P-value: .01993
71	359	AI128820	224.42+/-90.96		
			108.28+/-86.45		
			N1=40, N2=17	X	X
			Fold Change: 2.34		
<i>5</i> 0	2/1	1 T100(0)	P-value: .00033		
72	361	AI129626	278.92+/-134.16		
			134.17+/-77.75 N1=40, N2=17	X	X
			Fold Change: 2.13	<b>A</b>	
			P-value: .00023		
73	362	AI131078	299.48+/-223.81		299.48+/-223.81
/3	302	A1151076	111.16+/-71.9	•	67.7+/-89.93
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.6	A	Fold Change: 5.06
-			P-value: .0002		P-value: .04594
74	370	AI148006	241.17+/-193.5		1 (414)
_		<b>-</b>	77.61+/-92.82		
			N1=40, N2=17	X	<b>x</b>
			Fold Change: 2.93		
			P-value: .00043		
75	372	AI149637	212.6+/-241.64		212.6+/-241.64
			39.92+/-27.3		39.29+/-41.66
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.37		Fold Change: 3.31
			P-value: 0		P-value: .04204
76	380	AI189011	284.7+/-101.6		
			126.14+/-81.81		
			N1=40, N2=17	X	X
			Fold Change: 2.75		
			P-value: .00017	<u> </u>	
77	384	AI200954	524.84+/-319.36		
			253.81+/-173.45		
			N1=40, N2=17	X	X
			Fold Change: 2.17		
			P-value: .00291		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
78	386	AI201965			234.24+/-149.37
					59.16+/-44.89
			X	X	N1=40, N2=17
					Fold Change: 3.61
					P-value: .03602
79	394	AI222594	431.73+/-162.38		
			196.71+/-138.58		77
			N1=40, N2=17	X	X
			Fold Change: 2.48		
			P-value: .00005		
80	395	AI223817	221.5+/-204.3		
			686.72+/-465.96	v	х
			N1=40, N2=17	X	Λ.
			Fold Change: 3.28 P-value: .00041		
01	200	A Y2.47027			250.33+/-314.52
81	399	AI247837	250.33+/-314.52		28.03+/-28.56
			53.27+/-43.26 N1=40, N2=17	x	N1=40, N2=17
			Fold Change: 2.95	A	Fold Change: 4.49
			P-value: .00014		P-value: .00427
82	408	AI277612	1022.91+/-907.07		387.19+/-203.85
02	400	ALLITOIL	101.24+/-106.96		584.56+/-51.28
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 8.06		Fold Change: 2.01
			P-value: 0		P-value: .00012
83	417	AI300876	601.83+/-985.51		601.83+/-985.51
			26.36+/-32.43		28.36+/-46.5
			N1=40, N2=17	, <b>X</b>	N1=40, N2=17
			Fold Change: 7.1		Fold Change: 6.7
			P-value: 0		P-value: .00688
84	418	AI301060	1095.7+/-461.79		
			3285.81+/-2230.69		
İ			N1=40, N2=17	X	X
			Fold Change: 2.58		
			P-value: .00018		
85	422	AI333767	201.68+/-104.32		
ł			94.33+/-75	X	X
ł			N1=40, N2=17	<b>A</b>	A
Ì			Fold Change: 2.32 P-value: .00023		
86	423	AI333987	1-ValueVVV23		208.53+/-320.79
00	423	A1333701			-12.06+/-45.78
			Х	X	N1=40, N2=17
]			41		Fold Change: 4.29
					P-value: .00037
87	427	AI341602	137.44+/-280.1		137.44+/-280.1
			473.63+/-503.04		1084.1+/-558.85
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.72		Fold Change: 14.07
	<u>_</u>		P-value: .00123		P-value: .00013
88	430	AI344312	85.72+/-58.03		
]			241.24+/-132.01		
1			N1=40, N2=17	X	X
1			Fold Change: 2.77		
i			P-value: .00003		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
89	431	AI346341	635.18+/-426.52		
			192.7+/-146.21		
			N1=40, N2=17	X	X
	•		Fold Change: 2.74		
			P-value: .00095		
90	442	AI369840	239.87+/-167.43		
			91.16+/-73.21		
			N1=40, N2=17	X	X
			Fold Change: 2.54		
			P-value: .00091		
91	447	AI378584	815.22+/-371.96		815.22+/-371.96
			289.2+/-132.28		225.35+/-105.83
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.65		Fold Change: 3.53
			P-value: 0		P-value: .02945
92	448	AI379723	380.22+/-173.64		1 - (4140. 102) 15
-		12017125	171.75+/-85.82		
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 2.11	A	<b>A</b> ,
			P-value: .00049		
93	459	AI394013	1 14440.100015		81.65+/-57.28
-	,	111071015			206.8+/-28.72
			X	X	N1=40, N2=17
			Λ	A	Fold Change: 3.01
					P-value: 0
94	462	AI417267	933.35+/-487.41		933.35+/-487.41
77	-102	A117207	367.83+/-178.5		232.02+/-44.3
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.35	A	Fold Change: 3.44
			P-value: 0		P-value: 0
95	467	AI419030	445.97+/-259.12		445.97+/-259.12
75	407	A1417050	141.54+/-110.04		100.89+/-50.85
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.4	A	Fold Change: 3.94
			P-value: .00002		P-value: .00968
96	468	AI421837	293.96+/-147.73		r-value, .00908
<i>)</i>	700	ALTHIOS /	122.58+/-60.8		· may
			N1=40, N2=17	X	<b>x</b>
			Fold Change: 2.25	A	A
			P-value: .00003		
97	477	AI458003	280.16+/-202.76		200 161/ 202 76
91	4//	A1450005	58.35+/-64.44		280.16+/-202.76
				v	29.02+/-54.63
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.09		Fold Change: 6.1
00	40.4	AT450262	P-value: 0		P-value: .01261
98	484	AI479262	56.35+/-67.19		
			253.01+/-258.86	47	••
			N1=40, N2=17	X	X
			Fold Change: 3.34		
	100		P-value: .00113		
99	489	AI492051	382.34+/-177.78		382.34+/-177.78
			99.97+/-58.1		84.79+/-58.36
			N1=40, N2=17	· <b>X</b>	N1=40, N2=17
			Fold Change: 3.83		Fold Change: 4.59
			P-value: 0		P-value: .01274

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
100	493	AI492879	219.42+/-658.12		
İ			360.39+/-664.73		
			N1=40, N2=17	X	X
			Fold Change: 3.18		
			P-value: .00218		
101	500	AI524085	388.89+/-529.52		
1			<i>77.76</i> +/-117.23		
			N1=40, N2=17	· <b>X</b>	X
			Fold Change: 3.83		
			P-value: .00013		
102	501	AI525044	316.89+/-143.08		
		•	163.75+/-85.16		
			N1=40, N2=17	X	X
			Fold Change: 2.13		
			P-value: .00114		
103	505	AI537407	278.8+/-204.74		
			783.29+/-533.91		
			N1=40, N2=17	X	X
1			Fold Change: 2.81		
L			P-value: .00083		
104	506	AI539386	1924.9+/-2430.34		
			6121.55+/-7013.05		
			N1=40, N2=17	X	X
l			Fold Change: 3.2		
			P-value: .00044		
105	511	AI554514	90.74+/-52.8		
-			201.02+/-166.43		·
1			N1=40, N2=17	<b>X</b> .	Х .
			Fold Change: 2.08		
-			P-value: .00026		100 151/140 00
106	512	AI557210	129.15+/-140.98		129.15+/-140.98
			491.52+/-264.84	37	573+/-162.6
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 5.08		Fold Change: 6.68 P-value: .00001
105		AXECC020	P-value: 0		P-value: .00001
107	517	A1566038	257.62+/-109.32		
			124.43+/-63.25	x	x
			N1=40, N2=17	<b>A</b>	^
1			Fold Change: 2.16 P-value: .00015		
100	520	ATEMIENE			
108	520	AI571525	265.11+/-78.71		
			141.93+/-62.73 N1=40, N2=17	X	X
				Λ	^
			Fold Change: 2.04 P-value: .00015		
109	536	AI624853	373.05+/-166.36		
109	230	MIU44033	180.19+/-106.47		
1			N1=40, N2=17	X	X
			Fold Change: 2.21	А	13.
			P-value: .00004		
110	540	AI634852	278.07+/-162.92		
110	270	MIUJ40JE	122.35+/-122.97		
1	•		N1=40, N2=17	X	X
1			Fold Change: 2.6	7.	
			P-value: .00095		
			1 1444000073		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
111	542	AI638295			220.74+/-876.87
					3.1+/-10.99
			X	X	N1=40, N2=17
				_	Fold Change: 3.16
					P-value: 0
112	545	AI650341	123.6+/-154.23		
1			209.61+/-97.49		
			N1=40, N2=17	X	Х
			Fold Change: 2.41		
113	546	AI650514	P-value: .00028		
113	540	A1050514	110.57+/-163.5 295.11+/-242		
İ			N1=40, N2=17	X	x
1			Fold Change: 2.56	A	^
			P-value: .00744		
114	562	AI658925	542.56+/-347.67		
	502	111000720	259.65+/-161.58		
			N1=40, N2=17	X	$\mathbf{x}$ (1)
			Fold Change: 2.07		
			P-value: .00351		•
115	565	AI659418	261.02+/-116.11		
			133.75+/-108.49		1
			N1=40, N2=17	X	х
ļ			Fold Change: 2.41		
<u> </u>			P-value: .00088		
116	566	AI659533	563.4+/-201.34		
			291.04+/-136.51		
1			N1=40, N2=17	. <b>X</b>	X
1			Fold Change: 2.1		
117	500	ATC00541	P-value: .00023		
117	588	AI680541	510.08+/-201.29		510.08+/-201.29
			186.08+/-102.82 N1=40, N2=17	X	106.49+/-44.75 N1=40, N2=17
			Fold Change: 2.84	X	Fold Change: 4.54
			P-value: 0		P-value: .00246
118	591	AI683911	241.46+/-200.89		241.46+/-200.89
			27.24+/-52.93		32.69+/-57.65
			N1=40, N2=17	X	N1=40, N2=17
ļ			Fold Change: 4.58		Fold Change: 3.74
<u> </u>			P-value: 0		P-value: .01617
119	592	AI684457	96.99+/-74.31		
			253.71+/-245.09		
]			N1=40, N2=17	X	X
			Fold Change: 2.25		
100		A T/O/44 4	P-value: .00425		274 40 1 / 274 72
120	593	AI686114	374.48+/-274.59		374.48+/-274.59 76.06+/.93.43
			120.83+/-92.86	$\mathbf{v}$	76.06+/-83.42
			N1=40, N2=17 Fold Change: 3.03	X	N1=40, N2=17 Fold Change: 4.43
			P-value: .0001		P-value: .04695
121	612	AI701034	215.78+/-96.65		1 - value04033
***	UAL	231 / U1U34	111.85+/-71.77		
			N1=40, N2=17	x	X
			Fold Change: 2.11	**	
			P-value: .00036		
<u> </u>		···			

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
122	618	AI732274	947.08+/-989.69		
			285.99+/-458.46		
			N1=40, N2=17	· <b>X</b>	X
l			Fold Change: 3.94		Į.
			P-value: .00251		
123	619	AI733679	325.9+/-596.22		
^~~			48.5+/-33.81		
}			N1=40, N2=17	x	x
			Fold Change: 3.21		
			P-value: .00002		
124	623	AI740621	231.84+/-247.13		
			77.35+/-124.9		
			N1=40, N2=17	X	X
			Fold Change: 2.62		
			P-value: .00315		
125	627	AI742002	111.78+/-132.43		111.78+/-132.43
			379.6+/-168.26		388+/-292.79
1			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 4.61		Fold Change: 4.32
			P-value: 0		P-value: .0111
126	629	AI742239	159.76+/-199.32		
			419.47+/-377.4		
1			. N1=40, N2=17	X	x
l			Fold Change: 3.29		
			P-value: .00013		
127	631	A1742490	601.57+/-252.84		
			285.13+/-140.07		
			N1=40, N2=17	X	· X
1			Fold Change: 2.05		
L			P-value: .00003		
128	632	AI742521	215.93+/-234.91		215.93+/-234.91
			23.91+/-22.33		23.3+/-12.66
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.4		Fold Change: 4.76
L			P-value: 0		P-value: .00002
129	635	AI743671	582.82+/-317.91		
1			281.49+/-185.49		77
1			N1=40, N2=17	X	X
1			Fold Change: 2.26		•
<b></b>			P-value: .00964		
130	636	A1743715	312.02+/-238.55		
			99.48+/-141.4	77	v
			N1=40, N2=17	X	X
1			Fold Change: 3.47		†
			P-value: .0005		
131	637	AI743925	663.58+/-309.38		
			221.31+/-142.28	37	X
			N1=40, N2=17	X	^
1			Fold Change: 3.13		
L			P-value: 0		144.67+/-188.73
132	641	AI751438	144.67+/-188.73		612.92+/-347.94
			551.05+/-364.64	. 🕶	N1=40, N2=17
			N1=40, N2=17	· X	Fold Change: 5.61
			Fold Change: 4.85		P-value: .02877
į.			P-value: 0		r-value020//

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
133	643	AI758223	833.52+/-665.83		833.52+/-665.83
ŀ			89.52+/-74.43		98.81+/-90.66
			N1=40, N2=17	X	N1=40, N2=17
i			Fold Change: 8.3		Fold Change: 8
			P-value: 0		P-value: .02464
134	649	AI761241	883.3+/-332.12		
			415.64+/-208.2		
			N1=40, N2=17	X	x
ł			Fold Change: 2.21		
L			P-value: .00005	-	
135	650	AI761274	342.36+/-182.65		342.36+/-182.65
l			121.18+/-64.61		75.25+/-39.87
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.86		Fold Change: 4.5
			P-value: .00001		P-value: .01949
136	652	AI761844	278.83+/-138.41		278.83+/-138.41
			99.54+/-56.16		87.16+/-56.51
			N1=40, N2=17	x	N1=40, N2=17
			Fold Change: 2.79		Fold Change: 3.1
			P-value: .00001		P-value: .02791
137	653	AI763136	282.1+/-149.81		
			118.7+/-131.83		
			N1=40, N2=17	X	X
l			Fold Change: 2.53		
L			P-value: .00163		
138	655	AI766029	271.74+/-528.19		271.74+/-528.19
			22.11+/-18.39		30.31+/-29.22
}			N1=40, N2=17	X	N1=40, N2=17
l			Fold Change: 3.71		Fold Change: 3.07
			P-value: 0		P-value: .01978
139	657	AI768325	114.7+/-66.43		
			257.51+/-172.22		·
			N1=40, N2=17	X	X
			Fold Change: 2.12		
140	(()	A 7801100	P-value: .00044		
140	664	AI791182	286.48+/-162.61		- **,
ĺ			621.07+/-388.18	37	<b>.</b> ,
			N1=40, N2=17	X	X
			Fold Change: 2.07		
141	668	AI792635	P-value: .00052		800.24+/-717.81
141	UUU	AL 174033			1968.88+/-866
			Х	X	N1=40, N2=17
			Λ	A	Fold Change: 4.27
ľ					P-value: .0038
142	674	AI797276	271.48+/-136.73		271.48+/-136.73
- :-	· · ·		106.25+/-58.1		76.49+/-46.61
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.56	42	Fold Change: 3.58
			P-value: .00001		P-value: .02759
143	678	AI799784	603.99+/-383.42		603.99+/-383.42
	0,0		93.05+/-88.68		82.71+/-78.29
1	•		N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 6.66		Fold Change: 7.34
			P-value: 0		P-value: .01379
L			1 74140.0		1 101001.01017

#	Seq ID	Genbank	Normal vs Ali	Normal vs Malignant	Normal vs SII and SIII
144	684	A1804054	302.97+/-234.41		302.97+/-234.41
}			108.18+/-91.04		77.58+/-36.68
}			N1=40, N2=17	X	N1=40, N2=17
]			Fold Change: 2.83		Fold Change: 3.3
1			P-value: .00011		P-value: .01862
145	687	AI806324	211.46+/-131.17		
l			108.84+/-79.43		
1			N1=40, N2=17	X	X
l			Fold Change: 2.03		
<u> </u>			P-value: .00874		
146	691	AI809953	383.43+/-189.32		
			120.52+/-100.18		
İ			N1=40, N2=17	X	X
			Fold Change: 3.27		
			P-value: .00013		
147	693	AI810266	68.88+/-106.64		
<b>{</b>			761.49+/-1126.65		
1			N1=40, N2=17	X	X
j			Fold Change: 6.3		
\		1705055	P-value: .00013		
148	694	AI810764	202.16+/-159.83		
l			1084.09+/-1401.59		
			N1=40, N2=17	X	X
ĺ			Fold Change: 4.41		
140	701	A TO 1 602 E	P-value: .00007		
149	701	AI816835	360.85+/-289.77 171.05+/-158.66		
{			N1=40, N2=17	· <b>X</b>	X
Ì			Fold Change: 2.13	A	Λ.
}		•	P-value: .00229		
150	704	AI817967	1 / 41401 10 422		112.71+/-118.41
					308.86+/-160.78
1		٠	X	X	N1=40, N2=17
					Fold Change: 3.45
					P-value: .00951
151	706	AI818579	394.08+/-228.07		
1		•	204.91+/-197.94		
		•	N1=40, N2=17	X	X
1			Fold Change: 2.13		
			P-value: .00391		
152	712	AI821472	519.11+/-694.13		519.11+/-694.13
}			-5.59+/-218.89		-49.74+/-70.96
			N1=40, N2=17	X	N1=40, N2=17
}			Fold Change: 5.69		Fold Change: 9.33
150		1 7000 770	P-value: .00005		P-value: 0
153	713	AI823572	232.21+/-195.63		1
Ì			91.57+/-60.62	77	v
			N1=40, N2=17	X	X
}			Fold Change: 2.43		
154	721	A TOO SOO S	P-value: .00008		
154	/41	AI825936	229.86+/-148.12 98.58+/-81.47		
1			98.58+7-81.47 N1=40, N2=17	X	X
1			Fold Change: 2.58	Λ	^
1			P-value: .00016		
L			1-value00010		<del></del>

בו כפוכרייור -שיר האתפסידום ו

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
155	722	AI826437	45.86+/-118.99		
1			281.35+/-448.25		
			N1=40, N2=17	X	x
			Fold Change: 3.03		
			P-value: .0122		
156	744	AI863167	183.76+/-73.48		
			406.96+/-190.24		
			N1=40, N2=17	X	x
			Fold Change: 2.16		_
			P-value: 0		
157	747	AI864898	401.86+/-258.51		
			75.46+/-68.5		
			N1=40, N2=17	X	Х
1			Fold Change: 5.61		
			P-value: 0		
158	750	AI871044	766.39+/-500.99		766.39+/-500.99
			189.5+/-179.55		84.85+/-70.19
			N1=40, N2=17	X	N1=40, N2=17
l			Fold Change: 4.03		Fold Change: 8.12
			P-value: .00001		P-value: .00884
159	751	AI872267	267.23+/-203.1		
			627.26+/-368.25		
			N1=40, N2=17	$\mathbf{x}$	X
l		-	Fold Change: 2.55	•	
			P-value: .00015		
160	752	AI879337	431.51+/-184.18		
			215.5+/-115.86		
İ			N1=40, N2=17	X	· <b>X</b>
			Fold Change: 2.18		
			P-value: .00062		
161	758	AI888322			319.22+/-320.74
					71.54+/-51.15
Į.			X	X	N1=40, N2=17
l					Fold Change: 3.78
			<del> </del>	· · · · · · · · · · · · · · · · · · ·	P-value: .03277
162	772	AI916544	151.27+/-163.24		200
1			373.43+/-334.2		)
			N1=40, N2=17	X	X
			Fold Change: 2.45		
4.55		17045001	P-value: .00524		601 501 1015 15
163	775	AI917901	601.53+/-812.45		601.53+/-812.45
			76.98+/-131.25	~~	26.66+/-20.01
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.95		Fold Change: 7.3
100	<b>500</b>	17024:55	P-value: .00005		P-value: .00001
164	780	AI924465	448.27+/-478.27		
			149.48+/-115.97	77	37
1			N1=40, N2=17	X	X
1			Fold Change: 2.43		
100	707	4 TOO 40 C1	P-value: .00214		220 21 / 242 / 4
165	787	AI934361	220.01+/-243.16		220.01+/-243.16
			54.43+/-44.52	₹7	52.02+/-37.1
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.1		Fold Change: 3.01
L			P-value: .00001		P-value: .03711

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
166	789	AI934881	316.72+/-226.37		
			659.59+/-486.96		
			N1=40, N2=17	X	X
			Fold Change: 2.01		
			P-value: .00378		
167	816	AI968151	127.39+/-61.78		
			376.92+/-292.97		
\			N1=40, N2=17	X	X
			Fold Change: 2.53		
			P-value: .00031		
168	817	AI968379	295.46+/-388.02		295,46+/-388.02
			-8.49+/-25.52		.59+/-34.6
ł			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 6.27		Fold Change: 5.43
			P-value: 0		P-value: .00032
169	818	AI968904	738.79+/-292.65		
ļ			307.62+/-119.37	77	37
			N1=40, N2=17	X	X
l			Fold Change: 2.35		
170		A TOFO 400	P-value: 0		
170	830	AI972498	286.51+/-112.64		
l			135.46+/-66.44	x	X
			N1=40, N2=17	^	A
ļ			Fold Change: 2.18 P-value: .00003		
171	832	AI972873	436.16+/-215		
171	832	A19/20/3	132.01+/-99.1		
1		•	N1=40, N2=17	X	. <b>X</b>
1			Fold Change: 3.85	A	
			P-value: 0		
172	838	A1983045	281.02+/-338.08		281.02+/-338.08
1.2	000	1200012	40.45+/-125.75		-9.19+/-15.96
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.78		Fold Change: 7.52
			P-value: 0		P-value: 0
173	857	AL037805			614.2+/-317.15
					183.89+/-87.99
1			X	X	N1=40, N2=17
					Fold Change: 3.13
	•				P-value: .01435
174	865	AL040912	304.56+/-132.78		
			112.19+/-70.33		
1			N1=40, N2=17	X	X
			Fold Change: 2.8		
L			P-value: .00006		
175	867	AL042492	809.69+/-853.09		1022.91+/-907.07
			72.75+/-93.44	<b>~</b> *	85.76+/-67.41
1			N1=40, N2=17	· X	N1=40, N2=17
1			Fold Change: 9.48		Fold Change: 8.09
			P-value: 0		P-value: .00176
176	876	AL046941	428.58+/-238.89		428.58+/-238.89
			146.79+/-176.57	v	55.32+/-48.1 N1=40 N2-17
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 4.06	•	Fold Change: 7.58 P-value: .01267
L			P-value: .00007		F-Value: .0120/

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
177	881	AL048962	944+/-354.29		944+/-354.29
			399.3+/-211.63		289.62+/-184.81
			N1=40, N2=17	X	N1=40, N2=17
I			Fold Change: 2.5		Fold Change: 3.52
			P-value: .00001		P-value: .03411
178	893	AL050367	257.59+/-77.75		257.59+/-77.75
			111.77+/-59.21		76.12+/-36.74
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.47		Fold Change: 3.45
			P-value: 0		P-value: .01201
179	894	AL079279	313.49+/-189.76		
			127.56+/-77.14		
l			N1=40, N2=17	X	x
ł			Fold Change: 2.4		·
			P-value: .00036		
180	896	AL079707	261.69+/-226.08		
1			73.98+/-35.27		~
			N1=40, N2=17	X	$\mathbf{x} = \mathbf{y}$
			Fold Change: 3.16		
			P-value: 0		
181	902	AL118746	234.63+/-113.05		234.63+/-113.05
			84.77+/-47.29		46.19+/-34.43
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.86		Fold Change: 5.14
			P-value: .00001		P-value: .0179
182	905	AW000952	98.9+/-72.25		
			204.67+/-105.21		
ļ			N1=40, N2=17	· X	X
			Fold Change: 2.16		
			P-value: .00011		•
183	907	AW002846	283.14+/-201.6		
			119.62+/-87.38		
1			N1=40, N2=17	X	X
			Fold Change: 2.43		
Ĺ			P-value: .00065		
184	908	AW002941	959.64+/-342.08		~~
			493.25+/-243.21		)
1			N1=40, N2=17	X	X
1			Fold Change: 2.13		
			P-value: .0001		
185	916	AW006235	346.9+/-210.26		
1			121.01+/-58.03		<u></u>
1			N1=40, N2=17	X	X
1			Fold Change: 2.69		
L			P-value: 0		· · · · · · · · · · · · · · · · · · ·
186	917	AW006352	235.29+/-179.11		
1			534.97+/-420.56		
1			N1=40, N2=17	X	X
l			Fold Change: 2.17		
			P-value: .00953		
187	921	AW007080	223.2+/-116.87		223.2+/-116.87
1			69.24+/-50.48		36.39+/-14.01
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.27		Fold Change: 5.16
			P-value: .00001		P-value: .0001

• )

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
188	926	AW007803	153.39+/-142.06		•
			442.5+/-397.54		
1			N1=40, N2=17	X	X
			Fold Change: 2.55		
		•	P-value: .00867		
189	931	AW014155	214.48+/-209.56		
			624.36+/-372.34		
}			N1=40, N2=17	X	X
			Fold Change: 3.15		
		·	P-value: .00005		
190	953	AW051492	442.65+/-332.99		
]			203.39+/-140.38		
			N1=40, N2=17	X	X
			Fold Change: 2.22		
			P-value: .00151		
191	957	C17781	229.36+/-141.71		·
			84.23+/-69.19		
1			N1=40, N2=17	X	X
			Fold Change: 2.59		
			P-value: .00012		
192	975	F22640	416.82+/-153.5		
		•	204.94+/-169.19		
İ			N1=40, N2=17	X	X
			Fold Change: 2.37		
100		********	P-value: .00007		000 501/ 010 07
193	985	H16568	288.53+/-212.27		288.53+/-212.27
			74.99+/-76.74	v	32.47+/-46.57
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.32		Fold Change: 5.01 P-value: .01332
104	000	W20204	P-value: .00019		r-value: .01552
194	988	H30384	194.93+/-133.51 479.18+/-480.95	•	
			4/9.18+/-480.95 N1=40, N2=17	X	X
			Fold Change: 2.18	Λ	А
			P-value: .00329		
195	992	Н54254	377.04+/-687.01		377.04+/-687.01
193	37 <u>4</u>	1137437	38.27+/-23.01		36.82+/-32.95
			N1=40, N2=17	x	N1=40, N2=17
1			Fold Change: 4.25	A	Fold Change: 4.51
i			P-value: 0		P-value: .00966
196	997	H92988	390.91+/-149.13		
~~	,,,	11/11/00	205.04+/-140.06		
			N1=40, N2=17	X	X
			Fold Change: 2.33	==	
			P-value: .00168		
197	1074	N42752	63.77+/-48.02		
~~′	10		291.54+/-224.99		
			N1=40, N2=17	X	X
1			Fold Change: 3.86		
			P-value: .00006		
198	1085	N56877	109.5+/-80.79		
~~~	2000		402.12+/-388.61		
			N1=40, N2=17	X	X
			Fold Change: 3		
			P-value: .00087		
<u> </u>					

מוכחרורים ושב חוור המוכחום

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
199	1090	N63913	458.01+/-316.71		458.01+/-316.71
1			67.39+/-79.5		8.79+/-40.55
l			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 6.57	•	Fold Change: 11.59
1			P-value: 0		P-value: .00004
200	1101	R08000	502.76+/-694.51		502.76+/-694.51
			82.03+/-53.39		90.53+/-93.25
			N1=40, N2=17	X	N1=40, N2=17
l			Fold Change: 3.78		Fold Change: 4.05
			P-value: 0		P-value: .04964
201	1104	R20784	1112.78+/-843.96		
			359.34+/-233.36		
			N1=40, N2=17	. X	x
			Fold Change: 2.91		
			P-value: .00005		
202	1105	R39938	111.89+/-67.41	**************************************	
	1100	12,,,,,	222.22+/-111.16		
			N1=40, N2=17	X	$\mathbf{x}$ - )
1			Fold Change: 2.12	<b>A</b>	-2
			P-value: .00002		
203	1106	R42575	90.17+/-38.15		
203	1100	1042575	215.36+/-156.29		
			N1=40, N2=17	X	X
			Fold Change: 2.01	A	A
			P-value: .00211		
204	1112	R54660	200.26+/-133.86	······································	200.26+/-133.86
204	1112	1034000	48.69+/-33.36		29.39+/-27.33
		•	N1=40, N2=17	<b>X</b> .	N1=40, N2=17
l			Fold Change: 3.43	Α .	Fold Change: 4.69
1			P-value: 0		P-value: .0025
205	1116	R70255	241.29+/-181.34		241.29+/-181.34
1 200	1110	10255	14.29+/-38.71		-8.34+/-15.47
1			N1=40, N2=17	X	N1=40, N2=17
[			Fold Change: 5.79	11	Fold Change: 7.98
			P-value: 0		P-value: 0
206	1118	R74561	425.23+/-350.96		1 14140, 0
200	1110	AL/ HOUR	879.43+/-654.71		
1			N1=40, N2=17	X	$\mathbf{x}$
1			Fold Change: 2.16	11	22
l			P-value: .0019		
207	1119	R83604	304.76+/-867.74		
20,	1117	100004	-32.63+/-64.18		
			N1=40, N2=17	X	X
1			Fold Change: 3.15	21	24
			P-value: .00017		
208	1125	T61106	180.38+/-114.3		
200	IIAJ	X01100	349.03+/-164.74		
l			N1=40, N2=17	X	X
ł			Fold Change: 2.35	27	24
1			P-value: .00001		
209	1132	T05214	r-value00001		166.2+/-116.99
207	1134	T85314			644.58+/-401.95
			X	x	N1=40, N2=17
			Λ	^	Fold Change: 4.09
}				•	P-value: .03546
L					r-value: .03040

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
210	1171	W02823	217.4+/-87.18		217.4+/-87.18
			81.39+/-47.18		53.69+/-25.71
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.83		Fold Change: 3.92
			P-value: .00001		P-value: .00806
211	1173	W07043	299.21+/-164.12		299.21+/-164.12
			105.66+/-83.76		59.94+/-40.54
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.82		Fold Change: 4.46
			P-value: .00008		P-value: .01951
212	1174	W07304	1139.71+/-444.58		1139.71+/-444.58
Ì			502.93+/-458.99		349.93+/-213.71
			N1=40, N2=17	X	N1=40, N2=17
l			Fold Change: 2.64		Fold Change: 3.49
			P-value: .00012		P-value: .04978
213	1180	W27541	•		486.94+/-189.31
i					113.57+/-41.71
l			Χ .	X	N1=40, N2=17
İ					Fold Change: 4.17
İ					P-value: .0025
214	1183	W32480	720.17+/-951.89		720.17+/-951.89
			76.05+/-158.18		18.91+/-12.14
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 7.94		Fold Change: 12.97
			P-value: 0		P-value: 0
215	1184	W37770	208.87+/-62		
			108.93+/-55.29		
ļ ·			N1=40, N2=17	. <b>X</b>	Х
			Fold Change: 2.1		
ļ			P-value: .00006		
216	1185	W37896	499.73+/-192.2	٠	
ĺ			1636.96+/-1336.48	77	, 37
i			N1=40, N2=17	X	, X
			Fold Change: 2.49		
	4400	57755666	P-value: .00074		
217	1198	W72338 <sub>.</sub>	464.08+/-121.49		
			964.48+/-427.69	37	v
			N1=40, N2=17	X	X
			Fold Change: 2		
210	1100	TX1800.45	P-value: 0		
218	1199	W72347	368.08+/-157.32		
1			134.9+/-113.13	v	х
			N1=40, N2=17	X	^
			Fold Change: 3.01 P-value: .00008		
219	1200	W/72407	234.77+/-159.7	<del></del>	234.77+/-159.7
219	1200	W72407	50.76+/-52.77		44.31+/-63.03
			N1=40, N2=17	x	N1=40, N2=17
			Fold Change: 4.25	<b>A</b>	Fold Change: 5.12
			P-value: 0		P-value: .03464
220	1201	W72511	988.5+/-437.53		1-1410003404
220	1201	W 14311	477.34+/-271.59		
ŀ			N1=40, N2=17	x	x
			Fold Change: 2.11	Λ	41
1			P-value: .00006		
<b></b>	<del></del>		1-value00000		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
221	1204	W73386	248.29+/-403.35	469.37+/-905.14	
			35.26+/-68.97	101.34+/-51.41	
1			N1=40, N2=17	N1=17, N2=7	X
1			Fold Change: 3.18	Fold Change: 2.82	
			P-value: .0001	P-value: .01061	
222	1207	W73890	223.01+/-130.77		
1			84.82+/-49.32		
			N1=40, N2=17	X	X
ŀ			Fold Change: 2.49		
			P-value: 0		
223	1246	Z99386	611.71+/-209.91		
			288.23+/-106.96		
			N1=40, N2=17	X	X
			Fold Change: 2.19		
			P-value: .00001		

PCT/US02/02176

What is claimed is:

•

- 1. A method of diagnosing breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer.
  - 2. A method of detecting the progression of breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer progression.
  - 3. A method of monitoring the treatment of a patient with breast cancer, comprising:
    - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
  - (c) comparing the patient gene expression profile to a gene expression from a cell population selected from the group consisting of normal breast cells and cancerous breast cells.

20

25

5

10

- 4. A method of treating a patient with breast cancer, comprising:
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
- (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells; and
  - (c) comparing the patient expression profile to a gene expression profile selected from the group consisting of normal breast cells and cancerous breast cells.
  - 5. A method of typing breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of a type of breast cancer selected from a group consisting of infiltrating ductal carcinoma, microinvasive carcinoma, cribiform carcinoma, stage I carcinoma, stage II carcinoma or lobular carcinoma.

10

15

20

- 6. A method of detecting the presence or progression of infiltrating ductal carcinoma in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of infiltrating ductal carcinoma progression.
  - 7. A method of monitoring the treatment of a patient with infiltrating ductal carcinoma, comprising:
    - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
- (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising infiltrating ductal carcinoma cells or to both.
- 8. A method of treating a patient with infiltrating ductal carcinoma, comprising:
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
- (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising infiltrating ductal carcinoma cells; and
- (c) comparing the patient expression profile to a gene expression profile from a untreated cell population comprising infiltrating ductal carcinoma cells.
- 9. A method of diagnosing a microinvasive form of breast tumor in a patient, comprising:
  - (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of a microinvasive form of breast cancer.
  - 10. A method of detecting the progression of a microinvasive for of breast cancer in a patient, comprising:

15

20

· )

- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of the progression of a microinvasive form of breast cancer.
- 5 11. A method of monitoring the treatment of a patient with a microinvasive form of breast cancer, comprising:
  - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
  - (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising microinvasive breast cancer cells or to both.
  - 12. A method of treating a patient with a microinvasive form of breast cancer, comprising:
  - (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising microinvasive breast cancer cells; and
  - (c) comparing the patient expression profile to a gene expression profile from an untreated cell population comprising microinvasive breast cancer cells.
    - 13. A method of differentiating microinvasive breast cancer from a benign growth in a patient, comprising:
- 25 (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of microinvasive breast cancer rather than benign growth.
  - 14. A method of screening for an agent capable of modulating the onset or progression of breast cancer, comprising:
    - (a) preparing a first gene expression profile of a cell population comprising breast cancer cells, wherein the expression profile determines the expression level of one or more genes from Tables 1-5;
      - (b) exposing the cell population to the agent;

WO 02/059271 PCT/US02/02176

250

- (c) preparing second gene expression profile of the agent-exposed cell population; and
  - (d) comparing the first and second gene expression profiles.
- 5 15. The method of claim 14, wherein the breast cancer is a infiltrating ductal carcinoma.
  - 16. The method of claim 14, wherein the breast cancer is a microinvasive breast cancer.
- 17. A composition comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5.
  - 18. A composition according to claim 17, wherein the composition comprises at least 3 oligonucleotides.
- 15 19. A composition according to claim 17, wherein the composition comprises at least 5 oligonucleotides.

20

- 20. A composition according to claim 17, wherein the composition comprises at least 7 oligonucleotides.
- 21. A composition according to claim 17, wherein the composition comprises at least 10 oligonucleotides.
- 22. A composition according to any one of claims 17-21, wherein the oligonucleotides are attached to a solid support.
  - 23. A composition according to claim 22, wherein the solid support is selected from a group consisting of a membrane, a glass support, a filter, a tissue culture dish, a polymeric material, a bead and a silica support.
  - 24. A solid support comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5.

5

15

- 25. A solid support according to claim 24, wherein the oligonucleotides are covalently attached to the solid support.
- 26. A solid support according to claim 24, wherein the oligonucleotides are non-covalently attached to the solid support.
  - 27. A solid support according to claim 24, wherein the support comprises at least about 10 different oligonucleotides in discrete locations per square centimeter.
- 10 28. A solid support according to claim 24, wherein the support comprises at least about 100 different oligonucleotides in discrete locations per square centimeter.
  - 29. A solid support according to claim 24, wherein the support comprises at least about 1000 different oligonucleotides in discrete locations per square centimeter.
  - 30. A solid support according to claim 24, wherein the support comprises at least about 10,000 different oligonucleotides in discrete locations per square centimeter.
  - 31. A computer system comprising:
- 20 (a) a database containing information identifying the expression level in breast tissue of a set of genes comprising at least two genes in Tables 1-5; and
  - (b) a user interface to view the information.
- 32. A computer system of claim 31, wherein the database further comprises sequence information for the genes.
  - 33. A computer system of claim 31, wherein the database further comprises information identifying the expression level for the genes in normal breast tissue.
- 30 34. A computer system of claim 31, wherein the database further comprises information identifying the expression level for the genes in breast cancer tissue.
  - 35. A computer system of claim 34, wherein the breast cancer tissue comprises infiltrating ductal carcinoma cells.

- 36. A computer system of claim 34, wherein the breast cancer tissue comprises microinvasive breast cancer cells.
- 5 37. A computer system of any of claims 31-36, further comprising records including descriptive information from an external database, which information correlates said genes to records in the external database.
  - 38. A computer system of claim 37, wherein the external database is GenBank.

10

- 39. A method of using a computer system of any one of claims 31-36 to present information identifying the expression level in a tissue or cell of at least one gene in Tables 1-5, comprising:
- (a) comparing the expression level of at least one gene in Tables 1-5 in the tissue or cell to the level of expression of the gene in the database.
  - 40. A method of claim 39, wherein the expression level of at least two genes are compared.
- 20 41. A method of claim 39, wherein the expression level of at least five genes are compared.
  - 42. A method of claim 39, wherein the expression level of at least ten genes are compared.


25

- 43. A method of claim 39, further comprising displaying the level of expression of at least one gene in the tissue or cell sample compared to the expression level in breast cancer.
- 44. A kit comprising at least one solid support of any one of claims 24-30 packaged with gene expression information for said genes.
  - 45. A kit of claim 44, wherein the gene expression information comprises gene expression levels in a breast cancer tissue or cell sample.


WO 02/059271 PCT/US02/02176


253

46. A kit of claim 45, wherein the gene expression information is in an electronic format.



( )tty Ref 44921-5070-WO/1737678






3/5

Figure 6-28 Tissue Samples

Atty Ref 44921-5070-WO/1737678



## (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 1 August 2002 (01.08.2002)

#### **PCT**

## (10) International Publication Number WO 02/059271 A3

(51) International Patent Classification7: G01N 33/48

(21) International Application Number: PCT/US02/02176

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/263.757 25 January 2001 (25.01.2001) US 60/286.090 25 April 2001 (25.04.2001) US 60/292.517 23 May 2001 (23.05.2001) US

(71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ORR, Michael, S. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). NATION, Michele [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). DIGGANS, James, C. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ZENG, Wen [CN/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

(74) Agent: MORGAN, LEWIS & BOCKIUS LLP; TUS-CAN, Michael S., WEIMAR, Elizabeth C. et al., 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 7 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

8 \_\_\_\_

(54) Title: GENE EXPRESSION PROFILES IN BREAST TISSUE

(57) Abstract: The present invention results from the examination of tissue from breast carcinomas to identify genes differentially expressed between tumor biopsies and normal tissue. The invention includes diagnostic and screening methods using these genes as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.



#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/02176

		1	1 01/0302/021/0	<u>.</u> .
A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) : G01N 33/48  US CL : 702/19				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 702/19				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.
Y,P	US 6,312,909 B1 (SHYJAN et al) 06 November 2001 (06.11.2001), the entire document.			1-46
Y	US 5,759,776 A (SMITH et al) 02 June 1998 (02.06.1998), the entire document.			1-46
Y	US 5,776,683 A (SMITH et al) 07 July 1998 (07.06.1998), the entire document.			1-46
A	US 6,040,138 A (LOCKHART et al) 21 March 2000 (21.03.2000), the entire document.			1-46
·	·			
Further	r documents are listed in the continuation of Box C.	Sce patent i	family annex.	
Special categories of cited documents:				ernational filing date or priority
"A" document defining the general state of the art which is not considered to be of particular relevance			n contract with the appurence of underlying the inv	cation but cited to understand the ention
_	pplication or patent published on or after the international filing date	considered no	vel or cannot be conside	claimed invention cannot be red to involve an inventive step
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means		"Y" document of p	document is taken alone  for particular relevance; the claimed invention cannot be  d to involve an inventive step when the document is	
		combined with one or more other such documents, such combination being obvious to a person skilled in the art		
	t published prior to the international filing date but later than the late claimed	"&" document member of the same patent family		
	actual completion of the international search	Date of mailing of the international search report  1 9 CED 2002		
	002 (26.08.2002)	Australia de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Compa	W SEF /	11/
Con Box	ailing address of the ISA/US unissioner of Patents and Trademarks PCT PCT DC 20231	Shipo "Joe" Zhou Males fu		
Washington, D.C. 20231  Facsimile No. (703)305-3230  Telephone No. (703)-308-0196				
form PCT/ISA/210 (second cheet) (July 1008)				

Form PCT/ISA/210 (second sheet) (July 1998)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

### IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

## THIS PAGE BLANK (USPTO)